

10 Rec'd PCT/PTO 14 JUL 2004

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

501,841
(19) World Intellectual Property Organization
 International Bureau



(43) International Publication Date
 31 July 2003 (31.07.2003)

PCT

(10) International Publication Number
WO 03/062401 A2

(51) International Patent Classification⁷: C12N

Aijun [CN/US]; 3106 - 213th Place, SE, Issaquah, WA 98029 (US). ORDONEZ, Nadia [US/US]; 2011 No. 154 Court, Seattle, WA 98133 (US). CARTER, Lauren [US/US]; 7143 Beach Drive, SW, Seattle, WA 98136 (US). MCNEILL, Patricia, Dianne [US/US]; 1333 South - 290th Place, Federal Way, WA 98003 (US).

(21) International Application Number: PCT/US03/02353

(74) Agents: FANG, Carol, A. et al.; Townsend and Townsend and Crew LLP, Two Embarcadero Center, Eighth Floor, San Francisco, CA 94111 (US).

(22) International Filing Date: 22 January 2003 (22.01.2003)

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK,

(26) Publication Language: English

[Continued on next page]

(30) Priority Data: 10/057,475 22 January 2002 (22.01.2002) US


(71) Applicant (for all designated States except US): CORIXA CORPORATION [US/US]; 1124 Columbia Street, Suite 200, Seattle, WA 98104 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GAIGER, Alexander [AT/AT]; Doeblinger Hauptstrasse 62/14, A-1190 Vienna (AT). ALGATE, Paul, A. [GB/US]; 580 Kalmia Place, NW, Issaquah, WA 98027 (US). MANNION, Jane [US/US]; 8904 192nd Street, SW, Edmonds, WA 98026 (US). CLAPPER, Jonathan, David [US/US]; 2149 Dexter Avenue, North, #4, Seattle, WA 98109 (US). WANG,

(54) Title: COMPOSITIONS AND METHODS FOR THE DETECTION, DIAGNOSIS AND THERAPY OF HEMATOLOGICAL MALIGNANCIES

Outline of Microarray Chip Technology approach



WO 03/062401 A2

(57) Abstract: Disclosed are methods and compositions for the detection, diagnosis, prognosis, and therapy of hematological malignancies, and in particular, B cell leukemias, lymphomas and multiple myelomas. Disclosed are compositions, methods and kits for eliciting immune and T cell responses to specific malignancy-related antigenic polypeptides and antigenic polypeptide fragments thereof in an animal. Also disclosed are compositions and methods for use in the identification of cells and biological samples containing one or more hematological malignancy-related compositions, and methods for the detection and diagnosis of such diseases and affected cell types. Also disclosed are diagnostic and therapeutic kits, as well as methods for the diagnosis, therapy and/or prevention of a variety of leukemias and lymphomas.

259



TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent*

(AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*
- *of inventorship (Rule 4.17(iv)) for US only*

Published:

- *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

**COMPOSITIONS AND METHODS FOR THE DETECTION, DIAGNOSIS AND
THERAPY OF HEMATOLOGICAL MALIGNANCIES**

CROSS-REFERENCES TO RELATED APPLICATIONS

- 5 [01] This application is a continuation in part of U.S patent application Serial No. 10/057,475, filed January 22, 2002, which is a continuation in part of U.S. patent application Serial No. 10/040,862, filed November 6, 2001, which is a continuation in part of U.S. Serial No. 09/796,692 filed March 1, 2001, which claims priority to United States Provisional Patent Application Serial Nos. 60/186,126, filed March 1, 10 2000; Serial No. 60/190,479, filed March 17, 2000; Serial No. 60/200,545, filed April 27, 2000; Serial No. 60/200,303, filed April 28, 2000; Serial No. 60/200,779, filed April 28, 2000; Serial No. 60/200,999; filed May 1, 2000; Serial No. 60/202,084, filed May 4, 2000; Serial No. 60/206,201, filed May 22, 2000; Serial No. 60/218,950, filed July 14, 2000; Serial No. 60/222,903, filed August 3, 2000; Serial No. 15 60/223,416, filed August 4, 2000; and Serial No. 60/223,378, filed August 7, 2000; the entire specification, claims, sequences and figures of each of which is specifically incorporated herein by reference in its entirety without disclaimer and for all purposes.

20 **STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER
FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT**

- [02] Not applicable.

**REFERENCE TO A "SEQUENCE LISTING," A TABLE, OR A COMPUTER
PROGRAM LISTING APPENDIX SUBMITTED ON A COMPACT DISK.**

- 25 [03] Not applicable.

1. BACKGROUND OF THE INVENTION

1.1 FIELD OF THE INVENTION

- 30 [04] The present invention relates generally to the fields of cancer diagnosis and therapy. More particularly, it concerns the surprising discovery of compositions and methods for the detection and immunotherapy of hematological malignancies, and particularly, B cell leukemias, and lymphomas and multiple myelomas. The invention

provides new, effective methods, compositions and kits for eliciting immune and T-cell response to antigenic polypeptides, and antigenic peptide fragments isolated therefrom, and methods for the use of such compositions for diagnosis, detection, treatment, monitoring, and/or prevention of various types of human hematological malignancies. In particular, the invention provides polypeptide, peptide, antibody, antigen binding fragment, hybridoma, host cell, vector, and polynucleotide compounds and compositions for use in identification and discrimination between various types of hematological malignancies, and methods for the detection, diagnosis, prognosis, monitoring, and therapy of such conditions in an affected animal.

10

1.2 DESCRIPTION OF RELATED ART

1.2.1 HEMATOLOGICAL MALIGNANCIES

[05] Hematological malignancies, such as leukemias and lymphomas, are conditions characterized by abnormal growth and maturation of hematopoietic cells. Leukemias are generally neoplastic disorders of hematopoietic stem cells, and include adult and pediatric acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL) and secondary leukemia. Among lymphomas, there are two distinct groups: non-Hodgkin's lymphoma (NHL) and Hodgkin's disease. NHLs are the result of a clonal expansion of B- or T-cells, but the molecular pathogenesis of Hodgkin's disease, including lineage derivation and clonality, remains obscure. Other hematological malignancies include myelodysplastic syndromes (MDS), myeloproliferative syndromes (MPS) and multiple myeloma. Hematological malignancies are generally serious disorders, resulting in a variety of symptoms, including bone marrow failure and organ failure.

20

[06] NHLs are the sixth most common cause of cancer related deaths in the United States. Only prostate, breast, lung, colorectal and bladder cancer currently exceed lymphoma in annual incidence. In 1995, more than 45,000 new NHLs were diagnosed, and over 21,000 patients died of these diseases. The average age of lymphoma patients is relatively young (42 years), and the resulting number of years of life lost to these diseases renders NHLs fourth in economic impact among cancers in the United States. In the past 15 years, the American Cancer Society reported a 50% increase in the incidence of NHLs, one of the largest increases for any cancer group. Much of this increase has been attributed to the development of lymphomas in

younger men who have acquired AIDS. Lymphomas are also the third most common childhood malignancy and account for approximately 10% of cancers in children. The survival rate (all ages) varies from 73% (low risk) to 26% (high risk).

5 1.3 DEFICIENCIES IN THE PRIOR ART

- [07] Treatment for many hematological malignancies, including leukemias and lymphomas, remains difficult, and existing therapies are not universally effective. While treatments involving specific immunotherapy appear to have considerable potential, such treatments have been limited by the small number of known malignancy-associated antigens. Moreover the ability to detect such hematological malignancies in their early stages can be quite difficult depending upon the particular malady. The lack of a sufficient number of specific diagnostic and prognostic markers of the diseases, and identification of cells and tissues that can be affected, has significantly limited the field of oncology.
- 10 [08] Accordingly, there remains a need in the art for improved methods for detecting, screening, diagnosis and treatment of hematological malignancies such as B cell leukemias and lymphomas and multiple myelomas. The present invention fulfills these and other inherent needs in the field, and provides significant advantages in the detection of cells, and cell types that express one or more polypeptides that have been shown to be over-expressed in one or more of such hematological malignancies.
- 20

2. SUMMARY OF THE INVENTION

- [09] The present invention addresses the foregoing long-felt need and other deficiencies in the art by identifying new and effective strategies for the identification, detection, screening, diagnosis, prognosis, prophylaxis, therapy, and immunomodulation of one or more hematological malignancies, and in particular, B cell leukemias and lymphomas, and multiple myelomas.
- 25 [10] The present invention is based, in part, upon the surprising and unexpected discovery that certain previously unknown or unidentified human polypeptides, peptides, and antigenic fragments derived therefrom have now been identified that are overexpressed in one or more types of hematological malignancies. The genes encoding several of these polypeptides are now identified and obtained in isolated form, and have been characterized using a series of molecular biology methodologies including subtractive library analysis, microarray screening, polynucleotide
- 30

sequencing, peptide and epitopic identification and characterization, as well as expression profiling, and *in vitro* whole gene cell priming. A set of these polynucleotides, and the polypeptides, peptides, and antigenic fragments they encode are now identified and implicated in the complex processes of hematological malignancy disease onset, progression, and/or outcome, and in particular, diseases such as leukemias and lymphomas.

[11] The inventors have further demonstrated that a number of these polynucleotides, and their encoded polypeptides, as well as antibodies, antigen presenting cells, T cells, and the antigen binding fragments derived from such antibodies are useful in the development of particularly advantageous compositions and methods for the detection, diagnosis, prognosis, prophylaxis and/or therapy of one or more of these diseases, and particularly those conditions that are characterized by (a) an increased, altered, elevated, or sustained expression of one or more polynucleotides that comprise at least a first sequence region that comprises a nucleic acid sequence as disclosed in any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124 or (b) an increased, altered, elevated, or sustained biological activity of one or more polypeptides that comprise at least a first sequence region that comprises an amino acid sequence as encoded by any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124 or disclosed in any one of SEQ ID NOS: 4, 6, 8, 10, 12, 15, 18, 21, 26, 29, 32, 35, 37, 40, 43, 45, 48, 50, 52, 54, 56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121.

[12] The present invention also provides methods and uses for one or more of the disclosed peptide, polypeptide, antibody, antigen binding fragment, and polynucleotide compositions of the present invention in generating an immune response or in generating a T-cell response in an animal, and in particular in a mammal such as a human. The invention also provides methods and uses for one or more of these compositions in the identification, detection, and quantitation of hematological malignancy compositions in clinical samples, isolated cells, whole tissues, and even affected individuals. The compositions and methods disclosed

herein also may be used in the preparation of one or more diagnostic reagents, assays, medicaments, or therapeutics, for diagnosis and/or therapy of such diseases.

[13] In a first important embodiment, there is provided a composition comprising at least a first isolated peptide or polypeptide that comprises an amino acid sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identical to the amino acid sequence encoded by any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124 or disclosed in any one of SEQ ID NOS: 4, 6, 8, 10, 12, 15, 18, 21, 26, 29, 32, 35, 37, 40, 43, 45, 48, 50, 52, 54, 56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121. Exemplary preferred sequences are those that comprise at least a first coding region that comprises an amino acid sequence that is at least about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, or about 94% identical to the amino acid sequence as encoded by any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124 or disclosed in any one of SEQ ID NOS: 4, 6, 8, 10, 12, 15, 18, 21, 26, 29, 32, 35, 37, 40, 43, 45, 48, 50, 52, 54, 56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121, with those sequences that comprise at least a first coding region that comprises an amino acid sequence that is at least about 95%, about 96%, about 97%, about 98%, or about 99% identical to the amino acid sequence as encoded by any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124 or disclosed in any one of SEQ ID NOS: 4, 6, 8, 10, 12, 15, 18, 21, 26, 29, 32, 35, 37, 40, 43, 45, 48, 50, 52, 54, 56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121 being examples of particularly preferred sequences in the practice of the present invention. Likewise, peptide and polypeptide compounds and compositions are also provided that comprise, consist essentially of, or consist of the amino acid sequence as encoded by any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31,

33-34, 36, 38-39, 41-42, 44, 46-47, 49; 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124 or disclosed in any one of SEQ ID NOS: 4, 6, 8, 10, 12, 15, 18, 21, 26, 29, 32, 35, 37, 40, 43, 45, 48, 50, 52, 54, 56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121.

[14] In a similar fashion, there are also embodiments disclosed herein that provide compositions and methods for the detection, diagnosis, prognosis, prophylaxis, treatment, and therapy of B cell leukemia, lymphoma and multiple myeloma.

Exemplary preferred peptide and polypeptide compounds and compositions relating to this aspect of the invention include, but are not limited to, those peptide and

polypeptide compounds or compositions that comprise at least a first isolated peptide or polypeptide that comprises an amino acid sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about

95%, about 96%, about 97%, about 98%, or about 99% identical to the amino acid sequence as encoded by any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-

20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-

113, 115-116, 118, or 124 or disclosed in any one of SEQ ID NOS: 4, 6, 8, 10, 12, 15,

18, 21, 26, 29, 32, 35, 37, 40, 43, 45, 48, 50, 52, 54, 56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121, and those that comprise at least a

first coding region that comprises an amino acid sequence that is at least about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, or about 94% identical to the amino acid sequence as encoded by any one

25 of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124 or disclosed

30 in any one of SEQ ID NOS: 4, 6, 8, 10, 12, 15, 18, 21, 26, 29, 32, 35, 37, 40, 43, 45, 48, 50, 52, 54, 56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121, and even those sequences that comprise at least a first coding region that

comprises an amino acid sequence that is at least about 95%, about 96%, about 97%, about 98%, or about 99% identical to the amino acid sequence as encoded by any one

of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81,

83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124 or disclosed in any one of SEQ ID NOS: 4, 6, 8, 10, 12, 15, 18, 21, 26, 29, 32, 35, 37, 40, 43, 45, 48, 50, 52, 54, 56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121.

5 [15] Exemplary peptides of the present invention may be of any suitable length, depending upon the particular application thereof, and encompass those peptides that are about 9, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, or about 100 or so amino acids in length. Of course, the peptides of the invention may also encompass any intermediate lengths or integers within the stated ranges.

10 [16] Exemplary polypeptides and proteins of the present invention may be of any suitable length, depending upon the particular application thereof, and encompass those polypeptides and proteins that are about 100, about 150, about 200, about 250, about 300, about 350, or about 400 or so amino acids in length. Of course, the polypeptides and proteins of the invention may also encompass any intermediate lengths or integers within the stated ranges.

15 [17] The peptides, polypeptides, proteins, antibodies, and antigen binding fragments of the present invention will preferably comprise a sequence of at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 contiguous amino acids from any one of the peptides as encoded by any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124 or disclosed in any one of SEQ ID NOS: 4, 6, 8, 10, 12, 15, 18, 21, 26, 29, 32, 35, 37, 40, 43, 45, 48, 50, 52, 54, 56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121.

20 [18] Furthermore, the polypeptides, proteins, antibodies, and antigen binding fragments of the present invention will even more preferably comprise at least a first isolated coding region that comprises a sequence of at least about 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200 contiguous amino acids from any one of the peptides as encoded by any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113,

115-116, 118, or 124 or disclosed in any one of SEQ ID NOS: 4, 6, 8, 10, 12, 15, 18, 21, 26, 29, 32, 35, 37, 40, 43, 45, 48, 50, 52, 54, 56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121.

[19] Likewise, the polypeptides, proteins, antibodies, and antigen binding fragments of the present invention may comprise at least a first isolated coding region that comprises a substantially longer sequence, such as for example, one of at least about 200, 220, 240, 260, 280, or 300 or more contiguous amino acids from any one of the peptides as encoded by any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 32-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124 or disclosed in any one of SEQ ID NOS: 4, 6, 8, 10, 12, 15, 18, 21, 26, 29, 32, 35, 37, 40, 43, 45, 48, 50, 52, 54, 56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121.

[20] In illustrative embodiments, and particularly in those embodiments concerning methods and compositions relating to B cell leukemias, lymphomas and multiple myelomas, the polypeptides of the invention comprise an amino acid sequence that (a) comprises, (b) consists essentially of, or (c) consists of, the amino acid sequence encoded by any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124 or disclosed in any one of SEQ ID NOS: 4, 6, 8, 10, 12, 15, 18, 21, 26, 29, 32, 35, 37, 40, 43, 45, 48, 50, 52, 54, 56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121.

[21] The polypeptides and proteins of the invention preferably comprise an amino acid sequence that is encoded by at least a first nucleic acid segment that comprises an at least 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 contiguous nucleotide sequence of any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124.

[22] The polypeptides and proteins of the invention may also preferably comprise an amino acid sequence encoded by at least a first nucleic acid segment that comprises an at least about 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 contiguous nucleotide sequence of any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-

70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116,
118, or 124. The polypeptides and proteins of the invention may also preferably
comprise one or more coding regions that comprise an amino acid sequence encoded
by at least a first nucleic acid segment that comprises an at least about 41, 42, 43, 44,
5 45, 46, 47, 48, 49, or 50 contiguous nucleotide sequence of any one of SEQ ID NOS:
1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44,
46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-
100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124. The polypeptides and
proteins of the invention may also preferably comprise one or more coding regions
10 that comprise an amino acid sequence encoded by at least a first nucleic acid segment
that comprises an at least about 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 contiguous
nucleotide sequence of any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20,
22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62,
64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113,
15 115-116, 118, or 124. The polypeptides and proteins of the invention may also
preferably comprise one or more coding regions that comprise an amino acid sequence
encoded by at least a first nucleic acid segment that comprises an at least about 70, 80,
90, 100, 110, 120, 130, 140 or 150 contiguous nucleotide sequence of any one of SEQ
ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39,
20 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-
86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124. The polypeptides
and proteins of the invention may also preferably comprise one or more coding
regions that comprise an amino acid sequence encoded by at least a first nucleic acid
segment that comprises an at least about 175, 200, 225, 250, 275, 300, 325, 350, 375,
25 or 400 contiguous nucleotide sequence of any one of SEQ ID NOS: 1-3, 5, 7, 9, 11,
13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51,
53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103,
105-106, 108, 110-113, 115-116, 118, or 124. The polypeptides and proteins of the
invention may also preferably comprise one or more coding regions that comprise an
30 amino acid sequence encoded by at least a first nucleic acid segment that comprises an
at least about 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, or 1500
contiguous nucleotide sequence of any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14,
16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55,

57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106,
108, 110-113, 115-116, 118, or 124.

[23] In a second important embodiment, there is provided a composition comprising at least a first isolated polynucleotide that comprises a nucleic acid sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identical to the nucleic acid sequence of any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124. Exemplary preferred sequences are those that comprise a nucleic acid sequence that is at least about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, or about 94% identical to the nucleic acid sequence of any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124, with those sequences that comprise at least a nucleic acid sequence that is at least about 95%, about 96%, about 97%, about 98%, or about 99% identical to the nucleic acid sequence of any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124 being examples of particularly preferred sequences in the practice of the present invention.

5

10

15

20

25

30

[24] In embodiments that relate particularly to compositions and methods for the detection, diagnosis, prognosis, prophylaxis, treatment, and therapy of B cell leukemias, lymphomas, and multiple myelomas exemplary preferred polynucleotide compositions include those compositions that comprise at least a first isolated nucleic acid segment that comprises a sequence that is at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% identical to the nucleic acid sequence of any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124.

5

Such polynucleotides will preferably comprise one or more isolated coding region, each of which may (a) comprise, (b) consist essentially of, or (c) consist of, the nucleic acid sequence of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124.

10

15

20

25

30

[25] Exemplary polynucleotides of the present invention may be of any suitable length, depending upon the particular application thereof, and encompass those polynucleotides that (a) are at least about, or (b) comprise at least a first isolated nucleic acid segment that is at least about 27, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 120, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 320, 340, 360, 380, 400, 420, 440, 460, 480, 500, 520, 540, 560, 580, 600, 625, 650, 675, 700, 750, 800, 850, 900, 950, or 1000 or so nucleic acids in length, as well as longer polynucleotides that (a) are at least about, or (b) comprise at least a first isolated nucleic acid segment that is at least about 1000, 1025, 1050, 1075, 1100, 150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 1950, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, or 3000 or so nucleic acids in length, as well as substantially larger polynucleotides. Of course, the polynucleotides and nucleic acid segments of the invention may also encompass any intermediate lengths or integers within the stated ranges.

[26] The compositions of the present invention may comprise a single polypeptide or polynucleotide, or alternatively, may comprise two or more such hematological malignancy compounds, such as for example, two or more polypeptides, two or more polynucleotides, or even combinations of one or more peptides or polypeptides, along with one or more polynucleotides. When two or more polypeptides are contemplated for particular applications, the second and/or third and/or fourth, *etc.* isolated peptides and/or polypeptides will preferably comprise an amino acid sequence that is at least about 91%, 93%, 95%, 97%, or 99% identical to the amino acid sequence encoded by any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124 or disclosed in any one of SEQ ID NOS: 4, 6, 8, 10, 12, 15, 18, 21, 26, 29, 32, 35, 37, 40, 43, 45, 48, 50, 52, 54, 56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121. Alternatively, the polynucleotides of the invention may

comprise one or more coding regions that encode a first fusion protein or peptide, such as an adjuvant-coding region fused in correct reading frame to one or more of the disclosed hematological malignancy peptides or polypeptides. Alternatively, the fusion protein may comprise a hematological malignancy polypeptide or peptide fused, in correct reading frame, to a detectable protein or peptide, or to an immunostimulant protein or peptide, or other such construct. Fusion proteins such as these are particularly useful in those embodiments relating to diagnosis, detection, and therapy of one or more of the hematological malignancies as discussed herein.

[27] The invention also provides a composition comprising at least a first hybridoma cell line that produces a monoclonal antibody having immunospecificity for one or more of the peptides or polypeptides as disclosed herein, or at least a first monoclonal antibody, or an antigen-binding fragment thereof, that has immunospecificity for such a peptide or polypeptide. The antigen binding fragments may comprise a light chain variable region, a heavy-chain variable region, a Fab fragment, a F(ab)₂ fragment, an Fv fragment, an scFv fragment, or an antigen-binding fragment of such an antibody.

[28] The invention also provides a composition comprising at least a first isolated antigen-presenting cell that expresses a peptide or polypeptide as disclosed herein, or a plurality of isolated T cells that specifically react with such a peptide or polypeptide. Such pluralities of isolated T cells may be stimulated or expanded by contacting the T cells with one or more peptides or polypeptides as described herein. The T cells may be cloned prior to expansion, and may be obtained from bone marrow, a bone marrow fraction, peripheral blood, or a peripheral blood fraction from a healthy mammal, or from a mammal that is afflicted with at least a first hematological malignancy such as leukemia or lymphoma.

[29] As described above, the isolated polypeptides of the invention may be on the order of from 9 to about 1000 amino acids in length, or alternatively, may be on the order of from 50 to about 900 amino acids in length, from 75 to about 800 amino acids in length, from 100 to about 700 amino acids in length, or from 125 to about 600 amino acids in length, or any other such suitable range.

[30] The isolated nucleic acid segments that encode such isolated polypeptides may be on the order of from 27 to about 10,000 nucleotides in length, from 150 to about 8000 nucleotides in length, from 250 to about 6000 nucleotides in length, from

350 to about 4000 nucleotides in length, or from 450 to about 2000 nucleotides in length, or any other such suitable range.

[31] The nucleic acid segment may be operably positioned under the control of at least a first heterologous, recombinant promoter, such as a tissue-specific, cell-specific, inducible, or otherwise regulated promoter. Such promoters may be further controlled or regulated by the presence of one or more additional enhancers or regulatory regions depending upon the particular cell type in which expression of the polynucleotide is desired. The polynucleotides and nucleic acid segments of the invention may also be comprised within a vector, such as a plasmid, or viral vector. The polypeptides and polynucleotides of the invention may also be comprised within a host cell, such as a recombinant host cell, or a human host cell such as a blood or bone marrow cell.

[32] The polynucleotides of the invention may comprise at least a first isolated nucleic acid segment operably attached, in frame, to at least a second isolated nucleic acid segment, such that the polynucleotide encodes a fusion protein in which the first peptide or polypeptide is linked to the second peptide or polypeptide.

[33] The polypeptides of the present invention may comprise a contiguous amino acid of any suitable length, such as for example, those of about 2000, about 1900, about 1850, about 1800, about 1750, about 1700, about 1650, about 1600, about 1550, about 1500, about 1450, about 1400, about 1350, about 1300, about 1250, about 1200, about 1150, about 1100 amino acids, or about 1000 or so amino acids in length. Likewise, the polypeptides and peptides of the present invention may comprise slightly shorter contiguous amino acid coding regions, such as for example, those of about 950, about 900, about 850, about 800, about 750, about 700, about 650, about 600, about 550, about 500, about 450, about 400, about 350, about 300, about 250, about 200, about 150, or even about 100 amino acids or so in length.

[34] In similar fashion, the polypeptides and peptides of the present invention may comprise even smaller contiguous amino acid coding regions, such as for example, those of about 95, about 90, about 85, about 80, about 75, about 70, about 65, about 60, about 55, about 50, about 45, about 40, about 35, about 30, about 25, about 20, about 15, or even about 9 amino acids or so in length.

[35] In all such embodiments, those peptides and polypeptides having intermediate lengths including all integers within the preferred ranges (e.g., those peptides and polypeptides that comprise at least a first coding region of at least about 94, about 93,

about 92, about 91, about 89, about 88, about 87, about 86, about 84, about 83, about 82, about 81, about 79, about 78, about 77, about 76, about 74, about 73, about 72, about 71, about 69, about 68, about 67, about 66 or so amino acids in length, etc.) are all contemplated to fall within the scope of the present invention.

- 5 [36] In particular embodiments, the peptides and polypeptides of the present invention may comprise a sequence of at least about 9, or about 10, or about 11, or about 12, or about 13, or about 14, or about 15, or about 16, or about 17, or about 18, or about 19, or about 20, or about 21, or about 22, or about 23, or about 24, or about 25, or about 26, or about 27, or about 28, or about 29, or about 30, or about 31, or about 32, or about 33, or about 34, or about 35, or about 36, or about 37, or about 38, or about 39, or about 40, or about 41, or about 42, or about 43, or about 44, or about 45, or about 46, or about 47, or about 48, or about 49, or about 50 contiguous amino acids as disclosed in any one or more of the peptides encoded by any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124 or disclosed in any one of SEQ ID NOS: 4, 6, 8, 10, 12, 15, 18, 21, 26, 29, 32, 35, 37, 40, 43, 45, 48, 50, 52, 54, 56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121 herein.
- 10 [37] In other embodiments, the peptides and polypeptides of the present invention may comprise a sequence of at least about 51, or about 52, or about 53, or about 54, or about 55, or about 56, or about 57, or about 58, or about 59, or about 60, or about 61, or about 62, or about 63, or about 64, or about 65, or about 66, or about 67, or about 68, or about 69, or about 70, or about 71, or about 72, or about 73, or about 74, or about 75, or about 76, or about 77, or about 78, or about 79, or about 80, or about 81, or about 82, or about 83, or about 84, or about 85, or about 86, or about 87, or about 88, or about 89, or about 90, or about 91, or about 92, or about 93, or about 94, or about 95, or about 96, or about 97, or about 98, or about 99, or 100 contiguous amino acids as disclosed in any one or more of the peptides encoded by any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124 or disclosed in any one of SEQ ID NOS: 4, 6, 8, 10, 12, 15, 18, 21, 26, 29, 32, 35, 37, 40, 43, 45, 48, 50, 52, 54,

56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121
herein.

5 [38] In still other embodiments, the preferred peptides and polypeptides of the present invention comprise a sequence of at least about 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, or 400 or more contiguous amino acids as disclosed in any one or more of the peptides encoded by any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124 or disclosed in any one of SEQ ID NOS: 4, 6, 8, 10, 12, 15, 18, 21, 26, 29, 32, 35, 37, 40, 43, 45, 48, 50, 52, 54, 56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121 herein.

10 [39] The polypeptides of the invention typically will comprise at least a first contiguous amino acid sequence according to any one of the peptides encoded by any one of the above polynucleotides or disclosed in any one of SEQ ID NOs: 10,471-15 10,474; SEQ ID NO: 10,481; SEQ ID NOs: 10,599 – 10,819; SEQ ID NOs: 10,820-10,842; SEQ ID NOs: 10,849-10,908; and SEQ ID NOs: 10,909-10,968, but may also, optionally comprise at least a second, at least a third, or even at least a fourth or greater contiguous amino acid sequence according to any one of the peptides encoded by any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 20 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124 or disclosed in any one of SEQ ID NOS: 4, 6, 8, 10, 12, 15, 18, 21, 26, 29, 32, 35, 37, 40, 43, 45, 48, 50, 52, 54, 56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121. A single polypeptide may contain only a single coding region, 25 or alternatively, a single polypeptide may comprise a plurality of identical or distinctly different contiguous amino acid sequences in accordance with any one of the peptides encoded by any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 30 118, or 124 or disclosed in any one of SEQ ID NOS: 4, 6, 8, 10, 12, 15, 18, 21, 26, 29, 32, 35, 37, 40, 43, 45, 48, 50, 52, 54, 56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121. In fact, the polypeptide may comprise a plurality of the same contiguous amino acid sequences, or they may comprise one or more different contiguous amino acid sequences of any of the peptides encoded by any one

of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124 or disclosed in any one of SEQ ID NOS: 4, 6, 8, 10, 12, 15, 18, 21, 26, 29, 32, 35, 37, 40, 43, 45, 48, 50, 52, 54, 56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121. For example, a single polypeptide can comprise a single contiguous amino acid sequence from one or more of the peptides encoded by any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124 or disclosed in any one of SEQ ID NOS: 4, 6, 8, 10, 12, 15, 18, 21, 26, 29, 32, 35, 37, 40, 43, 45, 48, 50, 52, 54, 56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121, or alternatively, may comprise two or more distinctly different contiguous amino acid sequences from one or more of the peptides encoded by any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124 or disclosed in any one of SEQ ID NOS: 4, 6, 8, 10, 12, 15, 18, 21, 26, 29, 32, 35, 37, 40, 43, 45, 48, 50, 52, 54, 56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121. In fact, the polypeptide may comprise 2, 3, 4, or even 5 distinct contiguous amino sequences of any one of the peptides encoded by any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124 or disclosed in any one of SEQ ID NOS: 4, 6, 8, 10, 12, 15, 18, 21, 26, 29, 32, 35, 37, 40, 43, 45, 48, 50, 52, 54, 56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121. Alternatively, a single polypeptide may comprise 2, 3, 4, or even 5 distinct coding regions. For example, a polypeptide may comprise at least a first coding region that comprises a first contiguous amino acid sequence of any one of the peptides encoded by any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124 or disclosed in any one of SEQ ID NOS: 4, 6, 8, 10, 12, 15, 18, 21, 26, 29, 32, 35, 37, 40, 43, 45, 48, 50, 52, 54, 56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121.

or 119-121, and at least a second coding region that comprises a second contiguous amino acid sequence of any one of the peptides encoded by any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124 or disclosed in any one of SEQ ID NOS: 4, 6, 8, 10, 12, 15, 18, 21, 26, 29, 32, 35, 37, 40, 43, 45, 48, 50, 52, 54, 56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121. In contrast, a polypeptide may comprise at least a first coding region that comprises a first contiguous amino acid sequence of any one of the peptides encoded by any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124 or disclosed in any one of SEQ ID NOS: 4, 6, 8, 10, 12, 15, 18, 21, 26, 29, 32, 35, 37, 40, 43, 45, 48, 50, 52, 54, 56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121, and at least a second coding region that comprises a second distinctly different peptide or polypeptide, such as for example, an adjuvant or an immunostimulant peptide or polypeptide.

[40] In such cases, the two coding regions may be separate on the same polypeptide, or the two coding regions may be operatively attached, each in the correct reading frame, such that a fusion polypeptide is produced, in which the first amino acid sequence of the first coding region is linked to the second amino acid sequence of the second coding region.

[41] Throughout this disclosure, a phrase such as "a sequence as disclosed in SEQ ID NO:1 to SEQ ID NO:4" is intended to encompass any and all contiguous sequences disclosed by any one of these sequence identifiers. That is to say, "a sequence as disclosed in any of SEQ ID NO:1 through SEQ ID NO:4" means any sequence that is disclosed in any one of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:4. Likewise, "a sequence as disclosed in any of SEQ ID NOs:25 to 37" means any sequence that is disclosed in any one of SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, or SEQ ID NO:37, and so forth.

[42] Likewise, a phrase such as "at least a first sequence from any one of SEQ ID NO:55 to SEQ ID NO:62" is intended to refer to a first sequence that is disclosed in

any one of SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, or SEQ ID NO:62.

[43] It will also be understood that the kits, and compositions of the present invention comprise in an overall and general sense at least one or more particular polynucleotides, polypeptides, and peptides that comprise one or more contiguous sequence regions from one or more of the nucleic acid sequences disclosed herein in SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124 or from one or more of the amino acid sequences encoded by any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124 or disclosed in any one of SEQ ID NOS: 4, 6, 8, 10, 12, 15, 18, 21, 26, 29, 32, 35, 37, 40, 43, 45, 48, 50, 52, 54, 56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121, and that such peptide, polypeptide and polynucleotide compositions may be used in one or more of the particular methods and uses disclosed herein for the diagnosis, detection, prophylaxis, and therapy of one or more hematological cancers, and in particular, lymphomas of a variety of specific types. It will also be understood to the skilled artisan having benefit of the teachings of the present specification, that the peptide and polypeptide compositions may be used to generate a T cell or an immune response in an animal, and that such compositions may also be administered to an animal from which immunospecific antibodies and antigen binding fragments may be isolated or identified that specifically bind to such peptides or polypeptides. Such an artisan will also recognize that the polynucleotides identified by the present disclosure may be used to produce such peptides, polypeptides, antibodies, and antigen binding fragments, by recombinant protein production methodologies that are also within the capability of the skilled artisan having benefit of the specific amino acid and nucleic acid sequences provided herein.

[44] Likewise, it will be understood by a skilled artisan in the field, that one or more of the disclosed compositions may be used in one or more diagnostic or detection methodologies to identify certain antibodies, peptides, polynucleotides, or polypeptides in a biological sample, in a host cell, or even within the body or tissues of an animal. It will be understood by a skilled artisan in the field, that one or more of

the disclosed nucleic acid or amino acid compositions may be used in the preparation or manufacture of one or more medicaments for use in the diagnosis, detection, prognosis, prophylaxis, or therapy of one or more hematological malignancies in an animal, and particularly those malignant conditions disclosed and claimed herein.

5 [45] It will also be readily apparent to those of skill in the art, that the methods, kits, and uses, of the present invention preferably employ one or more of the compounds and/or compositions disclosed herein that comprise one or more contiguous nucleotide sequences as may be presented in SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124 of the attached sequence listing.

10 [46] Likewise, it will also be readily apparent to those of skill in the art, that the methods, kits, and uses, of the present invention may also employ one or more of the compounds and compositions disclosed herein that comprise one or more contiguous 15 amino acid sequences of any of the peptides encoded by any one of SEQ ID NOS: 1-3, 5, 7, 9, 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53, 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108, 110-113, 115-116, 118, or 124 or presented in any one of SEQ 20 ID NOS: 4, 6, 8, 10, 12, 15, 18, 21, 26, 29, 32, 35, 37, 40, 43, 45, 48, 50, 52, 54, 56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121 of the attached sequence listing.

3. BRIEF DESCRIPTION OF THE DRAWINGS AND SEQUENCES

25 [47] The invention may be understood by reference to the following description taken in conjunction with the accompanying drawings, in which like reference numerals identify like elements, and in which:

[48] FIG. 1 illustrates a schematic outline of the microarray chip technology approach used to identify the cDNA targets of the present invention as described Section 5.1.

30 [49] FIG. 2 illustrates a schematic outline of the general protocol for in vitro whole gene CD8⁺ T cell priming procedure used to generate antigen-specific lines and to identify clones of interest.

[50] FIG. 3 illustrates a schematic outline of the general protocol for in vitro whole gene CD4⁺ T cell priming procedure used to generate antigen-specific lines and to identify clones of interest.

5 [51] FIG. 4 illustrates the panel of probes used to identify cDNAs that are overexpressed in lymphoma cells.

[52] FIG. 5 lists the antigens that have similar tissue expression profiles as the known therapeutics, CD20 and CD52.

[53] FIG. 6 illustrates the results of the TMpred report for Ly1484 long and Ly1484 short.

10 [54] FIG. 7 illustrates the results of the TSITES analysis of Ly1484 long.

[55] FIG. 8 illustrates the results of the TSITES analysis of Ly1484 short.

[56] SEQ ID NO:1 is a full-length cDNA for Ly1728P.

[57] SEQ ID NO:2 is a full-length protein sequence for Ly1728P.

[58] SEQ ID NO:3 is a full-length cDNA sequence of Ly1732P.

15 [59] SEQ ID NO:4 is a full-length protein of Ly1732P.

[60] SEQ ID NO:5 is a full length cDNA sequence of Ly1888P.

[61] SEQ ID NO:6 is a full length protein sequence of Ly1888P.

[62] SEQ ID NO:7 is a full length cDNA sequence of Ly1452_His-tag-fusion.

[63] SEQ ID NO:8 is a full length protein sequence of Ly1452_His-tag-fusion.

20 [64] SEQ ID NO:9 is a full length cDNA sequence of Ly1452P, splice variant 1.

[65] SEQ ID NO:10 is a full length protein sequence of Ly1452P, splice variant 1.

[66] SEQ ID NO:11 is a full length cDNA sequence of Ly1452P, splice variant 2.

[67] SEQ ID NO:12 is a full length protein sequence of Ly1452P, splice variant 2.

[68] SEQ ID NO:13 is a partial cDNA sequence of Ly1462P.

25 [69] SEQ ID NO:14 is a full length cDNA sequence of Ly1462P.

[70] SEQ ID NO:15 is a full length protein sequence of Ly1462P.

[71] SEQ ID NO:16 is a partial cDNA sequence of Ly1484P.

[72] SEQ ID NO:17 is a full length cDNA sequence of Ly1484P.

[73] SEQ ID NO:18 is a full length protein sequence of Ly1484P.

30 [74] SEQ ID NO:19 is a partial cDNA sequence of Ly1486P.

[75] SEQ ID NO:20 is a full length cDNA sequence of Ly1486P.

[76] SEQ ID NO:21 is a full length protein sequence of Ly1486P.

[77] SEQ ID NO:22 is a partial cDNA sequence of Ly1677P.

[78] SEQ ID NO:23 is a partial cDNA sequence of Ly1682P.

- [79] SEQ ID NO:24 is a partial cDNA sequence of Ly1693P.
- [80] SEQ ID NO:25 is a full-length cDNA sequence of Ly1693P.
- [81] SEQ ID NO:26 is a full-length protein sequence of Ly1693P.
- [82] SEQ ID NO:27 is a partial cDNA sequence of Ly1697P.
- 5 [83] SEQ ID NO:28 is a full-length cDNA sequence of Ly1715P.
- [84] SEQ ID NO:29 is a full-length protein sequence of Ly1715P.
- [85] SEQ ID NO:30 is a partial cDNA sequence of Ly1727P.
- [86] SEQ ID NO:31 is a full-length cDNA sequence of Ly1727P.
- [87] SEQ ID NO:32 is a full-length protein sequence of Ly1727P.
- 10 [88] SEQ ID NO:33 is a partial cDNA sequence of Ly1885P.
- [89] SEQ ID NO:34 is a full-length cDNA sequence of Ly1885P.
- [90] SEQ ID NO:35 is a full-length protein sequence of Ly1885P.
- [91] SEQ ID NO:36 is a partial cDNA sequence of Ly1905P.
- [92] SEQ ID NO:37 is a partial protein sequence of Ly1905P.
- 15 [93] SEQ ID NO:38 is a partial cDNA sequence of Ly1905P.
- [94] SEQ ID NO:39 is a full-length cDNA sequence of Ly1905P.
- [95] SEQ ID NO:40 is a full-length protein sequence of Ly1905P.
- [96] SEQ ID NO:41 is a partial cDNA sequence of Ly663S.
- [97] SEQ ID NO:42 is a full-length cDNA sequence of Ly663S.
- 20 [98] SEQ ID NO:43 is a full-length protein sequence of Ly663S.
- [99] SEQ ID NO:44 is a full-length cDNA sequence of Ly664S.
- [100] SEQ ID NO:45 is a full-length protein sequence of Ly664S.
- [101] SEQ ID NO:46 is a partial cDNA sequence of Ly667S.
- [102] SEQ ID NO:47 is a full-length cDNA sequence of Ly667S.
- 25 [103] SEQ ID NO:48 is a full-length protein sequence of Ly667S.
- [104] SEQ ID NO:49 is a partial cDNA sequence of Ly677S.
- [105] SEQ ID NO:50 is a partial protein sequence of Ly677S.
- [106] SEQ ID NO:51 is a partial cDNA sequence of Ly677S.
- [107] SEQ ID NO:52 is a partial protein sequence of Ly677S.
- 30 [108] SEQ ID NO:53 is a full-length cDNA sequence of Ly677S.
- [109] SEQ ID NO:54 is a full-length protein sequence of Ly677S.
- [110] SEQ ID NO:55 is a full-length cDNA sequence of Ly1891P.
- [111] SEQ ID NO:56 is a full-length protein sequence of Ly1891P.
- [112] SEQ ID NO:57 is a full-length cDNA sequence of CD138.

- [113] SEQ ID NO:58 is a full-length protein sequence of CD158.
- [114] SEQ ID NO:59 is a partial cDNA sequence of CD22.
- [115] SEQ ID NO:60 is a full-length cDNA sequence of CD22.
- [116] SEQ ID NO:61 is a full-length protein sequence of CD22.
- 5 [117] SEQ ID NO:62 is a partial cDNA sequence of CD79beta.
- [118] SEQ ID NO:63 is a partial protein sequence of CD79beta.
- [119] SEQ ID NO:64 is a partial cDNA sequence of CD79beta.
- [120] SEQ ID NO:65 is a full-length cDNA sequence of CD79beta.
- [121] SEQ ID NO:66 is a full-length protein sequence of CD79beta.
- 10 [122] SEQ ID NO:67 is a partial cDNA sequence of Ly1450P.
- [123] SEQ ID NO:68 is a partial cDNA sequence of Ly1450P.
- [124] SEQ ID NO:69 is a partial cDNA sequence of Ly1451P.
- [125] SEQ ID NO:70 is a partial cDNA sequence of Ly1451P.
- [126] SEQ ID NO:71 is a partial protein sequence of Ly1451P.
- 15 [127] SEQ ID NO:7272>Ly1454P, Old-SEQ-ID_3577, partial cDNA
- [128] SEQ ID NO:73 is a full-length cDNA sequence of Ly1454P.
- [129] SEQ ID NO:74 is a full-length protein sequence of Ly1454P.
- [130] SEQ ID NO:75 is a partial cDNA sequence of Ly1485P.
- [131] SEQ ID NO:76 is a partial protein sequence of Ly1485P.
- 20 [132] SEQ ID NO:77 is a partial cDNA sequence of Ly1485P.
- [133] SEQ ID NO:78 is a partial cDNA sequence of Ly1500P.
- [134] SEQ ID NO:79 is a full-length cDNA sequence of Ly1500P, splice variant 1.
- [135] SEQ ID NO:80 is a full-length protein sequence of Ly1500P, splice variant 1.
- [136] SEQ ID NO:81 is a full-length cDNA sequence of Ly1500P, splice variant 2.
- 25 [137] SEQ ID NO:82 is a full-length protein sequence of Ly1500P, splice variant 2.
- [138] SEQ ID NO:83 is a full-length cDNA sequence of Ly1500P, splice variant 3.
- [139] SEQ ID NO:84 is a full-length protein sequence of Ly1500P, splice variant 3.
- [140] SEQ ID NO:85 is a partial cDNA sequence of Ly1516P.
- [141] SEQ ID NO:86 is a full-length cDNA sequence of Ly1516P, splice variant 1.
- 30 [142] SEQ ID NO:87 is a full-length protein sequence of Ly1516P, splice variant 1.
- [143] SEQ ID NO:88 is a partial cDNA sequence of Ly1516P, splice variant 2.
- [144] SEQ ID NO:89 is a partial cDNA sequence of Ly1516P, splice variant 3.
- [145] SEQ ID NO:90 is a partial cDNA sequence of Ly1678P.
- [146] SEQ ID NO:91 is a partial cDNA sequence of Ly1678P.

- [147] SEQ ID NO:92 is a partial cDNA sequence of Ly1678P.
- [148] SEQ ID NO:93 is a partial cDNA sequence of Ly1678P.
- [149] SEQ ID NO:94 is a partial cDNA sequence of Ly1680P.
- [150] SEQ ID NO:95 is a partial cDNA sequence of Ly1686P.
- 5 [151] SEQ ID NO:96 is a partial cDNA sequence of Ly1687P.
- [152] SEQ ID NO:97 is a partial cDNA sequence of Ly1706P.
- [153] SEQ ID NO:98 is a partial cDNA sequence of Ly1712P.
- [154] SEQ ID NO:99 is a partial cDNA sequence of Ly1729P.
- [155] SEQ ID NO:100 is a full-length cDNA sequence of Ly1729P.
- 10 [156] SEQ ID NO:101 is a full-length protein sequence of Ly1729P.
- [157] SEQ ID NO:102 is a partial cDNA sequence of Ly1848P.
- [158] SEQ ID NO:103 is a partial cDNA sequence of Ly1859P.
- [159] SEQ ID NO:104 is a partial protein sequence of Ly1859P.
- [160] SEQ ID NO:105 is a partial cDNA sequence of Ly1859P.
- 15 [161] SEQ ID NO:106 is a full-length cDNA sequence of Ly1859P.
- [162] SEQ ID NO:107 is a full-length protein sequence of Ly1859P.
- [163] SEQ ID NO:108 is a full length cDNA sequence for Ly1866P
- [164] SEQ ID NO:109 is a full length protein sequence for Ly1866P
- [165] SEQ ID NO:110 is a partial cDNA sequence for Ly1867P.
- 20 [166] SEQ ID NO:111 is a partial cDNA sequence for Ly1868P.
- [167] SEQ ID NO:112 is a partial cDNA sequence for Ly1886P.
- [168] SEQ ID NO:113 is a full length cDNA sequence for Ly669S.
- [169] SEQ ID NO:114 is a full length protein sequence for Ly669S.
- [170] SEQ ID NO:115 is a partial cDNA sequence for Ly672S.
- 25 [171] SEQ ID NO:116 is a full length cDNA sequence for Ly672S.
- [172] SEQ ID NO:117 is a full length cDNA sequence for Ly672S.
- [173] SEQ ID NO:118 is a partial cDNA sequence of Ly675S.
- [174] SEQ ID NO:119 is a partial protein sequence of Ly675S.
- [175] SEQ ID NO:120 is a partial protein sequence of Ly1484P.
- 30 [176] SEQ ID NO:121 is a partial protein sequence of Ly1484P.
- [177] SEQ ID NO:122 is a PCR primer sequence for His-Ly1452P.
- [178] SEQ ID NO:123 is a PCR primer sequence for His-Ly1452P.
- [179] SEQ ID NO:124 is an open reading frame sequence for Ly1451P.

4. DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

[180] In order that the invention herein described may be more fully understood, the following description of various illustrative embodiments is set forth.

5 [181] The present invention is generally directed to compositions and methods for the immunotherapy and diagnosis of Hematological malignancies, such as B cell leukemias and lymphomas and multiple myelomas.

4.1 METHODS OF NUCLEIC ACID DELIVERY AND DNA TRANSFECTION

10 [182] In certain embodiments, it is contemplated that one or more RNA or DNA and/or substituted polynucleotide compositions disclosed herein will be used to transfect an appropriate host cell. Technology for introduction of RNAs and DNAs, and vectors comprising them into suitable host cells is well known to those of skill in the art. In particular, such polynucleotides may be used to genetically transform one or more host cells, when therapeutic administration of one or more active peptides, compounds or vaccines is achieved through the expression of one or more polynucleotide constructs that encode one or more therapeutic compounds of interest.

15 [183] A variety of means for introducing polynucleotides and/or polypeptides into suitable target cells is known to those of skill in the art. For example, when polynucleotides are contemplated for delivery to cells, several non-viral methods for the transfer of expression constructs into cultured mammalian cells are available to the skilled artisan for his use. These include, for example, calcium phosphate precipitation (Graham and Van Der Eb, 1973; Chen and Okayama, 1987; Rippe *et al.*, 1990); DEAE-dextran precipitation (Gopal, 1985); electroporation (Wong and Neumann, 1982; Fromm *et al.*, 1985; Tur-Kaspa *et al.*, 1986; Potter *et al.*, 1984; Suzuki *et al.*, 1998; Vanbever *et al.*, 1998), direct microinjection (Capechi, 1980; Harland and Weintraub, 1985), DNA-loaded liposomes (Nicolau and Sene, 1982; Fraley *et al.*, 1979; Takakura, 1998) and lipofectamine-DNA complexes, cell sonication (Fechheimer *et al.*, 1987), gene bombardment using high velocity microprojectiles (Yang *et al.*, 1990; Klein *et al.*, 1992), and receptor-mediated transfection (Curiel *et al.*, 1991; Wagner *et al.*, 1992; Wu and Wu, 1987; Wu and Wu, 1988). Some of these techniques may be successfully adapted for *in vivo* or *ex vivo* use.

20 [184] A bacterial cell, a yeast cell, or an animal cell transformed with one or more of the disclosed expression vectors represent an important aspect of the present

5

invention. Such transformed host cells are often desirable for use in the expression of the various DNA gene constructs disclosed herein. In some aspects of the invention, it is often desirable to modulate, regulate, or otherwise control the expression of the gene segments disclosed herein. Such methods are routine to those of skill in the molecular genetic arts. Typically, when increased or over-expression of a particular gene is desired, various manipulations may be employed for enhancing the expression of the messenger RNA, particularly by using an active promoter, and in particular, a tissue-specific promoter such as those disclosed herein, as well as by employing sequences, which enhance the stability of the messenger RNA in the particular transformed host cell.

10

15

20

25

30

[185] Typically, the initiation and translational termination region will involve stop codon(s), a terminator region, and optionally, a polyadenylation signal. In the direction of transcription, namely in the 5' to 3' direction of the coding or sense sequence, the construct will involve the transcriptional regulatory region, if any, and the promoter, where the regulatory region may be either 5' or 3' of the promoter, the ribosomal binding site, the initiation codon, the structural gene having an open reading frame in phase with the initiation codon, the stop codon(s), the polyadenylation signal sequence, if any, and the terminator region. This sequence as a double strand may be used by itself for transformation of a microorganism or eukaryotic host, but will usually be included with a DNA sequence involving a marker, where the second DNA sequence may be joined to the expression construct during introduction of the DNA into the host.

[186] Where no functional replication system is present, the construct will also preferably include a sequence of at least about 30 or about 40 or about 50 base pairs (bp) or so, preferably at least about 60, about 70, about 80, or about 90 to about 100 or so bp, and usually not more than about 500 to about 1000 or so bp of a sequence homologous with a sequence in the host. In this way, the probability of legitimate recombination is enhanced, so that the gene will be integrated into the host and stably maintained by the host. Desirably, the regulatory regions of the expression construct will be in close proximity to (and also operably positioned relative to) the selected therapeutic gene providing for complementation as well as the gene providing for the competitive advantage. Therefore, in the event that the therapeutic gene is lost, the resulting organism will be likely to also lose the gene providing for the competitive

advantage, so that it will be unable to compete in the environment with the gene retaining the intact construct.

[187] The selected therapeutic gene can be introduced between the transcriptional and translational initiation region and the transcriptional and translational termination region, so as to be under the regulatory control of the initiation region. This construct may be included in a plasmid, which will include at least one replication system, but may include more than one, where one replication system is employed for cloning during the development of the plasmid and the second replication system is necessary for functioning in the ultimate host, in this case, a mammalian host cell. In addition, one or more markers may be present, which have been described previously. Where integration is desired, the plasmid will desirably include a sequence homologous with the host genome.

[188] Genes or other nucleic acid segments, as disclosed herein, can be inserted into host cells using a variety of techniques that are well known in the art. Five general methods for delivering a nucleic segment into cells have been described: (1) chemical methods (Graham and Van Der Eb, 1973); (2) physical methods such as microinjection (Capecchi, 1980), electroporation (U. S. Patent 5,472,869; Wong and Neumann, 1982; Fromm *et al.*, 1985), microprojectiles bombardment (U. S. Patent 5,874,265, specifically incorporated herein by reference in its entirety), "gene gun" (Yang *et al.*, 1990); (3) viral vectors (Eglitis and Anderson, 1988); (4) receptor-mediated mechanisms (Curiel *et al.*, 1991; Wagner *et al.*, 1992); and (5) bacterial-mediated transformation.

4.2 HEMATOLOGICAL MALIGNANCY RELATED-SPECIFIC ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF

[189] The present invention further provides antibodies and antigen-binding fragments thereof, that specifically bind to (or are immunospecific for) at least a first peptide or peptide variant as disclosed herein. As used herein, an antibody or an antigen-binding fragment is said to "specifically bind" to a peptide if it reacts at a detectable level (within, for example, an ELISA) with the peptide, and does not react detectably with unrelated peptides or proteins under similar conditions. As used herein, "binding" refers to a non-covalent association between two separate molecules such that a "complex" is formed. The ability to bind may be evaluated by, for example, determining a binding constant for the formation of the complex. The

5

binding constant is the value obtained when the concentration of the complex is divided by the product of the component concentrations. In the context of the present invention, in general, two compounds are said to "bind" when the binding constant for complex formation exceeds about 10^3 L/mol. The binding constant maybe determined using methods well known in the art.

10

15

20

25

30

[190] Any agent that satisfies the above requirements may be a binding agent. In illustrative embodiments, a binding agent is an antibody or an antigen-binding fragment thereof. Such antibodies may be prepared by any of a variety of techniques known to those of ordinary skill in the art (Harlow and Lane, 1988). In general, antibodies can be produced by cell culture techniques, including the generation of monoclonal antibodies as described herein, or via transfection of antibody genes into suitable bacterial or mammalian cell hosts, in order to allow for the production of recombinant antibodies. In one technique, an immunogen comprising the peptide is initially injected into any of a wide variety of mammals (e.g., mice, rats, rabbits, sheep or goats). In this step, the peptides of this invention may serve as the immunogen without modification. Alternatively, particularly for relatively short peptides, a superior immune response may be elicited if the peptide is joined to a carrier protein, such as bovine serum albumin or keyhole limpet hemocyanin. The immunogen is injected into the animal host, preferably according to a predetermined schedule incorporating one or more booster immunizations, and the animals are bled periodically. Polyclonal antibodies specific for the peptide may then be purified from such antisera by, for example, affinity chromatography using the peptide coupled to a suitable solid support.

[191] "Antibody" refers to a polypeptide encoded by an immunoglobulin gene or fragments thereof that specifically binds and recognizes an antigen. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.

[192] An exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kD) and one "heavy" chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino

acids primarily responsible for antigen recognition, *i.e.*, an antigen recognition domain. As used herein, "antigen recognition domain" means that part of the antibody, recombinant molecule, the fusion protein, or the immunoconjugate of the invention which recognizes the target or portions thereof. Typically the antigen 5 recognition domain comprises the variable region of the antibody or a portion thereof, *e.g.*, one, two, three, four, five, six, or more hypervariable regions. The terms " V_H " or "VH" refer to the variable region of an immunoglobulin heavy chain, including an Fv, scFv, dsFv or Fab. The terms " V_L " or "VL" refer to the variable region of an immunoglobulin light chain, including an Fv, scFv, dsFv or Fab.

10 [193] Antibodies exist, *e.g.*, as intact immunoglobulins or as a number of well-characterized fragments produced by digestion with various peptidases. Thus, for example, pepsin digests an antibody below the disulfide linkages in the hinge region to produce F(ab)'2, a dimer of Fab which itself is a light chain joined to VH-CH1 by a disulfide bond. The F(ab)'2 may be reduced under mild conditions to break the 15 disulfide linkage in the hinge region, thereby converting the F(ab)'2 dimer into an Fab' monomer. The Fab' monomer is essentially Fab with part of the hinge region (*see* Fundamental Immunology (Paul ed., 3d ed. 1993). Thus, the term antibody, as used herein, also includes antibody fragments either produced by the modification of whole antibodies.

20 [194] As used herein, "fragment" is defined as at least a portion of the variable region of the immunoglobulin molecule, which binds to its target, *i.e.* the antigen recognition domain or the antigen binding region. Some of the constant region of the immunoglobulin may be included. Examples of antibody functional fragments include, but are not limited to, complete antibody molecules, humanized antibodies, 25 antibody fragments, such as Fv, single chain Fv (scFv), hypervariable regions to complementarity determining regions (CDRs), V_L (light chain variable region), V_H (heavy chain variable region), Fab, F(ab)2' and any combination of those or any other portion of an immunoglobulin peptide capable of binding to target antigen (*see, e.g.*, Fundamental Immunology (Paul ed., 4th. 1999). As appreciated by one of skill in the art, various antibody fragments can be obtained by a variety of methods, for example, digestion of an intact antibody with an enzyme, such as pepsin; or *de novo* synthesis. Antibody fragments are often synthesized *de novo* either chemically or by using 30 recombinant DNA methodology. Thus, the term antibody, as used herein, includes antibody fragments either produced by the modification of whole antibodies, or those

synthesized de novo using recombinant DNA methodologies (e.g., single chain Fv) or those identified using phage display libraries (see, e.g., McCafferty *et al.*, (1990) *Nature* 348:552). The term antibody also includes bivalent or bispecific molecules, diabodies, triabodies, and tetrabodies. Bivalent and bispecific molecules are described in, e.g., Kostelny *et al.*, *J. Immunol.* 148: 1547 (1992), Pack and Pluckthun, *Biochemistry* 31: 1579 (1992), Zhu *et al.* *Protein Sci.* 6: 781 (1997), Hu *et al.* *Cancer Res.* 56: 3055 (1996), Adams *et al.*, *Cancer Res.* 53: 4026 (1993), and McCartney, *et al.*, *Protein Eng.* 8: 301 (1995).

5 [195] A "humanized antibody" refers to an antibody in which the antigen binding loops, *i.e.*, complementarity determining regions (CDRs), comprised by the V_H and V_L regions are grafted to a human framework sequence. Typically, the humanized antibodies have the same binding specificity as the non-humanized antibodies described herein. Techniques for humanizing antibodies are well known in the art and are described in *e.g.*, U.S. Patent Nos. 4,816,567; 5,530,101; 5,859,205; 5,585,089; 10 5,693,761; 5,693,762; 5,777,085; 6,180,370; 6,210,671; and 6,329,511; WO 15 87/02671; EP Patent Application 0173494; Jones *et al.*, *Nature* 321: 522 (1986); and Verhoyen *et al.*, *Science* 239: 1534 (1988). Humanized antibodies are further described in, *e.g.*, Winter and Milstein, *Nature* 349: 293 (1991).

20 [196] For preparation of monoclonal or polyclonal antibodies, any technique known in the art can be used (see, *e.g.*, Kohler & Milstein, *Nature* 256: 495-497 (1975); Kozbor *et al.*, *Immunology Today* 4: 72 (1983); Cole *et al.*, pp. 77-96 in MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc. (1985)).

25 [197] Methods of producing of polyclonal antibodies are known to those of skill in the art. In an exemplary method, an inbred strain of mice (*e.g.*, BALB/C mice) or rabbits is immunized with the chelate or a close structural analogue using a standard adjuvant, such as Freund's adjuvant, and a standard immunization protocol. Alternatively, or in addition to the use of an adjuvant, the chelate is coupled to a carrier that is itself immunogenic (*e.g.*, keyhole limpet hemocyanin ("KLH")). The animal's immune response to the immunogen preparation is monitored by taking test bleeds and determining the titer of reactivity to the beta subunits. When appropriately high titers of antibody to the immunogen are obtained, blood is collected from the animal and antisera are prepared. Further fractionation of the antisera to enrich for antibodies reactive to the protein can be done if desired.

[198] Monoclonal antibodies are obtained by various techniques familiar to those skilled in the art. Briefly, spleen cells from an animal immunized with a desired antigen are immortalized, commonly by fusion with a myeloma cell (*see, for example, Kohler & Milstein, Eur. J. Immunol. 6: 511-519 (1976)*). Alternative methods of immortalization include transformation with Epstein Barr Virus, oncogenes, or retroviruses, or other methods well known in the art. Colonies arising from single immortalized cells are screened for production of antibodies of the desired specificity and affinity for the antigen, and yield of the monoclonal antibodies produced by such cells may be enhanced by various techniques, including injection into the peritoneal cavity of a vertebrate host. Alternatively, one may isolate DNA sequences which encode a monoclonal antibody or a binding fragment thereof by screening a DNA library from human B cells according to the general protocol outlined by Huse *et al.*, *Science 246: 1275-1281 (1989)*.

[199] Monoclonal antibodies and polyclonal sera are collected and titered against the immunogen in an immunoassay, for example, a solid phase immunoassay with the immunogen immobilized on a solid support. Typically, polyclonal antisera with a titer of 10^4 or greater are selected and tested for cross reactivity against different chelates, using a competitive binding immunoassay. Specific polyclonal antisera and monoclonal antibodies will usually bind with a K_d of at least about 0.1 mM, more usually at least about 1 μ M, preferably, at least about 0.1 μ M or better, and most preferably, 0.01 μ M or better.

[200] Techniques for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce antibodies to reactive chelates and other diagnostic, analytical and therapeutic agents. Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies. Alternatively, phage display technology can be used to produce and identify antibodies and heteromeric Fab fragments that specifically bind to selected antigens (*see, e.g., McCafferty *et al.*, Nature 348: 552-554 (1990); Marks *et al.*, Biotechnology 10: 779-783 (1992)*).

[201] In an exemplary embodiment, an animal, such as a rabbit or mouse is immunized with a chelate, or an immunogenic construct. The antibodies produced as a result of the immunization are preferably isolated using standard methods.

[202] In a still further preferred embodiment, the antibody is a humanized antibody. "Humanized" refers to a non-human polypeptide sequence that has been modified to

minimize immunoreactivity in humans, typically by altering the amino acid sequence to mimic existing human sequences, without substantially altering the function of the polypeptide sequence (see, e.g., Jones *et al.*, *Nature* 321: 522-525 (1986), and published UK patent application No. 8707252).

5 [203] In another preferred embodiment, the present invention provides an antibody, as described above, further comprising a member selected from detectable labels, biologically active agents and combinations thereof attached to the antibody.

10 [204] When the antibody is conjugated to a detectable label, the label is preferably a member selected from the group consisting of radioactive isotopes, fluorescent agents, fluorescent agent precursors, chromophores, enzymes and combinations thereof.

Methods for conjugating various groups to antibodies are well known in the art. For example, a detectable label that is frequently conjugated to an antibody is an enzyme, such as horseradish peroxidase, alkaline phosphatase, β -galactosidase, and glucose oxidase.

15 [205] Methods of producing antibodies labeled with small molecules, for example, fluorescent agents, are well known in the art. Fluorescent labeled antibodies can be used in immunohistochemical staining (Osborn *et al.*, *Methods Cell Biol.* 24: 97-132 (1990); in flow cytometry or cell sorting techniques (Ormerod, M.G. (ed.), *FLOW CYTOMETRY. A PRACTICAL APPROACH*, IRL Press, New York, 1990); for tracking and localization of antigens, and in various double-staining methods (Kawamura, A., Jr., *FLUORESCENT ANTIBODY TECHNIQUES AND THEIR APPLICATION*, Univ. Tokyo Press, Baltimore, 1977).

20 [206] Many reactive fluorescent labels are available commercially (e.g., Molecular Probes, Eugene, OR) or they can be synthesized using art-recognized techniques. In an exemplary embodiment, an antibody of the invention is labeled with an amine-reactive fluorescent agent, such as fluorescein isothiocyanate under mildly basic conditions. For other examples of antibody labeling techniques, see, Goding, *J. Immunol. Methods* 13: 215-226 (1976); and in, *MONOCLONAL ANTIBODIES: PRINCIPLES AND PRACTICE*, pp. 6-58, Academic Press, Orlando (1988).

25 [207] Monoclonal antibodies specific for the antigenic peptide of interest may be prepared, for example, using the technique of Kohler and Milstein (1976) and improvements thereto. Briefly, these methods involve the preparation of immortal cell lines capable of producing antibodies having the desired specificity (*i.e.*, reactivity with the peptide of interest). Such cell lines may be produced, for example, from

spleen cells obtained from an animal immunized as described above. The spleen cells are then immortalized by, for example, fusion with a myeloma cell fusion partner, preferably one that is syngeneic with the immunized animal. A variety of fusion techniques may be employed. For example, the spleen cells and myeloma cells may be combined with a nonionic detergent for a few minutes and then plated at low density on a selective medium that supports the growth of hybrid cells, but not myeloma cells. A preferred selection technique uses HAT (hypoxanthine, aminopterin, thymidine) selection. After a sufficient time, usually about 1 to 2 weeks, colonies of hybrids are observed. Single colonies are selected and their culture supernatants tested for binding activity against the peptide. Hybridomas having high reactivity and specificity are preferred.

[208] Monoclonal antibodies may be isolated from the supernatants of growing hybridoma colonies. In addition, various techniques may be employed to enhance the yield, such as injection of the hybridoma cell line into the peritoneal cavity of a suitable vertebrate host, such as a mouse. Monoclonal antibodies may then be harvested from the ascites fluid or the blood. Contaminants may be removed from the antibodies by conventional techniques, such as chromatography, gel filtration, precipitation, and extraction. The peptides of this invention may be used in the purification process in, for example, an affinity chromatography step.

[209] Within certain embodiments, the use of antigen-binding fragments of antibodies may be preferred. Such fragments include Fab fragments, which may be prepared using standard techniques. Briefly, immunoglobulins may be purified from rabbit serum by affinity chromatography on Protein A bead columns (Harlow and Lane, 1988) and digested by papain to yield Fab and Fc fragments. The Fab and Fc fragments may be separated by affinity chromatography on Protein A bead columns.

[210] Monoclonal antibodies and fragments thereof may be coupled to one or more therapeutic agents. Suitable agents in this regard include radioactive tracers and chemotherapeutic agents, which may be used, for example, to purge autologous bone marrow *in vitro*). Representative therapeutic agents include radionuclides, differentiation inducers, drugs, toxins, and derivatives thereof. Preferred radionuclides include ⁹⁰Y, ¹²³I, ¹²⁵I, ¹³¹I, ¹⁸⁶Re, ¹⁸⁸Re, ²¹¹At, and ²¹²Bi. Preferred drugs include methotrexate, and pyrimidine and purine analogs. Preferred differentiation inducers include phorbol esters and butyric acid. Preferred toxins include ricin, abrin, diphtheria toxin, cholera toxin, gelonin, *Pseudomonas* exotoxin, *Shigella* toxin, and pokeweed

antiviral protein. For diagnostic purposes, coupling of radioactive agents may be used to facilitate tracing of metastases or to determine the location of hematological malignancy related-positive tumors.

[211] A therapeutic agent may be coupled (*e.g.*, covalently bonded) to a suitable monoclonal antibody either directly or indirectly (*e.g.*, *via* a linker group). A direct reaction between an agent and an antibody is possible when each possesses a substituent capable of reacting with the other. For example, a nucleophilic group, such as an amino or sulphydryl group, on one may be capable of reacting with a carbonyl-containing group, such as an anhydride or an acid halide, or with an alkyl group containing a good leaving group (*e.g.*, a halide) on the other.

[212] Alternatively, it may be desirable to couple a therapeutic agent and an antibody via a linker group. A linker group can function as a spacer to distance an antibody from an agent in order to avoid interference with binding capabilities. A linker group can also serve to increase the chemical reactivity of a substituent on an agent or an antibody, and thus increase the coupling efficiency. An increase in chemical reactivity may also facilitate the use of agents, or functional groups on agents, which otherwise would not be possible.

[213] It will be evident to those skilled in the art that a variety of bifunctional or polyfunctional reagents, both homo- and hetero-functional (such as those described in the catalog of the Pierce Chemical Co., Rockford, IL), may be employed as the linker group. Coupling may be affected, for example, through amino groups, carboxyl groups, and sulphydryl groups or oxidized carbohydrate residues. There are numerous references describing such methodology, *e.g.*, U. S. Patent No. 4,671,958.

[214] Where a therapeutic agent is more potent when free from the antibody portion of the immunoconjugates of the present invention, it may be desirable to use a linker group that is cleavable during or upon internalization into a cell. A number of different cleavable linker groups have been described. The mechanisms for the intracellular release of an agent from these linker groups include cleavage by reduction of a disulfide bond (U. S. Patent No. 4,489,710), by irradiation of a photolabile bond (U. S. Patent No. 4,625,014), by hydrolysis of derivatized amino acid side chains (U. S. Patent No. 4,638,045), by serum complement-mediated hydrolysis (U. S. Patent No. 4,671,958), and acid-catalyzed hydrolysis (U. S. Patent No. 4,569,789).

[215] It may be desirable to couple more than one agent to an antibody. In one embodiment, multiple molecules of an agent are coupled to one antibody molecule. In

another embodiment, more than one type of agent may be coupled to one antibody. Regardless of the particular embodiment, immunoconjugates with more than one agent may be prepared in a variety of ways. For example, more than one agent may be coupled directly to an antibody molecule, or linkers that provide multiple sites for attachment can be used. Alternatively, a carrier can be used. A carrier may bear the agents in a variety of ways, including covalent bonding either directly or via a linker group. Suitable carriers include proteins such as albumins (U. S. Patent No. 4,507,234), peptides and polysaccharides such as aminodextran (U. S. Patent No. 4,699,784). A carrier may also bear an agent by noncovalent bonding or by encapsulation, such as within a liposome vesicle (U. S. Patent No. 4,429,008 and U. S. Patent No. 4,873,088). Carriers specific for radionuclide agents include radiohalogenated small molecules and chelating compounds. For example, U. S. Patent No. 4,735,792 discloses representative radiohalogenated small molecules and their synthesis. A radionuclide chelate may be formed from chelating compounds that include those containing nitrogen and sulfur atoms as the donor atoms for binding the metal, or metal oxide, radionuclide. For example, U. S. Patent No. 4,673,562 discloses representative chelating compounds and their synthesis.

[216] A variety of routes of administration for the antibodies and immunoconjugates may be used. Typically, administration will be intravenous, intramuscular, subcutaneous or in the bed of a resected tumor. It will be evident that the precise dose of the antibody/ immunoconjugate will vary depending upon the antibody used, the antigen density on the tumor, and the rate of clearance of the antibody.

[217] Also provided herein are anti-idiotypic antibodies that mimic an immunogenic portion of hematological malignancy related. Such antibodies may be raised against an antibody, or an antigen-binding fragment thereof, that specifically binds to an immunogenic portion of hematological malignancy related, using well-known techniques. Anti-idiotypic antibodies that mimic an immunogenic portion of hematological malignancy related are those antibodies that bind to an antibody, or antigen-binding fragment thereof, that specifically binds to an immunogenic portion of hematological malignancy related, as described herein.

[218] Irrespective of the source of the original hematological malignancy related peptide-specific antibody, the intact antibody, antibody multimers, or any one of a variety of functional, antigen-binding regions of the antibody may be used in the present invention. Exemplary functional regions include scFv, Fv, Fab', Fab and

F(ab')₂ fragments of the hematological malignancy related peptide specific antibodies. Techniques for preparing such constructs are well known to those in the art and are further exemplified herein.

[219] The choice of antibody construct may be influenced by various factors. For example, prolonged half-life can result from the active readorption of intact antibodies within the kidney, a property of the Fc piece of immunoglobulin. IgG based antibodies, therefore, are expected to exhibit slower blood clearance than their Fab' counterparts. However, Fab' fragment-based compositions will generally exhibit better tissue penetrating capability.

[220] Antibody fragments can be obtained by proteolysis of the whole immunoglobulin by the non-specific thiol protease, papain. Papain digestion yields two identical antigen-binding fragments, termed "Fab fragments," each with a single antigen-binding site, and a residual "Fc fragment."

[221] Papain should first be activated by reducing the sulphydryl group in the active site with cysteine, 2-mercaptoethanol or dithiothreitol. Heavy metals in the stock enzyme should be removed by chelation with EDTA (2 mM) to ensure maximum enzyme activity. Enzyme and substrate are normally mixed together in the ratio of 1:100 by weight. After incubation, the reaction can be stopped by irreversible alkylation of the thiol group with iodoacetamide or simply by dialysis. The completeness of the digestion should be monitored by SDS-PAGE and the various fractions separated by Protein A-Sepharose or ion exchange chromatography.

[222] The usual procedure for preparation of F(ab')₂ fragments from IgG of rabbit and human origin is limited proteolysis by the enzyme pepsin. The conditions, 100x antibody excess wt./wt. in acetate buffer at pH 4.5, 37°C, suggest that antibody is cleaved at the C-terminal side of the inter-heavy-chain disulfide bond. Rates of digestion of mouse IgG may vary with subclass and it may be difficult to obtain high yields of active F(ab')₂ fragments without some undigested or completely degraded IgG. In particular, IgG_{2b} is highly susceptible to complete degradation. The other subclasses require different incubation conditions to produce optimal results, all of which is known in the art.

[223] Pepsin treatment of intact antibodies yields an F(ab')₂ fragment that has two antigen-combining sites and is still capable of cross-linking antigen. Digestion of rat IgG by pepsin requires conditions including dialysis in 0.1 M acetate buffer, pH 4.5, and then incubation for four hrs with 1% wt./wt. pepsin; IgG₁ and IgG_{2a} digestion is

improved if first dialyzed against 0.1 M formate buffer, pH 2.8, at 4°C, for 16 hrs followed by acetate buffer. IgG_{2b} gives more consistent results with incubation in staphylococcal V8 protease (3% wt./wt.) in 0.1 M sodium phosphate buffer, pH 7.8, for four hrs at 37°C.

5 [224] A Fab fragment also contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxyl terminus of the heavy chain CH1 domain including one or more cysteine(s) from the antibody hinge region. F(ab')₂ antibody fragments were originally produced as pairs of Fab' fragments that have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.

10 [225] The term "variable," as used herein in reference to antibodies, means that certain portions of the variable domains differ extensively in sequence among antibodies, and are used in the binding and specificity of each particular antibody to its particular antigen. However, the variability is not evenly distributed throughout the 15 variable domains of antibodies. It is concentrated in three segments termed "hypervariable regions," both in the light chain and the heavy chain variable domains.

20 [226] The more highly conserved portions of variable domains are called the framework region (FR). The variable domains of native heavy and light chains each comprise four FRs (FR1, FR2, FR3 and FR4, respectively), largely adopting a β-sheet configuration, connected by three hypervariable regions, which form loops connecting, and in some cases, forming part of, the β-sheet structure.

25 [227] The hypervariable regions in each chain are held together in close proximity by the FRs and, with the hypervariable regions from the other chain, contribute to the formation of the antigen-binding site of antibodies (Kabat *et al.*, 1991, specifically incorporated herein by reference). The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular toxicity.

30 [228] The term "hypervariable region," as used herein, refers to the amino acid residues of an antibody that are responsible for antigen-binding. The hypervariable region comprises amino acid residues from a "complementarity determining region" or "CDR" (*i.e.* residues 24-34 (L1), 50-56 (L2) and 89-97 (L3) in the light chain variable domain and 31-35 (H1), 50-56 (H2) and 95-102 (H3) in the heavy chain variable domain (Kabat *et al.*, 1991, specifically incorporated herein by reference) and/or those

residues from a "hypervariable loop" (i.e., residues 26-32 (L1), 50-52 (L2) and 91-96 (L3) in the light chain variable domain and 26-32 (H1), 53-55 (H2) and 96-101 (H3) in the heavy chain variable domain). "Framework" or "FR" residues are those variable domain residues other than the hypervariable region residues as herein defined.

5 [229] An "Fv" fragment is the minimum antibody fragment that contains a complete antigen-recognition and binding site. This region consists of a dimer of one heavy chain and one light chain variable domain in tight, con-covalent association. It is in this configuration that three hypervariable regions of each variable domain interact to define an antigen-binding site on the surface of the V_H - V_L dimer. Collectively, six hypervariable regions confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three hypervariable regions specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.

10 [230] "Single-chain Fv" or "sFv" antibody fragments comprise the V_H and V_L domains of antibody, wherein these domains are present in a single polypeptide chain. Generally, the Fv polypeptide further comprises a polypeptide linker between the V_H and V_L domains that enables the sFv to form the desired structure for antigen binding.

15 [231] "Diabodies" are small antibody fragments with two antigen-binding sites, which fragments comprise a heavy chain variable domain (V_H) connected to a light chain variable domain (V_L) in the same polypeptide chain (V_H - V_L). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies are described in European Pat. Appl. No. EP 404,097 and Intl. Pat. Appl. Publ. No. WO 93/11161, each specifically incorporated herein by reference. "Linear antibodies", which can be bispecific or monospecific, comprise a pair of tandem Fd segments (V_H -C_{H1}- V_H -C_{H1}) that form a pair of antigen binding regions, as described in Zapata *et al.* (1995), specifically incorporated herein by reference.

20 [232] Other types of variants are antibodies with improved biological properties relative to the parent antibody from which they are generated. Such variants, or second-generation compounds, are typically substitutional variants involving one or more substituted hypervariable region residues of a parent antibody. A convenient way for generating such substitutional variants is affinity maturation using phage display.

[233] In affinity maturation using phage display, several hypervariable region sites (e.g., 6 to 7 sites) are mutated to generate all possible amino substitutions at each site. The antibody variants thus generated are displayed in a monovalent fashion from filamentous phage particles as fusions to the gene III product of M13 packaged within each particle. The phage-displayed variants are then screened for their biological activity (e.g., binding affinity) as herein disclosed. In order to identify candidate hypervariable region sites for modification, alanine-scanning mutagenesis can be performed on hypervariable region residues identified as contributing significantly to antigen binding.

[234] Alternatively, or in addition, the crystal structure of the antigen-antibody complex be delineated and analyzed to identify contact points between the antibody and target. Such contact residues and neighboring residues are candidates for substitution. Once such variants are generated, the panel of variants is subjected to screening, and antibodies with analogues but different or even superior properties in one or more relevant assays are selected for further development.

[235] In using a Fab' or antigen binding fragment of an antibody, with the attendant benefits on tissue penetration, one may derive additional advantages from modifying the fragment to increase its half-life. A variety of techniques may be employed, such as manipulation or modification of the antibody molecule itself, and also conjugation to inert carriers. Any conjugation for the sole purpose of increasing half-life, rather than to deliver an agent to a target, should be approached carefully in that Fab' and other fragments are chosen to penetrate tissues. Nonetheless, conjugation to non-protein polymers, such PEG and the like, is contemplated.

[236] Modifications other than conjugation are therefore based upon modifying the structure of the antibody fragment to render it more stable, and/or to reduce the rate of catabolism in the body. One mechanism for such modifications is the use of D-amino acids in place of L-amino acids. Those of ordinary skill in the art will understand that the introduction of such modifications needs to be followed by rigorous testing of the resultant molecule to ensure that it still retains the desired biological properties. Further stabilizing modifications include the use of the addition of stabilizing moieties to either the N-terminal or the C-terminal, or both, which is generally used to prolong the half-life of biological molecules. By way of example only, one may wish to modify the termini by acylation or amination.

[237] Moderate conjugation-type modifications for use with the present invention include incorporating a salvage receptor binding epitope into the antibody fragment. Techniques for achieving this include mutation of the appropriate region of the antibody fragment or incorporating the epitope as a peptide tag that is attached to the antibody fragment. Intl. Pat. Appl. Publ. No. WO 96/32478 is specifically incorporated herein by reference for the purposes of further exemplifying such technology. Salvage receptor binding epitopes are typically regions of three or more amino acids from one or two loops of the Fc domain that are transferred to the analogous position on the antibody fragment. The salvage receptor-binding epitopes disclosed in Intl. Pat. Appl. Publ. No. WO 98/45331 are incorporated herein by reference for use with the present invention.

4.3 T CELL COMPOSITIONS SPECIFIC FOR HEMATOLOGICAL MALIGNANCY-RELATED PEPTIDES

[238] Immunotherapeutic compositions may also, or alternatively, comprise T cells specific for hematological malignancy related. Such cells may generally be prepared *in vitro* or *ex vivo*, using standard procedures. For example, T cells may be present within (or isolated from) bone marrow, peripheral blood or a fraction of bone marrow or peripheral blood of a mammal, such as a patient, using a commercially available cell separation system, such as the Isolex™ System, available from Nexell Therapeutics, Inc. (Irvine, CA; see also U. S. Patent No. 5,240,856; U. S. Patent No. 5,215,926; Intl. Pat. Appl. Publ. No. WO 89/06280; Intl. Pat. Appl. Publ. No. WO 91/16116 and Intl. Pat. Appl. Publ. No. WO 92/07243). Alternatively, T cells may be derived from related or unrelated humans, non-human mammals, cell lines or cultures.

[239] T cells may be stimulated with hematological malignancy related peptide, polynucleotide encoding a hematological malignancy related peptide and/or an antigen-presenting cell (APC) that expresses a hematological malignancy related peptide. Such stimulation is performed under conditions and for a time sufficient to permit the generation of T cells that are specific for the hematological malignancy related peptide. Preferably, a hematological malignancy related peptide or polynucleotide is present within a delivery vehicle, such as a microsphere, to facilitate the generation of antigen-specific T cells. Briefly, T cells, which may be isolated from a patient or a related or unrelated donor by routine techniques (such as by Ficoll/Hypaque® density gradient centrifugation of peripheral blood lymphocytes),

are incubated with hematological malignancy related peptide. For example, T cells may be incubated *in vitro* for 2-9 days (typically 4 days) at 37°C with hematological malignancy related peptide (e.g., 5 to 25 µg/ml) or cells synthesizing a comparable amount of hematological malignancy related peptide. It may be desirable to incubate a separate aliquot of a T cell sample in the absence of hematological malignancy related peptide to serve as a control.

[240] T cells are considered to be specific for a hematological malignancy related peptide if the T cells kill target cells coated with a hematological malignancy related peptide or expressing a gene encoding such a peptide. T cell specificity may be evaluated using any of a variety of standard techniques. For example, within a chromium release assay or proliferation assay, a stimulation index of more than two fold increase in lysis and/or proliferation, compared to negative controls, indicates T cell specificity. Such assays may be performed, for example, as described in Chen *et al.* (1994). Alternatively, detection of the proliferation of T cells may be accomplished by a variety of known techniques. For example, T cell proliferation can be detected by measuring an increased rate of DNA synthesis (e.g., by pulse-labeling cultures of T cells with tritiated thymidine and measuring the amount of tritiated thymidine incorporated into DNA). Other ways to detect T cell proliferation include measuring increases in interleukin-2 (IL-2) production, Ca²⁺ flux, or dye uptake, such as 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium. Alternatively, synthesis of lymphokines (such as interferon-gamma) can be measured or the relative number of T cells that can respond to a hematological malignancy related peptide may be quantified. Contact with a hematological malignancy related peptide (200 ng/ml - 100 µg/ml, preferably 100 ng/ml - 25 µg/ml) for 3-7 days should result in at least a two-fold increase in proliferation of the T cells and/or contact as described above for 2-3 hrs should result in activation of the T cells, as measured using standard cytokine assays in which a two-fold increase in the level of cytokine release (e.g., TNF or IFN-γ) is indicative of T cell activation (Coligan *et al.*, 1998). hematological malignancy related specific T cells may be expanded using standard techniques. Within preferred embodiments, the T cells are derived from a patient or a related or unrelated donor and are administered to the patient following stimulation and expansion.

[241] T cells that have been activated in response to a hematological malignancy related peptide, polynucleotide or hematological malignancy related-expressing APC may be CD4⁺ and/or CD8⁺. Specific activation of CD4⁺ or CD8⁺ T cells may be

detected in a variety of ways. Methods for detecting specific T cell activation include detecting the proliferation of T cells, the production of cytokines (e.g., lymphokines), or the generation of cytolytic activity (*i.e.*, generation of cytotoxic T cells specific for hematological malignancy related). For CD4⁺ T cells, a preferred method for detecting specific T cell activation is the detection of the proliferation of T cells. For CD8⁺ T cells, a preferred method for detecting specific T cell activation is the detection of the generation of cytolytic activity.

5 [242] For therapeutic purposes, CD4⁺ or CD8⁺ T cells that proliferate in response to the hematological malignancy related peptide, polynucleotide or APC can be expanded in number either *in vitro* or *in vivo*. Proliferation of such T cells *in vitro* may be accomplished in a variety of ways. For example, the T cells can be re-exposed to hematological malignancy related peptide, with or without the addition of T cell growth factors, such as interleukin-2, and/or stimulator cells that synthesize a hematological malignancy related peptide. The addition of stimulator cells is preferred where generating CD8⁺ T cell responses. T cells can be grown to large numbers *in vitro* with retention of specificity in response to intermittent restimulation with hematological malignancy related peptide. Briefly, for the primary *in vitro* stimulation (IVS), large numbers of lymphocytes (e.g., greater than 4×10^7) may be placed in flasks with media containing human serum. hematological malignancy related peptide (e.g., peptide at 10 µg/ml) may be added directly, along with tetanus toxoid (e.g., 5 µg/ml). The flasks may then be incubated (e.g., 37°C for 7 days). For a second IVS, T cells are then harvested and placed in new flasks with $2-3 \times 10^7$ irradiated peripheral blood mononuclear cells. hematological malignancy related peptide (e.g., 10 µg/ml) is added directly. The flasks are incubated at 37°C for 7 days.

10 On day 2 and day 4 after the second IVS, 2-5 units of interleukin-2 (IL-2) may be added. For a third IVS, the T cells may be placed in wells and stimulated with the individual's own EBV transformed B cells coated with the peptide. IL-2 may be added on days 2 and 4 of each cycle. As soon as the cells are shown to be specific cytotoxic T cells, they may be expanded using a 10-day stimulation cycle with higher IL-2 (20 units) on days 2, 4 and 6.

15

20

25

30

[243] Alternatively, one or more T cells that proliferate in the presence of hematological malignancy related peptide can be expanded in number by cloning. Methods for cloning cells are well known in the art, and include limiting dilution. Responder T cells may be purified from the peripheral blood of sensitized patients by

density gradient centrifugation and sheep red cell rosetting and established in culture by stimulating with the nominal antigen in the presence of irradiated autologous filler cells. In order to generate CD4⁺ T cell lines, hematological malignancy related peptide is used as the antigenic stimulus and autologous peripheral blood lymphocytes (PBL) or lymphoblastoid cell lines (LCL) immortalized by infection with Epstein Barr virus are used as antigen-presenting cells. In order to generate CD8⁺ T cell lines, autologous antigen-presenting cells transfected with an expression vector that produces hematological malignancy related peptide may be used as stimulator cells. Established T cell lines may be cloned 2-4 days following antigen stimulation by plating stimulated T cells at a frequency of 0.5 cells per well in 96-well flat-bottom plates with 1×10^6 irradiated PBL or LCL cells and recombinant interleukin-2 (rIL2) (50 U/ml). Wells with established clonal growth may be identified at approximately 2-3 weeks after initial plating and restimulated with appropriate antigen in the presence of autologous antigen-presenting cells, then subsequently expanded by the addition of low doses of rIL2 (10 U/ml) 2-3 days following antigen stimulation. T cell clones may be maintained in 24-well plates by periodic restimulation with antigen and rIL2 approximately every two weeks. Cloned and/or expanded cells may be administered back to the patient as described, for example, by Chang *et al.*, (1996).

[244] Within certain embodiments, allogeneic T-cells may be primed (*i.e.*, sensitized to hematological malignancy related) *in vivo* and/or *in vitro*. Such priming may be achieved by contacting T cells with a hematological malignancy related peptide, a polynucleotide encoding such a peptide or a cell producing such a peptide under conditions and for a time sufficient to permit the priming of T cells. In general, T cells are considered to be primed if, for example, contact with a hematological malignancy related peptide results in proliferation and/or activation of the T cells, as measured by standard proliferation, chromium release and/or cytokine release assays as described herein. A stimulation index of more than two fold increase in proliferation or lysis, and more than three fold increase in the level of cytokine, compared to negative controls indicates T-cell specificity. Cells primed *in vitro* may be employed, for example, within bone marrow transplantation or as donor lymphocyte infusion.

[245] T cells specific for hematological malignancy related can kill cells that express hematological malignancy related protein. Introduction of genes encoding T-cell receptor (TCR) chains for hematological malignancy related are used as a means

to quantitatively and qualitatively improve responses to hematological malignancy related bearing leukemia and cancer cells. Vaccines to increase the number of T cells that can react to hematological malignancy related positive cells are one method of targeting hematological malignancy related bearing cells. T cell therapy with T cells specific for hematological malignancy related is another method. An alternative method is to introduce the TCR chains specific for hematological malignancy related into T cells or other cells with lytic potential. In a suitable embodiment, the TCR alpha and beta chains are cloned out from a hematological malignancy related specific T cell line and used for adoptive T cell therapy, such as described in WO 96/30516, incorporated herein by reference.

4.4 PHARMACEUTICAL COMPOSITIONS AND VACCINE FORMULATIONS

[246] Within certain aspects, peptides, polynucleotides, antibodies and/or T cells may be incorporated into pharmaceutical compositions or immunogenic compositions (*i.e.*, vaccines). Alternatively, a pharmaceutical composition may comprise an antigen-presenting cell (*e.g.*, a dendritic cell) transfected with a hematological malignancy related polynucleotide such that the antigen-presenting cell expresses a hematological malignancy related peptide. Pharmaceutical compositions comprise one or more such compounds or cells and a physiologically acceptable carrier or excipient. Vaccines may comprise one or more such compounds or cells and an immunostimulant, such as an adjuvant or a liposome (into which the compound is incorporated). An immunostimulant may be any substance that enhances or potentiates an immune response (antibody- and/or cell-mediated) to an exogenous antigen. Examples of immunostimulants include adjuvants, biodegradable microspheres (*e.g.*, polylactic galactide) and liposomes (into which the compound is incorporated) (U. S. Patent No. 4,235,877). Vaccine preparation is generally described in, for example, Powell and Newman (1995). Pharmaceutical compositions and vaccines within the scope of the present invention may also contain other compounds, which may be biologically active or inactive. For example, one or more immunogenic portions of other tumor antigens may be present, either incorporated into a fusion peptide or as a separate compound, within the composition or vaccine.

[247] Within certain embodiments, pharmaceutical compositions and vaccines are designed to elicit T cell responses specific for a hematological malignancy related peptide in a patient, such as a human. In general, T cell responses may be favored

through the use of relatively short peptides (e.g., comprising less than 23 consecutive amino acid residues of a native hematological malignancy related peptide, preferably 4-16 consecutive residues, more preferably 8-16 consecutive residues and still more preferably 8-10 consecutive residues). Alternatively, or in addition, a vaccine may 5 comprise an immunostimulant that preferentially enhances a T cell response. In other words, the immunostimulant may enhance the level of a T cell response to a hematological malignancy related peptide by an amount that is proportionally greater than the amount by which an antibody response is enhanced. For example, when compared to a standard oil based adjuvant, such as CFA, an immunostimulant that 10 preferentially enhances a T cell response may enhance a proliferative T cell response by at least two fold, a lytic response by at least 10%, and/or T cell activation by at least two fold compared to hematological malignancy related-negative control cell lines, while not detectably enhancing an antibody response. The amount by which a T 15 cell or antibody response to a hematological malignancy related peptide is enhanced may generally be determined using any representative technique known in the art, such as the techniques provided herein.

[248] A pharmaceutical composition or vaccine may contain DNA encoding one or more of the peptides as described above, such that the peptide is generated *in situ*. As noted above, the DNA may be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid expression systems, bacterial and viral expression systems and mammalian expression systems. Numerous gene delivery techniques are well known in the art (Rolland, 1998, and references cited therein). Appropriate nucleic acid expression systems contain the necessary 20 DNA, cDNA or RNA sequences for expression in the patient (such as a suitable promoter and terminating signal). Bacterial delivery systems involve the administration of a bacterium (such as *Bacillus-Calmette-Guerrin*) that expresses an immunogenic portion of the peptide on its cell surface or secretes such an epitope. In a preferred embodiment, the DNA may be introduced using a viral expression system 25 (e.g., vaccinia or other pox virus, retrovirus, or adenovirus), which may involve the use of a non-pathogenic (defective), replication competent virus (Fisher-Hoch *et al.*, 1989; Flexner *et al.*, 1989; Flexner *et al.*, 1990; U. S. Patent No. 4,603,112, U. S. Patent No. 4,769,330, U. S. Patent No. 5,017,487; Intl. Pat. Appl. Publ. No. 30 WO 89/01973; U. S. Patent No. 4,777,127; Great Britain Patent No. GB 2,200,651; European Patent No. EP 0,345,242; Intl. Pat. Appl. Publ. No. WO 91/02805; Berkner,

1988; Rosenfeld *et al.*, 1991; Kolls *et al.*, 1994; Kass-Eisler *et al.*, 1993; Guzman *et al.*, 1993a; and Guzman *et al.*, 1993). Techniques for incorporating DNA into such expression systems are well known to those of ordinary skill in the art. The DNA may also be "naked," as described, for example, in Ulmer *et al.* (1993) and reviewed by Cohen (1993). The uptake of naked DNA may be increased by coating the DNA onto biodegradable beads, which are efficiently transported into the cells. It will be apparent that a vaccine may comprise both a polynucleotide and a peptide component. Such vaccines may provide for an enhanced immune response.

5 [249] As noted above, a pharmaceutical composition or vaccine may comprise an antigen-presenting cell that expresses a hematological malignancy related peptide. For therapeutic purposes, as described herein, the antigen-presenting cell is preferably an autologous dendritic cell. Such cells may be prepared and transfected using standard techniques (Reeves *et al.*, 1996; Tuting *et al.*, 1998; and Nair *et al.*, 1998). Expression of a hematological malignancy related peptide on the surface of an antigen-presenting cell may be confirmed by *in vitro* stimulation and standard proliferation as well as chromium release assays, as described herein.

10 [250] It will be apparent to those of ordinary skill in the art having the benefit of the present teachings that a vaccine may contain pharmaceutically acceptable salts of the polynucleotides and peptides provided herein. Such salts may be prepared from pharmaceutically acceptable non-toxic bases, including organic bases (e.g., salts of primary, secondary and tertiary amines and basic amino acids) and inorganic bases (e.g., sodium, potassium, lithium, ammonium, calcium and magnesium salts). The phrases "pharmaceutically or pharmacologically acceptable" refer to molecular entities and compositions that do not produce an adverse, allergic or other significant 15 untoward reaction when administered to an animal, or a human, as appropriate. As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical 20 active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic 25 compositions is contemplated. For human administration, preparations should meet sterility, pyrogenicity, and general safety and purity standards as required by the Food and Drug Administration Office of Biologics standards. Supplementary active 30 ingredients can also be incorporated into the compositions.

[251] While any suitable carrier known to those of ordinary skill in the art may be employed in the pharmaceutical compositions of this invention, the type of carrier will vary depending on the mode of administration. Compositions of the present invention may be formulated for any appropriate manner of administration, including for example, topical, oral, nasal, intravenous, intracranial, intraperitoneal, subcutaneous or intramuscular administration. For parenteral administration, such as subcutaneous injection, the carrier preferably comprises water, saline, alcohol, a fat, a wax or a buffer. For oral administration, any of the above carriers or a solid carrier, such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, and magnesium carbonate, may be employed. Biodegradable microspheres (e.g., polylactate polyglycolate) may also be employed as carriers for the pharmaceutical compositions of this invention. Suitable biodegradable microspheres are disclosed, for example, in U. S. Patent Nos. 4,897,268; 5,075,109; 5,928,647; 5,811,128; 5,820,883; 5,853,763; 5,814,344 and 5,942,252. For certain topical applications, formulation as a cream or lotion, using well-known components, is preferred.

[252] Such compositions may also comprise buffers (e.g., neutral buffered saline or phosphate buffered saline), carbohydrates (e.g., glucose, mannose, sucrose or dextrans), mannitol, proteins, peptides or amino acids such as glycine, antioxidants, bacteriostats, chelating agents such as EDTA or glutathione, adjuvants (e.g., aluminum hydroxide), solutes that render the formulation isotonic, hypotonic or weakly hypertonic with the blood of a recipient, suspending agents, thickening agents and/or preservatives. Alternatively, compositions of the present invention may be formulated as a lyophilizate, or formulated with one or more liposomes, microspheres, nanoparticles, or micronized delivery systems using well-known technology.

[253] Any of a variety of immunostimulants, such as adjuvants, may be employed in the preparation of vaccine compositions of this invention. Most adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A, *Bordetella pertussis* or *Mycobacterium tuberculosis* derived proteins. Suitable adjuvants are commercially available as, for example, alum-based adjuvants (e.g., Alhydrogel, Rehydragel, aluminum phosphate, Algammulin, aluminum hydroxide); oil based adjuvants (Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, MI), Specol, RIBI, TiterMax, Montanide ISA50 or Seppic

MONTANIDE ISA 720); nonionic block copolymer-based adjuvants, cytokines (e.g., GM-CSF or Flt3-ligand); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ); AS-2 (SmithKline Beecham, Philadelphia, PA); salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and Quil A. Cytokines, such as GM-CSF or interleukin-2, -7, or -12, may also be used as adjuvants.

5

[254] Hemocyanins and hemoerythrins may also be used in the invention. The use of hemocyanin from keyhole limpet (KLH) is particularly preferred, although other molluscan and arthropod hemocyanins and hemoerythrins may be employed. Various polysaccharide adjuvants may also be used. Polyamine varieties of polysaccharides are particularly preferred, such as chitin and chitosan, including deacetylated chitin.

10

[255] A further preferred group of adjuvants are the muramyl dipeptide (MDP, N-acetylmuramyl-L-alanyl-D-isoglutamine) group of bacterial peptidoglycans.

15

Derivatives of muramyl dipeptide, such as the amino acid derivative threonyl-MDP, and the fatty acid derivative MTPPE, are also contemplated.

20

[256] U. S. Patent No. 4,950,645 describes a lipophilic disaccharide-tripeptide derivative of muramyl dipeptide that is proposed for use in artificial liposomes formed from phosphatidyl choline and phosphatidyl glycerol. It is said to be effective in activating human monocytes and destroying tumor cells, but is non-toxic in generally high doses. The compounds of U. S. Patent No. 4,950,645, and Int'l. Pat. Appl. Publ. No. WO 91/16347 are also proposed for use in achieving particular aspects of the present invention.

25

[257] BCG and BCG-cell wall skeleton (CWS) may also be used as adjuvants in the invention, with or without trehalose dimycolate. Trehalose dimycolate may be used itself. Azuma *et al.* (1988) show that trehalose dimycolate administration correlates with augmented resistance to influenza virus infection in mice. Trehalose dimycolate may be prepared as described in U. S. Patent No. 4,579,945.

30

[258] Amphipathic and surface-active agents, e.g., saponin and derivatives such as QS21 (Cambridge Biotech), form yet another group of preferred adjuvants for use with the immunogens of the present invention. Nonionic block copolymer surfactants (Rabinovich *et al.*, 1994; Hunter *et al.*, 1991) may also be employed.

Oligonucleotides, as described by Yamamoto *et al.* (1988) are another useful group of adjuvants. Quil A and lentinen are also preferred adjuvants.

5

[259] Superantigens are also contemplated for use as adjuvants in the present invention. "Superantigens" are generally bacterial products that stimulate a greater proportion of T lymphocytes than peptide antigens without a requirement for antigen processing (Mooney *et. al.*, 1994). Superantigens include *Staphylococcus* exoproteins, such as the α , β , γ and δ enterotoxins from *S. aureus* and *S. epidermidis*, and the α , β , γ and δ *E. coli* exotoxins.

10

[260] Common *Staphylococcus* enterotoxins are known as staphylococcal enterotoxin A (SEA) and staphylococcal enterotoxin B (SEB), with enterotoxins through E (SEE) being described (Rott *et. al.*, 1992). *Streptococcus pyogenes* B (SEB), *Clostridium perfringens* enterotoxin (Bowness *et. al.*, 1992), cytoplasmic membrane-associated protein (CAP) from *S. pyogenes* (Sato *et. al.*, 1994) and toxic shock syndrome toxin-1 (TSST-1) from *S. aureus* (Schwab *et. al.*, 1993) are further useful superantigens.

15

[261] One group of adjuvants particularly preferred for use in the invention are the detoxified endotoxins, such as the refined detoxified endotoxin of U. S. Patent No. 4,866,034. These refined detoxified endotoxins are effective in producing adjuvant responses in mammals.

20

[262] The detoxified endotoxins may be combined with other adjuvants. Combination of detoxified endotoxins with trehalose dimycolate is contemplated, as described in U. S. Patent No. 4,435,386. Combinations of detoxified endotoxins with trehalose dimycolate and endotoxic glycolipids is also contemplated (U. S. Patent No. 4,505,899), as is combination of detoxified endotoxins with cell wall skeleton (CWS) or CWS and trehalose dimycolate, as described in U. S. Patent Nos. 4,436,727, 4,436,728 and 4,505,900. Combinations of just CWS and trehalose dimycolate, without detoxified endotoxins are also envisioned to be useful, as described in U. S. Patent No. 4,520,019.

25

30

[263] MPL is currently one preferred immunopotentiating agent for use herein. References that concern the uses of MPL include Tomai *et al.* (1987), Chen *et al.* (1991) and Garg and Subbarao (1992), that each concern certain roles of MPL in the reactions of aging mice; Elliott *et al.* (1991), that concerns the D-galactosamine loaded mouse and its enhanced sensitivity to lipopolysaccharide and MPL; Chase *et al.* (1986), that relates to bacterial infections; and Masihi *et al.* (1988), that describes the effects of MPL and endotoxin on resistance of mice to *Toxoplasma gondii*. Fitzgerald

(1991) also reported on the use of MPL to up-regulate the immunogenicity of a syphilis vaccine and to confer significant protection against challenge infection in rabbits.

[264] Thus MPL is known to be safe for use, as shown in the above model systems. Phase-I clinical trials have also shown MPL to be safe for use (Vosika *et al.*, 1984).

5 Indeed, 100 µg/m² is known to be safe for human use, even on an outpatient basis (Vosika *et al.*, 1984).

[265] MPL generally induces polyclonal B cell activation (Baker *et al.*, 1994), and has been shown to augment antibody production in many systems, for example, in 10 immunologically immature mice (Baker *et al.*, 1988); in aging mice (Tomai and Johnson, 1989); and in nude and Xid mice (Madonna and Vogel, 1986; Myers *et al.*, 1995). Antibody production has been shown against erythrocytes (Hraba *et al.*, 1993); 15 T cell dependent and independent antigens; Pnu-immune vaccine (Garg and Subbarao, 1992); isolated tumor-associated antigens (U. S. Patent 4,877,611); against syngeneic tumor cells (Livingston *et al.*, 1985; Ravindranath *et al.*, 1994a;b); and against tumor-associated gangliosides (Ravindranath *et al.*, 1994a;b).

[266] Another useful attribute of MPL is that it augments IgM responses, as shown 20 by Baker *et al.* (1988a), who describe the ability of MPL to increase antibody responses in young mice. This is a particularly useful feature of an adjuvant for use in certain embodiments of the present invention. Myers *et al.* (1995) recently reported on the ability of MPL to induce IgM antibodies, by virtue T cell-independent antibody 25 production.

[267] In the Myers *et al.* (1995) studies, MPL was conjugated to the hapten, TNP. MPL was proposed for use as a carrier for other haptens, such as peptides.

[268] MPL also activates and recruits macrophages (Verma *et al.*, 1992). Tomai 25 and Johnson (1989) showed that MPL-stimulated T cells enhance IL-1 secretion by macrophages. MPL is also known to activate superoxide production, lysozyme activity, phagocytosis, and killing of Candida in murine peritoneal macrophages (Chen *et al.*, 1991).

[269] The effects of MPL on T cells include the endogenous production of cytotoxic 30 factors, such as TNF, in serum of BCG-primed mice by MPL (Bennett *et al.*, 1988). Kovach *et al.* (1990) and Elliot *et al.* (1991) also show that MPL induces TNF activity. MPL is known to act with TNF-α to induce release of IFN-γ by NK cells. IFN-γ production by T cells in response to MPL was also documented by Tomai and Johnson (1989), and Odean *et al.* (1990).

[270] MPL is also known to be a potent T cell adjuvant. For example, MPL stimulates proliferation of melanoma-antigen specific CTLs (Mitchell *et al.*, 1988, 1993). Further, Baker *et al.* (1988b) showed that nontoxic MPL inactivated suppressor T cell activity. Naturally, in the physiological environment, the inactivation of T suppressor cells allows for increased benefit for the animal, as realized by, e.g., increased antibody production. Johnson and Tomai (1988) have reported on the possible cellular and molecular mediators of the adjuvant action of MPL.

[271] MPL is also known to induce aggregation of platelets and to phosphorylate a platelet protein prior to induction of serotonin secretion (Grabarek *et al.*, 1990). This study shows that MPL is involved in protein kinase C activation and signal transduction.

[272] Many articles concern the structure and function of MPL include. These include Johnson *et al.* (1990), that describes the structural characterization of MPL homologs obtained from *Salmonella minnesota* Re595 lipopolysaccharide. The work of Johnson *et al.* (1990), in common with Grabarek *et al.* (1990), shows that the fatty acid moieties of MPL can vary, even in commercial species. In separating MPL into eight fractions by thin layer chromatography, Johnson *et al.* (1990) found that three were particularly active, as assessed using human platelet responses. The chemical components of the various MPL species were characterized by Johnson *et al.* (1990).

[273] Baker *et al.* (1992) further analyzed the structural features that influence the ability of lipid A and its analogs to abolish expression of suppressor T cell activity. They reported that decreasing the number of phosphate groups in lipid A from two to one (i.e., creating monophosphoryl lipid A, MPL) as well as decreasing the fatty acyl content, primarily by removing the residue at the 3 position, resulted in a progressive reduction in toxicity; however, these structural modifications did not influence its ability to abolish the expression of Ts function (Baker *et al.*, 1992). These types of MPL are ideal for use in the present invention.

[274] Baker *et al.* (1992) also showed that reducing the fatty acyl content from five to four (lipid A precursor IV_A or I_a) eliminated the capacity to influence Ts function but not to induce polyclonal activation of B cells. These studies show that in order to be able to abolish the expression of Ts function, lipid A must be a glucosamine disaccharide; may have either one or two phosphate groups; and must have at least five fatty acyl groups. Also, the chain length of the nonhydroxylated fatty acid, as

well as the location of acyloxyacyl groups (2' versus 3' position), may play an important role (Baker *et al.*, 1992).

[275] In examining the relationship between chain length and position of fatty acyl groups on the ability of lipid A to abolish the expression of suppressor T-cell (Ts) activity, Baker *et al.* (1994) found that fatty acyl chain lengths of C₁₂ to C₁₄ appeared to be optimal for bioactivity. Therefore, although their use is still possible, lipid A preparations with fatty acyl groups of relatively short chain length (C₁₀ to C₁₂ from *Pseudomonas aeruginosa* and *Chromobacterium violaceum*) or predominantly long chain length (C₁₈ from *Helicobacter pylori*) are less preferred for use in this invention.

[276] Baker *et al.* (1994) also showed that the lipid A proximal inner core region oligosaccharides of some bacterial lipopolysaccharides increase the expression of Ts activity; due mainly to the capacity of such oligosaccharides, which are relatively conserved in structure among gram-negative bacterial, to enlarge or expand upon the population of CD8⁺ Ts generated during the course of a normal antibody response to unrelated microbial antigens. The minimal structure required for the expression of the added immunosuppression observed was reported to be a hexasaccharide containing one 2-keto-3-deoxyoctonate residue, two glucose residues, and three heptose residues to which are attached two pyrophosphorylethanolamine groups (Baker *et al.*, 1994). This information may be considered in utilizing or even designing further adjuvants for use in the invention.

[277] In a generally related line of work, Tanamoto *et al.* (1994a;b; 1995) described the dissociation of endotoxic activities in a chemically synthesized Lipid A precursor after acetylation or succinylation. Thus, compounds such as "acetyl 406" and "succinyl 516" (Tanamoto *et al.*, 1994a;b; 1995) are also contemplated for use in the invention.

[278] Synthetic MPLs form a particularly preferred group of antigens. For example, Brade *et al.* (1993) described an artificial glycoconjugate containing the bisphosphorylated glucosamine disaccharide backbone of lipid A that binds to anti-Lipid A MAbs. This is one candidate for use in certain aspects of the invention.

[279] The MPL derivatives described in U. S. Patent No. 4,987,237 are particularly contemplated for use in the present invention. U. S. Patent No. 4,987,237 describes MPL derivatives that contain one or more free groups, such as amines, on a side chain attached to the primary hydroxyl groups of the monophosphoryl lipid A nucleus through an ester group. The derivatives provide a convenient method for coupling the

lipid A through coupling agents to various biologically active materials. The immunostimulant properties of lipid A are maintained. All MPL derivatives in accordance with U. S. Patent No. 4,987,237 are envisioned for use in the MPL adjuvant-incorporated cells of this invention.

5 [280] Various adjuvants, even those that are not commonly used in humans, may still be employed in animals, where, for example, one desires to raise antibodies or to subsequently obtain activated T cells. The toxicity or other adverse effects that may result from either the adjuvant or the cells, *e.g.*, as may occur using non-irradiated tumor cells, is irrelevant in such circumstances.

10 [281] Within the vaccines provided herein, the adjuvant composition is preferably designed to induce an immune response predominantly of the Th1 type. High levels of Th1-type cytokines (*e.g.*, IFN- γ , TNF α , IL-2 and IL-12) tend to favor the induction of cell-mediated immune responses to an administered antigen. In contrast, high levels of Th2-type cytokines (*e.g.*, IL-4, IL-5, IL-6 and IL-10) tend to favor the induction of humoral immune responses. Following application of a vaccine as provided herein, a patient will support an immune response that includes Th1- and Th2-type responses. Within a preferred embodiment, in which a response is predominantly Th1-type, the level of Th1-type cytokines will increase to a greater extent than the level of Th2-type cytokines. The levels of these cytokines may be readily assessed using standard assays. For a review of the families of cytokines see *e.g.*, Mosmann and Coffman (1989).

20 [282] Preferred adjuvants for use in eliciting a predominantly Th1-type response include, for example, a combination of monophosphoryl lipid A, preferably 3-de-O-acetylated monophosphoryl lipid A (3D-MPL), together with an aluminum salt. MPL adjuvants are available from Corixa Corporation (Seattle, WA; see *e.g.*, U. S. Patent Nos. 4,436,727; 4,877,611; 4,866,034 and 4,912,094, each of which is specifically incorporated herein by reference in its entirety). CpG-containing oligonucleotides (in which the CpG dinucleotide is unmethylated) also induce a predominantly Th1 response. Such oligonucleotides are well known and are described, for example, in Intl. Pat. Appl. Publ. No. WO 96/02555 and Intl. Pat. Appl. Publ. No. WO 99/33488. Immunostimulatory DNA sequences are also described, for example, by Sato *et al.* (1996). Another preferred adjuvant is a saponin, preferably QS21 (Aquila Biopharmaceuticals Inc., Framingham, MA), which may be used alone or in combination with other adjuvants. For example, an enhanced system involves the

combination of a monophosphoryl lipid A and saponin derivative, such as the combination of QS21 and 3D-MPL (see e.g., Intl. Pat. Appl. Publ. No. WO 94/00153), or a less reactogenic composition where the QS21 is quenched with cholesterol (see e.g., Intl. Pat. Appl. Publ. No. WO 96/33739). Other preferred formulations comprise an oil-in-water emulsion and tocopherol. A particularly potent adjuvant formulation involving QS21, 3D-MPL and tocopherol in an oil-in-water emulsion has also been described (see e.g., Intl. Pat. Appl. Publ. No. WO 95/17210).

5

[283] Other preferred adjuvants include Montanide ISA 720 (Seppic), SAF (Chiron), ISCOMS (CSL), MF-59 (Chiron), the SBAS series of adjuvants (e.g., SBAS-2 or SBAS-4, available from SmithKline Beecham, Rixensart, Belgium), Detox (Corixa Corporation), RC-529 (Corixa Corporation) and aminoalkyl glucosaminide 4-phosphates (AGPs).

10

15

20

25

30

[284] Any vaccine provided herein may be prepared using well-known methods that result in a combination of one or more antigens, one or more immunostimulants or adjuvants and one or more suitable carriers, excipients, or pharmaceutically acceptable buffers. The compositions described herein may be administered as part of a sustained release formulation (*i.e.*, a formulation such as a capsule, sponge or gel [composed of polysaccharides, for example] that effects a slow release of compound following administration). Such formulations may generally be prepared using well-known technology (Coombes *et al.*, 1996) and administered by, for example, oral, rectal or subcutaneous implantation, or by implantation at the desired target site. Sustained-release formulations may contain a peptide, polynucleotide or antibody dispersed in a carrier matrix and/or contained within a reservoir surrounded by a rate-controlling membrane.

[285] Carriers for use within such formulations are preferably biocompatible, and may also be biodegradable; preferably the formulation provides a relatively constant level of active component release. Such carriers include microparticles of poly(lactide-co-glycolide), as well as polyacrylate, latex, starch, cellulose and dextran. Other delayed-release carriers include supramolecular biovectors, which comprise a non-liquid hydrophilic core (e.g., a cross-linked polysaccharide or oligosaccharide) and, optionally, an external layer comprising an amphiphilic compound, such as a phospholipid (U. S. Patent No. 5,151,254; Intl. Pat. Appl. Publ. No. WO 94/20078; Intl. Pat. Appl. Publ. No. WO/94/23701; and Intl. Pat. Appl. Publ. No. WO 96/06638). The amount of active compound contained within a sustained release formulation

depends upon the site of implantation, the rate and expected duration of release and the nature of the condition to be treated or prevented.

[286] Any of a variety of delivery vehicles may be employed within pharmaceutical compositions and vaccines to facilitate production of an antigen-specific immune response that targets tumor cells. Delivery vehicles include antigen-presenting cells (APCs), such as dendritic cells, macrophages, B cells, monocytes and other cells that may be engineered to be efficient APCs. Such cells may, but need not, be genetically modified to increase the capacity for presenting the antigen, to improve activation and/or maintenance of the T cell response, to have anti-tumor effects *per se* and/or to be immunologically compatible with the receiver (*i.e.*, matched HLA haplotype). APCs may generally be isolated from any of a variety of biological fluids and organs, including tumor and peritumoral tissues, and may be autologous, allogeneic, syngeneic or xenogeneic cells.

[287] Certain preferred embodiments of the present invention use dendritic cells or progenitors thereof as antigen-presenting cells. Dendritic cells are highly potent APCs (Banchereau and Steinman, 1998) and have been shown to be effective as a physiological adjuvant for eliciting prophylactic or therapeutic antitumor immunity (Timmerman and Levy, 1999). In general, dendritic cells may be identified based on their typical shape (stellate *in situ*, with marked cytoplasmic processes (dendrites) visible *in vitro*), their ability to take up, process and present antigens with high efficiency and their ability to activate naive T cell responses. Dendritic cells may, of course, be engineered to express specific cell-surface receptors or ligands that are not commonly found on dendritic cells *in vivo* or *ex vivo*, and such modified dendritic cells are contemplated by the present invention. As an alternative to dendritic cells, secreted vesicles antigen-loaded dendritic cells (called exosomes) may be used within a vaccine (Zitvogel *et al.*, 1998).

[288] Dendritic cells and progenitors may be obtained from peripheral blood, bone marrow, tumor-infiltrating cells, peritumoral tissues-infiltrating cells, lymph nodes, spleen, skin, umbilical cord blood or any other suitable tissue or fluid. For example, dendritic cells may be differentiated *ex vivo* by adding a combination of cytokines such as GM-CSF, IL-4, IL-13 and/or TNF α to cultures of monocytes harvested from peripheral blood. Alternatively, CD34 positive cells harvested from peripheral blood, umbilical cord blood or bone marrow may be differentiated into dendritic cells by adding to the culture medium combinations of GM-CSF, IL-3, TNF α , CD40 ligand,

LPS, flt3 ligand and/or other compound(s) that induce differentiation, maturation and proliferation of dendritic cells.

[289] Dendritic cells are conveniently categorized as "immature" and "mature" cells, which allows a simple way to discriminate between two well characterized phenotypes. However, this nomenclature should not be construed to exclude all possible intermediate stages of differentiation. Immature dendritic cells are characterized as APC with a high capacity for antigen uptake and processing, which correlates with the high expression of Fc γ receptor and mannose receptor. The mature phenotype is typically characterized by a lower expression of these markers, but a high expression of cell surface molecules responsible for T cell activation such as class I and class II MHC, adhesion molecules (e.g., CD54 and CD11) and costimulatory molecules (e.g., CD40, CD80, CD86 and 4-1BB).

[290] APCs may generally be transfected with a polynucleotide encoding a hematological malignancy related peptide, such that the peptide, or an immunogenic portion thereof, is expressed on the cell surface. Such transfection may take place *ex vivo*, and a composition or vaccine comprising such transfected cells may then be used for therapeutic purposes, as described herein. Alternatively, a gene delivery vehicle that targets a dendritic or other antigen-presenting cell may be administered to a patient, resulting in transfection that occurs *in vivo*. *In vivo* and *ex vivo* transfection of dendritic cells, for example, may generally be performed using any methods known in the art, such as those described in Intl. Pat. Appl. Publ. No. WO 97/24447, or the gene gun approach described by Mahvi *et al.* (1997). Antigen loading of dendritic cells may be achieved by incubating dendritic cells or progenitor cells with the hematological malignancy related peptide, DNA (naked or within a plasmid vector) or RNA; or with antigen-expressing recombinant bacterium or viruses (e.g., vaccinia, fowlpox, adenovirus or lentivirus vectors). Prior to loading, the peptide may be covalently conjugated to an immunological partner that provides T cell help (e.g., a carrier molecule). Alternatively, a dendritic cell may be pulsed with a non-conjugated immunological partner, separately or in the presence of the peptide.

[291] Combined therapeutics is also contemplated, and the same type of underlying pharmaceutical compositions may be employed for both single and combined medicaments. Vaccines and pharmaceutical compositions may be presented in unit-dose or multi-dose containers, such as sealed ampoules or vials. Such containers are preferably hermetically sealed to preserve sterility of the formulation until use. In

general, formulations may be stored as suspensions, solutions or emulsions in oily or aqueous vehicles. Alternatively, a vaccine or pharmaceutical composition may be stored in a freeze-dried condition requiring only the addition of a sterile liquid carrier immediately prior to use.

5

4.5 DIAGNOSTIC AND PROGNOSTIC METHODS FOR HEMATOLOGICAL MALIGNANCY DISEASES

[292] The present invention further provides methods for detecting a malignant disease associated with one or more of the polypeptide or polynucleotide compositions disclosed herein, and for monitoring the effectiveness of an immunization or therapy for such a disease. To determine the presence or absence of a malignant disease associated with one or more of the polypeptide or polynucleotide compositions disclosed herein, a patient may be tested for the level of T cells specific for one or more of such compositions. Within certain methods, a biological sample comprising CD4⁺ and/or CD8⁺ T cells isolated from a patient is incubated with one or more of the polypeptide or polynucleotide compositions disclosed herein, and/or an APC that expresses one or more of such peptides or polypeptides, and the presence or absence of specific activation of the T cells is detected, as described herein. Suitable biological samples include, but are not limited to, isolated T cells. For example, T cells may be isolated from a patient by routine techniques (such as by Ficoll/Hypaque density gradient centrifugation of peripheral blood lymphocytes). T cells may be incubated *in vitro* for 2-9 days (typically 4 days) at 37°C with one or more of the disclosed peptide, polypeptide or polynucleotide compositions (e.g., 5-25 µg/ml). It may be desirable to incubate another aliquot of a T cell sample in the absence of the composition to serve as a control. For CD4⁺ T cells, activation is preferably detected by evaluating proliferation of the T cells. For CD8⁺ T cells, activation is preferably detected by evaluating cytolytic activity. A level of proliferation that is at least two fold greater and/or a level of cytolytic activity that is at least 20% greater than in disease-free patients indicates the presence of a malignant disease associated with expression or one or more of the disclosed polypeptide or polynucleotide compositions. Further correlation may be made, using methods well known in the art, between the level of proliferation and/or cytolytic activity and the predicted response to therapy. In particular, patients that display a higher antibody, proliferative and/or lytic response may be expected to show a greater response to therapy.

[293] Within other methods, a biological sample obtained from a patient is tested for the level of antibody specific for one or more of the hematological malignancy-related peptides or polypeptides disclosed herein. The biological sample is incubated with hematological malignancy-related peptide or polypeptide, or a polynucleotide encoding such a peptide or polypeptide, and/or an APC that expresses such a peptide or polypeptide under conditions and for a time sufficient to allow immunocomplexes to form. Immunocomplexes formed between the selected peptide or polypeptide and antibodies in the biological sample that specifically bind to the selected peptide or polypeptide are then detected. A biological sample for use within such methods may be any sample obtained from a patient that would be expected to contain antibodies. Suitable biological samples include blood, sera, ascites, bone marrow, pleural effusion, and cerebrospinal fluid.

[294] The biological sample is incubated with the selected peptide or polypeptide in a reaction mixture under conditions and for a time sufficient to permit immunocomplexes to form between the selected peptide or polypeptide and antibodies that are immunospecific for such a peptide or polypeptide. For example, a biological sample and a selected peptide or polypeptide peptide may be incubated at 4°C for 24-48 hrs.

[295] Following the incubation, the reaction mixture is tested for the presence of immunocomplexes. Detection of immunocomplexes formed between the selected peptide or polypeptide and antibodies present in the biological sample may be accomplished by a variety of known techniques, such as radioimmunoassays (RIA) and enzyme linked immunosorbent assays (ELISA). Suitable assays are well known in the art and are amply described in the scientific and patent literature (Harlow and Lane, 1988). Assays that may be used include, but are not limited to, the double monoclonal antibody sandwich immunoassay technique (U. S. Patent No. 4,376,110); monoclonal-polyclonal antibody sandwich assays (Wide *et al.*, 1970); the "western blot" method (U. S. Patent No. 4,452,901); immunoprecipitation of labeled ligand (Brown *et al.*, 1980); enzyme-linked immunosorbent assays (Raines and Ross, 1982); immunocytochemical techniques, including the use of fluorochromes (Brooks *et al.*, 1980); and neutralization of activity (Bowen-Pope *et al.*, 1984). Other immunoassays include, but are not limited to, those described in U. S. Patent Nos. 3,817,827; 3,850,752; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; and 4,098,876.

[296] For detection purposes, the selected peptide or polypeptide may either be labeled or unlabeled. Unlabeled polypeptide peptide may be used in agglutination assays or in combination with labeled detection reagents that bind to the immunocomplexes (e.g., anti-immunoglobulin, protein G, Protein A or a lectin and secondary antibodies, or antigen-binding fragments thereof, capable of binding to the antibodies that specifically bind to the selected hematological malignancy-related peptide or polypeptide). If the selected peptide or polypeptide is labeled, the reporter group may be any suitable reporter group known in the art, including radioisotopes, fluorescent groups, luminescent groups, enzymes, biotin and dye particles.

[297] Within certain assays, unlabeled peptide or polypeptide is immobilized on a solid support. The solid support may be any material known to those of ordinary skill in the art to which the peptide may be attached. For example, the solid support may be a test well in a microtiter plate or a nitrocellulose or other suitable membrane. Alternatively, the support may be a bead or disc, such as glass, fiberglass, latex or a plastic material such as polystyrene or polyvinylchloride. The support may also be a magnetic particle or a fiber optic sensor, such as those disclosed, for example, in U. S. Patent No. 5,359,681. The peptide may be immobilized on the solid support using a variety of techniques known to those of skill in the art, which are amply described in the patent and scientific literature. In the context of the present invention, the term "immobilization" refers to both noncovalent association, such as adsorption, and covalent attachment (which may be a direct linkage between the antigen and functional groups on the support or may be a linkage by way of a cross-linking agent). Immobilization by adsorption to a well in a microtiter plate or to a membrane is preferred. In such cases, adsorption may be achieved by contacting the selected peptide or polypeptide, in a suitable buffer, with the solid support for a suitable amount of time. The contact time varies with temperature, but is typically between about 1 hour and about 1 day. In general, contacting a well of a plastic microtiter plate (such as polystyrene or polyvinylchloride) with an amount of peptide ranging from about 10 ng to about 10 µg, and preferably about 100 ng to about 1 µg, is sufficient to immobilize an adequate amount of peptide.

[298] Following immobilization, the remaining protein binding sites on the support are typically blocked. Any suitable blocking agent known to those of ordinary skill in the art, such as bovine serum albumin, Tween™ 20™ (Sigma Chemical Co., St. Louis, MO), heat-inactivated normal goat serum (NGS), or BLOTO (buffered solution of

nonfat dry milk which also contains a preservative, salts, and an anti-foaming agent) may be used. The support is then incubated with a biological sample suspected of containing specific antibody. The sample can be applied neat, or, more often, it can be diluted, usually in a buffered solution which contains a small amount (0.1%-5.0% by weight) of protein, such as BSA, NGS, or BLOTT. In general, an appropriate contact time (*i.e.*, incubation time) is a period of time that is sufficient to detect the presence of antibody or an antigen binding fragment that is immunospecific for the selected peptide or polypeptide within a sample containing such an antibody or binding fragment thereof. Preferably, the contact time is sufficient to achieve a level of binding that is at least about 95% of that achieved at equilibrium between bound and unbound antibody or antibody fragment. Those of ordinary skill in the art will recognize that the time necessary to achieve equilibrium may be readily determined by assaying the level of binding that occurs over a period of time. At room temperature, an incubation time of about 30 min is generally sufficient.

[299] Unbound sample may then be removed by washing the solid support with an appropriate buffer, such as PBS containing 0.1% Tween™ 20. A detection reagent that binds to the immunocomplexes and that comprises at least a first detectable label or "reporter" molecule may then be added. The detection reagent is incubated with the immunocomplex for an amount of time sufficient to detect the bound antibody or antigen binding fragment thereof. An appropriate amount of time may generally be determined by assaying the level of binding that occurs over a period of time. Unbound label or detection reagent is then removed and bound label or detection reagent is detected using a suitable assay or analytical instrument. The method employed for detecting the reporter group depends upon the nature of the reporter group. For radioactive labels, scintillation counting or autoradiographic methods are generally appropriate. Spectroscopic methods may be used to detect dyes, luminescent or chemiluminescent moieties and various chromogens, fluorescent labels and such like. Biotin may be detected using avidin, coupled to a different reporter group (commonly a radioactive or fluorescent group or an enzyme). Enzyme reporter groups (*e.g.*, horseradish peroxidase, β -galactosidase, alkaline phosphatase and glucose oxidase) may generally be detected by the addition of substrate (generally for a specific period of time), followed by spectroscopic or other analysis of the reaction products. Regardless of the specific method employed, a level of bound detection reagent that is at least two fold greater than background (*i.e.*, the level observed for a

biological sample obtained from a disease-free individual) indicate the presence of a malignant disease associated with expression of the selected peptide or polypeptide.

[300] In general, methods for monitoring the effectiveness of an immunization or therapy involve monitoring changes in the level of antibodies or T cells specific for the selected peptide or polypeptide in a sample, or in an animal such as a human patient.

5 Methods in which antibody levels are monitored may comprise the steps of:

(a) incubating a first biological sample, obtained from a patient prior to a therapy or immunization, with a selected peptide or polypeptide, wherein the incubation is performed under conditions and for a time sufficient to allow immunocomplexes to form; (b) detecting immunocomplexes formed between the selected peptide or polypeptide and antibodies or antigen binding fragments in the biological sample that specifically bind to the selected peptide or polypeptide; (c) repeating steps (a) and (b) using a second biological sample taken from the patient at later time, such as for example, following a given therapy or immunization; and (d) comparing the number of immunocomplexes detected in the first and second biological samples. Alternatively, a polynucleotide encoding the selected peptide or polypeptide, or an APC expressing the selected peptide or polypeptide may be employed in place of the selected peptide or polypeptide itself. Within such methods, immunocomplexes between the selected peptide or polypeptide encoded by a polynucleotide, or expressed by the APC, and antibodies and/or antigen binding fragments in the biological sample are detected.

20 [301] Methods in which T cell activation and/or the number of hematological malignancy polypeptide-specific precursors are monitored may comprise the steps of:

(a) incubating a first biological sample comprising CD4⁺ and/or CD8⁺ cells (e.g., bone marrow, peripheral blood or a fraction thereof), obtained from a patient prior to a therapy or immunization, with a hematological malignancy peptide or polypeptide, wherein the incubation is performed under conditions and for a time sufficient to allow specific activation, proliferation and/or lysis of T cells; (b) detecting an amount of activation, proliferation and/or lysis of the T cells; (c) repeating steps (a) and (b) using a second biological sample comprising CD4⁺ and/or CD8⁺ T cells, and taken from the same patient following therapy or immunization; and (d) comparing the amount of activation, proliferation and/or lysis of T cells in the first and second biological samples. Alternatively, a polynucleotide encoding a hematological malignancy related

peptide, or an APC expressing such a peptide may be employed in place of the hematological malignancy peptide itself.

[302] A biological sample for use within such methods may be any sample obtained from a patient that would be expected to contain antibodies, CD4⁺ T cells and/or CD8⁺ T cells. Suitable biological samples include blood, sera, ascites, bone marrow, pleural effusion and cerebrospinal fluid. A first biological sample may be obtained prior to initiation of therapy or immunization or part way through a therapy or vaccination regime. The second biological sample should be obtained in a similar manner, but at a time following additional therapy or immunization. The second biological sample may be obtained at the completion of, or part way through, therapy or immunization, provided that at least a portion of therapy or immunization takes place between the isolation of the first and second biological samples.

[303] Incubation and detection steps for both samples may generally be performed as described above. A statistically significant increase in the number of immunocomplexes in the second sample relative to the first sample reflects successful therapy or immunization.

4.6 ADMINISTRATION OF PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS

[304] In certain embodiments, the present invention concerns formulation of one or more of the polynucleotide, polypeptide, peptide, antibody, or antigen binding fragment compositions disclosed herein in pharmaceutically acceptable solutions for administration to a cell or an animal, either alone, or in combination with one or more other modalities of anti-cancer therapy, or in combination with one or more diagnostic or therapeutic agents.

[305] It will also be understood that, if desired, the nucleic acid segment, RNA, or DNA compositions disclosed herein may be administered in combination with other agents as well, such as, e.g., proteins or peptides or various pharmaceutically-active agents. As long as the composition comprises at least one of the genetic expression constructs disclosed herein, there is virtually no limit to other components that may also be included, given that the additional agents do not cause a significant adverse effect upon contact with the target cells or host tissues. The RNA- or DNA-derived compositions may thus be delivered along with various other agents as required in the particular instance. Such RNA or DNA compositions may be purified from host cells or other biological sources, or alternatively may be chemically synthesized as

described herein. Likewise, such compositions may comprise substituted or derivatized RNA or DNA compositions. Such compositions may include one or more therapeutic gene constructs, either alone, or in combination with one or more modified peptide or nucleic acid substituent derivatives, and/or other anticancer therapeutics.

5 [306] The formulation of pharmaceutically-acceptable excipients and carrier solutions are well-known to those of skill in the art, as is the development of suitable dosing and treatment regimens for using the particular compositions described herein in a variety of treatment regimens, including *e.g.*, oral, intravenous, intranasal, transdermal, intraprostatic, intratumoral, and/or intramuscular administration and
10 formulation.

4.6.1 INJECTABLE DELIVERY

15 [307] For example, the pharmaceutical compositions disclosed herein may be administered parenterally, intravenously, intramuscularly, or even intraperitoneally as described in U. S. Patent 5,543,158, U. S. Patent 5,641,515 and U. S. Patent 5,399,363 (each specifically incorporated herein by reference in its entirety). Solutions of the active compounds as free-base or pharmacologically acceptable salts may be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose.
20 Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

25 [308] The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions (U. S. Patent 5,466,468, specifically incorporated herein by reference in its entirety). In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol
30 (*e.g.*, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils. Proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and

antifungal agents, for example, parabens, chlorobutanol, phenol, ~~salic~~ acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

5 [309] For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, sterile aqueous media that can be employed will be known to those of skill in the art in light of the present disclosure. For example, one dosage may be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, Hoover, 1975). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject. Moreover, for human administration, preparations should meet sterility, pyrogenicity, and general safety and purity standards as required by FDA Office of Biologics standards.

10 [310] Sterile injectable solutions may be prepared by incorporating the gene therapy constructs in the required amount in the appropriate solvent with several of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

15 [311] The compositions disclosed herein may be formulated in a neutral or salt form. Pharmaceutically-acceptable salts, include the acid addition salts and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such

organic bases as isopropylamine, trimethylamine, histidine, procaine and the like. Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective. The formulations are easily administered in a variety of dosage forms such as injectable solutions, drug release capsules and the like.

5 [312] As used herein, "carrier" includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. 10 Supplementary active ingredients can also be incorporated into the compositions.

4.6.2 INTRANASAL DELIVERY

15 [313] One may use nasal solutions or sprays, aerosols or even inhalants for the treatment of hematological malignancies with one of more of the disclosed peptides and polynucleotides. Nasal solutions are usually aqueous solutions designed for administration to the nasal passages in drops or sprays. Nasal solutions are prepared so that they are similar in many respects to nasal secretions, so that normal ciliary action is maintained. Thus, the aqueous nasal solutions usually are isotonic and slightly buffered to maintain a pH of from about 5.5 to about 6.5. In addition, 20 antimicrobial preservatives, similar to those used in ophthalmic preparations, and appropriate drug stabilizers, if required, may be included in the formulation. Various commercial nasal preparations are known.

25 [314] Inhalations and inhalants are pharmaceutical preparations designed for delivering a drug or compound into the respiratory tree of a patient. A vapor or mist is administered and reaches the affected area, often to give relief from symptoms of bronchial and nasal congestion. However, this route can also be employed to deliver agents into the systemic circulation. Inhalations may be administered by the nasal or oral respiratory routes. The administration of inhalation solutions is only effective if the droplets are sufficiently fine and uniform in size so that the mist reaches the 30 bronchioles.

[315] Another group of products, also known as inhalations, and sometimes called insufflations, consists of finely powdered or liquid drugs that are carried into the

respiratory passages by the use of special delivery systems, such as pharmaceutical aerosols, that hold a solution or suspension of the drug in a liquefied gas propellant. When released through a suitable valve and oral adapter, a metered dose of the inhalation is propelled into the respiratory tract of the patient.

5 [316] Particle size is of importance in the administration of this type of preparation. It has been reported that the optimum particle size for penetration into the pulmonary cavity is of the order of about 0.5 to about 7 μm . Fine mists are produced by pressurized aerosols and hence their use is considered advantageous.

10 4.6.3 LIPOSOME-, NANOCAPSULE-, AND MICROPARTICLE-MEDIATED DELIVERY

15 [317] In certain embodiments, the inventors contemplate the use of liposomes, nanocapsules, microparticles, microspheres, lipid particles, vesicles, and the like, for the introduction of the polynucleotide compositions of the present invention into suitable host cells. In particular, the polynucleotide compositions of the present invention may be formulated for delivery either encapsulated in a lipid particle, a

liposome, a vesicle, a nanosphere, or a nanoparticle or the like.

20 [318] Such formulations may be preferred for the introduction of pharmaceutically acceptable formulations of the nucleic acids disclosed herein. The formation and use of liposomes is generally known to those of skill in the art (see for example, Couvreur *et al.*, 1977; Couvreur, 1988; Lasic, 1998; which describes the use of liposomes and nanocapsules in the targeted antibiotic therapy for intracellular bacterial infections and diseases). Recently, liposomes were developed with improved serum stability and circulation half-lives (Gabizon and Papahadjopoulos, 1988; Allen and Choun, 1987; U. S. Patent 5,741,516, specifically incorporated herein by reference in its entirety). Further, various methods of liposome and liposome like preparations as potential drug carriers have been reviewed (Takakura, 1998; Chandran *et al.*, 1997; Margalit, 1995; U. S. Patent 5,567,434; U. S. Patent 5,552,157; U. S. Patent 5,565,213; U. S. Patent 5,738,868 and U. S. Patent 5,795,587, each specifically incorporated herein by reference in its entirety).

25 [319] Liposomes have been used successfully with a number of cell types that are normally resistant to transfection by other procedures including T cell suspensions, primary hepatocyte cultures and PC12 cells (Renneisen *et al.*, 1990; Muller *et al.*, 1990). In addition, liposomes are free of the DNA length constraints that are typical of viral-based delivery systems. Liposomes have been used effectively to introduce

genes, drugs (Heath and Martin, 1986; Heath *et al.*, 1986; Balazs *et al.*, 1989; Fresta and Puglisi, 1996), radiotherapeutic agents (Pikul *et al.*, 1987), enzymes (Imaizumi *et al.*, 1990a; Imaizumi *et al.*, 1990b), viruses (Faller and Baltimore, 1984), transcription factors and allosteric effectors (Nicolau and Gersonde, 1979) into a variety of cultured cell lines and animals. In addition, several successful clinical trials examining the effectiveness of liposome-mediated drug delivery have been completed (Lopez-Berestein *et al.*, 1985a; 1985b; Coune, 1988; Sculier *et al.*, 1988). Furthermore, several studies suggest that the use of liposomes is not associated with autoimmune responses, toxicity or gonadal localization after systemic delivery (Mori and Fukatsu, 1992).

10 [320] Liposomes are formed from phospholipids that are dispersed in an aqueous medium and spontaneously form multilamellar concentric bilayer vesicles (also termed multilamellar vesicles (MLVs). MLVs generally have diameters of from 25 nm to 4 μm . Sonication of MLVs results in the formation of small unilamellar vesicles (SUVs) with diameters in the range of 200 to 500 Å, containing an aqueous solution in the core.

15 [321] Liposomes bear resemblance to cellular membranes and are contemplated for use in connection with the present invention as carriers for the peptide compositions. They are widely suitable as both water- and lipid-soluble substances can be entrapped, *i.e.* in the aqueous spaces and within the bilayer itself, respectively. It is possible that the drug-bearing liposomes may even be employed for site-specific delivery of active agents by selectively modifying the liposomal formulation.

20 [322] In addition to the teachings of Couvreur *et al.* (1977; 1988), the following information may be utilized in generating liposomal formulations. Phospholipids can form a variety of structures other than liposomes when dispersed in water, depending on the molar ratio of lipid to water. At low ratios the liposome is the preferred structure. The physical characteristics of liposomes depend on pH, ionic strength and the presence of divalent cations. Liposomes can show low permeability to ionic and polar substances, but at elevated temperatures undergo a phase transition which markedly alters their permeability. The phase transition involves a change from a closely packed, ordered structure, known as the gel state, to a loosely packed, less-ordered structure, known as the fluid state. This occurs at a characteristic phase-transition temperature and results in an increase in permeability to ions, sugars, and drugs.

[323] Alternatively, the invention provides for pharmaceutically acceptable nanocapsule formulations of the polynucleotide compositions of the present invention. Nanocapsules can generally entrap compounds in a stable and reproducible way (Henry-Michelland *et al.*, 1987; Quintanar-Guerrero *et al.*, 1998; Douglas *et al.*, 1987). To avoid side effects due to intracellular polymeric overloading, such ultrafine particles (sized around 0.1 µm) should be designed using polymers able to be degraded *in vivo*. Biodegradable polyalkyl-cyanoacrylate nanoparticles that meet these requirements are contemplated for use in the present invention, and such particles may be easily made, as described (Couvreur *et al.*, 1980; 1988; zur Muhlen *et al.*, 1998; Zambaux *et al.* 1998; Pinto-Alphandry *et al.*, 1995 and U. S. Patent 5,145,684, specifically incorporated herein by reference in its entirety). In particular, methods of polynucleotide delivery to a target cell using either nanoparticles or nanospheres (Schwab *et al.*, 1994; Truong-Le *et al.*, 1998) are also particularly contemplated to be useful in formulating the disclosed compositions for administration to an animal, and to a human in particular.

4.7 THERAPEUTIC AGENTS AND KITS

[324] The invention also provides one or more of the hematological malignancy-related compositions formulated with one or more pharmaceutically acceptable excipients, carriers, diluents, adjuvants, and/or other components for use in the preparation of medicaments, or diagnostic reagents, as well as various kits comprising one or more of such compositions, medicaments, or formulations intended for administration to an animal in need thereof, or for use in one or more diagnostic assays for identifying polynucleotides, polypeptides, and/or antibodies that are specific for one or more hematological malignancy-related compounds as described herein. In addition to the disclosed epitopes, antibodies and antigen binding fragments, antibody- or antigen binding fragment-encoding polynucleotides or additional anticancer agents, polynucleotides, peptides, antigens, or other therapeutic compounds as may be employed in the formulation of particular compositions and formulations disclosed herein, and particularly in the preparation of anticancer agents or anti-hematological malignancies therapies for administration to the affected mammal.

[325] As such, preferred animals for administration of the pharmaceutical compositions disclosed herein include mammals, and particularly humans. Other preferred animals include primates, sheep, goats, bovines, equines, porcines, lupines,

canines, and felines, as well as any other mammalian species commonly considered pets, livestock, or commercially relevant animal species. The compositions and formulations may include partially or significantly purified polypeptide, polynucleotide, or antibody or antigen binding fragment compositions, either alone, or in combination with one or more additional active ingredients, anticancer agents, vaccines, adjuvants, or other therapeutics which may be obtained from natural or recombinant sources, or which may be obtainable naturally or either chemically synthesized, or alternatively produced *in vitro* from recombinant host cells expressing one or more nucleic acid segments that encode one or more such additional active ingredients, carriers, adjuvants, cofactors, or other therapeutic compound.

4.8 DIAGNOSTIC REAGENTS AND KITS

[326] The invention further provides diagnostic reagents and kits comprising one or more such reagents for use in a variety of diagnostic assays, including for example, immunoassays such as ELISA and "sandwich"-type immunoassays. Such kits may preferably include at least a first peptide, or a first antibody or antigen binding fragment of the invention, a functional fragment thereof, or a cocktail thereof, and means for signal generation. The kit's components may be pre-attached to a solid support, or may be applied to the surface of a solid support when the kit is used. The signal generating means may come pre-associated with an antibody of the invention or may require combination with one or more components, *e.g.*, buffers, antibody-enzyme conjugates, enzyme substrates, or the like, prior to use. Kits may also include additional reagents, *e.g.*, blocking reagents for reducing nonspecific binding to the solid phase surface, washing reagents, enzyme substrates, and the like. The solid phase surface may be in the form of microtiter plates, microspheres, or other materials suitable for immobilizing proteins, peptides, or polypeptides. Preferably, an enzyme that catalyzes the formation of a chemiluminescent or chromogenic product or the reduction of a chemiluminescent or chromogenic substrate is a component of the signal generating means. Such enzymes are well known in the art.

[327] Such kits are useful in the detection, monitoring and diagnosis of conditions characterized by over-expression or inappropriate expression of hematological malignancy-related peptides, polypeptides, antibodies, and/or polynucleotides, as well as hybridomas, host cells, and vectors comprising one or more such compositions as disclosed herein.

[328] The therapeutic and diagnostic kits of the present invention may also be prepared that comprise at least one of the antibody, peptide, antigen binding fragment, hybridoma, vector, vaccine, polynucleotide, or cellular compositions disclosed herein and instructions for using the composition as a diagnostic reagent or therapeutic agent.

5 Containers for use in such kits may typically comprise at least one vial, test tube, flask, bottle, syringe or other suitable container, into which one or more of the diagnostic and/or therapeutic composition(s) may be placed, and preferably suitably aliquoted.

10 Where a second therapeutic agent is also provided, the kit may also contain a second distinct container into which this second diagnostic and/or therapeutic composition may be placed. Alternatively, a plurality of compounds may be prepared in a single pharmaceutical composition, and may be packaged in a single container means, such as a vial, flask, syringe, bottle, or other suitable single container. The kits of the present invention will also typically include a means for containing the vial(s) in close confinement for commercial sale, such as, e.g., injection or blow-molded plastic

15 containers into which the desired vial(s) are retained. Where a radiolabel, chromogenic, fluorogenic, or other type of detectable label or detecting means is included within the kit, the labeling agent may be provided either in the same container as the diagnostic or therapeutic composition itself, or may alternatively be placed in a second distinct container means into which this second composition may be placed and suitably aliquoted. Alternatively, the detection reagent and the label

20 may be prepared in a single container means, and in most cases, the kit will also typically include a means for containing the vial(s) in close confinement for commercial sale and/or convenient packaging and delivery.

25 4.9 POLYNUCLEOTIDE COMPOSITIONS

[329] As used herein, the terms "DNA segment" and "polynucleotide" refer to a DNA molecule that has been isolated free of total genomic DNA of a particular species. Therefore, a DNA segment encoding a polypeptide refers to a DNA segment that contains one or more coding sequences yet is substantially isolated away from, or purified free from, total genomic DNA of the species from which the DNA segment is obtained. Included within the terms "DNA segment" and "polynucleotide" are DNA segments and smaller fragments of such segments, and also recombinant vectors, including, for example, plasmids, cosmids, phagemids, phage, viruses, and the like.

[330] As will be understood by those skilled in the art, the DNA segments of this invention can include genomic sequences, extra-genomic and plasmid-encoded sequences and smaller engineered gene segments that express, or may be adapted to express, proteins, polypeptides, peptides and the like. Such segments may be naturally isolated, or modified synthetically by the hand of man.

5

[331] "Isolated," as used herein, means that a polynucleotide is substantially away from other coding sequences, and that the DNA segment does not contain large portions of unrelated coding DNA, such as large chromosomal fragments or other functional genes or polypeptide coding regions. Of course, this refers to the DNA segment as originally isolated, and does not exclude genes or coding regions later added to the segment by the hand of man.

10

15

[332] As will be recognized by the skilled artisan, polynucleotides may be single-stranded (coding or antisense) or double-stranded, and may be DNA (genomic, cDNA or synthetic) or RNA molecules. RNA molecules include HnRNA molecules, which contain introns and correspond to a DNA molecule in a one-to-one manner, and mRNA molecules, which do not contain introns. Additional coding or non-coding sequences may, but need not, be present within a polynucleotide of the present invention, and a polynucleotide may, but need not, be linked to other molecules and/or support materials.

20

25

[333] Polynucleotides may comprise a native sequence (*i.e.*, an endogenous sequence that encodes a hematological malignancy-related tumor protein or a portion thereof) or may comprise a variant, or a biological or antigenic functional equivalent of such a sequence. Polynucleotide variants may contain one or more substitutions, additions, deletions and/or insertions, as further described below, preferably such that the immunogenicity of the encoded polypeptide is not diminished, relative to a native tumor protein. The effect on the immunogenicity of the encoded polypeptide may generally be assessed as described herein. The term "variants" also encompasses homologous genes of xenogenic origin.

30

[334] When comparing polynucleotide or polypeptide sequences, two sequences are said to be "identical" if the sequence of nucleotides or amino acids in the two sequences is the same when aligned for maximum correspondence, as described below. Comparisons between two sequences are typically performed by comparing the sequences over a comparison window to identify and compare local regions of sequence similarity. A "comparison window" as used herein, refers to a segment of at

least about 20 contiguous positions, usually 30 to about 75, 40 to about 50, in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.

[335] Optimal alignment of sequences for comparison may be conducted using the Megalign program in the Lasergene suite of bioinformatics software (DNASTAR, Inc., Madison, WI), using default parameters. This program embodies several alignment schemes described in the following references: Dayhoff, M.O. (1978) A model of evolutionary change in proteins – Matrices for detecting distant relationships. In Dayhoff, M.O. (ed.) *Atlas of Protein Sequence and Structure*, National Biomedical Research Foundation, Washington DC Vol. 5, Suppl. 3, pp. 345-358; Hein J. (1990) *Unified Approach to Alignment and Phylogenies* pp. 626-645 *Methods in Enzymology* vol. 183, Academic Press, Inc., San Diego, CA; Higgins, D.G. and Sharp, P.M. (1989) *CABIOS* 5:151-153; Myers, E.W. and Muller W. (1988) *CABIOS* 4:11-17; Robinson, E.D. (1971) *Comb. Theor* 11:105; Santou, N. Nes, M. (1987) *Mol. Biol. Evol.* 4:406-425; Sneath, P.H.A. and Sokal, R.R. (1973) *Numerical Taxonomy – the Principles and Practice of Numerical Taxonomy*, Freeman Press, San Francisco, CA; Wilbur, W.J. and Lipman, D.J. (1983) *Proc. Natl. Acad. Sci. USA* 80:726-730.

[336] Alternatively, optimal alignment of sequences for comparison may be conducted by the local identity algorithm of Smith and Waterman (1981) *Add. APL. Math* 2:482, by the identity alignment algorithm of Needleman and Wunsch (1970) *J. Mol. Biol.* 48:443, by the search for similarity methods of Pearson and Lipman (1988) *Proc. Natl. Acad. Sci. USA* 85: 2444, by computerized implementations of these algorithms (GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, WI), or by inspection.

[337] One preferred example of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul *et al.* (1977) *Nucl. Acids Res.* 25:3389-3402 and Altschul *et al.* (1990) *J. Mol. Biol.* 215:403-410, respectively. BLAST and BLAST 2.0 can be used, for example with the parameters described herein, to determine percent sequence identity for the polynucleotides and polypeptides of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. In one illustrative example, cumulative scores can be calculated using, for nucleotide sequences, the parameters M (reward score for

a pair of matching residues; always >0) and N (penalty score for mismatching residues; always <0). For amino acid sequences, a scoring matrix can be used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1989) *Proc. Natl. Acad. Sci. USA* 89:10915) alignments, (B) of 50, expectation (E) of 10, M=5, N=-4 and a comparison of both strands.

[338] Preferably, the "percentage of sequence identity" is determined by comparing two optimally aligned sequences over a window of comparison of at least 20 positions, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions (*i.e.*, gaps) of 20 percent or less, usually 5 to 15 percent, or 10 to 12 percent, as compared to the reference sequences (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid bases or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the reference sequence (*i.e.*, the window size) and multiplying the results by 100 to yield the percentage of sequence identity.

[339] Therefore, the present invention encompasses polynucleotide and polypeptide sequences having substantial identity to the sequences disclosed herein, for example those comprising at least 50% sequence identity, preferably at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or higher, sequence identity compared to a polynucleotide or polypeptide sequence of this invention using the methods described herein, (*e.g.*, BLAST analysis using standard parameters, as described below). One skilled in this art will recognize that these values can be appropriately adjusted to determine corresponding identity of proteins encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid similarity, reading frame positioning and the like.

5

10

15

20

25

30

[340] In additional embodiments, the present invention provides isolated polynucleotides and polypeptides comprising various lengths of contiguous stretches of sequence identical to or complementary to one or more of the sequences disclosed herein. For example, polynucleotides are provided by this invention that comprise at least about 15, 20, 30, 40, 50, 75, 100, 150, 200, 300, 400, 500 or 1000 or more contiguous nucleotides of one or more of the sequences disclosed herein as well as all intermediate lengths there between. It will be readily understood that "intermediate lengths", in this context, means any length between the quoted values, such as 16, 17, 18, 19, *etc.*; 21, 22, 23, *etc.*; 30, 31, 32, *etc.*; 50, 51, 52, 53, *etc.*; 100, 101, 102, 103, *etc.*; 150, 151, 152, 153, *etc.*; including all integers through 200-500; 500-1,000, and the like.

[341] The polynucleotides of the present invention, or fragments thereof, regardless of the length of the coding sequence itself, may be combined with other DNA sequences, such as promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, and the like, such that their overall length may vary considerably. It is therefore contemplated that a nucleic acid fragment of almost any length may be employed, with the total length preferably being limited by the ease of preparation and use in the intended recombinant DNA protocol. For example, illustrative DNA segments with total lengths of about 10,000, about 5000, about 3000, about 2,000, about 1,000, about 500, about 200, about 100, about 50 base pairs in length, and the like, (including all intermediate lengths) are contemplated to be useful in many implementations of this invention.

[342] In other embodiments, the present invention is directed to polynucleotides that are capable of hybridizing under moderately stringent conditions to a polynucleotide sequence provided herein, or a fragment thereof, or a complementary sequence thereof. Hybridization techniques are well known in the art of molecular biology. For purposes of illustration, suitable moderately stringent conditions for testing the hybridization of a polynucleotide of this invention with other polynucleotides include prewashing in a solution of 5 X SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0); hybridizing at 50°C-65°C, 5 X SSC, overnight; followed by washing twice at 65°C for 20 minutes with each of 2X, 0.5X and 0.2X SSC containing 0.1% SDS.

[343] Moreover, it will be appreciated by those of ordinary skill in the art that, as a result of the degeneracy of the genetic code, there are many nucleotide sequences that encode a polypeptide as described herein. Some of these polynucleotides bear

minimal homology to the nucleotide sequence of any native gene. Nonetheless, polynucleotides that vary due to differences in codon usage are specifically contemplated by the present invention. Further, alleles of the genes comprising the polynucleotide sequences provided herein are within the scope of the present invention. Alleles are endogenous genes that are altered as a result of one or more mutations, such as deletions, additions and/or substitutions of nucleotides. The resulting mRNA and protein may, but need not, have an altered structure or function. Alleles may be identified using standard techniques (such as hybridization, amplification and/or database sequence comparison).

10

4.10 PROBES AND PRIMERS

15

[344] In other embodiments of the present invention, the polynucleotide sequences provided herein can be advantageously used as probes or primers for nucleic acid hybridization. As such, it is contemplated that nucleic acid segments that comprise a sequence region of at least about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, or 95 nucleotide long contiguous sequence that has the same sequence as, or is complementary to, at least a 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, or 95 nucleotide long contiguous sequence the disclosed polynucleotides will find particular utility in a variety of hybridization embodiments. Longer contiguous identical or complementary sequences, *e.g.*, those of about 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 525, 550, 575, 600, 650, 700, 750, 800, 850, 900, 950, or even 1000 or so nucleotides (including all intermediate lengths) and all full-length sequences as the disclosed polynucleotides will also be of use in certain embodiments as probes, primers, or amplification targets and such like.

20

25

30

[345] The ability of such nucleic acid probes to specifically hybridize to a sequence of interest will enable them to be of use in detecting the presence of complementary sequences in a given sample. However, other uses are also envisioned, such as the use of the sequence information for the preparation of mutant species primers, or primers, for use in preparing other genetic constructions, and for identifying and characterizing full-length polynucleotides and full, or substantially full-length cDNAs, mRNAs, and such like.

[346] Polynucleotide molecules having sequence regions consisting of contiguous nucleotide stretches identical or complementary to one or more polynucleotide sequences as disclosed herein, are particularly contemplated as hybridization probes for use in, e.g., Southern hybridization analyses and Northern blotting. This would allow a gene product, or fragment thereof, to be analyzed, both in diverse cell types and also in various bacterial cells. The total size of fragment, as well as the size of the complementary stretch(es), will ultimately depend on the intended use or application of the particular nucleic acid segment. Smaller fragments will generally find use in hybridization embodiments, wherein the length of the contiguous complementary region may be varied, such as between about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60 or so and up to and including larger contiguous complementary sequences, including those of about 70, 80, 90, 100, 120, 140, 160, 180, or 200 or so nucleotides in length may also be used, according to the given desired goal, and the particular length of the complementary sequences one wishes to detect by hybridization analysis.

[347] The use of a hybridization probe of about between about 20 and about 500 nucleotides in length allows the formation of a duplex molecule that is both stable and selective. Molecules having contiguous complementary sequences over stretches greater than about 20 or so bases in length are generally preferred, though, in order to increase stability and selectivity of the hybrid, and thereby improve the quality and degree of specific hybrid molecules obtained. One will generally prefer to design nucleic acid molecules having gene-complementary stretches of between about 25 and 300 or so contiguous nucleotides, or even longer where desired.

[348] Hybridization probes may be selected from any portion of any of the sequences disclosed herein. All that is required is to review the disclosed sequences, or to any contiguous portion of such a sequence, from about 15 to 30 nucleotides in length up to and including the full length sequence, that one wishes to utilize as a probe or primer. The choice of probe and primer sequences may be governed by various factors. For example, one may wish to employ primers from towards the termini of the total sequence.

[349] Small polynucleotide segments or fragments may be readily prepared by, for example, directly synthesizing the fragment by chemical means, as is commonly practiced using an automated oligonucleotide synthesizer. Also, fragments may be obtained by application of nucleic acid reproduction technology, such as the PCR™ technology of U. S. Patent 4,683,202 (incorporated herein by reference), by

introducing selected sequences into recombinant vectors for recombinant production, and by other recombinant DNA techniques generally known to those of skill in the art of molecular biology.

[350] The nucleotide sequences of the invention may be used for their ability to selectively form duplex molecules with complementary stretches of the entire gene or gene fragments of interest. Depending on the application envisioned, one will typically desire to employ varying conditions of hybridization to achieve varying degrees of selectivity of probe towards target sequence. For applications requiring high selectivity, one will typically desire to employ relatively stringent conditions to form the hybrids, *e.g.*, one will select relatively low salt and/or high temperature conditions, such as provided by a salt concentration of from about 0.02 M to about 0.15 M salt at temperatures of from about 50°C to about 70°C. Such selective conditions tolerate little, if any, mismatch between the probe and the template or target strand, and would be particularly suitable for isolating related sequences.

[351] Of course, for some applications, for example, where one desires to prepare mutants employing a mutant primer strand hybridized to an underlying template, less stringent (reduced stringency) hybridization conditions will typically be needed in order to allow formation of the heteroduplex. In these circumstances, one may desire to employ salt conditions such as those of from about 0.15 M to about 0.9 M salt, at temperatures ranging from about 20°C to about 55°C. Cross-hybridizing species can thereby be readily identified as positively hybridizing signals with respect to control hybridizations. In any case, it is generally appreciated that conditions can be rendered more stringent by the addition of increasing amounts of formamide, which serves to destabilize the hybrid duplex in the same manner as increased temperature. Thus, hybridization conditions can be readily manipulated, and thus will generally be a method of choice depending on the desired results.

4.11 POLYNUCLEOTIDE IDENTIFICATION AND CHARACTERIZATION

[352] Polynucleotides may be identified, prepared and/or manipulated using any of a variety of well established techniques. For example, a polynucleotide may be identified, as described in more detail below, by screening a microarray of cDNAs for tumor-associated expression (*i.e.*, expression that is at least two fold greater in a tumor than in normal tissue, as determined using a representative assay provided herein). Such screens may be performed, for example, using a Synteni microarray (Palo Alto,

CA) according to the manufacturer's instructions (and essentially as described by Schena *et al.*, *Proc. Natl. Acad. Sci. USA* 93:10614-10619, 1996 and Heller *et al.*, *Proc. Natl. Acad. Sci. USA* 94:2150-2155, 1997). Alternatively, polynucleotides may be amplified from cDNA prepared from cells expressing the proteins described herein, such as hematological malignancy-related tumor cells. Such polynucleotides may be amplified via polymerase chain reaction (PCR). For this approach, sequence-specific primers may be designed based on the sequences provided herein, and may be purchased or synthesized.

5

[353] An amplified portion of a polynucleotide of the present invention may be used to isolate a full length gene from a suitable library (e.g., a hematological malignancy-related tumor cDNA library) using well known techniques. Within such techniques, a library (cDNA or genomic) is screened using one or more polynucleotide probes or primers suitable for amplification. Preferably, a library is size-selected to include larger molecules. Random primed libraries may also be preferred for identifying 5' and upstream regions of genes. Genomic libraries are preferred for obtaining introns and extending 5' sequences.

10

15

20

25

30

[354] For hybridization techniques, a partial sequence may be labeled (e.g., by nick-translation or end-labeling with ^{32}P) using well known techniques. A bacterial or bacteriophage library is then generally screened by hybridizing filters containing denatured bacterial colonies (or lawns containing phage plaques) with the labeled probe (*see Sambrook et al., Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY, 1989). Hybridizing colonies or plaques are selected and expanded, and the DNA is isolated for further analysis. cDNA clones may be analyzed to determine the amount of additional sequence by, for example, PCR using a primer from the partial sequence and a primer from the vector. Restriction maps and partial sequences may be generated to identify one or more overlapping clones. The complete sequence may then be determined using standard techniques, which may involve generating a series of deletion clones. The resulting overlapping sequences can then assembled into a single contiguous sequence. A full length cDNA molecule can be generated by ligating suitable fragments, using well known techniques.

[355] Alternatively, there are numerous amplification techniques for obtaining a full length coding sequence from a partial cDNA sequence. Within such techniques, amplification is generally performed via PCR. Any of a variety of commercially

available kits may be used to perform the amplification step. Primers may be designed using, for example, software or algorithms or formulas well known in the art.

[356] One such amplification technique is inverse PCR (*see Triglia et al., Nucl. Acids Res. 16:8186, 1988*), which uses restriction enzymes to generate a fragment in the known region of the gene. The fragment is then circularized by intramolecular ligation and used as a template for PCR with divergent primers derived from the known region. Within an alternative approach, sequences adjacent to a partial sequence may be retrieved by amplification with a primer to a linker sequence and a primer specific to a known region. The amplified sequences are typically subjected to a second round of amplification with the same linker primer and a second primer specific to the known region. A variation on this procedure, which employs two primers that initiate extension in opposite directions from the known sequence, is described in WO 96/38591. Another such technique is known as "rapid amplification of cDNA ends" or RACE. This technique involves the use of an internal primer and an external primer, which hybridizes to a polyA region or vector sequence, to identify sequences that are 5' and 3' of a known sequence. Additional techniques include capture PCR (*Lagerstrom et al., PCR Methods Applic. 1:111-19, 1991*) and walking PCR (*Parker et al., Nucl. Acids. Res. 19:3055-60, 1991*). Other methods employing amplification may also be employed to obtain a full length cDNA sequence.

[357] In certain instances, it is possible to obtain a full length cDNA sequence by analysis of sequences provided in an expressed sequence tag (EST) database, such as that available from GenBank. Searches for overlapping ESTs may generally be performed using well known programs (*e.g., NCBI BLAST searches*), and such ESTs may be used to generate a contiguous full length sequence. Full length DNA sequences may also be obtained by analysis of genomic fragments.

4.12 POLYNUCLEOTIDE EXPRESSION IN HOST CELLS

[358] In other embodiments of the invention, polynucleotide sequences or fragments thereof which encode polypeptides of the invention, or fusion proteins or functional equivalents thereof, may be used in recombinant DNA molecules to direct expression of a polypeptide in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences that encode substantially the same or a functionally equivalent amino acid sequence may be produced and these sequences may be used to clone and express a given polypeptide.

[359] As will be understood by those of skill in the art, it may be advantageous in some instances to produce polypeptide-encoding nucleotide sequences possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce a recombinant RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.

5

10

15

20

25

30

[360] Moreover, the polynucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter polypeptide encoding sequences for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the gene product. For example, DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. In addition, site-directed mutagenesis may be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, or introduce mutations, and so forth.

[361] In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences may be ligated to a heterologous sequence to encode a fusion protein. For example, to screen peptide libraries for inhibitors of polypeptide activity, it may be useful to encode a chimeric protein that can be recognized by a commercially available antibody. A fusion protein may also be engineered to contain a cleavage site located between the polypeptide-encoding sequence and the heterologous protein sequence, so that the polypeptide may be cleaved and purified away from the heterologous moiety.

[362] Sequences encoding a desired polypeptide may be synthesized, in whole or in part, using chemical methods well known in the art (see Caruthers, M. H. *et al.* (1980) *Nucl. Acids Res. Symp. Ser.* 215-223, Horn, T. *et al.* (1980) *Nucl. Acids Res. Symp. Ser.* 225-232). Alternatively, the protein itself may be produced using chemical methods to synthesize the amino acid sequence of a polypeptide, or a portion thereof. For example, peptide synthesis can be performed using various solid-phase techniques (Roberge, J. Y. *et al.* (1995) *Science* 269:202-204) and automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin Elmer, Palo Alto, CA).

[363] A newly synthesized peptide may be substantially purified by preparative high performance liquid chromatography (e.g., Creighton, T. (1983) Proteins, Structures and Molecular Principles, WH Freeman and Co., New York, N.Y.) or other comparable techniques available in the art. The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure). Additionally, the amino acid sequence of a polypeptide, or any part thereof, may be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

[364] In order to express a desired polypeptide, the nucleotide sequences encoding the polypeptide, or functional equivalents, may be inserted into appropriate expression vector, *i.e.*, a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence. Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding a polypeptide of interest and appropriate transcriptional and translational control elements. These methods include *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination. Such techniques are described in Sambrook, J. *et al.* (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview, N.Y., and Ausubel, F. M. *et al.* (1989) Current Protocols in Molecular Biology, John Wiley & Sons, New York. N.Y.

[365] A variety of expression vector/host systems may be utilized to contain and express polynucleotide sequences. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus); plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems.

[366] The "control elements" or "regulatory sequences" present in an expression vector are those non-translated regions of the vector--enhancers, promoters, 5' and 3' untranslated regions--which interact with host cellular proteins to carry out transcription and translation. Such elements may vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used.

For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the PBLUESCRIPT phagemid (Stratagene, La Jolla, Calif.) or PSPORT1 plasmid (Gibco BRL, Gaithersburg, MD) and the like may be used. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are generally preferred. If it is necessary to generate a cell line that contains multiple copies of the sequence encoding a polypeptide, vectors based on SV40 or EBV may be advantageously used with an appropriate selectable marker.

[367] In bacterial systems, a number of expression vectors may be selected depending upon the use intended for the expressed polypeptide. For example, when large quantities are needed, for example for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be used. Such vectors include, but are not limited to, the multifunctional *E. coli* cloning and expression vectors such as BLUESCRIPT (Stratagene), in which the sequence encoding the polypeptide of interest may be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of .beta.-galactosidase so that a hybrid protein is produced; pIN vectors (Van Heeke, G. and S. M. Schuster (1989) *J. Biol. Chem.* 264:5503-5509); and the like. pGEX Vectors (Promega, Madison, Wis.) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems may be designed to include heparin, thrombin, or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

[368] In the yeast, *Saccharomyces cerevisiae*, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH may be used. For reviews, see Ausubel *et al.* (supra) and Grant *et al.* (1987) *Methods Enzymol.* 153:516-544.

[369] In cases where plant expression vectors are used, the expression of sequences encoding polypeptides may be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV may be used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) *EMBO J.* 6:307-311. Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used (Coruzzi, G. *et al.* (1984) *EMBO J.*

3:1671-1680; Broglie, R. *et al.* (1984) *Science* 224:838-843; and Winter, J. *et al.* (1991) *Results Probl. Cell Differ.* 17:85-105). These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. Such techniques are described in a number of generally available reviews (see, for example, Hobbs, S. or Murry, L. E. in McGraw Hill Yearbook of Science and Technology 5 (1992) McGraw Hill, New York, N.Y.; pp. 191-196).

[370] An insect system may also be used to express a polypeptide of interest. For example, in one such system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in *Spodoptera frugiperda* cells or in *Trichoplusia* larvae. The sequences encoding the polypeptide may be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of the polypeptide-encoding sequence will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses may then be used to infect, for example, *S. frugiperda* cells or *Trichoplusia* larvae in which the polypeptide of interest may be expressed (Engelhard, E. K. *et al.* (1994) *Proc. Natl. Acad. Sci.* 91 :3224-3227).

[371] In mammalian host cells, a number of viral-based expression systems are generally available. For example, in cases where an adenovirus is used as an expression vector, sequences encoding a polypeptide of interest may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain a viable virus which is capable of expressing the polypeptide in infected host cells (Logan, J. and Shenk, T. (1984) *Proc. Natl. Acad. Sci.* 81:3655-3659). In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

[372] Specific initiation signals may also be used to achieve more efficient translation of sequences encoding a polypeptide of interest. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding the polypeptide, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a portion thereof, is inserted, exogenous translational control signals including the ATG initiation codon should be provided. Furthermore, the initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational

elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers which are appropriate for the particular cell system which is used, such as those described in the literature (Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162).

5 [373] In addition, a host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "pro" form of the protein may also be used to facilitate correct insertion, folding and/or function. Different host cells such as 10 CHO, HeLa, MDCK, HEK293, and WI38, which have specific cellular machinery and characteristic mechanisms for such post-translational activities, may be chosen to ensure the correct modification and processing of the foreign protein.

15 [374] For long-term, high-yield production of recombinant proteins, stable expression is generally preferred. For example, cell lines which stably express a polynucleotide of interest may be transformed using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction 20 of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be proliferated using tissue culture techniques appropriate to the cell type.

25 [375] Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler, M. et al. (1977) *Cell* 11:223-32) and adenine phosphoribosyltransferase (Lowy, I. et al. (1990) *Cell* 22:817-23) genes which can be employed in tk.sup.- or aprt.sup.- cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dhfr which confers resistance to methotrexate (Wigler, M. et al. (1980) *Proc. Natl. Acad. Sci.* 77:3567-70); npt, which confers resistance to the aminoglycosides, neomycin and G-418 (Colbere-Garapin, F. et al (1981) *J. Mol. Biol.* 150:1-14); and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, *supra*). Additional selectable genes have been described, for example, trpB, which allows cells

to utilize indole in place of tryptophan, or hisD, which allows cells to utilize histinol in place of histidine (Hartman, S. C. and R. C. Mulligan (1988) *Proc. Natl. Acad. Sci.* 85:8047-51). Recently, the use of visible markers has gained popularity with such markers as anthocyanins, beta-glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, being widely used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes, C. A. *et al.* (1995) *Methods Mol. Biol.* 55:121-131).

5

10

15

20

25

30

[376] Although the presence/absence of marker gene expression suggests that the gene of interest is also present, its presence and expression may need to be confirmed. For example, if the sequence encoding a polypeptide is inserted within a marker gene sequence, recombinant cells containing sequences can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a polypeptide-encoding sequence under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

[377] Alternatively, host cells which contain and express a desired polynucleotide sequence may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein.

[378] A variety of protocols for detecting and measuring the expression of polynucleotide-encoded products, using either polyclonal or monoclonal antibodies specific for the product are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on a given polypeptide may be preferred for some applications, but a competitive binding assay may also be employed. These and other assays are described, among other places, in Hampton, R. *et al.* (1990; *Serological Methods, a Laboratory Manual*, APS Press, St Paul. Minn.) and Maddox, D. E. *et al.* (1983; *J. Exp. Med.* 158:1211-1216).

[379] A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences

related to polynucleotides include oligolabeling, nick translation, ~~ex~~ labeling or PCR amplification using a labeled nucleotide. Alternatively, the sequences, or any portions thereof may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits. Suitable reporter molecules or labels, which may be used include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

[380] Host cells transformed with a polynucleotide sequence of interest may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a recombinant cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides of the invention may be designed to contain signal sequences which direct secretion of the encoded polypeptide through a prokaryotic or eukaryotic cell membrane. Other recombinant constructions may be used to join sequences encoding a polypeptide of interest to nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, Wash.). The inclusion of cleavable linker sequences such as those specific for Factor XA or enterokinase (Invitrogen, San Diego, Calif.) between the purification domain and the encoded polypeptide may be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing a polypeptide of interest and a nucleic acid encoding 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification on IMIAC (immobilized metal ion affinity chromatography) as described in Porath, J. *et al.* (1992, *Prot. Exp. Purif.* 3:263-281) while the enterokinase cleavage site provides a means for purifying the desired polypeptide from the fusion protein. A discussion of vectors which contain fusion proteins is provided in Kroll, D. J. *et al.* (1993; *DNA Cell Biol.* 12:441-453).

[381] In addition to recombinant production methods, polypeptides of the invention, and fragments thereof, may be produced by direct peptide synthesis using solid-phase techniques (Merrifield J. (1963) *J. Am. Chem. Soc.* 85:2149-2154). Protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer). Alternatively, various fragments may be chemically synthesized separately and combined using chemical methods to produce the full length molecule.

4.13 SITE-SPECIFIC MUTAGENESIS

[382] Site-specific mutagenesis is a technique useful in the preparation of individual peptides, or biologically functional equivalent polypeptides, through specific mutagenesis of the underlying polynucleotides that encode them. The technique, well-known to those of skill in the art, further provides a ready ability to prepare and test sequence variants, for example, incorporating one or more of the foregoing considerations, by introducing one or more nucleotide sequence changes into the DNA. Site-specific mutagenesis allows the production of mutants through the use of specific oligonucleotide sequences which encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient size and sequence complexity to form a stable duplex on both sides of the deletion junction being traversed. Mutations may be employed in a selected polynucleotide sequence to improve, alter, decrease, modify, or otherwise change the properties of the polynucleotide itself, and/or alter the properties, activity, composition, stability, or primary sequence of the encoded polypeptide.

[383] In certain embodiments of the present invention, the inventors contemplate the mutagenesis of the disclosed polynucleotide sequences to alter one or more properties of the encoded polypeptide, such as the antigenicity of a polypeptide vaccine. The techniques of site-specific mutagenesis are well-known in the art, and are widely used to create variants of both polypeptides and polynucleotides. For example, site-specific mutagenesis is often used to alter a specific portion of a DNA molecule. In such embodiments, a primer comprising typically about 14 to about 25 nucleotides or so in length is employed, with about 5 to about 10 residues on both sides of the junction of the sequence being altered.

[384] As will be appreciated by those of skill in the art, site-specific mutagenesis techniques have often employed a phage vector that exists in both a single stranded

5

and double stranded form. Typical vectors useful in site-directed mutagenesis include vectors such as the M13 phage. These phage are readily commercially-available and their use is generally well-known to those skilled in the art. Double-stranded plasmids are also routinely employed in site directed mutagenesis that eliminates the step of transferring the gene of interest from a plasmid to a phage.

10

[385] In general, site-directed mutagenesis in accordance herewith is performed by first obtaining a single-stranded vector or melting apart of two strands of a double-stranded vector that includes within its sequence a DNA sequence that encodes the desired peptide. An oligonucleotide primer bearing the desired mutated sequence is prepared, generally synthetically. This primer is then annealed with the single-stranded vector, and subjected to DNA polymerizing enzymes such as *E. coli* polymerase I Klenow fragment, in order to complete the synthesis of the mutation-bearing strand. Thus, a heteroduplex is formed wherein one strand encodes the original non-mutated sequence and the second strand bears the desired mutation. This heteroduplex vector is then used to transform appropriate cells, such as *E. coli* cells, and clones are selected which include recombinant vectors bearing the mutated sequence arrangement.

20

[386] The preparation of sequence variants of the selected peptide-encoding DNA segments using site-directed mutagenesis provides a means of producing potentially useful species and is not meant to be limiting as there are other ways in which sequence variants of peptides and the DNA sequences encoding them may be obtained. For example, recombinant vectors encoding the desired peptide sequence may be treated with mutagenic agents, such as hydroxylamine, to obtain sequence variants. Specific details regarding these methods and protocols are found in the teachings of Maloy *et al.*, 1994; Segal, 1976; Prokop and Bajpai, 1991; Kuby, 1994; and Maniatis *et al.*, 1982, each incorporated herein by reference, for that purpose.

25

[387] As used herein, the term "oligonucleotide directed mutagenesis procedure" refers to template-dependent processes and vector-mediated propagation which result in an increase in the concentration of a specific nucleic acid molecule relative to its initial concentration, or in an increase in the concentration of a detectable signal, such as amplification. As used herein, the term "oligonucleotide directed mutagenesis procedure" is intended to refer to a process that involves the template-dependent extension of a primer molecule. The term template dependent process refers to nucleic acid synthesis of an RNA or a DNA molecule wherein the sequence of the newly

5

synthesized strand of nucleic acid is dictated by the well-known rule of complementary base pairing (see, for example, Watson, 1987). Typically, vector mediated methodologies involve the introduction of the nucleic acid fragment into a DNA or RNA vector, the clonal amplification of the vector, and the recovery of the amplified nucleic acid fragment. Examples of such methodologies are provided by U. S. Patent No. 4,237,224, specifically incorporated herein by reference in its entirety.

4.14 POLYNUCLEOTIDE AMPLIFICATION TECHNIQUES

[388] A number of template dependent processes are available to amplify the target sequences of interest present in a sample. One of the best known amplification methods is the polymerase chain reaction (PCR™) which is described in detail in U.S. Patent Nos. 4,683,195, 4,683,202 and 4,800,159, each of which is incorporated herein by reference in its entirety. Briefly, in PCR™, two primer sequences are prepared which are complementary to regions on opposite complementary strands of the target sequence. An excess of deoxynucleoside triphosphates is added to a reaction mixture along with a DNA polymerase (*e.g.*, *Taq* polymerase). If the target sequence is present in a sample, the primers will bind to the target and the polymerase will cause the primers to be extended along the target sequence by adding on nucleotides. By raising and lowering the temperature of the reaction mixture, the extended primers will dissociate from the target to form reaction products, excess primers will bind to the target and to the reaction product and the process is repeated. Preferably reverse transcription and PCR™ amplification procedure may be performed in order to quantify the amount of mRNA amplified. Polymerase chain reaction methodologies are well known in the art.

[389] Another method for amplification is the ligase chain reaction (referred to as LCR), disclosed in Eur. Pat. Appl. Publ. No. 320,308 (specifically incorporated herein by reference in its entirety). In LCR, two complementary probe pairs are prepared, and in the presence of the target sequence, each pair will bind to opposite complementary strands of the target such that they abut. In the presence of a ligase, the two probe pairs will link to form a single unit. By temperature cycling, as in PCR™, bound ligated units dissociate from the target and then serve as "target sequences" for ligation of excess probe pairs. U.S. Patent No. 4,883,750, incorporated herein by reference in its entirety, describes an alternative method of amplification similar to LCR for binding probe pairs to a target sequence.

[390] Qbeta Replicase, described in PCT Intl. Pat. Appl. Publ. No. PCT/US87/00880, incorporated herein by reference in its entirety, may also be used as still another amplification method in the present invention. In this method, a replicative sequence of RNA that has a region complementary to that of a target is added to a sample in the presence of an RNA polymerase. The polymerase will copy the replicative sequence that can then be detected.

5 [391] An isothermal amplification method, in which restriction endonucleases and ligases are used to achieve the amplification of target molecules that contain nucleotide 5'-[α -thio]triphosphates in one strand of a restriction site (Walker *et al.*, 1992, incorporated herein by reference in its entirety), may also be useful in the amplification of nucleic acids in the present invention.

10 [392] Strand Displacement Amplification (SDA) is another method of carrying out isothermal amplification of nucleic acids which involves multiple rounds of strand displacement and synthesis, *i.e.* nick translation. A similar method, called Repair Chain Reaction (RCR) is another method of amplification which may be useful in the present invention and is involves annealing several probes throughout a region targeted for amplification, followed by a repair reaction in which only two of the four bases are present. The other two bases can be added as biotinylated derivatives for easy detection. A similar approach is used in SDA.

15 [393] Sequences can also be detected using a cyclic probe reaction (CPR). In CPR, a probe having a 3' and 5' sequences of non-target DNA and an internal or "middle" sequence of the target protein specific RNA is hybridized to DNA which is present in a sample. Upon hybridization, the reaction is treated with RNaseH, and the products of the probe are identified as distinctive products by generating a signal that is released after digestion. The original template is annealed to another cycling probe and the reaction is repeated. Thus, CPR involves amplifying a signal generated by hybridization of a probe to a target gene specific expressed nucleic acid.

20 [394] Still other amplification methods described in Great Britain Pat. Appl. No. 2 202 328, and in PCT Intl. Pat. Appl. Publ. No. PCT/US89/01025, each of which is incorporated herein by reference in its entirety, may be used in accordance with the present invention. In the former application, "modified" primers are used in a PCR-like, template and enzyme dependent synthesis. The primers may be modified by labeling with a capture moiety (*e.g.*, biotin) and/or a detector moiety (*e.g.*, enzyme). In the latter application, an excess of labeled probes is added to a sample. In the

presence of the target sequence, the probe binds and is cleaved catalytically. After cleavage, the target sequence is released intact to be bound by excess probe. Cleavage of the labeled probe signals the presence of the target sequence.

[395] Other nucleic acid amplification procedures include transcription-based amplification systems (TAS) (Kwoh *et al.*, 1989; PCT Int'l. Pat. Appl. Publ. No. WO 88/10315, incorporated herein by reference in its entirety), including nucleic acid sequence based amplification (NASBA) and 3SR. In NASBA, the nucleic acids can be prepared for amplification by standard phenol/chloroform extraction, heat denaturation of a sample, treatment with lysis buffer and minispin columns for isolation of DNA and RNA or guanidinium chloride extraction of RNA. These amplification techniques involve annealing a primer that has sequences specific to the target sequence. Following polymerization, DNA/RNA hybrids are digested with RNase H while double stranded DNA molecules are heat-denatured again. In either case the single stranded DNA is made fully double stranded by addition of second target-specific primer, followed by polymerization. The double stranded DNA molecules are then multiply transcribed by a polymerase such as T7 or SP6. In an isothermal cyclic reaction, the RNAs are reverse transcribed into DNA, and transcribed once again with a polymerase such as T7 or SP6. The resulting products, whether truncated or complete, indicate target-specific sequences.

[396] Eur. Pat. Appl. Publ. No. 329,822, incorporated herein by reference in its entirety, disclose a nucleic acid amplification process involving cyclically synthesizing single-stranded RNA ("ssRNA"), ssDNA, and double-stranded DNA (dsDNA), which may be used in accordance with the present invention. The ssRNA is a first template for a first primer oligonucleotide, which is elongated by reverse transcriptase (RNA-dependent DNA polymerase). The RNA is then removed from resulting DNA:RNA duplex by the action of ribonuclease H (RNase H, an RNase specific for RNA in a duplex with either DNA or RNA). The resultant ssDNA is a second template for a second primer, which also includes the sequences of an RNA polymerase promoter (exemplified by T7 RNA polymerase) 5' to its homology to its template. This primer is then extended by DNA polymerase (exemplified by the large "Klenow" fragment of *E. coli* DNA polymerase I), resulting as a double-stranded DNA ("dsDNA") molecule, having a sequence identical to that of the original RNA between the primers and having additionally, at one end, a promoter sequence. This promoter sequence can be used by the appropriate RNA polymerase to make many

RNA copies of the DNA. These copies can then re-enter the cycle leading to very swift amplification. With proper choice of enzymes, this amplification can be done isothermally without addition of enzymes at each cycle. Because of the cyclical nature of this process, the starting sequence can be chosen to be in the form of either DNA or RNA.

5

[397] PCT Int'l. Pat. Appl. Publ. No. WO 89/06700, incorporated herein by reference in its entirety, disclose a nucleic acid sequence amplification scheme based on the hybridization of a promoter/primer sequence to a target single-stranded DNA ("ssDNA") followed by transcription of many RNA copies of the sequence. This scheme is not cyclic; *i.e.* new templates are not produced from the resultant RNA transcripts. Other amplification methods include "RACE" (Frohman, 1990), and "one-sided PCR" (Ohara, 1989) which are well-known to those of skill in the art.

10

[398] Methods based on ligation of two (or more) oligonucleotides in the presence of nucleic acid having the sequence of the resulting "di-oligonucleotide", thereby amplifying the di-oligonucleotide (Wu and Dean, 1996, incorporated herein by reference in its entirety), may also be used in the amplification of DNA sequences of the present invention.

15

4.15 IN VIVO POLYNUCLEOTIDE DELIVERY TECHNIQUES

20

[399] In additional embodiments, genetic constructs comprising one or more of the polynucleotides of the invention are introduced into cells *in vivo*. This may be achieved using any of a variety of well known approaches, several of which are outlined below for the purpose of illustration.

25

4.15.1 ADENOVIRUS

30

[400] One of the preferred methods for *in vivo* delivery of one or more nucleic acid sequences involves the use of an adenovirus expression vector. "Adenovirus expression vector" is meant to include those constructs containing adenovirus sequences sufficient to (a) support packaging of the construct and (b) to express a polynucleotide that has been cloned therein in a sense or antisense orientation. Of course, in the context of an antisense construct, expression does not require that the gene product be synthesized.

[401] The expression vector comprises a genetically engineered form of an adenovirus. Knowledge of the genetic organization of adenovirus, a 36 kb, linear,

double-stranded DNA virus, allows substitution of large pieces of adenoviral DNA with foreign sequences up to 7 kb (Grunhaus and Horwitz, 1992). In contrast to retrovirus, the adenoviral infection of host cells does not result in chromosomal integration because adenoviral DNA can replicate in an episomal manner without potential genotoxicity. Also, adenoviruses are structurally stable, and no genome rearrangement has been detected after extensive amplification. Adenovirus can infect virtually all epithelial cells regardless of their cell cycle stage. So far, adenoviral infection appears to be linked only to mild disease such as acute respiratory disease in humans.

[402] Adenovirus is particularly suitable for use as a gene transfer vector because of its mid-sized genome, ease of manipulation, high titer, wide target-cell range and high infectivity. Both ends of the viral genome contain 100-200 base pair inverted repeats (ITRs), which are *cis* elements necessary for viral DNA replication and packaging. The early (E) and late (L) regions of the genome contain different transcription units that are divided by the onset of viral DNA replication. The E1 region (E1A and E1B) encodes proteins responsible for the regulation of transcription of the viral genome and a few cellular genes. The expression of the E2 region (E2A and E2B) results in the synthesis of the proteins for viral DNA replication. These proteins are involved in DNA replication, late gene expression and host cell shut-off (Renan, 1990). The products of the late genes, including the majority of the viral capsid proteins, are expressed only after significant processing of a single primary transcript issued by the major late promoter (MLP). The MLP, (located at 16.8 m.u.) is particularly efficient during the late phase of infection, and all the mRNA's issued from this promoter possess a 5'-tripartite leader (TPL) sequence which makes them preferred mRNA's for translation.

[403] In a current system, recombinant adenovirus is generated from homologous recombination between shuttle vector and provirus vector. Due to the possible recombination between two proviral vectors, wild-type adenovirus may be generated from this process. Therefore, it is critical to isolate a single clone of virus from an individual plaque and examine its genomic structure.

[404] Generation and propagation of the current adenovirus vectors, which are replication deficient, depend on a unique helper cell line, designated 293, which was transformed from human embryonic kidney cells by Ad5 DNA fragments and constitutively expresses E1 proteins (Graham *et al.*, 1977). Since the E3 region is

5

10

15

20

25

30

dispensable from the adenovirus genome (Jones and Shenk, 1978), the current adenovirus vectors, with the help of 293 cells, carry foreign DNA in either the E1, the D3 or both regions (Graham and Prevec, 1991). In nature, adenovirus can package approximately 105% of the wild-type genome (Ghosh-Choudhury *et al.*, 1987), providing capacity for about 2 extra kB of DNA. Combined with the approximately 5.5 kB of DNA that is replaceable in the E1 and E3 regions, the maximum capacity of the current adenovirus vector is under 7.5 kB, or about 15% of the total length of the vector. More than 80% of the adenovirus viral genome remains in the vector backbone and is the source of vector-borne cytotoxicity. Also, the replication deficiency of the E1-deleted virus is incomplete. For example, leakage of viral gene expression has been observed with the currently available vectors at high multiplicities of infection (MOI) (Mulligan, 1993).

[405] Helper cell lines may be derived from human cells such as human embryonic kidney cells, muscle cells, hematopoietic cells or other human embryonic mesenchymal or epithelial cells. Alternatively, the helper cells may be derived from the cells of other mammalian species that are permissive for human adenovirus. Such cells include, *e.g.*, Vero cells or other monkey embryonic mesenchymal or epithelial cells. As stated above, the currently preferred helper cell line is 293.

[406] Recently, Racher *et al.* (1995) disclosed improved methods for culturing 293 cells and propagating adenovirus. In one format, natural cell aggregates are grown by inoculating individual cells into 1 liter siliconized spinner flasks (Techne, Cambridge, UK) containing 100-200 ml of medium. Following stirring at 40 rpm, the cell viability is estimated with trypan blue. In another format, Fibra-Cel microcarriers (Bibby Sterlin, Stone, UK) (5 g/l) is employed as follows. A cell inoculum, resuspended in 5 ml of medium, is added to the carrier (50 ml) in a 250 ml Erlenmeyer flask and left stationary, with occasional agitation, for 1 to 4 h. The medium is then replaced with 50 ml of fresh medium and shaking initiated. For virus production, cells are allowed to grow to about 80% confluence, after which time the medium is replaced (to 25% of the final volume) and adenovirus added at an MOI of 0.05. Cultures are left stationary overnight, following which the volume is increased to 100% and shaking commenced for another 72 h.

[407] Other than the requirement that the adenovirus vector be replication defective, or at least conditionally defective, the nature of the adenovirus vector is not believed to be crucial to the successful practice of the invention. The adenovirus may be of any

of the 42 different known serotypes or subgroups A-F. Adenovirus type 5 of subgroup C is the preferred starting material in order to obtain a conditional replication-defective adenovirus vector for use in the present invention, since Adenovirus type 5 is a human adenovirus about which a great deal of biochemical and genetic information is known, and it has historically been used for most constructions employing adenovirus as a vector.

5

10

15

20

30

[408] As stated above, the typical vector according to the present invention is replication defective and will not have an adenovirus E1 region. Thus, it will be most convenient to introduce the polynucleotide encoding the gene of interest at the position from which the E1-coding sequences have been removed. However, the position of insertion of the construct within the adenovirus sequences is not critical to the invention. The polynucleotide encoding the gene of interest may also be inserted in lieu of the deleted E3 region in E3 replacement vectors as described by Karlsson *et al.* (1986) or in the E4 region where a helper cell line or helper virus complements the E4 defect.

[409] Adenovirus is easy to grow and manipulate and exhibits broad host range *in vitro* and *in vivo*. This group of viruses can be obtained in high titers, e.g., 10^9 - 10^{11} plaque-forming units per ml, and they are highly infective. The life cycle of adenovirus does not require integration into the host cell genome. The foreign genes delivered by adenovirus vectors are episomal and, therefore, have low genotoxicity to host cells. No side effects have been reported in studies of vaccination with wild-type adenovirus (Couch *et al.*, 1963; Top *et al.*, 1971), demonstrating their safety and therapeutic potential as *in vivo* gene transfer vectors.

[410] Adenovirus vectors have been used in eukaryotic gene expression (Levrero *et al.*, 1991; Gomez-Foix *et al.*, 1992) and vaccine development (Grunhaus and Horwitz, 1992; Graham and Prevec, 1992). Recently, animal studies suggested that recombinant adenovirus could be used for gene therapy (Stratford-Perricaudet and Perricaudet, 1991; Stratford-Perricaudet *et al.*, 1990; Rich *et al.*, 1993). Studies in administering recombinant adenovirus to different tissues include trachea instillation (Rosenfeld *et al.*, 1991; Rosenfeld *et al.*, 1992), muscle injection (Ragot *et al.*, 1993), peripheral intravenous injections (Herz and Gerard, 1993) and stereotactic inoculation into the brain (Le Gal La Salle *et al.*, 1993).

4.15.2 RETROVIRUSES

[411] The retroviruses are a group of single-stranded RNA viruses characterized by an ability to convert their RNA to double-stranded DNA in infected cells by a process of reverse-transcription (Coffin, 1990). The resulting DNA then stably integrates into 5 cellular chromosomes as a provirus and directs synthesis of viral proteins. The integration results in the retention of the viral gene sequences in the recipient cell and its descendants. The retroviral genome contains three genes, gag, pol, and env that code for capsid proteins, polymerase enzyme, and envelope components, respectively. A sequence found upstream from the gag gene contains a signal for packaging of the 10 genome into virions. Two long terminal repeat (LTR) sequences are present at the 5' and 3' ends of the viral genome. These contain strong promoter and enhancer sequences and are also required for integration in the host cell genome (Coffin, 1990).

[412] In order to construct a retroviral vector, a nucleic acid encoding one or more 15 oligonucleotide or polynucleotide sequences of interest is inserted into the viral genome in the place of certain viral sequences to produce a virus that is replication-defective. In order to produce virions, a packaging cell line containing the gag, pol, and env genes but without the LTR and packaging components is constructed (Mann 20 *et al.*, 1983). When a recombinant plasmid containing a cDNA, together with the retroviral LTR and packaging sequences is introduced into this cell line (by calcium phosphate precipitation for example), the packaging sequence allows the RNA transcript of the recombinant plasmid to be packaged into viral particles, which are then secreted into the culture media (Nicolas and Rubenstein, 1988; Temin, 1986; Mann *et al.*, 1983). The media containing the recombinant retroviruses is then 25 collected, optionally concentrated, and used for gene transfer. Retroviral vectors are able to infect a broad variety of cell types. However, integration and stable expression require the division of host cells (Paskind *et al.*, 1975).

[413] A novel approach designed to allow specific targeting of retrovirus vectors was recently developed based on the chemical modification of a retrovirus by the 30 chemical addition of lactose residues to the viral envelope. This modification could permit the specific infection of hepatocytes *via* sialoglycoprotein receptors.

[414] A different approach to targeting of recombinant retroviruses was designed in which biotinylated antibodies against a retroviral envelope protein and against a specific cell receptor were used. The antibodies were coupled *via* the biotin 35 components by using streptavidin (Roux *et al.*, 1989). Using antibodies against major

histocompatibility complex class I and class II antigens, they demonstrated the infection of a variety of human cells that bore those surface antigens with an ecotropic virus *in vitro* (Roux *et al.*, 1989).

5 4.15.3 ADENO-ASSOCIATED VIRUSES

[415] AAV (Ridgeway, 1988; Hermonat and Muzyczka, 1984) is a parovirus, discovered as a contamination of adenoviral stocks. It is a ubiquitous virus (antibodies are present in 85% of the US human population) that has not been linked to any disease. It is also classified as a dependovirus, because its replication is dependent on the presence of a helper virus, such as adenovirus. Five serotypes have been isolated, of which AAV-2 is the best characterized. AAV has a single-stranded linear DNA that is encapsidated into capsid proteins VP1, VP2 and VP3 to form an icosahedral virion of 20 to 24 nm in diameter (Muzyczka and McLaughlin, 1988).

[416] The AAV DNA is approximately 4.7 kilobases long. It contains two open reading frames and is flanked by two ITRs. There are two major genes in the AAV genome: *rep* and *cap*. The *rep* gene codes for proteins responsible for viral replication, whereas *cap* codes for capsid protein VP1-3. Each ITR forms a T-shaped hairpin structure. These terminal repeats are the only essential *cis* components of the AAV for chromosomal integration. Therefore, the AAV can be used as a vector with all viral coding sequences removed and replaced by the cassette of genes for delivery. Three viral promoters have been identified and named p5, p19, and p40, according to their map position. Transcription from p5 and p19 results in production of *rep* proteins, and transcription from p40 produces the capsid proteins (Hermonat and Muzyczka, 1984).

[417] There are several factors that prompted researchers to study the possibility of using rAAV as an expression vector. One is that the requirements for delivering a gene to integrate into the host chromosome are surprisingly few. It is necessary to have the 145-bp ITRs, which are only 6% of the AAV genome. This leaves room in the vector to assemble a 4.5-kb DNA insertion. While this carrying capacity may prevent the AAV from delivering large genes, it is amply suited for delivering the antisense constructs of the present invention.

[418] AAV is also a good choice of delivery vehicles due to its safety. There is a relatively complicated rescue mechanism: not only wild type adenovirus but also AAV genes are required to mobilize rAAV. Likewise, AAV is not pathogenic and not

associated with any disease. The removal of viral coding sequences minimizes immune reactions to viral gene expression, and therefore, rAAV does not evoke an inflammatory response.

5 4.15.4 OTHER VIRAL VECTORS AS EXPRESSION CONSTRUCTS

[419] Other viral vectors may be employed as expression constructs in the present invention for the delivery of oligonucleotide or polynucleotide sequences to a host cell. Vectors derived from viruses such as vaccinia virus (Ridgeway, 1988; Coupar *et al.*, 1988), lentiviruses, polio viruses and herpes viruses may be employed. They offer several attractive features for various mammalian cells (Friedmann, 1989; Ridgeway, 10 Coupar *et al.*, 1988; Horwich *et al.*, 1990).

With the recent recognition of defective hepatitis B viruses, new insight was gained into the structure-function relationship of different viral sequences. In vitro studies showed that the virus could retain the ability for helper-dependent packaging and reverse transcription despite 15 the deletion of up to 80% of its genome (Horwich *et al.*, 1990). This suggested that large portions of the genome could be replaced with foreign genetic material. The hepatotropism and persistence (integration) were particularly attractive properties for liver-directed gene transfer. Chang *et al.* (1991) introduced the chloramphenicol acetyltransferase (CAT) gene into duck hepatitis B virus genome in the place of the polymerase, surface, and pre-surface coding 20 sequences. It was cotransfected with wild-type virus into an avian hepatoma cell line. Culture media containing high titers of the recombinant virus were used to infect primary duckling hepatocytes. Stable CAT gene expression was detected for at least 24 days after transfection (Chang *et al.*, 1991).

25 4.15.5 NON-VIRAL VECTORS

[420] In order to effect expression of the oligonucleotide or polynucleotide sequences of the present invention, the expression construct must be delivered into a cell. This delivery may be accomplished *in vitro*, as in laboratory procedures for transforming cells lines, or *in vivo* or *ex vivo*, as in the treatment of certain disease states. As described above, one preferred mechanism for delivery is *via* viral infection where the expression construct is encapsulated in an infectious viral particle. 30

[421] Once the expression construct has been delivered into the cell the nucleic acid encoding the desired oligonucleotide or polynucleotide sequences may be positioned and expressed at different sites. In certain embodiments, the nucleic acid encoding the

construct may be stably integrated into the genome of the cell. The integration may be in the specific location and orientation *via* homologous recombination (gene replacement) or it may be integrated in a random, non-specific location (gene augmentation). In yet further embodiments, the nucleic acid may be stably maintained in the cell as a separate, episomal segment of DNA. Such nucleic acid segments or "episomes" encode sequences sufficient to permit maintenance and replication independent of or in synchronization with the host cell cycle. How the expression construct is delivered to a cell and where in the cell the nucleic acid remains is dependent on the type of expression construct employed.

[422] In certain embodiments of the invention, the expression construct comprising one or more oligonucleotide or polynucleotide sequences may simply consist of naked recombinant DNA or plasmids. Transfer of the construct may be performed by any of the methods mentioned above which physically or chemically permeabilize the cell membrane. This is particularly applicable for transfer *in vitro* but it may be applied to *in vivo* use as well. Dubensky *et al.* (1984) successfully injected polyomavirus DNA in the form of calcium phosphate precipitates into liver and spleen of adult and newborn mice demonstrating active viral replication and acute infection. Benvenisty and Reshef (1986) also demonstrated that direct intraperitoneal injection of calcium phosphate-precipitated plasmids results in expression of the transfected genes. It is envisioned that DNA encoding a gene of interest may also be transferred in a similar manner *in vivo* and express the gene product.

[423] Another embodiment of the invention for transferring a naked DNA expression construct into cells may involve particle bombardment. This method depends on the ability to accelerate DNA-coated microprojectiles to a high velocity allowing them to pierce cell membranes and enter cells without killing them (Klein *et al.*, 1987). Several devices for accelerating small particles have been developed. One such device relies on a high voltage discharge to generate an electrical current, which in turn provides the motive force (Yang *et al.*, 1990). The microprojectiles used have consisted of biologically inert substances such as tungsten or gold beads.

[424] Selected organs including the liver, skin, and muscle tissue of rats and mice have been bombarded *in vivo* (Yang *et al.*, 1990; Zelenin *et al.*, 1991). This may require surgical exposure of the tissue or cells, to eliminate any intervening tissue between the gun and the target organ, *i.e.* *ex vivo* treatment. Again, DNA encoding a

particular gene may be delivered *via* this method and still be incorporated by the present invention.

4.16 ANTISENSE OLIGONUCLEOTIDES

- 5 [425] The end result of the flow of genetic information is the synthesis of protein. DNA is transcribed by polymerases into messenger RNA and translated on the ribosome to yield a folded, functional protein. Thus there are several steps along the route where protein synthesis can be inhibited. The native DNA segment coding for a polypeptide described herein, as all such mammalian DNA strands, has two strands: a sense strand and an antisense strand held together by hydrogen bonding. The messenger RNA coding for polypeptide has the same nucleotide sequence as the sense DNA strand except that the DNA thymidine is replaced by uridine. Thus, synthetic antisense nucleotide sequences will bind to a mRNA and inhibit expression of the protein encoded by that mRNA.
- 10 [426] The targeting of antisense oligonucleotides to mRNA is thus one mechanism to shut down protein synthesis, and, consequently, represents a powerful and targeted therapeutic approach. For example, the synthesis of polygalacturonase and the muscarine type 2 acetylcholine receptor are inhibited by antisense oligonucleotides directed to their respective mRNA sequences (U. S. Patent 5,739,119 and U. S. Patent 5,759,829, each specifically incorporated herein by reference in its entirety). Further, examples of antisense inhibition have been demonstrated with the nuclear protein cyclin, the multiple drug resistance gene (MDG1), ICAM-1, E-selectin, STK-1, striatal GABA_A receptor and human EGF (Jaskulski *et al.*, 1988; Vasanthakumar and Ahmed, 1989; Peris *et al.*, 1998; U. S. Patent 5,801,154; U. S. Patent 5,789,573; U. S. Patent 5,718,709 and U. S. Patent 5,610,288, each specifically incorporated herein by reference in its entirety). Antisense constructs have also been described that inhibit and can be used to treat a variety of abnormal cellular proliferations, *e.g.* cancer (U. S. Patent 5,747,470; U. S. Patent 5,591,317 and U. S. Patent 5,783,683, each specifically incorporated herein by reference in its entirety).
- 15 [427] Therefore, in exemplary embodiments, the invention provides oligonucleotide sequences that comprise all, or a portion of, any sequence that is capable of specifically binding to polynucleotide sequence described herein, or a complement thereof. In one embodiment, the antisense oligonucleotides comprise DNA or derivatives thereof. In another embodiment, the oligonucleotides comprise RNA or

derivatives thereof. In a third embodiment, the oligonucleotides are modified DNAs comprising a phosphorothioated modified backbone. In a fourth embodiment, the oligonucleotide sequences comprise peptide nucleic acids or derivatives thereof. In each case, preferred compositions comprise a sequence region that is complementary, and more preferably substantially-complementary, and even more preferably, completely complementary to one or more portions of polynucleotides disclosed herein.

[428] Selection of antisense compositions specific for a given gene sequence is based upon analysis of the chosen target sequence (*i.e.* in these illustrative examples the rat and human sequences) and determination of secondary structure, T_m , binding energy, relative stability, and antisense compositions were selected based upon their relative inability to form dimers, hairpins, or other secondary structures that would reduce or prohibit specific binding to the target mRNA in a host cell.

[429] Highly preferred target regions of the mRNA, are those which are at or near the AUG translation initiation codon, and those sequences which were substantially complementary to 5' regions of the mRNA. These secondary structure analyses and target site selection considerations were performed using v.4 of the OLIGO primer analysis software (Rychlik, 1997) and the BLASTN 2.0.5 algorithm software (Altschul *et al.*, 1997).

[430] The use of an antisense delivery method employing a short peptide vector, termed MPG (27 residues), is also contemplated. The MPG peptide contains a hydrophobic domain derived from the fusion sequence of HIV gp41 and a hydrophilic domain from the nuclear localization sequence of SV40 T-antigen (Morris *et al.*, 1997). It has been demonstrated that several molecules of the MPG peptide coat the antisense oligonucleotides and can be delivered into cultured mammalian cells in less than 1 hour with relatively high efficiency (90%). Further, the interaction with MPG strongly increases both the stability of the oligonucleotide to nuclease and the ability to cross the plasma membrane (Morris *et al.*, 1997).

30 4.17 RIBOZYMES

[431] Although proteins traditionally have been used for catalysis of nucleic acids, another class of macromolecules has emerged as useful in this endeavor. Ribozymes are RNA-protein complexes that cleave nucleic acids in a site-specific fashion. Ribozymes have specific catalytic domains that possess endonuclease activity (Kim

and Cech, 1987; Gerlach *et al.*, 1987; Forster and Symons, 1987). For example, a large number of ribozymes accelerate phosphoester transfer reactions with a high degree of specificity, often cleaving only one of several phosphoesters in an oligonucleotide substrate (Cech *et al.*, 1981; Michel and Westhof, 1990; Reinhold-Hurek and Shub, 1992). This specificity has been attributed to the requirement that the substrate bind via specific base-pairing interactions to the internal guide sequence ("IGS") of the ribozyme prior to chemical reaction.

[432] Ribozyme catalysis has primarily been observed as part of sequence-specific cleavage/ligation reactions involving nucleic acids (Joyce, 1989; Cech *et al.*, 1981). For example, U. S. Patent No. 5,354,855 (specifically incorporated herein by reference) reports that certain ribozymes can act as endonucleases with a sequence specificity greater than that of known ribonucleases and approaching that of the DNA restriction enzymes. Thus, sequence-specific ribozyme-mediated inhibition of gene expression may be particularly suited to therapeutic applications (Scanlon *et al.*, 1991; Sarver *et al.*, 1990). Recently, it was reported that ribozymes elicited genetic changes in some cell lines to which they were applied; the altered genes included the oncogenes H-ras, c-fos and genes of HIV. Most of this work involved the modification of a target mRNA, based on a specific mutant codon that is cleaved by a specific ribozyme.

[433] Six basic varieties of naturally-occurring enzymatic RNAs are known presently. Each can catalyze the hydrolysis of RNA phosphodiester bonds *in trans* (and thus can cleave other RNA molecules) under physiological conditions. In general, enzymatic nucleic acids act by first binding to a target RNA. Such binding occurs through the target binding portion of a enzymatic nucleic acid which is held in close proximity to an enzymatic portion of the molecule that acts to cleave the target RNA. Thus, the enzymatic nucleic acid first recognizes and then binds a target RNA through complementary base-pairing, and once bound to the correct site, acts enzymatically to cut the target RNA. Strategic cleavage of such a target RNA will destroy its ability to direct synthesis of an encoded protein. After an enzymatic nucleic acid has bound and cleaved its RNA target, it is released from that RNA to search for another target and can repeatedly bind and cleave new targets.

[434] The enzymatic nature of a ribozyme is advantageous over many technologies, such as antisense technology (where a nucleic acid molecule simply binds to a nucleic acid target to block its translation) since the concentration of ribozyme necessary to

affect a therapeutic treatment is lower than that of an antisense oligonucleotide. This advantage reflects the ability of the ribozyme to act enzymatically. Thus, a single ribozyme molecule is able to cleave many molecules of target RNA. In addition, the ribozyme is a highly specific inhibitor, with the specificity of inhibition depending not only on the base pairing mechanism of binding to the target RNA, but also on the mechanism of target RNA cleavage. Single mismatches, or base-substitutions, near the site of cleavage can completely eliminate catalytic activity of a ribozyme. Similar mismatches in antisense molecules do not prevent their action (Woolf *et al.*, 1992). Thus, the specificity of action of a ribozyme is greater than that of an antisense oligonucleotide binding the same RNA site.

[435] The enzymatic nucleic acid molecule may be formed in a hammerhead, hairpin, a hepatitis δ virus, group I intron or RNaseP RNA (in association with an RNA guide sequence) or Neurospora VS RNA motif. Examples of hammerhead motifs are described by Rossi *et al.* (1992). Examples of hairpin motifs are described by Hampel *et al.* (Eur. Pat. Appl. Publ. No. EP 0360257), Hampel and Tritz (1989), Hampel *et al.* (1990) and U. S. Patent 5,631,359 (specifically incorporated herein by reference). An example of the hepatitis δ virus motif is described by Perrotta and Been (1992); an example of the RNaseP motif is described by Guerrier-Takada *et al.* (1983); Neurospora VS RNA ribozyme motif is described by Collins (Saville and Collins, 1990; Saville and Collins, 1991; Collins and Olive, 1993); and an example of the Group I intron is described in (U. S. Patent 4,987,071, specifically incorporated herein by reference). All that is important in an enzymatic nucleic acid molecule of this invention is that it has a specific substrate binding site which is complementary to one or more of the target gene RNA regions, and that it have nucleotide sequences within or surrounding that substrate binding site which impart an RNA cleaving activity to the molecule. Thus the ribozyme constructs need not be limited to specific motifs mentioned herein.

[436] In certain embodiments, it may be important to produce enzymatic cleaving agents which exhibit a high degree of specificity for the RNA of a desired target, such as one of the sequences disclosed herein. The enzymatic nucleic acid molecule is preferably targeted to a highly conserved sequence region of a target mRNA. Such enzymatic nucleic acid molecules can be delivered exogenously to specific cells as required. Alternatively, the ribozymes can be expressed from DNA or RNA vectors that are delivered to specific cells.

[437] Small enzymatic nucleic acid motifs (*e.g.*, of the hammerhead or the hairpin structure) may also be used for exogenous delivery. The simple structure of these molecules increases the ability of the enzymatic nucleic acid to invade targeted regions of the mRNA structure. Alternatively, catalytic RNA molecules can be expressed within cells from eukaryotic promoters (*e.g.*, Scanlon *et al.*, 1991; Kashani-Sabet *et al.*, 1992; Dropulic *et al.*, 1992; Weerasinghe *et al.*, 1991; Ojwang *et al.*, 1992; Chen *et al.*, 1992; Sarver *et al.*, 1990). Those skilled in the art realize that any ribozyme can be expressed in eukaryotic cells from the appropriate DNA vector. The activity of such ribozymes can be augmented by their release from the primary transcript by a second ribozyme (Int. Pat. Appl. Publ. No. WO 93/23569, and Int. Pat. Appl. Publ. No. WO 94/02595, both hereby incorporated by reference; Ohkawa *et al.*, 1992; Taira *et al.*, 1991; and Ventura *et al.*, 1993).

[438] Ribozymes may be added directly, or can be complexed with cationic lipids, lipid complexes, packaged within liposomes, or otherwise delivered to target cells. The RNA or RNA complexes can be locally administered to relevant tissues *ex vivo*, or *in vivo* through injection, aerosol inhalation, infusion pump or stent, with or without their incorporation in biopolymers.

[439] Ribozymes may be designed as described in Int. Pat. Appl. Publ. No. WO 93/23569 and Int. Pat. Appl. Publ. No. WO 94/02595, each specifically incorporated herein by reference) and synthesized to be tested *in vitro* and *in vivo*, as described. Such ribozymes can also be optimized for delivery. While specific examples are provided, those in the art will recognize that equivalent RNA targets in other species can be utilized when necessary.

[440] Hammerhead or hairpin ribozymes may be individually analyzed by computer folding (Jaeger *et al.*, 1989) to assess whether the ribozyme sequences fold into the appropriate secondary structure. Those ribozymes with unfavorable intramolecular interactions between the binding arms and the catalytic core are eliminated from consideration. Varying binding arm lengths can be chosen to optimize activity. Generally, at least 5 or so bases on each arm are able to bind to, or otherwise interact with, the target RNA.

[441] Ribozymes of the hammerhead or hairpin motif may be designed to anneal to various sites in the mRNA message, and can be chemically synthesized. The method of synthesis used follows the procedure for normal RNA synthesis as described in Usman *et al.* (1987) and in Scaringe *et al.* (1990) and makes use of common nucleic

acid protecting and coupling groups, such as dimethoxytrityl at the 5'-end, and phosphoramidites at the 3'-end. Average stepwise coupling yields are typically >98%. Hairpin ribozymes may be synthesized in two parts and annealed to reconstruct an active ribozyme (Chowrira and Burke, 1992). Ribozymes may be modified extensively to enhance stability by modification with nuclease resistant groups, for example, 2'-amino, 2'-C-allyl, 2'-flouro, 2'-o-methyl, 2'-H (for a review see e.g., Usman and Cedergren, 1992). Ribozymes may be purified by gel electrophoresis using general methods or by high pressure liquid chromatography and resuspended in water.

10 [442] Ribozyme activity can be optimized by altering the length of the ribozyme binding arms, or chemically synthesizing ribozymes with modifications that prevent their degradation by serum ribonucleases (see e.g., Int. Pat. Appl. Publ. No. WO 92/07065; Perrault *et al.*, 1990; Pieken *et al.*, 1991; Usman and Cedergren, 1992; Int. Pat. Appl. Publ. No. WO 93/15187; Int. Pat. Appl. Publ. No. WO 91/03162; Eur. Pat. Appl. Publ. No. 92110298.4; U. S. Patent 5,334,711; and Int. Pat. Appl. Publ. No. WO 94/13688, which describe various chemical modifications that can be made to the sugar moieties of enzymatic RNA molecules), modifications which enhance their efficacy in cells, and removal of stem II bases to shorten RNA synthesis times and reduce chemical requirements.

20 [443] Sullivan *et al.* (Int. Pat. Appl. Publ. No. WO 94/02595) describes the general methods for delivery of enzymatic RNA molecules. Ribozymes may be administered to cells by a variety of methods known to those familiar to the art, including, but not restricted to, encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres. For some indications, ribozymes may be directly delivered *ex vivo* to cells or tissues with or without the aforementioned vehicles. Alternatively, the RNA/vehicle combination may be locally delivered by direct inhalation, by direct injection or by use of a catheter, infusion pump or stent. Other routes of delivery include, but are not limited to, intravascular, intramuscular, subcutaneous or joint injection, aerosol inhalation, oral (tablet or pill form), topical, systemic, ocular, intraperitoneal and/or intrathecal delivery. More detailed descriptions of ribozyme delivery and administration are provided in Int. Pat. Appl. Publ. No. WO 94/02595 and Int. Pat. Appl. Publ. No. WO 93/23569, each specifically incorporated herein by reference.

[444] Another means of accumulating high concentrations of a ribozyme(s) within cells is to incorporate the ribozyme-encoding sequences into a DNA expression vector. Transcription of the ribozyme sequences are driven from a promoter for eukaryotic RNA polymerase I (pol I), RNA polymerase II (pol II), or RNA polymerase III (pol III). Transcripts from pol II or pol III promoters will be expressed at high levels in all cells; the levels of a given pol II promoter in a given cell type will depend on the nature of the gene regulatory sequences (enhancers, silencers, *etc.*) present nearby. Prokaryotic RNA polymerase promoters may also be used, providing that the prokaryotic RNA polymerase enzyme is expressed in the appropriate cells (Elroy-Stein and Moss, 1990; Gao and Huang, 1993; Lieber *et al.*, 1993; Zhou *et al.*, 1990). Ribozymes expressed from such promoters can function in mammalian cells (*e.g.* Kashani-Saber *et al.*, 1992; Ojwang *et al.*, 1992; Chen *et al.*, 1992; Yu *et al.*, 1993; L'Huillier *et al.*, 1992; Lisziewicz *et al.*, 1993). Such transcription units can be incorporated into a variety of vectors for introduction into mammalian cells, including but not restricted to, plasmid DNA vectors, viral DNA vectors (such as adenovirus or adeno-associated vectors), or viral RNA vectors (such as retroviral, semliki forest virus, sindbis virus vectors).

[445] Ribozymes may be used as diagnostic tools to examine genetic drift and mutations within diseased cells. They can also be used to assess levels of the target RNA molecule. The close relationship between ribozyme activity and the structure of the target RNA allows the detection of mutations in any region of the molecule which alters the base-pairing and three-dimensional structure of the target RNA. By using multiple ribozymes, one may map nucleotide changes which are important to RNA structure and function *in vitro*, as well as in cells and tissues. Cleavage of target RNAs with ribozymes may be used to inhibit gene expression and define the role (essentially) of specified gene products in the progression of disease. In this manner, other genetic targets may be defined as important mediators of the disease. These studies will lead to better treatment of the disease progression by affording the possibility of combinational therapies (*e.g.*, multiple ribozymes targeted to different genes, ribozymes coupled with known small molecule inhibitors, or intermittent treatment with combinations of ribozymes and/or other chemical or biological molecules). Other *in vitro* uses of ribozymes are well known in the art, and include detection of the presence of mRNA associated with an IL-5 related condition. Such

RNA is detected by determining the presence of a cleavage product after treatment with a ribozyme using standard methodology.

4.18 PEPTIDE NUCLEIC ACIDS

[446] In certain embodiments, the inventors contemplate the use of peptide nucleic acids (PNAs) in the practice of the methods of the invention. PNA is a DNA mimic in which the nucleobases are attached to a pseudopeptide backbone (Good and Nielsen, 1997). PNA is able to be utilized in a number methods that traditionally have used RNA or DNA. Often PNA sequences perform better in techniques than the corresponding RNA or DNA sequences and have utilities that are not inherent to RNA or DNA. A review of PNA including methods of making, characteristics of, and methods of using, is provided by Corey (1997) and is incorporated herein by reference. As such, in certain embodiments, one may prepare PNA sequences that are complementary to one or more portions of the ACE mRNA sequence, and such PNA compositions may be used to regulate, alter, decrease, or reduce the translation of ACE-specific mRNA, and thereby alter the level of ACE activity in a host cell to which such PNA compositions have been administered.

[447] PNAs have 2-aminoethyl-glycine linkages replacing the normal phosphodiester backbone of DNA (Nielsen *et al.*, 1991; Hanvey *et al.*, 1992; Hyrup and Nielsen, 1996; Nielsen, 1996). This chemistry has three important consequences: firstly, in contrast to DNA or phosphorothioate oligonucleotides, PNAs are neutral molecules; secondly, PNAs are achiral, which avoids the need to develop a stereoselective synthesis; and thirdly, PNA synthesis uses standard Boc (Dueholm *et al.*, 1994) or Fmoc (Thomson *et al.*, 1995) protocols for solid-phase peptide synthesis, although other methods, including a modified Merrifield method, have been used (Christensen *et al.*, 1995).

[448] PNA monomers or ready-made oligomers are commercially available from PerSeptive Biosystems (Framingham, MA). PNA syntheses by either Boc or Fmoc protocols are straightforward using manual or automated protocols (Norton *et al.*, 1995). The manual protocol lends itself to the production of chemically modified PNAs or the simultaneous synthesis of families of closely related PNAs.

[449] As with peptide synthesis, the success of a particular PNA synthesis will depend on the properties of the chosen sequence. For example, while in theory PNAs can incorporate any combination of nucleotide bases, the presence of adjacent purines

can lead to deletions of one or more residues in the product. In expectation of this difficulty, it is suggested that, in producing PNAs with adjacent purines, one should repeat the coupling of residues likely to be added inefficiently. This should be followed by the purification of PNAs by reverse-phase high-pressure liquid chromatography (Norton *et al.*, 1995) providing yields and purity of product similar to those observed during the synthesis of peptides.

5 [450] Modifications of PNAs for a given application may be accomplished by coupling amino acids during solid-phase synthesis or by attaching compounds that contain a carboxylic acid group to the exposed N-terminal amine. Alternatively, 10 PNAs can be modified after synthesis by coupling to an introduced lysine or cysteine. The ease with which PNAs can be modified facilitates optimization for better solubility or for specific functional requirements. Once synthesized, the identity of PNAs and their derivatives can be confirmed by mass spectrometry. Several studies have made and utilized modifications of PNAs (Norton *et al.*, 1995; Haaima *et al.*, 15 1996; Stetsenko *et al.*, 1996; Petersen *et al.*, 1995; Ulmann *et al.*, 1996; Koch *et al.*, 1995; Orum *et al.*, 1995; Footer *et al.*, 1996; Griffith *et al.*, 1995; Kremsky *et al.*, 1996; Pardridge *et al.*, 1995; Boffa *et al.*, 1995; Landsdorp *et al.*, 1996; Gambacorti-Passerini *et al.*, 1996; Armitage *et al.*, 1997; Seeger *et al.*, 1997; Ruskowski *et al.*, 20 1997). U.S. Patent No. 5,700,922 discusses PNA-DNA-PNA chimeric molecules and their uses in diagnostics, modulating protein in organisms, and treatment of conditions susceptible to therapeutics.

25 [451] In contrast to DNA and RNA, which contain negatively charged linkages, the PNA backbone is neutral. In spite of this dramatic alteration, PNAs recognize complementary DNA and RNA by Watson-Crick pairing (Egholm *et al.*, 1993), validating the initial modeling by Nielsen *et al.* (1991). PNAs lack 3' to 5' polarity and can bind in either parallel or anti-parallel fashion, with the anti-parallel mode being preferred (Egholm *et al.*, 1993).

30 [452] Hybridization of DNA oligonucleotides to DNA and RNA is destabilized by electrostatic repulsion between the negatively charged phosphate backbones of the complementary strands. By contrast, the absence of charge repulsion in PNA-DNA or PNA-RNA duplexes increases the melting temperature (T_m) and reduces the dependence of T_m on the concentration of mono- or divalent cations (Nielsen *et al.*, 1991). The enhanced rate and affinity of hybridization are significant because they are responsible for the surprising ability of PNAs to perform strand invasion of

5

complementary sequences within relaxed double-stranded DNA. In addition, the efficient hybridization at inverted repeats suggests that PNAs can recognize secondary structure effectively within double-stranded DNA. Enhanced recognition also occurs with PNAs immobilized on surfaces, and Wang *et al.* have shown that support-bound PNAs can be used to detect hybridization events (Wang *et al.*, 1996).

10

[453] One might expect that tight binding of PNAs to complementary sequences would also increase binding to similar (but not identical) sequences, reducing the sequence specificity of PNA recognition. As with DNA hybridization, however, selective recognition can be achieved by balancing oligomer length and incubation temperature. Moreover, selective hybridization of PNAs is encouraged by PNA-DNA hybridization being less tolerant of base mismatches than DNA-DNA hybridization. For example, a single mismatch within a 16 bp PNA-DNA duplex can reduce the T_m by up to 15°C (Egholm *et al.*, 1993). This high level of discrimination has allowed the development of several PNA-based strategies for the analysis of point mutations (Wang *et al.*, 1996; Carlsson *et al.*, 1996; Thiede *et al.*, 1996; Webb and Hurskainen, 1996; Perry-O'Keefe *et al.*, 1996).

20

[454] High-affinity binding provides clear advantages for molecular recognition and the development of new applications for PNAs. For example, 11-13 nucleotide PNAs inhibit the activity of telomerase, a ribonucleo-protein that extends telomere ends using an essential RNA template, while the analogous DNA oligomers do not (Norton *et al.*, 1996).

25

[455] Neutral PNAs are more hydrophobic than analogous DNA oligomers, and this can lead to difficulty solubilizing them at neutral pH, especially if the PNAs have a high purine content or if they have the potential to form secondary structures. Their solubility can be enhanced by attaching one or more positive charges to the PNA termini (Nielsen *et al.*, 1991).

30

[456] Findings by Allfrey and colleagues suggest that strand invasion will occur spontaneously at sequences within chromosomal DNA (Boffa *et al.*, 1995; Boffa *et al.*, 1996). These studies targeted PNAs to triplet repeats of the nucleotides CAG and used this recognition to purify transcriptionally active DNA (Boffa *et al.*, 1995) and to inhibit transcription (Boffa *et al.*, 1996). This result suggests that if PNAs can be delivered within cells then they will have the potential to be general sequence-specific regulators of gene expression. Studies and reviews concerning the use of PNAs as antisense and anti-gene agents include Nielsen *et al.* (1993b), Hanvey *et al.* (1992),

and Good and Nielsen (1997). Koppelhus *et al.* (1997) have used PNAs to inhibit HIV-1 inverse transcription, showing that PNAs may be used for antiviral therapies.

[457] Methods of characterizing the antisense binding properties of PNAs are discussed in Rose (1993) and Jensen *et al.* (1997). Rose uses capillary gel electrophoresis to determine binding of PNAs to their complementary oligonucleotide, measuring the relative binding kinetics and stoichiometry. Similar types of measurements were made by Jensen *et al.* using BIACore™ technology.

[458] Other applications of PNAs include use in DNA strand invasion (Nielsen *et al.*, 1991), antisense inhibition (Hanvey *et al.*, 1992), mutational analysis (Orum *et al.*, 1993), enhancers of transcription (Mollegaard *et al.*, 1994), nucleic acid purification (Orum *et al.*, 1995), isolation of transcriptionally active genes (Boffa *et al.*, 1995), blocking of transcription factor binding (Vickers *et al.*, 1995), genome cleavage (Veselkov *et al.*, 1996), biosensors (Wang *et al.*, 1996), *in situ* hybridization (Thisted *et al.*, 1996), and in a alternative to Southern blotting (Perry-O'Keefe, 1996).

4.19 POLYPEPTIDE, PEPTIDES AND PEPTIDE VARIANTS

[459] The present invention, in other aspects, provides polypeptide compositions. Generally, a polypeptide of the invention will be an isolated polypeptide (or an epitope, variant, or active fragment thereof) derived from a mammalian species. Preferably, the polypeptide is encoded by a polynucleotide sequence disclosed herein or a sequence which hybridizes under moderately stringent conditions to a polynucleotide sequence disclosed herein. Alternatively, the polypeptide may be defined as a polypeptide which comprises a contiguous amino acid sequence from an amino acid sequence disclosed herein, or which polypeptide comprises an entire amino acid sequence disclosed herein.

[460] In the present invention, a polypeptide composition is also understood to comprise one or more polypeptides that are immunologically reactive with antibodies generated against a polypeptide of the invention, particularly a polypeptide having the amino acid sequence encoded by the disclosed polynucleotides, or to active fragments, or to variants or biological functional equivalents thereof.

[461] Likewise, a polypeptide composition of the present invention is understood to comprise one or more polypeptides that are capable of eliciting antibodies that are immunologically reactive with one or more polypeptides encoded by one or more contiguous nucleic acid sequences disclosed in this application, or to active fragments,

or to variants thereof, or to one or more nucleic acid sequences which hybridize to one or more of these sequences under conditions of moderate to high stringency.

5

[462] As used herein, an active fragment of a polypeptide includes a whole or a portion of a polypeptide which is modified by conventional techniques, e.g., mutagenesis, or by addition, deletion, or substitution, but which active fragment exhibits substantially the same structure function, antigenicity, etc., as a polypeptide as described herein.

10

[463] In certain illustrative embodiments, the polypeptides of the invention will comprise at least an immunogenic portion of a hematological malignancy-related tumor protein or a variant thereof, as described herein. As noted above, a "hematological malignancy-related tumor protein" is a protein that is expressed by hematological malignancy-related tumor cells. Proteins that are hematological malignancy-related tumor proteins also react detectably within an immunoassay (such as an ELISA) with antisera from a patient with hematological malignancy.

15

Polypeptides as described herein may be of any length. Additional sequences derived from the native protein and/or heterologous sequences may be present, and such sequences may (but need not) possess further immunogenic or antigenic properties.

20

[464] An "immunogenic portion," as used herein is a portion of a protein that is recognized (*i.e.*, specifically bound) by a B-cell and/or T-cell surface antigen receptor. Such immunogenic portions generally comprise at least 5 amino acid residues, more preferably at least 10, and still more preferably at least 20 amino acid residues of a hematological malignancy-related tumor protein or a variant thereof. Certain preferred immunogenic portions include peptides in which an N-terminal leader sequence and/or transmembrane domain have been deleted. Other preferred

25

immunogenic portions may contain a small N- and/or C-terminal deletion (*e.g.*, 1-30 amino acids, preferably 5-15 amino acids), relative to the mature protein.

30

[465] Immunogenic portions may generally be identified using well known techniques, such as those summarized in Paul, *Fundamental Immunology*, 3rd ed., 243-247 (Raven Press, 1993) and references cited therein. Such techniques include screening polypeptides for the ability to react with antigen-specific antibodies, antisera and/or T-cell lines or clones. As used herein, antisera and antibodies are "antigen-specific" if they specifically bind to an antigen (*i.e.*, they react with the protein in an ELISA or other immunoassay, and do not react detectably with unrelated proteins). Such antisera and antibodies may be prepared as described herein, and using well

known techniques. An immunogenic portion of a native hematological malignancy-related tumor protein is a portion that reacts with such antisera and/or T-cells at a level that is not substantially less than the reactivity of the full length polypeptide (e.g., in an ELISA and/or T-cell reactivity assay). Such immunogenic portions may react within such assays at a level that is similar to or greater than the reactivity of the full length polypeptide. Such screens may generally be performed using methods well known to those of ordinary skill in the art, such as those described in Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988. For example, a polypeptide may be immobilized on a solid support and contacted with patient sera to allow binding of antibodies within the sera to the immobilized polypeptide. Unbound sera may then be removed and bound antibodies detected using, for example, ¹²⁵I-labeled Protein A.

[466] As noted above, a composition may comprise a variant of a native hematological malignancy-related tumor protein. A polypeptide "variant," as used herein, is a polypeptide that differs from a native hematological malignancy-related tumor protein in one or more substitutions, deletions, additions and/or insertions, such that the immunogenicity of the polypeptide is not substantially diminished. In other words, the ability of a variant to react with antigen-specific antisera may be enhanced or unchanged, relative to the native protein, or may be diminished by less than 50%, and preferably less than 20%, relative to the native protein. Such variants may generally be identified by modifying one of the above polypeptide sequences and evaluating the reactivity of the modified polypeptide with antigen-specific antibodies or antisera as described herein. Preferred variants include those in which one or more portions, such as an N-terminal leader sequence or transmembrane domain, have been removed. Other preferred variants include variants in which a small portion (e.g., 1-30 amino acids, preferably 5-15 amino acids) has been removed from the N- and/or C-terminal of the mature protein.

[467] Polypeptide variants encompassed by the present invention include those exhibiting at least about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more identity (determined as described above) to the polypeptides disclosed herein.

[468] Preferably, a variant contains conservative substitutions. A "conservative substitution" is one in which an amino acid is substituted for another amino acid that has similar properties, such that one skilled in the art of peptide chemistry would

expect the secondary structure and hydropathic nature of the polypeptide to be substantially unchanged. Amino acid substitutions may generally be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity and/or the amphipathic nature of the residues. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine and valine; glycine and alanine; asparagine and glutamine; and serine, threonine, phenylalanine and tyrosine. Other groups of amino acids that may represent conservative changes include: (1) ala, pro, gly, glu, asp, gln, asn, ser, thr; (2) cys, ser, tyr, thr; (3) val, ile, leu, met, ala, phe; (4) lys, arg, his; and (5) phe, tyr, trp, his. A variant may also, or alternatively, contain nonconservative changes. In a preferred embodiment, variant polypeptides differ from a native sequence by substitution, deletion or addition of five amino acids or fewer. Variants may also (or alternatively) be modified by, for example, the deletion or addition of amino acids that have minimal influence on the immunogenicity, secondary structure and hydropathic nature of the polypeptide.

[469] As noted above, polypeptides may comprise a signal (or leader) sequence at the N-terminal end of the protein, which co-translationally or post-translationally directs transfer of the protein. The polypeptide may also be conjugated to a linker or other sequence for ease of synthesis, purification or identification of the polypeptide (e.g., poly-His), or to enhance binding of the polypeptide to a solid support. For example, a polypeptide may be conjugated to an immunoglobulin Fc region.

[470] Polypeptides may be prepared using any of a variety of well known techniques. Recombinant polypeptides encoded by DNA sequences as described above may be readily prepared from the DNA sequences using any of a variety of expression vectors known to those of ordinary skill in the art. Expression may be achieved in any appropriate host cell that has been transformed or transfected with an expression vector containing a DNA molecule that encodes a recombinant polypeptide. Suitable host cells include prokaryotes, yeast, and higher eukaryotic cells, such as mammalian cells and plant cells. Preferably, the host cells employed are *E. coli*, yeast or a mammalian cell line such as COS or CHO. Supernatants from suitable host/vector systems which secrete recombinant protein or polypeptide into culture media may be first concentrated using a commercially available filter. Following concentration, the concentrate may be applied to a suitable purification

matrix such as an affinity matrix or an ion exchange resin. Finally, one or more reverse phase HPLC steps can be employed to further purify a recombinant polypeptide.

[471] Portions and other variants having less than about 100 amino acids, and generally less than about 50 amino acids, may also be generated by synthetic means, using techniques well known to those of ordinary skill in the art. For example, such polypeptides may be synthesized using any of the commercially available solid-phase techniques, such as the Merrifield solid-phase synthesis method, where amino acids are sequentially added to a growing amino acid chain. *See Merrifield, J. Am. Chem. Soc.* 85:2149-2146, 1963. Equipment for automated synthesis of polypeptides is commercially available from suppliers such as Perkin Elmer/Applied BioSystems Division (Foster City, CA), and may be operated according to the manufacturer's instructions.

[472] Within certain specific embodiments, a polypeptide may be a fusion protein that comprises multiple polypeptides as described herein, or that comprises at least one polypeptide as described herein and an unrelated sequence, such as a known tumor protein. A fusion partner may, for example, assist in providing T helper epitopes (an immunological fusion partner), preferably T helper epitopes recognized by humans, or may assist in expressing the protein (an expression enhancer) at higher yields than the native recombinant protein. Certain preferred fusion partners are both immunological and expression enhancing fusion partners. Other fusion partners may be selected so as to increase the solubility of the protein or to enable the protein to be targeted to desired intracellular compartments. Still further fusion partners include affinity tags, which facilitate purification of the protein.

[473] Fusion proteins may generally be prepared using standard techniques, including chemical conjugation. Preferably, a fusion protein is expressed as a recombinant protein, allowing the production of increased levels, relative to a non-fused protein, in an expression system. Briefly, DNA sequences encoding the polypeptide components may be assembled separately, and ligated into an appropriate expression vector. The 3' end of the DNA sequence encoding one polypeptide component is ligated, with or without a peptide linker, to the 5' end of a DNA sequence encoding the second polypeptide component so that the reading frames of the sequences are in phase. This permits translation into a single fusion protein that retains the biological activity of both component polypeptides.

[474] A peptide linker sequence may be employed to separate the first and second polypeptide components by a distance sufficient to ensure that each polypeptide folds into its secondary and tertiary structures. Such a peptide linker sequence is incorporated into the fusion protein using standard techniques well known in the art.

5 Suitable peptide linker sequences may be chosen based on the following factors:

(1) their ability to adopt a flexible extended conformation; (2) their inability to adopt a secondary structure that could interact with functional epitopes on the first and second polypeptides; and (3) the lack of hydrophobic or charged residues that might react with the polypeptide functional epitopes. Preferred peptide linker sequences contain Gly, Asn and Ser residues. Other near neutral amino acids, such as Thr and Ala may also be used in the linker sequence. Amino acid sequences which may be usefully employed as linkers include those disclosed in Maratea *et al.*, *Gene* 40:39-46, 1985; Murphy *et al.*, *Proc. Natl. Acad. Sci. USA* 83:8258-8262, 1986; U.S. Patent No. 4,935,233 and U.S. Patent No. 4,751,180. The linker sequence may generally be from 1 to about 50 amino acids in length. Linker sequences are not required when the first and second polypeptides have non-essential N-terminal amino acid regions that can be used to separate the functional domains and prevent steric interference.

10 [475] The ligated DNA sequences are operably linked to suitable transcriptional or translational regulatory elements. The regulatory elements responsible for expression of DNA are located only 5' to the DNA sequence encoding the first polypeptides. Similarly, stop codons required to end translation and transcription termination signals are only present 3' to the DNA sequence encoding the second polypeptide.

15 [476] Fusion proteins are also provided. Such proteins comprise a polypeptide as described herein together with an unrelated immunogenic protein. Preferably the immunogenic protein is capable of eliciting a recall response. Examples of such proteins include tetanus, tuberculosis and hepatitis proteins (*see, for example, Stoute et al. New Engl. J. Med.*, 336:86-91, 1997).

20 [477] Within preferred embodiments, an immunological fusion partner is derived from protein D, a surface protein of the gram-negative bacterium *Haemophilus influenzae* B (WO 91/18926). Preferably, a protein D derivative comprises approximately the first third of the protein (e.g., the first N-terminal 100-110 amino acids), and a protein D derivative may be lipidated. Within certain preferred embodiments, the first 109 residues of a Lipoprotein D fusion partner is included on the N-terminus to provide the polypeptide with additional exogenous T-cell epitopes

5

and to increase the expression level in *E. coli* (thus functioning as an expression enhancer). The lipid tail ensures optimal presentation of the antigen to antigen presenting cells. Other fusion partners include the non-structural protein from influenzae virus, NS1 (hemagglutinin). Typically, the N-terminal 81 amino acids are used, although different fragments that include T-helper epitopes may be used.

10

15

[478] In another embodiment, the immunological fusion partner is the protein known as LYTA, or a portion thereof (preferably a C-terminal portion). LYTA is derived from *Streptococcus pneumoniae*, which synthesizes an N-acetyl-L-alanine amidase known as amidase LYTA (encoded by the LytA gene; *Gene* 43:265-292, 1986). LYTA is an autolysin that specifically degrades certain bonds in the peptidoglycan backbone. The C-terminal domain of the LYTA protein is responsible for the affinity to the choline or to some choline analogues such as DEAE. This property has been exploited for the development of *E. coli* C-LYTA expressing plasmids useful for expression of fusion proteins. Purification of hybrid proteins containing the C-LYTA fragment at the amino terminus has been described (see *Biotechnology* 10:795-798, 1992). Within a preferred embodiment, a repeat portion of LYTA may be incorporated into a fusion protein. A repeat portion is found in the C-terminal region starting at residue 178. A particularly preferred repeat portion incorporates residues 188-305.

20

25

[479] In general, polypeptides (including fusion proteins) and polynucleotides as described herein are isolated. An "isolated" polypeptide or polynucleotide is one that is removed from its original environment. For example, a naturally-occurring protein is isolated if it is separated from some or all of the coexisting materials in the natural system. Preferably, such polypeptides are at least about 90% pure, more preferably at least about 95% pure and most preferably at least about 99% pure. A polynucleotide is considered to be isolated if, for example, it is cloned into a vector that is not a part of the natural environment.

4.20 BINDING AGENTS

30

[480] The present invention further employs agents, such as antibodies and antigen-binding fragments thereof, that specifically bind to a hematological malignancy-related antigen. As used herein, an antibody, or antigen-binding fragment thereof, is said to "specifically bind" to a hematological malignancy-related antigen if it reacts at a detectable level (within, for example, an ELISA) with , and does not react detectably

with unrelated proteins under similar conditions. As used herein, "binding" refers to a noncovalent association between two separate molecules such that a complex is formed. The ability to bind may be evaluated by, for example, determining a binding constant for the formation of the complex. The binding constant is the value obtained when the concentration of the complex is divided by the product of the component concentrations. In general, two compounds are said to "bind," in the context of the present invention, when the binding constant for complex formation exceeds about 10^3 L/mol. The binding constant maybe determined using methods well known in the art.

[481] Binding agents may be further capable of differentiating between patients with and without a hematological malignancy. Such binding agents generate a signal indicating the presence of a hematological malignancy in at least about 20% of patients with the disease, and will generate a negative signal indicating the absence of the disease in at least about 90% of individuals without the disease. To determine whether a binding agent satisfies this requirement, biological samples (e.g., blood, sera, urine and/or tumor biopsies) from patients with and without a hematological malignancy (as determined using standard clinical tests) may be assayed as described herein for the presence of polypeptides that bind to the binding agent. It will be apparent that a statistically significant number of samples with and without the disease should be assayed. Each binding agent should satisfy the above criteria; however, those of ordinary skill in the art will recognize that binding agents may be used in combination to improve sensitivity.

[482] Any agent that satisfies the above requirements may be a binding agent. For example, a binding agent may be a ribosome, with or without a peptide component, an RNA molecule or a polypeptide. In a preferred embodiment, a binding agent is an antibody or an antigen-binding fragment thereof. Antibodies may be prepared by any of a variety of techniques known to those of ordinary skill in the art. See, e.g., Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988. In general, antibodies can be produced by cell culture techniques, including the generation of monoclonal antibodies as described herein, or via transfection of antibody genes into suitable bacterial or mammalian cell hosts, in order to allow for the production of recombinant antibodies. In one technique, an immunogen comprising the polypeptide is initially injected into any of a wide variety of mammals (e.g., mice, rats, rabbits, sheep or goats). In this step, the polypeptides of this invention may serve as the immunogen without modification. Alternatively,

particularly for relatively short polypeptides, a superior immune response may be elicited if the polypeptide is joined to a carrier protein, such as bovine serum albumin or keyhole limpet hemocyanin. The immunogen is injected into the animal host, preferably according to a predetermined schedule incorporating one or more booster immunizations, and the animals are bled periodically. Polyclonal antibodies specific for the polypeptide may then be purified from such antisera by, for example, affinity chromatography using the polypeptide coupled to a suitable solid support.

5

[483] Monoclonal antibodies specific for an antigenic polypeptide of interest may be prepared, for example, using the technique of Kohler and Milstein, *Eur. J. Immunol.* 6:511-519, 1976, and improvements thereto. Briefly, these methods involve the preparation of immortal cell lines capable of producing antibodies having the desired specificity (*i.e.*, reactivity with the polypeptide of interest). Such cell lines may be produced, for example, from spleen cells obtained from an animal immunized as described above. The spleen cells are then immortalized by, for example, fusion with a myeloma cell fusion partner, preferably one that is syngeneic with the immunized animal. A variety of fusion techniques may be employed. For example, the spleen cells and myeloma cells may be combined with a nonionic detergent for a few minutes and then plated at low density on a selective medium that supports the growth of hybrid cells, but not myeloma cells. A preferred selection technique uses HAT (hypoxanthine, aminopterin, thymidine) selection. After a sufficient time, usually about 1 to 2 weeks, colonies of hybrids are observed. Single colonies are selected and their culture supernatants tested for binding activity against the polypeptide. Hybridomas having high reactivity and specificity are preferred.

10

15

20

25

30

[484] Monoclonal antibodies may be isolated from the supernatants of growing hybridoma colonies. In addition, various techniques may be employed to enhance the yield, such as injection of the hybridoma cell line into the peritoneal cavity of a suitable vertebrate host, such as a mouse. Monoclonal antibodies may then be harvested from the ascites fluid or the blood. Contaminants may be removed from the antibodies by conventional techniques, such as chromatography, gel filtration, precipitation, and extraction. The polypeptides of this invention may be used in the purification process in, for example, an affinity chromatography step.

[485] Within certain embodiments, the use of antigen-binding fragments of antibodies may be preferred. Such fragments include Fab fragments, which may be prepared using standard techniques. Briefly, immunoglobulins may be purified from

rabbit serum by affinity chromatography on Protein A bead column (Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988) and digested by papain to yield Fab and Fc fragments. The Fab and Fc fragments may be separated by affinity chromatography on protein A bead columns.

5 [486] Monoclonal antibodies, and fragments thereof, of the present invention may be coupled to one or more therapeutic agents, such as radionuclides, differentiation inducers, drugs, toxins, and derivatives thereof. Preferred radionuclides include ⁹⁰Y, ¹²³I, ¹²⁵I, ¹³¹I, ¹⁸⁶Re, ¹⁸⁸Re, ²¹¹At, and ²¹²Bi. Preferred drugs include methotrexate, and pyrimidine and purine analogs. Preferred differentiation inducers include phorbol esters and butyric acid. Preferred toxins include ricin, abrin, diphtheria toxin, cholera toxin, gelonin, *Pseudomonas* exotoxin, *Shigella* toxin, and pokeweed antiviral protein. For certain *in vivo* and *ex vivo* therapies, an antibody or fragment thereof is preferably coupled to a cytotoxic agent, such as a radioactive or chemotherapeutic moiety.

10 [487] A therapeutic agent may be coupled (*e.g.*, covalently bonded) to a suitable monoclonal antibody either directly or indirectly (*e.g.*, via a linker group). A direct reaction between an agent and an antibody is possible when each possesses a substituent capable of reacting with the other. For example, a nucleophilic group, such as an amino or sulfhydryl group, on one may be capable of reacting with a carbonyl-containing group, such as an anhydride or an acid halide, or with an alkyl group containing a good leaving group (*e.g.*, a halide) on the other.

15 [488] Alternatively, it may be desirable to couple a therapeutic agent and an antibody via a linker group. A linker group can function as a spacer to distance an antibody from an agent in order to avoid interference with binding capabilities. A linker group can also serve to increase the chemical reactivity of a substituent on an agent or an antibody, and thus increase the coupling efficiency. An increase in chemical reactivity may also facilitate the use of agents, or functional groups on agents, which otherwise would not be possible.

20 [489] It will be evident to those skilled in the art that a variety of bifunctional or polyfunctional reagents, both homo- and hetero-functional (such as those described in the catalog of the Pierce Chemical Co., Rockford, IL), may be employed as the linker group. Coupling may be effected, for example, through amino groups, carboxyl groups, sulfhydryl groups or oxidized carbohydrate residues. There are numerous references describing such methodology, *e.g.*, U. S. Patent No. 4,671,958.

[490] Where a therapeutic agent is more potent when free from [REDACTED] antibody portion of the immunoconjugates of the present invention, it may be desirable to use a linker group which is cleavable during or upon internalization into a cell. A number of different cleavable linker groups have been described. The mechanisms for the intracellular release of an agent from these linker groups include cleavage by reduction of a disulfide bond (*e.g.*, U. S. Patent No. 4,489,710), by irradiation of a photolabile bond (*e.g.*, U. S. Patent No. 4,625,014), by hydrolysis of derivatized amino acid side chains (*e.g.*, U. S. Patent No. 4,638,045), by serum complement-mediated hydrolysis (*e.g.*, U. S. Patent No. 4,671,958), and acid-catalyzed hydrolysis (*e.g.*, U. S. Patent No. 4,569,789).

[491] It may be desirable to couple more than one agent to an antibody. In one embodiment, multiple molecules of an agent are coupled to one antibody molecule. In another embodiment, more than one type of agent may be coupled to one antibody. Regardless of the particular embodiment, immunoconjugates with more than one agent may be prepared in a variety of ways. For example, more than one agent may be coupled directly to an antibody molecule, or linkers which provide multiple sites for attachment can be used. Alternatively, a carrier can be used.

[492] A carrier may bear the agents in a variety of ways, including covalent bonding either directly or via a linker group. Suitable carriers include proteins such as albumins (*e.g.*, U. S. Patent No. 4,507,234), peptides and polysaccharides such as aminodextran (*e.g.*, U. S. Patent No. 4,699,784). A carrier may also bear an agent by noncovalent bonding or by encapsulation, such as within a liposome vesicle (*e.g.*, U. S. Patent Nos. 4,429,008 and 4,873,088). Carriers specific for radionuclide agents include radiohalogenated small molecules and chelating compounds. For example, U. S. Patent No. 4,735,792 discloses representative radiohalogenated small molecules and their synthesis. A radionuclide chelate may be formed from chelating compounds that include those containing nitrogen and sulfur atoms as the donor atoms for binding the metal, or metal oxide, radionuclide. For example, U. S. Patent No. 4,673,562 discloses representative chelating compounds and their synthesis.

[493] A variety of routes of administration for the antibodies and immunoconjugates may be used. Typically, administration will be intravenous, intramuscular, subcutaneous or in the bed of a resected tumor. It will be evident that the precise dose of the antibody/immunoconjugate will vary depending upon the antibody used, the antigen density on the tumor, and the rate of clearance of the antibody.

4.21 VACCINES

[494] In certain preferred embodiments of the present invention, vaccines are provided. The vaccines will generally comprise one or more pharmaceutical compositions, such as those discussed above, in combination with an immunostimulant. An immunostimulant may be any substance that enhances or potentiates an immune response (antibody and/or cell-mediated) to an exogenous antigen. Examples of immunostimulants include adjuvants, biodegradable microspheres (e.g., polylactic galactide) and liposomes (into which the compound is incorporated; see e.g., Fullerton, U.S. Patent No. 4,235,877). Vaccine preparation is generally described in, for example, M.F. Powell and M.J. Newman, eds., "Vaccine Design (the subunit and adjuvant approach)," Plenum Press (NY, 1995). Pharmaceutical compositions and vaccines within the scope of the present invention may also contain other compounds, which may be biologically active or inactive. For example, one or more immunogenic portions of other tumor antigens may be present, either incorporated into a fusion polypeptide or as a separate compound, within the composition or vaccine.

[495] Illustrative vaccines may contain DNA encoding one or more of the polypeptides as described above, such that the polypeptide is generated *in situ*. As noted above, the DNA may be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid expression systems, bacteria and viral expression systems. Numerous gene delivery techniques are well known in the art, such as those described by Rolland, *Crit. Rev. Therap. Drug Carrier Systems* 15:143-198, 1998, and references cited therein. Appropriate nucleic acid expression systems contain the necessary DNA sequences for expression in the patient (such as a suitable promoter and terminating signal). Bacterial delivery systems involve the administration of a bacterium (such as *Bacillus-Calmette-Guerrin*) that expresses an immunogenic portion of the polypeptide on its cell surface or secretes such an epitope. In a preferred embodiment, the DNA may be introduced using a viral expression system (e.g., vaccinia or other pox virus, retrovirus, or adenovirus), which may involve the use of a non-pathogenic (defective), replication competent virus. Suitable systems are disclosed, for example, in Fisher-Hoch *et al.*, *Proc. Natl. Acad. Sci. USA* 86:317-321, 1989; Flexner *et al.*, *Ann. N.Y. Acad. Sci.* 569:86-103, 1989; Flexner *et al.*, *Vaccine* 8:17-21, 1990; U.S. Patent Nos. 4,603,112, 4,769,330, and

5,017,487; WO 89/01973; U.S. Patent No. 4,777,127; GB 2,200,632; EP 0,345,242;
WO 91/02805; Berkner, *Biotechniques* 6:616-627, 1988; Rosenfeld *et al.*, *Science*
252:431-434, 1991; Kolls *et al.*, *Proc. Natl. Acad. Sci. USA* 91:215-219, 1994;

5 Kass-Eisler *et al.*, *Proc. Natl. Acad. Sci. USA* 90:11498-11502, 1993; Guzman *et al.*,
Circulation 88:2838-2848, 1993; and Guzman *et al.*, *Cir. Res.* 73:1202-1207, 1993.
Techniques for incorporating DNA into such expression systems are well known to
those of ordinary skill in the art. The DNA may also be "naked," as described, for
example, in Ulmer *et al.*, *Science* 259:1745-1749, 1993 and reviewed by Cohen,
Science 259:1691-1692, 1993. The uptake of naked DNA may be increased by
coating the DNA onto biodegradable beads, which are efficiently transported into the
cells. It will be apparent that a vaccine may comprise both a polynucleotide and a
polypeptide component. Such vaccines may provide for an enhanced immune
response.

10 15 [496] It will be apparent that a vaccine may contain pharmaceutically acceptable
salts of the polynucleotides and polypeptides provided herein. Such salts may be
prepared from pharmaceutically acceptable non-toxic bases, including organic bases
(e.g., salts of primary, secondary and tertiary amines and basic amino acids) and
inorganic bases (e.g., sodium, potassium, lithium, ammonium, calcium and
magnesium salts).

20 [497] While any suitable carrier known to those of ordinary skill in the art may be
employed in the vaccine compositions of this invention, the type of carrier will vary
depending on the mode of administration. Compositions of the present invention may
be formulated for any appropriate manner of administration, including for example,
topical, oral, nasal, intravenous, intracranial, intraperitoneal, subcutaneous or
25 intramuscular administration. For parenteral administration, such as subcutaneous
injection, the carrier preferably comprises water, saline, alcohol, a fat, a wax or a
buffer. For oral administration, any of the above carriers or a solid carrier, such as
mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose,
glucose, sucrose, and magnesium carbonate, may be employed. Biodegradable
30 microspheres (e.g., polylactate polyglycolate) may also be employed as carriers for the
pharmaceutical compositions of this invention. Suitable biodegradable microspheres
are disclosed, for example, in U.S. Patent Nos. 4,897,268; 5,075,109; 5,928,647;
5,811,128; 5,820,883; 5,853,763; 5,814,344 and 5,942,252. One may also employ a
carrier comprising the particulate-protein complexes described in U.S. Patent No.

5,928,647, which are capable of inducing a class I-restricted cytotoxic T lymphocyte responses in a host.

5 [498] Such compositions may also comprise buffers (e.g., neutral buffered saline or phosphate buffered saline), carbohydrates (e.g., glucose, mannose, sucrose or dextrans), mannitol, proteins, polypeptides or amino acids such as glycine, antioxidants, bacteriostats, chelating agents such as EDTA or glutathione, adjuvants (e.g., aluminum hydroxide), solutes that render the formulation isotonic, hypotonic or weakly hypertonic with the blood of a recipient, suspending agents, thickening agents and/or preservatives. Alternatively, compositions of the present invention may be 10 formulated as a lyophilizate. Compounds may also be encapsulated within liposomes using well known technology.

15 [499] Any of a variety of immunostimulants may be employed in the vaccines of this invention. For example, an adjuvant may be included. Most adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A, *Bordetella pertussis* or *Mycobacterium tuberculosis* derived proteins. Suitable adjuvants are commercially available as, for example, Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, MI); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ); AS-2 (SmithKline Beecham, Philadelphia, PA); 20 aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quill A. Cytokines, such as GM-CSF or interleukin-2, -7, or -12, may also be used as adjuvants.

25 [500] Within the vaccines provided herein, the adjuvant composition is preferably designed to induce an immune response predominantly of the Th1 type. High levels of Th1-type cytokines (e.g., IFN- γ , TNF α , IL-2 and IL-12) tend to favor the induction of cell mediated immune responses to an administered antigen. In contrast, high levels of Th2-type cytokines (e.g., IL-4, IL-5, IL-6 and IL-10) tend to favor the induction of 30 humoral immune responses. Following application of a vaccine as provided herein, a patient will support an immune response that includes Th1- and Th2-type responses. Within a preferred embodiment, in which a response is predominantly Th1-type, the level of Th1-type cytokines will increase to a greater extent than the level of Th2-type cytokines. The levels of these cytokines may be readily assessed using standard

assays. For a review of the families of cytokines, see Mosmann and Coffman, *Ann. Rev. Immunol.* 7:145-173, 1989.

[501] Preferred adjuvants for use in eliciting a predominantly Th1-type response include, for example, a combination of monophosphoryl lipid A, preferably 3-de-O-acylated monophosphoryl lipid A (3D-MPL), together with an aluminum salt. MPL adjuvants are available from Corixa Corporation (Seattle, WA; *see* US Patent Nos. 4,436,727; 4,877,611; 4,866,034 and 4,912,094). CpG-containing oligonucleotides (in which the CpG dinucleotide is unmethylated) also induce a predominantly Th1 response. Such oligonucleotides are well known and are described, for example, in WO 96/02555, WO 99/33488 and U.S. Patent Nos. 6,008,200 and 5,856,462. Immunostimulatory DNA sequences are also described, for example, by Sato *et al.*, *Science* 273:352, 1996. Another preferred adjuvant is a saponin, preferably QS21 (Aquila Biopharmaceuticals Inc., Framingham, MA), which may be used alone or in combination with other adjuvants. For example, an enhanced system involves the combination of a monophosphoryl lipid A and saponin derivative, such as the combination of QS21 and 3D-MPL as described in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol, as described in WO 96/33739. Other preferred formulations comprise an oil-in-water emulsion and tocopherol. A particularly potent adjuvant formulation involving QS21, 3D-MPL and tocopherol in an oil-in-water emulsion is described in WO 95/17210.

[502] Other preferred adjuvants include Montanide ISA 720 (Seppic, France), SAF (Chiron, California, United States), ISCOMS (CSL), MF-59 (Chiron), the SBAS series of adjuvants (*e.g.*, SBAS-2 or SBAS-4, available from SmithKline Beecham, Rixensart, Belgium), Detox (Corixa, Hamilton, MT), RC-529 (Corixa, Hamilton, MT) and other aminoalkyl glucosaminide 4-phosphates (AGPs), such as those described in pending U.S. Patent Application Serial Nos. 08/853,826 and 09/074,720, the disclosures of which are incorporated herein by reference in their entireties.

[503] Any vaccine provided herein may be prepared using well known methods that result in a combination of antigen, immune response enhancer and a suitable carrier or excipient. The compositions described herein may be administered as part of a sustained release formulation (*i.e.*, a formulation such as a capsule, sponge or gel (composed of polysaccharides, for example) that effects a slow release of compound following administration). Such formulations may generally be prepared using well known technology (*see, e.g.*, Coombes *et al.*, *Vaccine* 14:1429-1438, 1996) and

administered by, for example, oral, rectal or subcutaneous implantation, or by implantation at the desired target site. Sustained-release formulations may contain a polypeptide, polynucleotide or antibody dispersed in a carrier matrix and/or contained within a reservoir surrounded by a rate controlling membrane.

5 [504] Carriers for use within such formulations are biocompatible, and may also be biodegradable; preferably the formulation provides a relatively constant level of active component release. Such carriers include microparticles of poly(lactide-co-glycolide), polyacrylate, latex, starch, cellulose, dextran and the like. Other delayed-release carriers include supramolecular biovectors, which comprise a non-liquid hydrophilic core (e.g., a cross-linked polysaccharide or oligosaccharide) and, optionally, an external layer comprising an amphiphilic compound, such as a phospholipid (see e.g., U.S. Patent No. 5,151,254 and PCT applications WO 94/20078, WO/94/23701 and WO 96/06638). The amount of active compound contained within a sustained release formulation depends upon the site of implantation, the rate and expected duration of release and the nature of the condition to be treated or prevented.

10 [505] Any of a variety of delivery vehicles may be employed within pharmaceutical compositions and vaccines to facilitate production of an antigen-specific immune response that targets tumor cells. Delivery vehicles include antigen presenting cells (APCs), such as dendritic cells, macrophages, B cells, monocytes and other cells that may be engineered to be efficient APCs. Such cells may, but need not, be genetically modified to increase the capacity for presenting the antigen, to improve activation and/or maintenance of the T cell response, to have anti-tumor effects *per se* and/or to be immunologically compatible with the receiver (*i.e.*, matched HLA haplotype).
20 APCs may generally be isolated from any of a variety of biological fluids and organs, including tumor and peritumoral tissues, and may be autologous, allogeneic, syngeneic or xenogeneic cells.

25 [506] Certain preferred embodiments of the present invention use dendritic cells or progenitors thereof as antigen-presenting cells. Dendritic cells are highly potent APCs (Banchereau and Steinman, *Nature* 392:245-251, 1998) and have been shown to be effective as a physiological adjuvant for eliciting prophylactic or therapeutic antitumor immunity (see Timmerman and Levy, *Ann. Rev. Med.* 50:507-529, 1999). In general, dendritic cells may be identified based on their typical shape (stellate *in situ*, with marked cytoplasmic processes (dendrites) visible *in vitro*), their ability to take up, process and present antigens with high efficiency and their ability to activate naïve T

cell responses. Dendritic cells may, of course, be engineered to express specific cell-surface receptors or ligands that are not commonly found on dendritic cells *in vivo* or *ex vivo*, and such modified dendritic cells are contemplated by the present invention. As an alternative to dendritic cells, secreted vesicles antigen-loaded dendritic cells (called exosomes) may be used within a vaccine (*see Zitvogel et al., Nature Med.* 4:594-600, 1998).

5 [507] Dendritic cells and progenitors may be obtained from peripheral blood, bone marrow, tumor-infiltrating cells, peritumoral tissues-infiltrating cells, lymph nodes, spleen, skin, umbilical cord blood or any other suitable tissue or fluid. For example, 10 dendritic cells may be differentiated *ex vivo* by adding a combination of cytokines such as GM-CSF, IL-4, IL-13 and/or TNF α to cultures of monocytes harvested from peripheral blood. Alternatively, CD34 positive cells harvested from peripheral blood, umbilical cord blood or bone marrow may be differentiated into dendritic cells by 15 adding to the culture medium combinations of GM-CSF, IL-3, TNF α , CD40 ligand, LPS, flt3 ligand and/or other compound(s) that induce differentiation, maturation and proliferation of dendritic cells.

15 [508] Dendritic cells are conveniently categorized as "immature" and "mature" cells, which allows a simple way to discriminate between two well characterized phenotypes. However, this nomenclature should not be construed to exclude all 20 possible intermediate stages of differentiation. Immature dendritic cells are characterized as APC with a high capacity for antigen uptake and processing, which correlates with the high expression of Fc γ receptor and mannose receptor. The mature phenotype is typically characterized by a lower expression of these markers, but a high expression of cell surface molecules responsible for T cell activation such as class I 25 and class II MHC, adhesion molecules (*e.g.*, CD54 and CD11) and costimulatory molecules (*e.g.*, CD40, CD80, CD86 and 4-1BB).

30 [509] APCs may generally be transfected with a polynucleotide encoding a hematological malignancy-related tumor protein (or portion or other variant thereof) such that the hematological malignancy-related tumor polypeptide, or an immunogenic portion thereof, is expressed on the cell surface. Such transfection may take place *ex vivo*, and a composition or vaccine comprising such transfected cells may then be used for therapeutic purposes, as described herein. Alternatively, a gene delivery vehicle that targets a dendritic or other antigen presenting cell may be administered to a patient, resulting in transfection that occurs *in vivo*. *In vivo* and *ex vivo* transfection of

5

10

dendritic cells, for example, may generally be performed using any methods known in the art, such as those described in WO 97/24447, or the gene gun approach described by Mahvi *et al.*, *Immunology and cell Biology* 75:456-460, 1997. Antigen loading of dendritic cells may be achieved by incubating dendritic cells or progenitor cells with the hematological malignancy-related tumor polypeptide, DNA (naked or within a plasmid vector) or RNA; or with antigen-expressing recombinant bacterium or viruses (e.g., vaccinia, fowlpox, adenovirus or lentivirus vectors). Prior to loading, the polypeptide may be covalently conjugated to an immunological partner that provides T cell help (e.g., a carrier molecule). Alternatively, a dendritic cell may be pulsed with a non-conjugated immunological partner, separately or in the presence of the polypeptide.

15

[510] Vaccines and pharmaceutical compositions may be presented in unit-dose or multi-dose containers, such as sealed ampoules or vials. Such containers are preferably hermetically sealed to preserve sterility of the formulation until use. In general, formulations may be stored as suspensions, solutions or emulsions in oily or aqueous vehicles. Alternatively, a vaccine or pharmaceutical composition may be stored in a freeze-dried condition requiring only the addition of a sterile liquid carrier immediately prior to use.

20

4.22 CANCER THERAPY

25

30

[511] In further aspects of the present invention, the compositions described herein may be used for immunotherapy of cancer, such as hematological malignancy. Within such methods, pharmaceutical compositions and vaccines are typically administered to a patient. As used herein, a "patient" refers to any warm-blooded animal, preferably a human. A patient may or may not be afflicted with cancer. Accordingly, the above pharmaceutical compositions and vaccines may be used to prevent the development of a cancer or to treat a patient afflicted with a cancer. A cancer may be diagnosed using criteria generally accepted in the art, including the presence of a malignant tumor. Pharmaceutical compositions and vaccines may be administered either prior to or following surgical removal of primary tumors and/or treatment such as administration of radiotherapy or conventional chemotherapeutic drugs. Administration may be by any suitable method, including administration by intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal, intradermal, anal, vaginal, topical and oral routes.

[512] Within certain embodiments, immunotherapy may be active immunotherapy, in which treatment relies on the *in vivo* stimulation of the endogenous host immune system to react against tumors with the administration of immune response-modifying agents (such as polypeptides and polynucleotides as provided herein).

5 [513] Within other embodiments, immunotherapy may be passive immunotherapy, in which treatment involves the delivery of agents with established tumor-immune reactivity (such as effector cells or antibodies) that can directly or indirectly mediate antitumor effects and does not necessarily depend on an intact host immune system. Examples of effector cells include T cells as discussed above, T lymphocytes (such as CD8⁺ cytotoxic T lymphocytes and CD4⁺ T-helper tumor-infiltrating lymphocytes), killer cells (such as Natural Killer cells and lymphokine-activated killer cells), B cells and antigen-presenting cells (such as dendritic cells and macrophages) expressing a polypeptide provided herein. T cell receptors and antibody receptors specific for the polypeptides recited herein may be cloned, expressed and transferred into other vectors or effector cells for adoptive immunotherapy. The polypeptides provided herein may also be used to generate antibodies or anti-idiotypic antibodies (as described above and in U.S. Patent No. 4,918,164) for passive immunotherapy.

10

15 [514] Effector cells may generally be obtained in sufficient quantities for adoptive immunotherapy by growth *in vitro*, as described herein. Culture conditions for expanding single antigen-specific effector cells to several billion in number with retention of antigen recognition *in vivo* are well known in the art. Such *in vitro* culture conditions typically use intermittent stimulation with antigen, often in the presence of cytokines (such as IL-2) and non-dividing feeder cells. As noted above, immunoreactive polypeptides as provided herein may be used to rapidly expand antigen-specific T cell cultures in order to generate a sufficient number of cells for immunotherapy. In particular, antigen-presenting cells, such as dendritic, macrophage, monocyte, fibroblast and/or B cells, may be pulsed with immunoreactive polypeptides or transfected with one or more polynucleotides using standard techniques well known in the art. For example, antigen-presenting cells can be transfected with a polynucleotide having a promoter appropriate for increasing expression in a recombinant virus or other expression system. Cultured effector cells for use in therapy must be able to grow and distribute widely, and to survive long term *in vivo*. Studies have shown that cultured effector cells can be induced to grow *in vivo* and to survive long term in substantial numbers by repeated stimulation with antigen.

20

25

30

supplemented with IL-2 (see, for example, Cheever *et al.*, *Immunological Reviews* 157:177, 1997).

[515] Alternatively, a vector expressing a polypeptide recited herein may be introduced into antigen presenting cells taken from a patient and clonally propagated *ex vivo* for transplant back into the same patient. Transfected cells may be reintroduced into the patient using any means known in the art, preferably in sterile form by intravenous, intracavitory, intraperitoneal or intratumor administration.

[516] Routes and frequency of administration of the therapeutic compositions described herein, as well as dosage, will vary from individual to individual, and may be readily established using standard techniques. In general, the pharmaceutical compositions and vaccines may be administered by injection (*e.g.*, intracutaneous, intramuscular, intravenous or subcutaneous), intranasally (*e.g.*, by aspiration) or orally. Preferably, between 1 and 10 doses may be administered over a 52 week period. Preferably, 6 doses are administered, at intervals of 1 month, and booster vaccinations may be given periodically thereafter. Alternate protocols may be appropriate for individual patients. A suitable dose is an amount of a compound that, when administered as described above, is capable of promoting an anti-tumor immune response, and is at least 10-50% above the basal (*i.e.*, untreated) level. Such response can be monitored by measuring the anti-tumor antibodies in a patient or by vaccine-dependent generation of cytolytic effector cells capable of killing the patient's tumor cells *in vitro*. Such vaccines should also be capable of causing an immune response that leads to an improved clinical outcome (*e.g.*, more frequent remissions, complete or partial or longer disease-free survival) in vaccinated patients as compared to non-vaccinated patients. In general, for pharmaceutical compositions and vaccines comprising one or more polypeptides, the amount of each polypeptide present in a dose ranges from about 25 µg to 5 mg per kg of host. Suitable dose sizes will vary with the size of the patient, but will typically range from about 0.1 mL to about 5 mL.

[517] In general, an appropriate dosage and treatment regimen provides the active compound(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit. Such a response can be monitored by establishing an improved clinical outcome (*e.g.*, more frequent remissions, complete or partial, or longer disease-free survival) in treated patients as compared to non-treated patients. Increases in preexisting immune responses to a hematological malignancy-related tumor protein generally correlate with an improved clinical outcome. Such immune responses may

generally be evaluated using standard proliferation, cytotoxicity or cytokine assays, which may be performed using samples obtained from a patient before and after treatment.

4.23 CANCER DETECTION AND DIAGNOSIS

[518] In general, a cancer may be detected in a patient based on the presence of one or more hematological malignancy-related tumor proteins and/or polynucleotides encoding such proteins in a biological sample (for example, blood, sera, sputum urine and/or tumor biopsies) obtained from the patient. In other words, such proteins may be used as markers to indicate the presence or absence of a cancer such as hematological malignancy. In addition, such proteins may be useful for the detection of other cancers. The binding agents provided herein generally permit detection of the level of antigen that binds to the agent in the biological sample. Polynucleotide primers and probes may be used to detect the level of mRNA encoding a tumor protein, which is also indicative of the presence or absence of a cancer. In general, a hematological malignancy-related tumor sequence should be present at a level that is at least three fold higher in tumor tissue than in normal tissue

[519] There are a variety of assay formats known to those of ordinary skill in the art for using a binding agent to detect polypeptide markers in a sample. See, e.g., Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988.

In general, the presence or absence of a cancer in a patient may be determined by (a) contacting a biological sample obtained from a patient with a binding agent; (b) detecting in the sample a level of polypeptide that binds to the binding agent; and (c) comparing the level of polypeptide with a predetermined cut-off value.

[520] In a preferred embodiment, the assay involves the use of binding agent immobilized on a solid support to bind to and remove the polypeptide from the remainder of the sample. The bound polypeptide may then be detected using a detection reagent that contains a reporter group and specifically binds to the binding agent/polypeptide complex. Such detection reagents may comprise, for example, a binding agent that specifically binds to the polypeptide or an antibody or other agent that specifically binds to the binding agent, such as an anti-immunoglobulin, protein G, protein A or a lectin. Alternatively, a competitive assay may be utilized, in which a polypeptide is labeled with a reporter group and allowed to bind to the immobilized binding agent after incubation of the binding agent with the sample. The extent to which components of the sample inhibit the binding of the labeled polypeptide to the

binding agent is indicative of the reactivity of the sample with the immobilized binding agent. Suitable polypeptides for use within such assays include full length hematological malignancy-related tumor proteins and portions thereof to which the binding agent binds, as described above.

5 [521] The solid support may be any material known to those of ordinary skill in the art to which the tumor protein may be attached. For example, the solid support may be a test well in a microtiter plate or a nitrocellulose or other suitable membrane. Alternatively, the support may be a bead or disc, such as glass, fiberglass, latex or a plastic material such as polystyrene or polyvinylchloride. The support may also be a magnetic particle or a fiber optic sensor, such as those disclosed, for example, in U.S. Patent No. 5,359,681. The binding agent may be immobilized on the solid support using a variety of techniques known to those of skill in the art, which are amply described in the patent and scientific literature. In the context of the present invention, the term "immobilization" refers to both noncovalent association, such as adsorption, and covalent attachment (which may be a direct linkage between the agent and functional groups on the support or may be a linkage by way of a cross-linking agent). Immobilization by adsorption to a well in a microtiter plate or to a membrane is preferred. In such cases, adsorption may be achieved by contacting the binding agent, in a suitable buffer, with the solid support for a suitable amount of time. The contact time varies with temperature, but is typically between about 1 hour and about 1 day. In general, contacting a well of a plastic microtiter plate (such as polystyrene or polyvinylchloride) with an amount of binding agent ranging from about 10 ng to about 10 µg, and preferably about 100 ng to about 1 µg, is sufficient to immobilize an adequate amount of binding agent.

20 [522] Covalent attachment of binding agent to a solid support may generally be achieved by first reacting the support with a bifunctional reagent that will react with both the support and a functional group, such as a hydroxyl or amino group, on the binding agent. For example, the binding agent may be covalently attached to supports having an appropriate polymer coating using benzoquinone or by condensation of an aldehyde group on the support with an amine and an active hydrogen on the binding partner (see, e.g., Pierce Immunotechnology Catalog and Handbook, 1991, at A12-A13).

25 [523] In certain embodiments, the assay is a two-antibody sandwich assay. This assay may be performed by first contacting an antibody that has been immobilized on

a solid support, commonly the well of a microtiter plate, with the sample, such that polypeptides within the sample are allowed to bind to the immobilized antibody. Unbound sample is then removed from the immobilized polypeptide-antibody complexes and a detection reagent (preferably a second antibody capable of binding to a different site on the polypeptide) containing a reporter group is added. The amount of detection reagent that remains bound to the solid support is then determined using a method appropriate for the specific reporter group.

5 [524] More specifically, once the antibody is immobilized on the support as described above, the remaining protein binding sites on the support are typically blocked. Any suitable blocking agent known to those of ordinary skill in the art, such as bovine serum albumin or Tween 20TM (Sigma Chemical Co., St. Louis, MO). The immobilized antibody is then incubated with the sample, and polypeptide is allowed to bind to the antibody. The sample may be diluted with a suitable diluent, such as phosphate-buffered saline (PBS) prior to incubation. In general, an appropriate contact time (*i.e.*, incubation time) is a period of time that is sufficient to detect the presence of polypeptide within a sample obtained from an individual with hematological malignancy. Preferably, the contact time is sufficient to achieve a level of binding that is at least about 95% of that achieved at equilibrium between bound and unbound polypeptide. Those of ordinary skill in the art will recognize that the time necessary to achieve equilibrium may be readily determined by assaying the level of binding that occurs over a period of time. At room temperature, an incubation time of about 30 minutes is generally sufficient.

10 [525] Unbound sample may then be removed by washing the solid support with an appropriate buffer, such as PBS containing 0.1% Tween 20TM. The second antibody, which contains a reporter group, may then be added to the solid support. Preferred reporter groups include those groups recited above.

15 [526] The detection reagent is then incubated with the immobilized antibody-polypeptide complex for an amount of time sufficient to detect the bound polypeptide. An appropriate amount of time may generally be determined by assaying the level of binding that occurs over a period of time. Unbound detection reagent is then removed and bound detection reagent is detected using the reporter group. The method

20 employed for detecting the reporter group depends upon the nature of the reporter group. For radioactive groups, scintillation counting or autoradiographic methods are generally appropriate. Spectroscopic methods may be used to detect dyes,

5

luminescent groups and fluorescent groups. Biotin may be detected using avidin, coupled to a different reporter group (commonly a radioactive or fluorescent group or an enzyme). Enzyme reporter groups may generally be detected by the addition of substrate (generally for a specific period of time), followed by spectroscopic or other analysis of the reaction products.

10

[527] To determine the presence or absence of a cancer, such as hematological malignancy, the signal detected from the reporter group that remains bound to the solid support is generally compared to a signal that corresponds to a predetermined cut-off value. In one preferred embodiment, the cut-off value for the detection of a cancer is the average mean signal obtained when the immobilized antibody is incubated with samples from patients without the cancer. In general, a sample generating a signal that is three standard deviations above the predetermined cut-off value is considered positive for the cancer. In an alternate preferred embodiment, the cut-off value is determined using a Receiver Operator Curve, according to the method of Sackett *et al.*, *Clinical Epidemiology: A Basic Science for Clinical Medicine*, Little Brown and Co., 1985, p. 106-7. Briefly, in this embodiment, the cut-off value may be determined from a plot of pairs of true positive rates (*i.e.*, sensitivity) and false positive rates (100%-specificity) that correspond to each possible cut-off value for the diagnostic test result. The cut-off value on the plot that is the closest to the upper left-hand corner (*i.e.*, the value that encloses the largest area) is the most accurate cut-off value, and a sample generating a signal that is higher than the cut-off value determined by this method may be considered positive. Alternatively, the cut-off value may be shifted to the left along the plot, to minimize the false positive rate, or to the right, to minimize the false negative rate. In general, a sample generating a signal that is higher than the cut-off value determined by this method is considered positive for a cancer.

20

[528] In a related embodiment, the assay is performed in a flow-through or strip test format, wherein the binding agent is immobilized on a membrane, such as nitrocellulose. In the flow-through test, polypeptides within the sample bind to the immobilized binding agent as the sample passes through the membrane. A second, labeled binding agent then binds to the binding agent-polypeptide complex as a solution containing the second binding agent flows through the membrane. The detection of bound second binding agent may then be performed as described above. In the strip test format, one end of the membrane to which binding agent is bound is

immersed in a solution containing the sample. The sample migrates along the membrane through a region containing second binding agent and to the area of immobilized binding agent. Concentration of second binding agent at the area of immobilized antibody indicates the presence of a cancer. Typically, the concentration of second binding agent at that site generates a pattern, such as a line, that can be read visually. The absence of such a pattern indicates a negative result. In general, the amount of binding agent immobilized on the membrane is selected to generate a visually discernible pattern when the biological sample contains a level of polypeptide that would be sufficient to generate a positive signal in the two-antibody sandwich assay, in the format discussed above. Preferred binding agents for use in such assays are antibodies and antigen-binding fragments thereof. Preferably, the amount of antibody immobilized on the membrane ranges from about 25 ng to about 1 µg, and more preferably from about 50 ng to about 500 ng. Such tests can typically be performed with a very small amount of biological sample.

[529] Of course, numerous other assay protocols exist that are suitable for use with the tumor proteins or binding agents of the present invention. The above descriptions are intended to be exemplary only. For example, it will be apparent to those of ordinary skill in the art that the above protocols may be readily modified to use hematological malignancy-related tumor polypeptides to detect antibodies that bind to such polypeptides in a biological sample. The detection of such hematological malignancy-related tumor protein specific antibodies may correlate with the presence of a cancer.

[530] A cancer may also, or alternatively, be detected based on the presence of T cells that specifically react with a hematological malignancy-related tumor protein in a biological sample. Within certain methods, a biological sample comprising CD4⁺ and/or CD8⁺ T cells isolated from a patient is incubated with a hematological malignancy-related tumor polypeptide, a polynucleotide encoding such a polypeptide and/or an APC that expresses at least an immunogenic portion of such a polypeptide, and the presence or absence of specific activation of the T cells is detected. Suitable biological samples include, but are not limited to, isolated T cells. For example, T cells may be isolated from a patient by routine techniques (such as by Ficoll/Hypaque density gradient centrifugation of peripheral blood lymphocytes). T cells may be incubated *in vitro* for 2-9 days (typically 4 days) at 37°C with polypeptide (e.g., 5 - 25 µg/ml). It may be desirable to incubate another aliquot of a T cell sample in the

absence of hematological malignancy-related tumor polypeptide to serve as a control. For CD4⁺ T cells, activation is preferably detected by evaluating proliferation of the T cells. For CD8⁺ T cells, activation is preferably detected by evaluating cytolytic activity. A level of proliferation that is at least two fold greater and/or a level of cytolytic activity that is at least 20% greater than in disease-free patients indicates the presence of a cancer in the patient.

5 [531] As noted above, a cancer may also, or alternatively, be detected based on the level of mRNA encoding a hematological malignancy-related tumor protein in a biological sample. For example, at least two oligonucleotide primers may be employed in a polymerase chain reaction (PCR) based assay to amplify a portion of a hematological malignancy-related tumor cDNA derived from a biological sample, wherein at least one of the oligonucleotide primers is specific for (*i.e.*, hybridizes to) a polynucleotide encoding the hematological malignancy-related tumor protein. The amplified cDNA is then separated and detected using techniques well known in the art, such as gel electrophoresis. Similarly, oligonucleotide probes that specifically hybridize to a polynucleotide encoding a hematological malignancy-related tumor protein may be used in a hybridization assay to detect the presence of polynucleotide encoding the tumor protein in a biological sample.

10 [532] To permit hybridization under assay conditions, oligonucleotide primers and probes should comprise an oligonucleotide sequence that has at least about 60%, preferably at least about 75% and more preferably at least about 90%, identity to a portion of a polynucleotide encoding a hematological malignancy-related tumor protein that is at least 10 nucleotides, and preferably at least 20 nucleotides, in length. Preferably, oligonucleotide primers and/or probes hybridize to a polynucleotide encoding a polypeptide described herein under moderately stringent conditions, as defined above. Oligonucleotide primers and/or probes which may be usefully employed in the diagnostic methods described herein preferably are at least 10-40 nucleotides in length. In a preferred embodiment, the oligonucleotide primers comprise at least 10 contiguous nucleotides, more preferably at least 15 contiguous nucleotides, of a DNA molecule having a sequence disclosed in this application. Techniques for both PCR based assays and hybridization assays are well known in the art (*see*, for example, Mullis *et al.*, *Cold Spring Harbor Symp. Quant. Biol.*, 51:263, 1987; Erlich ed., *PCR Technology*, Stockton Press, NY, 1989).

[533] One preferred assay employs RT-PCR, in which PCR is applied in conjunction with reverse transcription. Typically, RNA is extracted from a biological sample, such as biopsy tissue, and is reverse transcribed to produce cDNA molecules. PCR amplification using at least one specific primer generates a cDNA molecule, which may be separated and visualized using, for example, gel electrophoresis.

5 Amplification may be performed on biological samples taken from a test patient and from an individual who is not afflicted with a cancer. The amplification reaction may be performed on several dilutions of cDNA spanning two orders of magnitude. A two-fold or greater increase in expression in several dilutions of the test patient sample as compared to the same dilutions of the non-cancerous sample is typically considered positive.

10

[534] In another embodiment, the compositions described herein may be used as markers for the progression of cancer. In this embodiment, assays as described above for the diagnosis of a cancer may be performed over time, and the change in the level 15 of reactive polypeptide(s) or polynucleotide(s) evaluated. For example, the assays may be performed every 24-72 hours for a period of 6 months to 1 year, and thereafter performed as needed. In general, a cancer is progressing in those patients in whom the level of polypeptide or polynucleotide detected increases over time. In contrast, the cancer is not progressing when the level of reactive polypeptide or polynucleotide either remains constant or decreases with time.

20

[535] Certain *in vivo* diagnostic assays may be performed directly on a tumor. One such assay involves contacting tumor cells with a binding agent. The bound binding agent may then be detected directly or indirectly via a reporter group. Such binding agents may also be used in histological applications. Alternatively, polynucleotide probes may be used within such applications.

25

[536] As noted above, to improve sensitivity, multiple hematological malignancy-related tumor protein markers may be assayed within a given sample. It will be apparent that binding agents specific for different proteins provided herein may be combined within a single assay. Further, multiple primers or probes may be used concurrently. The selection of tumor protein markers may be based on routine experiments to determine combinations that results in optimal sensitivity. In addition, or alternatively, assays for tumor proteins provided herein may be combined with assays for other known tumor antigens.

30

4.24 PREPARATION OF DNA SEQUENCES

[537] Certain nucleic acid sequences of cDNA molecules encoding portions of hematological malignancy-related antigens were isolated by PCR™-based subtraction. This technique serves to normalize differentially expressed cDNAs, facilitating the recovery of rare transcripts, and also has the advantage of permitting enrichment of cDNAs with small amounts of polyA RNA material and without multiple rounds of hybridization. To obtain antigens overexpressed in non-Hodgkin's lymphomas, two subtractions were performed with a tester library prepared from a pool of three T cell non-Hodgkin's lymphoma mRNAs. The two libraries were independently subtracted with different pools of driver cDNAs. Driver #1 contained cDNA prepared from specific normal tissues (lymph node, bone marrow, T cells, heart and brain), and this subtraction generated the library TCS-D1 (T cell non-Hodgkin's lymphoma subtracted library with driver #1). Driver #2 contained non-specific normal tissues (colon, large intestine, lung, pancreas, spinal cord, skeletal muscle, liver, kidney, skin and brain), and this subtraction generated the library TCS-D2 (T cell non-Hodgkin's lymphoma subtraction library with driver #2). Two other subtractions were performed with a tester library prepared from a pool of three B cell non-Hodgkin's lymphoma mRNAs. The two libraries were independently subtracted with different pools of driver cDNAs. Driver #1 contained cDNA prepared from specific normal tissues (lymph node, bone marrow, B cells, heart and brain), and this subtraction generated the library BCNHL/D1 (B cell non-Hodgkin's lymphoma subtracted library with driver #1). Driver #2 contained non-specific normal tissues (brain, lung, pancreas, spinal cord, skeletal muscle, colon, spleen, large intestine and PBMC), and this subtraction generated the library BCNHL/D2 (B cell non-Hodgkin's lymphoma subtraction library with driver #2). PCR™-amplified pools were generated from the subtracted libraries and clones were sequenced.

[538] Hematological malignancy-related antigen sequences may be further characterized using any of a variety of well known techniques. For example, PCR™ amplified clones may be arrayed onto glass slides for microarray analysis. To determine tissue distribution, the arrayed clones may be used as targets to be hybridized with different first strand cDNA probes, including lymphoma probes, leukemia probes and probes from different normal tissues. Leukemia and lymphoma probes may be generated from cryopreserved samples obtained at the time of diagnosis from NHL, Hodgkin's disease, AML, CML, CLL, ALL, MDS and myeloma patients

with poor outcome (patients who failed to achieve complete remission following conventional chemotherapy or relapsed) or good outcome (patients who achieved long term remission). To analyze gene expression during hematopoietic differentiation, probes may be generated from >95% pure fractions of CD34+, CD2+, CD14+, CD15+ and CD19+ cells derived from healthy individuals.

5 [539] Polynucleotide variants may generally be prepared by any method known in the art, including chemical synthesis by, for example, solid phase phosphoramidite chemical synthesis. Modifications in a polynucleotide sequence may also be introduced using standard mutagenesis techniques, such as oligonucleotide-directed site-specific mutagenesis (see Adelman *et al.*, *DNA* 2:183, 1983). Alternatively, RNA molecules may be generated by *in vitro* or *in vivo* transcription of DNA sequences, provided that the DNA is incorporated into a vector with a suitable RNA polymerase promoter (such as T7 or SP6). Certain portions may be used to prepare an encoded polypeptide, as described herein. In addition, or alternatively, a portion may be administered to a patient such that the encoded polypeptide is generated *in vivo* (e.g., by transfecting antigen-presenting cells, such as dendritic cells, with a cDNA construct encoding a hematological malignancy-related antigen, and administering the transfected cells to the patient).

10 [540] A portion of a sequence complementary to a coding sequence (*i.e.*, an antisense polynucleotide) may also be used as a probe or to modulate hematological malignancy-related antigen expression. cDNA constructs that can be transcribed into antisense RNA may also be introduced into cells or tissues to facilitate the production of antisense RNA. An antisense polynucleotide may be used, as described herein, to inhibit expression of a hematological malignancy-related antigen. Antisense 15 technology can be used to control gene expression through triple-helix formation, which compromises the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors or regulatory molecules (see Gee *et al.*, *In Huber and Carr, Molecular and Immunologic Approaches*, Futura Publishing Co. (Mt. Kisco, NY; 1994)). Alternatively, an antisense molecule may be designed to hybridize with a 20 control region of a gene (*e.g.*, promoter, enhancer or transcription initiation site), and block transcription of the gene; or to block translation by inhibiting binding of a transcript to ribosomes.

25 [541] A portion of a coding sequence or of a complementary sequence may also be designed as a probe or primer to detect gene expression. Probes may be labeled with a 30

variety of reporter groups, such as radionuclides and enzymes, and [REDACTED] preferably at least 10 nucleotides in length, more preferably at least 20 nucleotides in length and still more preferably at least 30 nucleotides in length. Primers, as noted above, are preferably 22-30 nucleotides in length.

5 [542] Any polynucleotide may be further modified to increase stability *in vivo*. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends; the use of phosphorothioate or 2' O-methyl rather than phosphodiester linkages in the backbone; and/or the inclusion of nontraditional bases such as inosine, queosine and wybutoxine, as well as acetyl-
10 methyl-, thio- and other modified forms of adenine, cytidine, guanine, thymine and uridine.

15 [543] Hematological malignancy-related antigen polynucleotides may be joined to a variety of other nucleotide sequences using established recombinant DNA techniques. For example, a polynucleotide may be cloned into any of a variety of cloning vectors, including plasmids, phagemids, lambda phage derivatives and cosmids. Vectors of particular interest include expression vectors, replication vectors, probe generation vectors and sequencing vectors. In general, a vector will contain an origin of replication functional in at least one organism, convenient restriction endonuclease sites and one or more selectable markers. Other elements will depend upon the
20 desired use, and will be apparent to those of ordinary skill in the art.

25 [544] Within certain embodiments, polynucleotides may be formulated so as to permit entry into a cell of a mammal, and expression therein. Such formulations are particularly useful for therapeutic purposes, as described below. Those of ordinary skill in the art will appreciate that there are many ways to achieve expression of a polynucleotide in a target cell, and any suitable method may be employed. For example, a polynucleotide may be incorporated into a viral vector such as, but not limited to, adenovirus, adeno-associated virus, retrovirus, or vaccinia or other pox virus (e.g., avian pox virus). Techniques for incorporating DNA into such vectors are well known to those of ordinary skill in the art. A retroviral vector may additionally transfer or incorporate a gene for a selectable marker (to aid in the identification or selection of transduced cells) and/or a targeting moiety, such as a gene that encodes a ligand for a receptor on a specific target cell, to render the vector target specific.
30 Targeting may also be accomplished using an antibody, by methods known to those of ordinary skill in the art.

5

[545] Other formulations for therapeutic purposes include colloidal dispersion systems, such as macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. A preferred colloidal system for use as a delivery vehicle *in vitro* and *in vivo* is a liposome (*i.e.*, an artificial membrane vesicle). The preparation and use of such systems is well known in the art.

4.25 THERAPEUTIC METHODS

10 [546] In further aspects of the present invention, the compositions described herein may be used for immunotherapy of hematological malignancies including adult and pediatric AML, CML, ALL, CLL, myelodysplastic syndromes (MDS), myeloproliferative syndromes (MPS), secondary leukemia, multiple myeloma, Hodgkin's lymphoma and Non-Hodgkin's lymphomas. In addition, compositions described herein may be used for therapy of diseases associated with an autoimmune response against hematopoietic precursor cells, such as severe aplastic anemia.

15 [547] Immunotherapy may be performed using any of a variety of techniques, in which compounds or cells provided herein function to remove hematological malignancy-related antigen-expressing cells from a patient. Such removal may take place as a result of enhancing or inducing an immune response in a patient specific for hematological malignancy-related antigen or a cell expressing hematological malignancy-related antigen. Alternatively, hematological malignancy-related antigen-expressing cells may be removed *ex vivo* (*e.g.*, by treatment of autologous bone marrow, peripheral blood or a fraction of bone marrow or peripheral blood). Fractions of bone marrow or peripheral blood may be obtained using any standard technique in the art.

20 [548] Within such methods, pharmaceutical compositions and vaccines are typically administered to a patient. As used herein, a "patient" refers to any warm-blooded animal, preferably a human. A patient may or may not be afflicted with a hematological malignancy. Accordingly, the above pharmaceutical compositions and vaccines may be used to prevent the development of a malignancy or to treat a patient afflicted with a malignancy. A hematological malignancy may be diagnosed using criteria generally accepted in the art. Pharmaceutical compositions and vaccines may be administered either prior to or following surgical removal of primary tumors and/or

treatment such as administration of radiotherapy or conventional chemotherapeutic drugs, or bone marrow transplantation (autologous, allogeneic or syngeneic).

5 [549] Within certain embodiments, immunotherapy may be active immunotherapy, in which treatment relies on the *in vivo* stimulation of the endogenous host immune system to react against tumors with the administration of immune response-modifying agents (such as polypeptides and polynucleotides as provided herein).

10 [550] Within other embodiments, immunotherapy may be passive immunotherapy, in which treatment involves the delivery of agents with established tumor-immune reactivity (such as effector cells or antibodies) that can directly or indirectly mediate antitumor effects and does not necessarily depend on an intact host immune system. Examples of effector cells include T cells as discussed above, T lymphocytes (such as CD8⁺ cytotoxic T lymphocytes and CD4⁺ T-helper tumor-infiltrating lymphocytes), killer cells (such as Natural Killer cells and lymphokine-activated killer cells), B cells and antigen-presenting cells (such as dendritic cells and macrophages) expressing a polypeptide provided herein. T cell receptors and antibody receptors specific for the polypeptides recited herein may be cloned, expressed and transferred into other vectors or effector cells for adoptive immunotherapy. The polypeptides provided herein may also be used to generate antibodies or anti-idiotypic antibodies (as described above and in U.S. Patent No. 4,918,164) for passive immunotherapy.

15 [551] Effector cells may generally be obtained in sufficient quantities for adoptive immunotherapy by growth *in vitro*, as described herein. Culture conditions for expanding single antigen-specific effector cells to several billion in number with retention of antigen recognition *in vivo* are well known in the art. Such *in vitro* culture conditions typically use intermittent stimulation with antigen, often in the presence of cytokines (such as IL-2) and non-dividing feeder cells. As noted above, immunoreactive polypeptides as provided herein may be used to rapidly expand antigen-specific T cell cultures in order to generate a sufficient number of cells for immunotherapy. In particular, antigen-presenting cells, such as dendritic, macrophage or B cells, may be pulsed with immunoreactive polypeptides or transfected with one or more polynucleotides using standard techniques well known in the art. For example, antigen-presenting cells can be transfected with a polynucleotide having a promoter appropriate for increasing expression in a recombinant virus or other expression system. Cultured effector cells for use in therapy must be able to grow and distribute widely, and to survive long term *in vivo*. Studies have shown that cultured effector

cells can be induced to grow *in vivo* and to survive long term in substantial numbers by repeated stimulation with antigen supplemented with IL-2 (see, for example, Cheever *et al.*, *Immunological Reviews* 157:177, 1997).

5 [552] Alternatively, a vector expressing a polypeptide recited herein may be introduced into antigen presenting cells taken from a patient and clonally propagated *ex vivo* for transplant back into the same patient. Transfected cells may be reintroduced into the patient using any means known in the art, preferably in sterile form by intravenous, intracavitory, intraperitoneal or intratumor administration.

10 [553] The compositions provided herein may be used alone or in combination with conventional therapeutic regimens such as surgery, irradiation, chemotherapy and/or bone marrow transplantation (autologous, syngeneic, allogeneic or unrelated). As discussed in greater detail below, binding agents and T cells as provided herein may be used for purging of autologous stem cells. Such purging may be beneficial prior to, for example, bone marrow transplantation or transfusion of blood or components thereof. Binding agents, T cells, antigen presenting cells (APC) and compositions provided herein may further be used for expanding and stimulating (or priming) autologous, allogeneic, syngeneic or unrelated hematological malignancy-related antigen-specific T-cells *in vitro* and/or *in vivo*. Such hematological malignancy-related antigen-specific T cells may be used, for example, within donor lymphocyte infusions.

15

20 [554] Routes and frequency of administration of the therapeutic compositions described herein, as well as dosage, will vary from individual to individual, and may be readily established using standard techniques. In general, the pharmaceutical compositions and vaccines may be administered by injection (*e.g.*, intracutaneous, intramuscular, intravenous or subcutaneous), intranasally (*e.g.*, by aspiration) or orally. Preferably, between 1 and 10 doses may be administered over a 52 week period. Preferably, 6 doses are administered, at intervals of 1 month, and booster vaccinations may be given periodically thereafter. Alternate protocols may be appropriate for individual patients. A suitable dose is an amount of a compound that, when administered as described above, is capable of promoting an anti-tumor immune response, and is at least 10-50% above the basal (*i.e.*, untreated) level. Such response can be monitored by measuring the anti-tumor antibodies in a patient or by vaccine-dependent generation of cytolytic effector cells capable of killing the patient's tumor cells *in vitro*. Such vaccines should also be capable of causing an immune response

25

30

that leads to an improved clinical outcome (e.g., more frequent remissions, complete or partial or longer disease-free survival) in vaccinated patients as compared to non-vaccinated patients. In general, for pharmaceutical compositions and vaccines comprising one or more polypeptides, the amount of each polypeptide present in a dose ranges from about 100 µg to 5 mg per kg of host. Suitable dose sizes will vary with the size of the patient, but will typically range from about 0.1 mL to about 5 mL.

5 [555] In general, an appropriate dosage and treatment regimen provides the active compound(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit. Such a response can be monitored by establishing an improved clinical outcome (e.g., more frequent remissions, complete or partial, or longer disease-free survival) in treated patients as compared to non-treated patients. Increases in preexisting immune responses to a hematological malignancy-related antigen generally correlate with an improved clinical outcome. Such immune responses may generally be evaluated using standard proliferation, cytotoxicity or cytokine assays,

10 15 which may be performed using samples obtained from a patient before and after treatment.

20 [556] Within further aspects, methods for inhibiting the development of a malignant disease associated with hematological malignancy-related antigen expression involve the administration of autologous T cells that have been activated in response to a hematological malignancy-related antigen polypeptide or hematological malignancy-related antigen-expressing APC, as described above. Such T cells may be CD4⁺ and/or CD8⁺, and may be proliferated as described above. The T cells may be administered to the individual in an amount effective to inhibit the development of a malignant disease. Typically, about 1×10^9 to 1×10^{11} T cells/M² are administered intravenously, intracavitory or in the bed of a resected tumor. It will be evident to those skilled in the art that the number of cells and the frequency of administration will be dependent upon the response of the patient.

25 [557] Within certain embodiments, T cells may be stimulated prior to an autologous bone marrow transplantation. Such stimulation may take place *in vivo* or *in vitro*. For *in vitro* stimulation, bone marrow and/or peripheral blood (or a fraction of bone marrow or peripheral blood) obtained from a patient may be contacted with a hematological malignancy-related antigen polypeptide, a polynucleotide encoding a hematological malignancy-related antigen polypeptide and/or an APC that expresses a hematological malignancy-related antigen polypeptide under conditions and for a time

sufficient to permit the stimulation of T cells as described above. Bone marrow, peripheral blood stem cells and/or hematological malignancy-related antigen-specific T cells may then be administered to a patient using standard techniques.

[558] Within related embodiments, T cells of a related or unrelated donor may be stimulated prior to a syngeneic or allogeneic (related or unrelated) bone marrow transplantation. Such stimulation may take place *in vivo* or *in vitro*. For *in vitro* stimulation, bone marrow and/or peripheral blood (or a fraction of bone marrow or peripheral blood) obtained from a related or unrelated donor may be contacted with a hematological malignancy-related antigen polypeptide, hematological malignancy-related antigen polynucleotide and/or APC that expresses a hematological malignancy-related antigen polypeptide under conditions and for a time sufficient to permit the stimulation of T cells as described above. Bone marrow, peripheral blood stem cells and/or hematological malignancy-related antigen-specific T cells may then be administered to a patient using standard techniques.

[559] Within other embodiments, hematological malignancy-related antigen-specific T cells, antibodies or antigen-binding fragments thereof as described herein may be used to remove cells expressing hematological malignancy-related antigen from a biological sample, such as autologous bone marrow, peripheral blood or a fraction of bone marrow or peripheral blood (e.g., CD34⁺ enriched peripheral blood (PB) prior to administration to a patient). Such methods may be performed by contacting the biological sample with such T cells, antibodies or antibody fragments under conditions and for a time sufficient to permit the reduction of hematological malignancy-related antigen expressing cells to less than 10%, preferably less than 5% and more preferably less than 1%, of the total number of myeloid or lymphatic cells in the bone marrow or peripheral blood. Such contact may be achieved, for example, using a column to which antibodies are attached using standard techniques. Antigen-expressing cells are retained on the column. The extent to which such cells have been removed may be readily determined by standard methods such as, for example, qualitative and quantitative PCR analysis, morphology, immunohistochemistry and FACS analysis. Bone marrow or PB (or a fraction thereof) may then be administered to a patient using standard techniques.

4.26 DIAGNOSTIC METHODS

[560] In general, a hematological malignancy may be detected in a patient based on the presence of hematological malignancy-related antigen and/or polynucleotide in a biological sample (such as blood, sera, urine and/or tumor biopsies) obtained from the patient. In other words, hematological malignancy-related antigens may be used as a marker to indicate the presence or absence of such a malignancy. The binding agents provided herein generally permit detection of the level of antigen that binds to the agent in the biological sample. Polynucleotide primers and probes may be used to detect the level of mRNA encoding hematological malignancy-related antigen, which is also indicative of the presence or absence of a hematological malignancy. In general, hematological malignancy-related antigen should be present at a level that is at least three fold higher in a sample obtained from a patient afflicted with a hematological malignancy than in the sample obtained from an individual not so afflicted.

[561] There are a variety of assay formats known to those of ordinary skill in the art for using a binding agent to detect polypeptide markers in a sample. See, e.g., Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988. In general, the presence or absence of a hematological malignancy in a patient may be determined by (a) contacting a biological sample obtained from a patient with a binding agent; (b) detecting in the sample a level of polypeptide that binds to the binding agent; and (c) comparing the level of polypeptide with a predetermined cut-off value.

[562] In a preferred embodiment, the assay involves the use of binding agent immobilized on a solid support to bind to and remove the polypeptide from the remainder of the sample. The bound polypeptide may then be detected using a detection reagent that contains a reporter group and specifically binds to the binding agent/polypeptide complex. Such detection reagents may comprise, for example, a binding agent that specifically binds to the polypeptide or an antibody or other agent that specifically binds to the binding agent, such as an anti-immunoglobulin, protein G, protein A or a lectin. Alternatively, a competitive assay may be utilized, in which a polypeptide is labeled with a reporter group and allowed to bind to the immobilized binding agent after incubation of the binding agent with the sample. The extent to which components of the sample inhibit the binding of the labeled polypeptide to the binding agent is indicative of the reactivity of the sample with the immobilized

binding agent. Suitable polypeptides for use within such assays include full length hematological malignancy-related antigens and portions thereof to which the binding agent binds, as described above.

[563] The solid support may be any material known to those of ordinary skill in the art to which the hematological malignancy-related antigen polypeptide may be attached. For example, the solid support may be a test well in a microtiter plate or a nitrocellulose or other suitable membrane. Alternatively, the support may be a bead or disc, such as glass, fiberglass, latex or a plastic material such as polystyrene or polyvinylchloride. The support may also be a magnetic particle or a fiber optic sensor, such as those disclosed, for example, in U.S. Patent No. 5,359,681. The binding agent may be immobilized on the solid support using a variety of techniques known to those of skill in the art, which are amply described in the patent and scientific literature. In the context of the present invention, the term "immobilization" refers to both noncovalent association, such as adsorption, and covalent attachment (which may be a direct linkage between the agent and functional groups on the support or may be a linkage by way of a cross-linking agent). Immobilization by adsorption to a well in a microtiter plate or to a membrane is preferred. In such cases, adsorption may be achieved by contacting the binding agent, in a suitable buffer, with the solid support for a suitable amount of time. The contact time varies with temperature, but is typically between about 1 hour and about 1 day. In general, contacting a well of a plastic microtiter plate (such as polystyrene or polyvinylchloride) with an amount of binding agent ranging from about 10 ng to about 10 µg, and preferably about 100 ng to about 1 µg, is sufficient to immobilize an adequate amount of binding agent.

[564] Covalent attachment of binding agent to a solid support may generally be achieved by first reacting the support with a bifunctional reagent that will react with both the support and a functional group, such as a hydroxyl or amino group, on the binding agent. For example, the binding agent may be covalently attached to supports having an appropriate polymer coating using benzoquinone or by condensation of an aldehyde group on the support with an amine and an active hydrogen on the binding partner (see, e.g., Pierce Immunotechnology Catalog and Handbook, 1991, at A12-A13).

[565] In certain embodiments, the assay is a two-antibody sandwich assay. This assay may be performed by first contacting an antibody that has been immobilized on a solid support, commonly the well of a microtiter plate, with the sample, such that

polypeptides within the sample are allowed to bind to the immobilized antibody. Unbound sample is then removed from the immobilized polypeptide-antibody complexes and a detection reagent (preferably a second antibody capable of binding to a different site on the polypeptide) containing a reporter group is added. The amount of detection reagent that remains bound to the solid support is then determined using a method appropriate for the specific reporter group.

5

10

15

20

25

30

[566] More specifically, once the antibody is immobilized on the support as described above, the remaining protein binding sites on the support are typically blocked. Any suitable blocking agent known to those of ordinary skill in the art, such as bovine serum albumin or Tween 20TM (Sigma Chemical Co., St. Louis, MO). The immobilized antibody is then incubated with the sample, and polypeptide is allowed to bind to the antibody. The sample may be diluted with a suitable diluent, such as phosphate-buffered saline (PBS) prior to incubation. In general, an appropriate contact time (*i.e.*, incubation time) is a period of time that is sufficient to detect the presence of polypeptide within a sample obtained from an individual with a hematological malignancy. Preferably, the contact time is sufficient to achieve a level of binding that is at least about 95% of that achieved at equilibrium between bound and unbound polypeptide. Those of ordinary skill in the art will recognize that the time necessary to achieve equilibrium may be readily determined by assaying the level of binding that occurs over a period of time. At room temperature, an incubation time of about 30 minutes is generally sufficient.

[567] Unbound sample may then be removed by washing the solid support with an appropriate buffer, such as PBS containing 0.1% Tween 20TM. The second antibody, which contains a reporter group, may then be added to the solid support. Preferred reporter groups include those groups recited above.

[568] The detection reagent is then incubated with the immobilized antibody-polypeptide complex for an amount of time sufficient to detect the bound polypeptide. An appropriate amount of time may generally be determined by assaying the level of binding that occurs over a period of time. Unbound detection reagent is then removed and bound detection reagent is detected using the reporter group. The method employed for detecting the reporter group depends upon the nature of the reporter group. For radioactive groups, scintillation counting or autoradiographic methods are generally appropriate. Spectroscopic methods may be used to detect dyes, luminescent groups and fluorescent groups. Biotin may be detected using avidin,

coupled to a different reporter group (commonly a radioactive or fluorescent group or an enzyme). Enzyme reporter groups may generally be detected by the addition of substrate (generally for a specific period of time), followed by spectroscopic or other analysis of the reaction products.

5 [569] To determine the presence or absence of a hematological malignancy, the signal detected from the reporter group that remains bound to the solid support is generally compared to a signal that corresponds to a predetermined cut-off value. In one preferred embodiment, the cut-off value for the detection of a hematological malignancy is the average mean signal obtained when the immobilized antibody is
10 incubated with samples from patients without the malignancy. In general, a sample generating a signal that is three standard deviations above the predetermined cut-off value is considered positive for the malignancy. In an alternate preferred embodiment, the cut-off value is determined using a Receiver Operator Curve, according to the method of Sackett *et al.*, *Clinical Epidemiology: A Basic Science for Clinical Medicine*, Little Brown and Co., 1985, p. 106-7. Briefly, in this embodiment, the cut-off value may be determined from a plot of pairs of true positive rates (*i.e.*, sensitivity) and false positive rates (100%-specificity) that correspond to each possible cut-off value for the diagnostic test result. The cut-off value on the plot that is the closest to the upper left-hand corner (*i.e.*, the value that encloses the largest area) is the most accurate cut-off value, and a sample generating a signal that is higher than the cut-off value determined by this method may be considered positive. Alternatively, the cut-off value may be shifted to the left along the plot, to minimize the false positive rate, or to the right, to minimize the false negative rate. In general, a sample generating a signal that is higher than the cut-off value determined by this method is considered
15 positive for a malignancy.
20

25 [570] In a related embodiment, the assay is performed in a flow-through or strip test format, wherein the binding agent is immobilized on a membrane, such as nitrocellulose. In the flow-through test, polypeptides within the sample bind to the immobilized binding agent as the sample passes through the membrane. A second, labeled binding agent then binds to the binding agent-polypeptide complex as a solution containing the second binding agent flows through the membrane. The detection of bound second binding agent may then be performed as described above. In the strip test format, one end of the membrane to which binding agent is bound is immersed in a solution containing the sample. The sample migrates along the
30

membrane through a region containing second binding agent and to the area of immobilized binding agent. Concentration of second binding agent at the area of immobilized antibody indicates the presence of a hematological malignancy. Typically, the concentration of second binding agent at that site generates a pattern, such as a line, that can be read visually. The absence of such a pattern indicates a negative result. In general, the amount of binding agent immobilized on the membrane is selected to generate a visually discernible pattern when the biological sample contains a level of polypeptide that would be sufficient to generate a positive signal in the two-antibody sandwich assay, in the format discussed above. Preferred binding agents for use in such assays are antibodies and antigen-binding fragments thereof. Preferably, the amount of antibody immobilized on the membrane ranges from about 25 ng to about 1 μ g, and more preferably from about 50 ng to about 500 ng. Such tests can typically be performed with a very small amount of biological sample.

[571] Of course, numerous other assay protocols exist that are suitable for use with the hematological malignancy-related antigen sequences or binding agents of the present invention. The above descriptions are intended to be exemplary only. For example, it will be apparent to those of ordinary skill in the art that the above protocols may be readily modified to use hematological malignancy-related antigen polypeptides to detect antibodies that bind to such polypeptides in a biological sample.

20 The detection of hematological malignancy-related antigen-specific antibodies may correlate with the presence of a hematological.

[572] A malignancy may also, or alternatively, be detected based on the presence of T cells that specifically react with hematological malignancy-related antigen in a biological sample. Within certain methods, a biological sample comprising CD4 $^{+}$ and/or CD8 $^{+}$ T cells isolated from a patient is incubated with a hematological malignancy-related antigen polypeptide, a polynucleotide encoding such a polypeptide and/or an APC that expresses such a polypeptide, and the presence or absence of specific activation of the T cells is detected. Suitable biological samples include, but are not limited to, isolated T cells. For example, T cells may be isolated from a patient by routine techniques (such as by Ficoll/Hypaque density gradient centrifugation of peripheral blood lymphocytes). T cells may be incubated *in vitro* for 2-9 days (typically 4 days) at 37°C with Mtb-81 or Mtb-67.2 polypeptide (e.g., 5 - 25 μ g/ml). It may be desirable to incubate another aliquot of a T cell sample in the absence of hematological malignancy-related antigen polypeptide to serve as a control. For CD4 $^{+}$

T cells, activation is preferably detected by evaluating proliferation of the T cells. For CD8⁺ T cells, activation is preferably detected by evaluating cytolytic activity. A level of proliferation that is at least two fold greater and/or a level of cytolytic activity that is at least 20% greater than in disease-free patients indicates the presence of a hematological malignancy in the patient.

5 [573] As noted above, a hematological malignancy may also, or alternatively, be detected based on the level of mRNA encoding hematological malignancy-related antigen in a biological sample. For example, at least two oligonucleotide primers may be employed in a polymerase chain reaction (PCR) based assay to amplify a portion of hematological malignancy-related antigen cDNA derived from a biological sample, wherein at least one of the oligonucleotide primers is specific for (*i.e.*, hybridizes to) a polynucleotide encoding the hematological malignancy-related antigen protein. The amplified cDNA is then separated and detected using techniques well known in the art, such as gel electrophoresis. Similarly, oligonucleotide probes that specifically hybridize to a polynucleotide encoding hematological malignancy-related antigen may be used in a hybridization assay to detect the presence of polynucleotide encoding hematological malignancy-related antigen in a biological sample.

10 [574] To permit hybridization under assay conditions, oligonucleotide primers and probes should comprise an oligonucleotide sequence that has at least about 60%, preferably at least about 75% and more preferably at least about 90%, identity to a portion of a polynucleotide encoding hematological malignancy-related antigen that is at least 10 nucleotides, and preferably at least 20 nucleotides, in length. Preferably, oligonucleotide primers and/or probes hybridize to a polynucleotide encoding a polypeptide described herein under moderately stringent conditions, as defined above. Oligonucleotide primers and/or probes which may be usefully employed in the diagnostic methods described herein preferably are at least 10-40 nucleotides in length. Techniques for both PCR based assays and hybridization assays are well known in the art (*see*, for example, Mullis *et al.*, *Cold Spring Harbor Symp. Quant. Biol.*, 51:263, 1987; Erlich ed., *PCR Technology*, Stockton Press, NY, 1989).

15 [575] One preferred assay employs RT-PCR, in which PCR is applied in conjunction with reverse transcription. Typically, RNA is extracted from a biological sample such as a biopsy tissue and is reverse transcribed to produce cDNA molecules. PCR amplification using at least one specific primer generates a cDNA molecule, which may be separated and visualized using, for example, gel electrophoresis.

Amplification may be performed on biological samples taken from [REDACTED] patient and from an individual who is not afflicted with a hematological malignancy. The amplification reaction may be performed on several dilutions of cDNA spanning two orders of magnitude. A two-fold or greater increase in expression in several dilutions of the test patient sample as compared to the same dilutions of the sample from a normal individual is typically considered positive.

5

10

15

20

25

30

[576] In preferred embodiments, such assays may be performed using samples enriched for cells expressing the hematological malignancy-related antigen(s) of interest. Such enrichment may be achieved, for example, using a binding agent as provided herein to remove the cells from the remainder of the biological sample. The removed cells may then be assayed as described above for biological samples.

[577] In further embodiments, hematological malignancy-related antigens may be used as markers for monitoring disease progression or the response to therapy of a hematological malignancy. In this embodiment, assays as described above for the diagnosis of a hematological malignancy may be performed over time, and the change in the level of reactive polypeptide(s) evaluated. For example, the assays may be performed every 24-72 hours for a period of 6 months to 1 year, and thereafter performed as needed. In general, a malignancy is progressing in those patients in whom the level of polypeptide detected by the binding agent increases over time. In contrast, the malignancy is not progressing when the level of reactive polypeptide either remains constant or decreases with time.

[578] Certain *in vivo* diagnostic assays may be performed directly on a tumor. One such assay involves contacting tumor cells with a binding agent. The bound binding agent may then be detected directly or indirectly via a reporter group. Such binding agents may also be used in histological applications. Alternatively, polynucleotide probes may be used within such applications.

[579] As noted above, to improve sensitivity, multiple markers may be assayed within a given sample. It will be apparent that binding agents specific for different proteins provided herein may be combined within a single assay. Further, multiple primers or probes may be used concurrently. The selection of markers may be based on routine experiments to determine combinations that results in optimal sensitivity.

[580] Further diagnostic applications include the detection of extramedullary disease (e.g., cerebral infiltration of blasts in leukemias). Within such methods, a binding agent may be coupled to a tracer substance, and the diagnosis is performed *in*

5

vivo using well known techniques. Coupled binding agent may be administered as described above, and extramedullary disease may be detected based on assaying the presence of tracer substance. Alternatively, a tracer substance may be associated with a T cell specific for hematological malignancy-related antigen, permitting detection of extramedullary disease based on assays to detect the location of the tracer substance.

4.27 EXEMPLARY DEFINITIONS

- [581] In accordance with the present invention, nucleic acid sequences include, but are not limited to, DNAs (including and not limited to genomic or extragenomic DNAs), genes, peptide nucleic acids (PNAs) RNAs (including, but not limited to, rRNAs, mRNAs and tRNAs), nucleosides, and suitable nucleic acid segments either obtained from native sources, chemically synthesized, modified, or otherwise prepared in whole or in part by the hand of man.
- [582] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and compositions similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and compositions are described herein. For purposes of the present invention, the following terms are defined below:
- [583] **A, an:** In accordance with long standing patent law convention, the words "a" and "an" when used in this application, including the claims, denotes "one or more".
- [584] **Expression:** The combination of intracellular processes, including transcription and translation undergone by a polynucleotide such as a structural gene to synthesize the encoded peptide or polypeptide.
- [585] **Promoter:** a term used to generally describe the region or regions of a nucleic acid sequence that regulates transcription.
- [586] **Regulatory Element:** a term used to generally describe the region or regions of a nucleic acid sequence that regulates transcription.
- [587] **Structural gene:** A gene or sequence region that is expressed to produce an encoded peptide or polypeptide.
- [588] **Transformation:** A process of introducing an exogenous polynucleotide sequence (e.g., a vector, a recombinant DNA or RNA molecule) into a host cell or protoplast in which that exogenous nucleic acid segment is incorporated into at least a first chromosome or is capable of autonomous replication within the transformed host

cell. Transfection, electroporation, and naked nucleic acid uptake are present examples of techniques used to transform a host cell with one or more polynucleotides.

5 [589] **Transformed cell:** A host cell whose nucleic acid complement has been altered by the introduction of one or more exogenous polynucleotides into that cell.

[590] **Transgenic cell:** Any cell derived or regenerated from a transformed cell or derived from a transgenic cell, or from the progeny or offspring of any generation of such a transformed host cell.

10 [591] **Transgenic animal:** An animal or a progeny or an offspring of any generation thereof that is derived from a transformed animal cell, wherein the animal's DNA contains an introduced exogenous nucleic acid molecule not originally present in a native, wild type, non-transgenic animal of the same species. The terms "transgenic animal" and "transformed animal" have sometimes been used in the art as synonymous terms to define an animal, the genetic contents of which has been modified to contain 15 one or more exogenous nucleic acid segments.

20 [592] **Vector:** A nucleic acid molecule, typically comprised of DNA, capable of replication in a host cell and/or to which another nucleic acid segment can be operatively linked so as to bring about replication of the attached segment. A plasmid, cosmid, or a virus is an exemplary vector.

25 [593] The terms "substantially corresponds to", "substantially homologous", or "substantial identity" as used herein denotes a characteristic of a nucleic acid or an amino acid sequence, wherein a selected nucleic acid or amino acid sequence has at least about 70 or about 75 percent sequence identity as compared to a selected reference nucleic acid or amino acid sequence. More typically, the selected sequence and the reference sequence will have at least about 76, 77, 78, 79, 80, 81, 82, 83, 84 or even 85 percent sequence identity, and more preferably at least about 86, 87, 88, 89, 90, 91, 92, 93, 94, or 95 percent sequence identity. More preferably still, highly homologous sequences often share greater than at least about 96, 97, 98, or 99 percent sequence identity between the selected sequence and the reference sequence to which 30 it was compared. The percentage of sequence identity may be calculated over the entire length of the sequences to be compared, or may be calculated by excluding small deletions or additions which total less than about 25 percent or so of the chosen reference sequence. The reference sequence may be a subset of a larger sequence, such as a portion of a gene or flanking sequence, or a repetitive portion of a

chromosome. However, in the case of sequence homology of two or more polynucleotide sequences, the reference sequence will typically comprise at least about 18-25 nucleotides, more typically at least about 26 to 35 nucleotides, and even more typically at least about 40, 50, 60, 70, 80, 90, or even 100 or so nucleotides.

5 Desirably, which highly homologous fragments are desired, the extent of percent identity between the two sequences will be at least about 80%, preferably at least about 85%, and more preferably about 90% or 95% or higher, as readily determined by one or more of the sequence comparison algorithms well-known to those of skill in the art, such as e.g., the FASTA program analysis described by Pearson and Lipman 10 (1988).

[594] The term "naturally occurring" as used herein as applied to an object refers to the fact that an object can be found in nature. For example, a polypeptide or polynucleotide sequence that is present in an organism (including viruses) that can be isolated from a source in nature and which has not been intentionally modified by the hand of man in a laboratory is naturally-occurring. As used herein, laboratory strains 15 of rodents that may have been selectively bred according to classical genetics are considered naturally occurring animals.

[595] As used herein, a "heterologous" is defined in relation to a predetermined referenced gene sequence. For example, with respect to a structural gene sequence, a 20 heterologous promoter is defined as a promoter which does not naturally occur adjacent to the referenced structural gene, but which is positioned by laboratory manipulation. Likewise, a heterologous gene or nucleic acid segment is defined as a gene or segment that does not naturally occur adjacent to the referenced promoter and/or enhancer elements.

[596] "Transcriptional regulatory element" refers to a polynucleotide sequence that activates transcription alone or in combination with one or more other nucleic acid sequences. A transcriptional regulatory element can, for example, comprise one or more promoters, one or more response elements, one or more negative regulatory elements, and/or one or more enhancers.

[597] As used herein, a "transcription factor recognition site" and a "transcription factor binding site" refer to a polynucleotide sequence(s) or sequence motif(s) which are identified as being sites for the sequence-specific interaction of one or more transcription factors, frequently taking the form of direct protein-DNA binding. Typically, transcription factor binding sites can be identified by DNA footprinting, gel

mobility shift assays, and the like, and/or can be predicted on the basis of known consensus sequence motifs, or by other methods known to those of skill in the art.

[598] As used herein, the term "operably linked" refers to a linkage of two or more polynucleotides or two or more nucleic acid sequences in a functional relationship. A nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For instance, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the coding sequence. Operably linked means that the DNA sequences being linked are typically contiguous and, where necessary to join two protein coding regions, contiguous and in reading frame. However, since enhancers generally function when separated from the promoter by several kilobases and intronic sequences may be of variable lengths, some polynucleotide elements may be operably linked but not contiguous.

[599] "Transcriptional unit" refers to a polynucleotide sequence that comprises at least a first structural gene operably linked to at least a first *cis*-acting promoter sequence and optionally linked operably to one or more other *cis*-acting nucleic acid sequences necessary for efficient transcription of the structural gene sequences, and at least a first distal regulatory element as may be required for the appropriate tissue-specific and developmental transcription of the structural gene sequence operably positioned under the control of the promoter and/or enhancer elements, as well as any additional *cis* sequences that are necessary for efficient transcription and translation (e.g., polyadenylation site(s), mRNA stability controlling sequence(s), etc.).

[600] As noted above, the present invention is generally directed to compositions and methods for using the compositions, for example in the therapy and diagnosis of cancer, such as hematological malignancy. Certain illustrative compositions described herein include hematological malignancy-related tumor polypeptides, polynucleotides encoding such polypeptides, binding agents such as antibodies, antigen presenting cells (APCs) and/or immune system cells (e.g., T cells). A "hematological malignancy-related tumor protein," as the term is used herein, refers generally to a protein that is expressed in hematological malignancy-related tumor cells at a level that is at least two fold, and preferably at least five fold, greater than the level of expression in a normal tissue, as determined using a representative assay provided herein. Certain hematological malignancy-related tumor proteins are tumor proteins that react detectably (within an immunoassay, such as an ELISA or Western blot) with antisera of a patient afflicted with hematological malignancy.

4.28 BIOLOGICAL FUNCTIONAL EQUIVALENTS

[601] Modification and changes may be made in the structure of the polynucleotides and peptides of the present invention and still obtain a functional molecule that encodes a peptide with desirable characteristics, or still obtain a genetic construct with the desirable expression specificity and/or properties. As it is often desirable to introduce one or more mutations into a specific polynucleotide sequence, various means of introducing mutations into a polynucleotide or peptide sequence known to those of skill in the art may be employed for the preparation of heterologous sequences that may be introduced into the selected cell or animal species. In certain circumstances, the resulting encoded peptide sequence is altered by this mutation, or in other cases, the sequence of the peptide is unchanged by one or more mutations in the encoding polynucleotide. In other circumstances, one or more changes are introduced into the promoter and/or enhancer regions of the polynucleotide constructs to alter the activity, or specificity of the expression elements and thus alter the expression of the heterologous therapeutic nucleic acid segment operably positioned under the control of the elements.

[602] When it is desirable to alter the amino acid sequence of one or more of the heterologous peptides encoded by the expression construct to create an equivalent, or even an improved, second-generation molecules, the amino acid changes may be achieved by changing one or more of the codons of the encoding DNA sequence, according to Table 1.

[603] For example, certain amino acids may be substituted for other amino acids in a protein structure without appreciable loss of interactive binding capacity with structures such as, for example, antigen-binding regions of antibodies or binding sites on substrate molecules. Since it is the interactive capacity and nature of a protein that defines that protein's biological functional activity, certain amino acid sequence substitutions can be made in a protein sequence, and, of course, its underlying DNA coding sequence, and nevertheless obtain a protein with like properties. It is thus contemplated by the inventors that various changes may be made in the peptide sequences of the disclosed compositions, or corresponding DNA sequences which encode said peptides without appreciable loss of their biological utility or activity.

TABLE 1

Amino Acids		Codons						
Alanine	Ala	A	GCA	GCC	GCG	GCU		
Cysteine	Cys	C	UGC	UGU				
Aspartic acid	Asp	D	GAC	GAU				
Glutamic acid	Glu	E	GAA	GAG				
Phenylalanine	Phe	F	UUC	UUU				
Glycine	Gly	G	GGA	GGC	GGG	GGU		
Histidine	His	H	CAC	CAU				
Isoleucine	Ile	I	AUA	AUC	AUU			
Lysine	Lys	K	AAA	AAG				
Leucine	Leu	L	UUA	UUG	CUA	CUC	CUG	CUU
Methionine	Met	M	AUG					
Asparagine	Asn	N	AAC	AAU				
Proline	Pro	P	CCA	CCC	CCG	CCU		
Glutamine	Gln	Q	CAA	CAG				
Arginine	Arg	R	AGA	AGG	CGA	CGC	CGG	CGU
Serine	Ser	S	AGC	AGU	UCA	UCC	UCG	UCU
Threonine	Thr	T	ACA	ACC	ACG	ACU		
Valine	Val	V	GUU	GUC	GUG	GUU		
Tryptophan	Trp	W	UGG					
Tyrosine	Tyr	Y	UAC	UAU				

[604] In making such changes, the hydropathic index of amino acids may be considered. The importance of the hydropathic amino acid index in conferring interactive biologic function on a protein is generally understood in the art (Kyte and Doolittle, 1982, incorporate herein by reference). It is accepted that the relative hydropathic character of the amino acid contributes to the secondary structure of the resultant protein, which in turn defines the interaction of the protein with other molecules, for example, enzymes, substrates, receptors, DNA, antibodies, antigens, and the like. Each amino acid has been assigned a hydropathic index on the basis of their hydrophobicity and charge characteristics (Kyte and Doolittle, 1982), these are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine

(-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.0); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).

[605] It is known in the art that certain amino acids may be substituted by other amino acids having a similar hydropathic index or score and still result in a protein with similar biological activity, *i.e.* still obtain a biological functionally equivalent protein. In making such changes, the substitution of amino acids whose hydropathic indices are within ± 2 is preferred, those that are within ± 1 are particularly preferred, and those within ± 0.5 are even more particularly preferred. It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity. U. S. Patent 4,554,101, incorporated herein by reference, states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with a biological property of the protein.

[606] As detailed in U. S. Patent 4,554,101, the following hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate ($+3.0 \pm 1$); glutamate ($+3.0 \pm 1$); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5 ± 1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4). It is understood that an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent, and in particular, an immunologically equivalent protein. In such changes, the substitution of amino acids whose hydrophilicity values are within ± 2 is preferred, those that are within ± 1 are particularly preferred, and those within ± 0.5 are even more particularly preferred.

[607] As outlined above, amino acid substitutions are generally therefore based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. Exemplary substitutions which take several of the foregoing characteristics into consideration are well known to those of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine.

5. EXAMPLES

[608] The following examples are included to demonstrate preferred embodiments of the invention. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention described in the appended claims.

5.1 EXAMPLE 1 – IDENTIFICATION OF HEMATOLOGICAL MALIGNANCY-RELATED ANTIGEN POLYNUCLEOTIDES

[609] This Example illustrates the identification of hematological malignancy-related antigen polynucleotides from non-Hodgkin's lymphomas.

[610] Hematological malignancy-related antigen polynucleotides were isolated by PCR-based subtraction. PolyA mRNA was prepared from T cell non-Hodgkin's lymphomas, B cell non-Hodgkin's lymphomas and normal tissues. Six cDNA libraries were constructed, PCR-subtracted and analyzed. Two libraries were constructed using pools of three T cell non-Hodgkin's lymphoma mRNAs (referred to herein as TCS libraries). Two others were constructed using pools of three B cell non-Hodgkin's lymphoma mRNAs (referred to herein as BCNHL libraries). Two other libraries were constructed using a pool of 2 Hodgkin's lymphoma mRNAs (referred to herein as HLS libraries). cDNA synthesis, hybridization and PCR amplification were performed according to Clontech's user manual (PCR-Select cDNA Subtraction), with the following changes: 1) cDNA was restricted with a mixture of enzymes, including *MscI*, *PvuII*, *StuI* and *DraI*, instead of the single enzyme *RsaI*; and 2) the ratio of driver to tester cDNA was increased in the hybridization steps (to 76:1) to give a more stringent subtraction.

[611] The two TCS libraries were independently subtracted with different pools of driver cDNAs. Driver #1 contained cDNA prepared from specific normal tissues (lymph node, bone marrow, T cells, heart and brain), and this subtraction generated the library TCS-D1 (T cell non-Hodgkin's lymphoma subtracted library with driver #1). Driver #2 contained non-specific normal tissues (colon, large intestine, lung, pancreas, spinal cord, skeletal muscle, liver, kidney, skin and brain), and this subtraction generated the library TCS-D2 (T cell non-Hodgkin's lymphoma subtraction library with driver #2).

[612] Similarly, the two BCNHL libraries were independently subtracted with different pools of driver cDNAs. Driver #1 contained cDNA prepared from specific normal tissues (lymph node, bone marrow, B cells, heart and brain), and this subtraction generated the library BCNHL/D1 (B cell non-Hodgkin's lymphoma subtracted library with driver #1). Driver #2 contained non-specific normal tissues (brain, lung, pancreas, spinal cord, skeletal muscle, colon, spleen, large intestine and PBMC), and this subtraction generated the library BCNHL/D2 (B cell non-Hodgkin's lymphoma subtraction library with driver #2).

5 [613] The two HLS libraries were independently subtracted with different pools of driver cDNAs. Driver #1 contained cDNA prepared from specific normal tissues (lymph node, bone marrow, B cells and lung) and this subtraction generated HLS-D1 (Hodgkin's lymphoma subtraction library with driver #1). Driver #2 contained non-specific normal tissues (colon, large intestine, lung, pancreas, spinal cord, skeletal muscle, liver, kidney, skin and brain) and this generated the library HLS-D2 (Hodgkin's lymphoma subtraction library with driver #2).

10 [614] To analyze the efficiency of the subtraction, actin (a housekeeping gene) was PCR amplified from dilutions of subtracted as well as unsubtracted PCR samples. Furthermore, the complexity and redundancy of each library was characterized by sequencing 96 clones from each of the PCR subtraction libraries (TCS-D1, TCS-D2, BCNHL/D1, BCNHL/D2, HLS-D1 and HLS-D2). These analyses indicated that the 15 libraries are enriched for genes overexpressed in leukemia tissues and specifically T cell and B cell non-Hodgkin's lymphoma and M. Hodgkin's lymphoma samples.

20 [615] Following PCR amplification, the cDNAs were cloned into the pCR2.1-TOPO plasmid vector (Invitrogen).

25 [616] Sequences obtained from these analyses were searched against known sequences in the publicly available databases using the BLAST 2.0 release. The default BLAST parameters used were as follows: GAP PARAMETERS: Open Gap = 0, Extended Gap = 0; OUTPUT PARAMETERS: Expect = 10.0, Threshold = 0, Number of Alignments = 250; For BLASTN, the search parameters were as follows: 30 Mismatch = -3, Reward = 1, Word size = 0. The alignments were presented pairwise, with a window percent identity = 22. All available protein and nucleotide databases were searched, including, PIR, SwissPROT, GenBank, Mouse EST, Human EST, Other EST, Human repeat and high throughput sequences, and published patents and patent application database.

[617] From these, a number of unique sequences were identified [REDACTED] represented novel polynucleotide sequences that had not previously been described in the GenBank and other sequence databases. A number of other sequences were identified that appeared to contain significant homology with one or more sequences previously identified in the databases, although they were described only as genomic or cDNA clones, and had no known function. The remaining sequences corresponded to known genes. The clones obtained from this analysis are summarized in Tables 2-6 in co-pending application USSN 09/796,692.

5

10 5.2 **EXAMPLE 2 – ANALYSIS OF SUBTRACTED cDNA SEQUENCES BY
MICROARRAY ANALYSIS**

15

[618] Subtracted cDNA sequences were analyzed by microarray analysis to evaluate their expression in hematological malignancies and normal tissues. Using this approach, cDNA sequences were PCR amplified and their mRNA expression profiles in hematological malignancies and normal tissues are examined using cDNA microarray technology essentially as described (Shena *et al.*, 1995).

20

25

30

[619] In brief, the clones identified from the subtracted cDNA libraries analyses were immobilized and arrayed onto glass slides as multiple replicas on microarray slides and the slides were hybridized with two different sets of probes, with each location on the microarray slide corresponding to a unique cDNA clone (as many as 5500 clones can be arrayed on a single slide, or chip). Each chip is hybridized with a pair of cDNA probes that are fluorescence-labeled with Cy3 and Cy5, respectively. The set of probes derived from the hematological malignancies was labeled with cy3 while the other set of probes derived from a pool of normal tissues was labeled with cy5. Typically, 1 µg of polyA⁺ RNA was used to generate each cDNA probe. After hybridization, the chips were scanned and the fluorescence intensity recorded for both Cy3 and Cy5 channels. The difference in intensities (*i.e.*, cy3/cy5 ratios) following hybridization with both probe sets provided the information on the relative expression level of each cDNA sequences immobilized on the slide in tumor versus normal tissues. There are multiple built-in quality control steps. First, the probe quality is monitored using a panel of ubiquitously expressed genes. Secondly, the control plate also can include yeast DNA fragments of which complementary RNA may be spiked into the probe synthesis for measuring the quality of the probe and the sensitivity of the analysis. This methodology provides a sensitivity of 1 in 100,000 copies of

mRNA, and the reproducibility of the technology may be ensured by including duplicated control cDNA elements at different locations.

5 [620] Analysis of hematological malignancy subtracted clones by microarray analyses on a variety of microarray chips identified the sequences set forth in SEQ ID NO:1 through SEQ ID NO:668 of co-pending application USSN 09/796,692 as being at least two-fold overexpressed in hematological malignancies versus normal tissues.

5.3 EXAMPLE 3 -- POLYNUCLEOTIDE AND POLYPEPTIDE COMPOSITIONS: BRIEF DESCRIPTION OF THE cDNA CLONES AND OPEN READING FRAMES IDENTIFIED BY SUBTRACTIVE HYBRIDIZATION AND MICROARRAY ANALYSIS

10 [621] Table 7 in co-pending application USSN 09/796,692 lists the sequences of the polynucleotides obtained during the analyses of the present invention. Shown are the 668 polynucleotide sequences, along with their clone name identifiers, as well as the serial number and filing date of the priority provisional patent application in which the

15 clone was first identified.

20 [622] Table 8 in co-pending application USSN 09/796,692 identifies the putative open reading frames obtained from analyses of the cDNA sequences obtained in SEQ ID NO:1-SEQ ID NO:668 in the co-pending application. Shown are the sequence identifiers, the clone name and translation frame, and the start and stop nucleotides in the corresponding DNA sequence used to generate the polypeptide sequence of the open reading frame.

25 [623] Table 9 in co-pending application USSN 09/796,692 identifies an additional set of particular hematological malignancy-related cDNA sequences that were obtained using the subtractive library and microarray methods as described above. These sequences, designated SEQ ID NO:2533-SEQ ID NO:9597 in the co-pending application, are shown in the Table along with the original clone name, and the serial number and filing date of the priority provisional application in which the clone was first described.

30 **5.4 EXAMPLE 4 – ADDITIONAL ANALYSIS OF cDNA CLONES AND ORFS IDENTIFIED BY SUBTRACTIVE HYBRIDIZATION AND MICROARRAY ANALYSIS**

[624] This example describes microarray analysis of leukemia tumor- and tissue-specific cDNAs.

[625] Microarray analysis identifies many potential genes that are overexpressed in specific tissues/tumors. However, these genes often represent known genes or genes that subsequently are found by RealTime PCR analysis to have a broader expression profile. This disclosure describes analyses which combine microarray analysis (CorixArray) and comparisons to public databases to identify and prioritize candidate sequences for RealTime analysis, thus allowing the identification of sequences with favorable expression profiles in a more efficient manner.

5 [626] Clones are tested for overexpression in lymphoma tumor samples as compared to normal tissues using Corixa Leukemia/Lymphoma Chip#3 (LyC3). The analyzed clones are originally randomly picked from lymphoma PCR subtracted libraries: B-cell non-Hodgkin's lymphoma libraries (BCNHL/D1 and BCNHL/D2; CID000153); T-cell non-Hodgkin's lymphoma libraries (TCS-D1 and TCS-D2; CID000166); Hodgkin's lymphoma libraries (HLS-D1 and HLS-D2; CID000204 and CID000275) and a Clontech-generated T8 leukemia PCR subtracted library. A total of 10 5184 clones were arrayed: 2304 from BCNHL libraries, 288 from TCS libraries, 1344 from HLS libraries, and 960 from a Clontech-T8 library. In addition, a selection of 15 288 clones from the above libraries that had been identified from prior leukemia/lymphoma chips were re-analyzed on LyC3.

20 [627] cDNA inserts for arraying are amplified by PCR using vector-specific primers. The arrays are probed with 43 probe pairs. Analysis is performed using CorixArray computational analysis. Analysis consisted of determining the ratio of the mean or median hybridization signal for a particular element (cDNA) using two sets of probes. The ratio is a reflection of the over- or under-expression of the element (cDNA) within the probe population. Probe groups are set up to identify elements 25 (cDNAs) with high differential expression in probe group #1. Probe group #1 typically consists of 20 tumor RNAs, each probe representing a subset of lymphoma (e.g., B-cell non-Hodgkins lymphoma, T-cell non-Hodgkins lymphoma and Hodgkins lymphoma). Probes in group #2 include 16 essential and non-essential normal tissues (see, Figure 4). A threshold (fold-overexpression in probe group #1) is set at 3.0. This 30 threshold is set to identify elements with overexpression that could be reproducibly detected based on the quality of the chip. The sequences are sorted initially based on their CorixArray analysis, specifically on the basis of their mean signal 2 values.

[628] Sequences having a mean signal 2 < 0.1 can be considered as sequences with low/no expression in normal tissues. Sequences having a mean signal 2 between 0.1

and 0.2 can be considered as clones with a potential for some expression in normal tissues. Sequences having a mean signal $2 > 0.2$ and can be considered as clones that have the potential to have expression in some normal tissues.

5 5.5 **EXAMPLE 5 – IDENTIFICATION OF CANDIDATE GENES WITH THE SAME TISSUE
EXPRESSION PROFILE AS CD20 AND CD52**

[629] This example identifies leukemia tumor and tissue-specific genes that have similar tissue expression profiles as CD20 and CD52 (Figure 3). Antibodies against these two markers have been used for the therapy of hematological malignancies and other diseases associated with expression of these markers, *i.e.*, FDA-approved Rituximab (anti-CD20 Ab) and Campath (anti-CD52 Ab). The similarity in gene expression between our candidate genes and CD20 and CD52 suggests that the described genes will also be useful as compounds for the diagnosis and therapy of hematological malignancies and other cancerous and non-cancerous diseases associated with expression of one or more of the described antigens.

[630] RealTime PCR was used to compare the expression profiles of the candidate genes with the expression profiles of CD20 and CD52. Figure 8 illustrates the expression of the candidate genes in hematopoietic subsets and hematological malignancies. Data summarized in this sheets shows that using a combination of the PCR subtracted cDNA libraries, microarray analyses, and RealTime PCR, it is possible to identify genes differentially expressed in normal B-cells, lymphomas, myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia.

25 **5.6 EXAMPLE 6 – ANALYSIS OF LY1484 (SEQ ID NOS:16-18 AND 120-121), ONE OF THE
GENES WITH A SIMILAR EXPRESSION PROFILE AS CD20 AND CD52**

[631] This example illustrates the typical procedure used to identify antigens for use as therapeutics, diagnostics, etc. and preferred methods for developing therapeutics and diagnostics for leukemia/lymphoma diseases. First, candidate genes highly enriched in leukemia/lymphoma cells are identified using PCR subtraction library cloning. Next, subtracted cDNA sequences are analyzed by microarray analysis to evaluate their expression in hematological malignancies and normal tissues. Since microarray analysis often identifies genes that represent known genes or genes that subsequently are found by RealTime analysis to have broader expression profiles, the

microarray analysis is combined with comparisons to public databases to identify and prioritize candidate sequences for analysis. Next, RealTime PCR is used to analyze the expression profiles in various hematological subsets. In some cases, further analysis is focused on antigens with expression profiles similar to known therapeutics.

5 For these genes, structural prediction programs are used to identify transmembrane domains, antigen-specific CTL are generated using human *in vitro* priming, and humanized monoclonal and polyclonal antibodies are generated as reagents for the diagnosis and therapy of malignancies and autoimmune disorders associated with antigen expression.

10 [632] Ly1484P PCR subtraction library clone sequences matched the Genbank clone KIAA1607 (acc. no. XM033378, XM033379 and AB046827) and FJL00111 (acc. no. AK024502). Overexpression of Ly1484 was documented by microarray analyses and RealTime PCR. Ly1484P is overexpressed in B cell neoplasms, while expression in normal tissues is restricted to normal B-cells.

15 [633] A full length sequence of candidate Ly1484P was obtained using the Genbank database. Ly1484P was mapped to human chromosome 10. There is both a long and short version of Ly1484P (long version – SEQ ID NO:120; short version – SEQ ID NO:121). TMpred analysis of Ly1484P indicates that this protein contains a transmembrane domain. Using the TSITES program, T-helper epitopes have also been identified (Figures 7 & 8). Polypeptides have been generated and are being used to generate antibodies that are specific for Ly1484P. These humanized monoclonal antibodies may be used (conjugated or unconjugated) for the diagnosis and therapy of malignancies and autoimmune disorders associated with Ly1484 expression.

25 **5.7 EXAMPLE 7 – IDENTIFICATION OF TRANSMEMBRANE DOMAINS**

[634] Structural prediction programs known to those of skill in the art were used to identify transmembrane domains in the candidate antigens described herein.

[635] For Ly1728P, amino acid residues 6-22, 47-65, 227-243, and 228-245 of SEQ ID NO:2 were identified as putative transmembrane domains.

30 [636] For Ly1732P, amino acid residues 60-76 and 55-76 of SEQ ID NO:4 were identified as putative transmembrane domains.

[637] For Ly1888P, amino acids 1-22, 3-21, 52-68, 254-273, 252-273, and 256-272 of SEQ ID NO: 6 were identified as putative transmembrane domains.

[638] For Ly1452P amino acids 354-375, 355-377 and 425-441 of SEQ ID NO: 10 (splice variant 1) were identified as putative transmembrane domains and amino acids 354-375, 355-377 and 425-441 of SEQ ID NO: 12 (splice variant 2) were identified as putative transmembrane domains.

5 [639] Ly1462P, amino acids 2-23, 3-21, 369-385, 976-999, 977-993, and 979-1000 of SEQ ID NO: 15 were identified as putative transmembrane domains.

[640] For Ly1484P, amino acids 51-67, 322-338, 666-682, 736-752, 1078-1094, 24-43, 53-69, 118-136, 319-335, 730-752, 1586-1602, 48-69, 88-109, 114-135, 196-217, 300-321, 323-344, 389-410, 502-523, 659-680, 714-735, 1076-1097, 1158-1179, and 1321-1342 of SEQ ID NO: 18 were identified as putative transmembrane domains, amino acids 10-86, 63-84, 118-139, 480-501, 562-583, 725-746, 70-86, 113-129, 134-156, 280-296, 481-497, 560 - 577, 653-674, 721-738, 734-752, 833-869, 879-895, 990-1006, 1023-1048, 1070-1087, 1112-1138, 1135-1170, and 1146-1170 of SEQ ID NO: 120 were identified as putative transmembrane domains, amino acids 94-129, 102-123, 367-383, 394-423, 447-464, and 493-513, of SEQ ID NO: 121 were identified as putative transmembrane domains.

15 [641] For Ly1486P, amino acids 24-40 and 24-45 of SEQ ID NO: 21 were identified as putative transmembrane domains.

20 [642] For Ly1693P, amino acids 47-63, 80-96, 114-130, 158-174, 207-223, 237-253, 289-305, 117-134, 144-160, 167-184, 516-535, 44-65, 85-106, 111-132, 150-171, 204-225, 242-263, and 290-311 of SEQ ID NO: 26 were identified as putative transmembrane domains.

25 [643] For Ly1715P, amino acids 38-54, 38-56, and 34-55 of SEQ ID NO: 29 were identified as putative transmembrane domains.

[644] For Ly1727P, amino acids 68-100, 214-234, 304-320, 84-105, 217-238, and 302-323 of SEQ ID NO: 32 were identified as putative transmembrane domains.

[645] For Ly1905P, amino acids 68-100, 214-234, 84-105, and 217-238 of SEQ ID NO: 40 were identified as putative transmembrane domains.

30 [646] For Ly1885P, amino acids 218-234, 219-235, 626-654, and 219-240 of SEQ ID NO: 35 were identified as putative transmembrane domains.

[647] For Ly663S, amino acids 22-38, 41-57, 60-76, 92-108, 242-258, 20-38, 23-57, 60-77, 86-102, 241-257, 14-35, 89-110, and 248-269 of SEQ ID NO: 43 were identified as putative transmembrane domains.

[648] For Ly664S, amino acids 11-27, 15-31, 74-93, 209-227, 8-[REDACTED] and 67-88 of SEQ ID NO: 45 were identified as putative transmembrane domains.

[649] For Ly667S, amino acids 13-31, 139-157, 184-202, 231-247, 329-351, 435-451, 473-490, 609-626, 685-705, 688-704, 7-28, 233-254, and 685-706 of SEQ ID NO: 48 were identified as putative transmembrane domains.

[650] For Ly677S, amino acids 149-165, 10-30, 144-165, 7-28, and 144-165 of SEQ ID NO: 54 were identified as putative transmembrane domains.

[651] For Ly1891P, amino acids 31-47, 66-82, 93-109, 128-144, 171-187, 205-221, 242-258, 31-48, 64-82, 94-111, 120-145, 170-187, 205-221, 244-266, and 29-50, 63-84, 93-114, 124-145, 168-189, 206-227, and 241-262 of SEQ ID NO: 56 were identified as putative transmembrane domains.

[652] For CD138, amino acids 255-271, 4-21, 258-276, 6-27, and 256-277 of SEQ ID NO: 58 were identified as putative transmembrane domains.

[653] For CD22, amino acids 688-704, 3-19, 29-46, 157-174, 185-201, 349-366, 386-406, 479-505, 688-709, 1-22, 159-180, and 689-710 of SEQ ID NO: 61 were identified as putative transmembrane domains.

[654] For CD79beta, amino acids 161-177, 4-29, 59-78, 160-181, 4-25, and 161-180 of SEQ ID NO: 66 were identified as putative transmembrane domains.

[655] For Ly1454P, amino acids 5-22, 231-249, 7-28, and 425-446 of SEQ ID NO: 74 were identified as putative transmembrane domains.

[656] For Ly1485P, amino acid residues 2-19 of SEQ ID NO: 76 were identified as a putative transmembrane domain.

[657] Ly1500P, amino acid residues 10-31 and 327-344 of SEQ ID NO: 80 (splice variant 1) were identified as putative transmembrane domains, amino acid residues 13-38, 71-92, and 388-405 of SEQ ID NO: 82 (splice variant 2) were identified as putative transmembrane domains, and amino acids 25-46 and 341-359 of SEQ ID NO: 84 (splice variant 3) were identified as putative transmembrane domains.

[658] For Ly1516P, amino acids 142-158, 177-193, 207-223, 238-254, 271-287, 142-158, 177-193, 207-223, 238-254, and 271-287 of SEQ ID NO: 87 were identified as putative transmembrane domains.

[659] For Ly1729P, amino acids 420-436 431-437, and 412-433 of SEQ ID NO: 101 were identified as putative transmembrane domains.

[660] For Ly1859P, amino acid residues 128-144, 293-311, 408-[REDACTED], 435-454, 465-483, 516-533, 290-311; 435-456, and 507-528 of SEQ ID NO 107 were identified as putative transmembrane domains.

5 [661] For Ly1866P, amino acids 47-65 and 50-71 of SEQ ID NO:109 were identified as putative transmembrane domains.

[662] For Ly669S, amino acids 489-505, 13-29, 38-57, 73-89, 94-114, 252-268, 307-324, 329-346, 489-509, 4-25, and 486-507 of SEQ ID NO:114 were identified as putative transmembrane domains.

10 [663] For Ly672S, amino acids 11-27, 284-300, 325-341, 345-361, 407-423, 7-28, 102-118, 174-198, 283-299, 325-341, 347-383, 403-423, 431-454, 473-492, 11-32, 286-307, 322-343, 345-366, 404-425, 430-451, and 469-490 of SEQ ID NO:117 were identified as putative transmembrane domains.

15 [664] For Ly675S, amino acids 154-170, 187-203, 428-444, 518-534, 846-862, 81-97, 155-172, 235-251, 374-391, 428-444, 477-195, 520-542, 539-573, 694-714, 807-823, 843-862, 50-71, 77-98, 145-166, 518-539, 802-823, and 845-866 of SEQ ID NO:119 were identified as putative transmembrane domains.

5.8 EXAMPLE 8 – REALTIME PCR ANALYSIS TO IDENTIFY ANTIGENS OVEREXPRESSED IN CHRONIC LYMPHOCYTIC LEUKEMIA AND MULTIPLE MYELOMA

20 [665] Overexpression of candidate antigens in chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) was confirmed by RealTime PCR.

[666] Real-time PCR evaluates the level of PCR product accumulation during amplification (*see, e.g.*, Gibson *et al.*, *Genome Research* 6:995-1001 (1996); Heid *et al.*, *Genome Research* 6:986-994 (1996)). RealTime PCR permits quantitative evaluation of mRNA levels in multiple samples. Briefly, mRNA is extracted from tumor and normal tissue and cDNA is prepared using standard techniques. Real-time PCR is performed, for example, using a Perkin Elmer/Applied Biosystems (Foster City, CA) 9700 Prism instrument. Matching primers are designed for genes of interest using, for example, the primer express program provided by Perkin Elmer/Applied Biosystems (Foster City, CA). Optimal concentrations of primers and probes are initially determined by those of ordinary skill in the art, and control (*e.g.*, β -actin) primers and probes are obtained commercially from, for example, Perkin Elmer/Applied Biosystems (Foster City, CA). To quantitate the amount of specific RNA in a sample, a standard curve is generated using a plasmid containing the gene of

5

interest. Standard curves are generated using the Ct values determined in the real-time PCR, which are related to the initial cDNA concentration used in the assay. Standard dilutions ranging from 10-10⁶ copies of the gene of interest are generally sufficient. In addition, a standard curve is generated for the control sequence. This permits standardization of initial RNA content of a tissue sample to the amount of control for comparison purposes.

Summary of Results

Antigen	CLL	MM
Ly1728P	no	yes
Ly1732P	yes	yes
Ly1888P	yes	no
Ly1452P	yes	no
Ly1462P	yes	no
Ly1484P	not determined	not determined
Ly1486P	yes	no
Ly1677P	yes	no
Ly1682P	yes	no
Ly1693P	yes	yes
Ly1697P	yes	no
Ly1715P	yes	yes
Ly1727P	yes	yes
Ly1905P	yes	yes
Ly1885P	yes	yes
Ly663S	yes	yes
Ly664S	yes	yes
Ly667S	yes	yes
Ly677S	yes	yes
Ly1891P	not determined	not determined
CD138	no	yes
CD22	yes	no
CD79beta	yes	yes
Ly1450P	not determined	not determined
Ly1451P	yes	yes
Ly1454P	yes	not determined
Ly1485P	not determined	not determined
Ly1500P	yes	no
Ly1516P	not determined	not determined
Ly1678P	yes	yes
Ly1680P	yes	no
Ly1686P	yes	no
Ly1687P	yes	no
Ly1706P	yes	yes
Ly1712P	yes	yes
Ly1729P	yes	yes
Ly1848P	yes	yes
Ly1859P	yes	no

Ly1866P	yes	yes
Ly1867P	yes	no
Ly1868P	yes	no
Ly1886P	yes	no
Ly669S	yes	yes
Ly672S	yes	yes
Ly675S	yes	yes

5 [667] These sequences can conveniently be used to diagnose, treat, and prevent malignant diseases that overexpress these genes, including multiple myeloma, B-cell lymphomas, and B-CLL. For example, monoclonal antibodies, including humanized monoclonal antibodies can be used for diagnosis and therapy of disorders associated with expression of antigens overexpressed in hematological malignancies.

10 **5.9 EXAMPLE 9 - SEQUENCE ANALYSES, EXPRESSION ANALYSES, AND STRUCTURE ANALYSES OF OTHER ANTIGENS WITH SIMILAR EXPRESSION PROFILES AS CD20 & CD52**

Summary of Results

Antigen	Sequence Analysis
Ly1728P	FOAP-2 ("novel gene over-expressed in macrophages")
Ly1732P	B-cell maturation factor (BCM), tumor necrosis factor receptor superfamily, member 17. BCM bins to TALL-1, a member of the TNF family.
Ly1888P	anti-Fas-induced apoptosis protein (TOSO); experimentally shown to be expressed on the cell surface.
Ly 1452P	anti-Fas-induced apoptosis protein (TOSO); experimentally shown to be expressed on the cell surface.
Ly1462P	Human Epstein-Barr virus complement receptor type II
Ly1484P	KIAA1607 (cDNA sequence present in GenBank).
Ly1486P	Fc fragment of IgE, low affinity II receptor.
Ly1677P	novel
Ly1682P	novel
Ly1693P	Chemokine receptor CXCR4
Ly1697P	novel
Ly1715P	lectin-like NK cell receptor
Ly1727P	Splice variants of the hpim-2 gene (homologs of the mouse pim-2 oncogene). Predicted to be a serine threonine kinase with a role in cell proliferation.
Ly1905P	Splice variants of the hpim-2 gene (homologs of the mouse pim-2 oncogene). Predicted to be a serine threonine kinase with a role in cell proliferation.
Ly1885P	An apparent splice form of the cell cycle progression 8 protein: one of a family of proteins involved in restoration of cell cycle progression (by blocking arrest in G1 phase).
Ly663S	leukocyte surface antigen CD37

Ly664S	protein with unknown function that shares 30-40% identity with various thioredoxins
Ly667S	Semaphorin B (semaphorins are a large family of secreted and transmembrane proteins; sema domains occur in the hepatocyte growth factor receptor)
Ly677S	leukocyte surface receptor CD79A
Ly1891P	orphan G-protein coupled receptor (GPRC5D)
CD138	CD138
CD22	CD22
CD79beta	CD79beta
Ly1450P	novel (matches GenBank seq FLJ23202; no ORF)
Ly1451P	novel (matches GenBank seq FLJ39358 no ORF)
Ly1454P	novel (matches GenBank seq FLJ40597; ORF)
Ly1485P	novel (matches genomic DNA only)
Ly1500P	BANK protein: B-cell scaffold protein with ankyrin repeats; a substrate for tyrosine phosphorylation upon B-cell antigen receptor stimulation.
Ly1516P	Rh-related antigen CD47, a signal transducer integrin-associated protein
Ly1678P	novel (matches genomic DNA only)
Ly1680P	novel (matches genomic DNA only)
Ly1686P	novel (matches genomic DNA only)
Ly1687P	novel (matches genomic DNA only)
Ly1706P	novel (matches genomic DNA only)
Ly1712P	novel
Ly1729P	Hematopoietic cell-specific Lyn substrate 1 (HCLS1) protein; N-terminal half has repeats with significant identity to a helix-turn-helix DNA binding motif; the C-terminal half is similar to domains that act as substrates for protein tyrosine kinases suggesting that this protein may be involved in signal transduction and regulation of gene expression.
Ly1848P	novel (matches genomic DNA only)
Ly1859P	novel (matches GenBank seq FLJ00140; ORF)
Ly1866P	Matches a gene in GenBank referred to as "similar to hypothetical protein PRO1722."
Ly1867P	novel (matches genomic DNA only)
Ly1868P	novel (matches genomic DNA only)
Ly1886P	novel (matches genomic DNA only)
Ly669S	intercellular adhesion molecule 3 (ICAM3)
Ly672S	cisplatin resistance related protein CRR9p
Ly675S	KIAA0906 (partial cDNA/protein sequences present in GenBank).

5.10 EXAMPLE 10 – SEQUENCE ANALYSIS OF LY1451

[668] The Ly1451 (SEQ ID NOS:69-71 and 124) sequence derived from a lymphoma PCR subtraction library clone was used to query several public databases, including GenBank and GenSeq. No matches (>90 identity) were detected for the 5'-proximal 51 bp suggesting that this sequence may contain a repeat element. A BLASTN search of the LifeSeq database (Incyte) identified a 980 bp template

(template #1076101.8; SEQ ID NO:124 that contained all 240bp of Ly1451. This template consisted of sequences from 6 clones, of which 2 (33%) were derived from hematologic/immune tissue libraries. Template #1076101.8 was part of a bin containing 11 templates derived from a total of 104 clones, of which 12 (9%) were derived from hematologic/immune tissue libraries.

[669] This sequence (SEQ ID NO:124) was used to search further public databases but no additional sequences were obtained. However, these searches indicate this sequence is a human endogenous retroviral sequence (HERV) encoding polypeptides corresponding to portions of the integrase and envelope genes. A single ORF with an ATG translational start site is contained in the forward read of LS1076101.8

[670] The polypeptide encoded by this ORF (SEQ ID NO:124) is not predicted to have a transmembrane domain.

**5. 11 EXAMPLE 11 --EXPRESSION OF LY1452 LYMPHOMA ANTIGENS ENCODED BYA
15 SPECIFIC GENE, LY1452, ASSOCIATED WITH B CELL LEUKEMIAS, LYMPHOMAS
AND MULTIPLE MYELOMAS**

[671] Recombinantly expressed Ly1452 antigens were constructed to allow for quick and easy purification of the protein.

[672] The open reading frame for Ly1452 was PCR amplified and subcloned into a modified pET28 vector with a His tag in-frame and recombinantly expressed in *E. coli* (His-Ly1452: SEQ ID NO:10,482 (nt), SEQ ID NO:10,483 (protein)).

Ly1452P expression in E. coli

[673] The open reading frame of the LS coding region was PCR amplified with the following primers:

25 PDM-797 5' gtgtcacaatctacagtcaaggcaggattctcc 3' Tin 64°C
(SEQ ID NO:10,975)

PDM-799 5' gttatgtagcggccgcttatcatgttgctgcagag 3' Tm 67°C
(SEQ ID NO:10,976)

[674] Using the following conditions:

30 10μl 10X Herculase buffer

1 μl 10mM dNTPs

2μl 10μM each oligo

83μl sterile water

1.0μl Herculase DNA polymerase (Stratagene, La Jolla, CA)

35 50 ng DNA

	98°C 3 minutes		72°C 2 minute X 10 cycles
	98°C 40 seconds	60°C 30 seconds	72°C 2 minutes 30 seconds X 10
	98°C 40 seconds	60°C 30 seconds	
	cycles		
5	98°C 40 seconds	60°C 30 seconds	72°C 3 minutes X10 cycles
	98°C 40 seconds	60°C 30 seconds	72°C 3 minutes 30 seconds X10
	cycles		
	72°C 4 minutes		

[675] The PCR product was digested with Xho I and cloned into pPDM His (a modified pET28 vector with a His tag in frame on the 5' end) that had been digested with Eco72I and Xhol. Construct was confirmed through sequence analysis and transformed into BLR (DE3) pLysS and HMS 174 pLys S cells.

[676] Recombinant proteins are also expressed without a histidine tag or with other lymphoma antigens. They are also expressed in other vectors, including other *E. coli* constructs, Baculovirus, yeast, and mammalian expression vectors. This recombinant antigen can be used to make polyclonal and monoclonal antibodies or used in immunological assays.

6. REFERENCES

[677] The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.

[678] U. S. Patent 3,817,827.

[679] U. S. Patent 3,850,752.

25 [680] U. S. Patent 3,901,654.

[681] U. S. Patent 3,935,074.

[682] U. S. Patent 3,984,533.

[683] U. S. Patent 3,996,345.

[684] U. S. Patent 4,034,074.

30 [685] U. S. Patent 4,098,876.

[686] U. S. Patent 4,235,877.

[687] U. S. Patent 4,376,110.

[688] U. S. Patent 4,429,008.

[689] U. S. Patent 4,436,727.

35 [690] U. S. Patent 4,452,901.

[691] U. S. Patent 4,489,710.

- [692] U. S. Patent 4,507,234.
- [693] U. S. Patent 4,554,101.
- [694] U. S. Patent 4,569,789.
- [695] U. S. Patent 4,603,112.
- 5 [696] U. S. Patent 4,625,014.
- [697] U. S. Patent 4,638,045.
- [698] U. S. Patent 4,671,958.
- [699] U. S. Patent 4,673,562.
- [700] U. S. Patent 4,683,195.
- 10 [701] U. S. Patent 4,699,784.
- [702] U. S. Patent 4,735,792.
- [703] U. S. Patent 4,751,180.
- [704] U. S. Patent 4,769,330.
- [705] U. S. Patent 4,777,127.
- 15 [706] U. S. Patent 4,866,034.
- [707] U. S. Patent 4,873,088.
- [708] U. S. Patent 4,877,611.
- [709] U. S. Patent 4,897,268.
- [710] U. S. Patent 4,912,094.
- 20 [711] U. S. Patent 4,935,233.
- [712] U. S. Patent 5,017,487.
- [713] U. S. Patent 5,075,109.
- [714] U. S. Patent 5,145,684.
- [715] U. S. Patent 5,151,254.
- 25 [716] U. S. Patent 5,215,926.
- [717] U. S. Patent 5,240,856.
- [718] U. S. Patent 5,350,840.
- [719] U. S. Patent 5,359,681.
- [720] U. S. Patent 5,399,346.
- 30 [721] U. S. Patent 5,399,363.
- [722] U. S. Patent 5,466,468.
- [723] U. S. Patent 5,472,869.
- [724] U. S. Patent 5,543,158.
- [725] U. S. Patent 5,552,157.

- [726] U. S. Patent 5,565,213.
- [727] U. S. Patent 5,567,434.
- [728] U. S. Patent 5,633,234.
- [729] U. S. Patent 5,641,515.
- 5 [730] U. S. Patent 5,738,868.
- [731] U. S. Patent 5,741,516.
- [732] U. S. Patent 5,795,587.
- [733] U. S. Patent 5,811,128.
- [734] U. S. Patent 5,814,344.
- 10 [735] U. S. Patent 5,820,883.
- [736] U. S. Patent 5,853,763.
- [737] U. S. Patent 5,874,265.
- [738] U. S. Patent 5,928,647.
- [739] U. S. Patent 5,942,252.
- 15 [740] U. S. Patent 6,110,702.
- [741] European Patent No. EP 0,345,242.
- [742] Great Britain Patent No. GB 2,200,651.
- [743] Intl. Pat. Appl. Publ. No. WO 89/01973.
- [744] Intl. Pat. Appl. Publ. No. WO 89/06280.
- 20 [745] Intl. Pat. Appl. Publ. No. WO 91/02805.
- [746] Intl. Pat. Appl. Publ. No. WO 91/16116.
- [747] Intl. Pat. Appl. Publ. No. WO 92/07243.
- [748] Intl. Pat. Appl. Publ. No. WO 94/00153.
- [749] Intl. Pat. Appl. Publ. No. WO 94/20078.
- 25 [750] Intl. Pat. Appl. Publ. No. WO/94/23701.
- [751] Intl. Pat. Appl. Publ. No. WO 95/17210.
- [752] Intl. Pat. Appl. Publ. No. WO 96/02555.
- [753] Intl. Pat. Appl. Publ. No. WO 96/06638.
- [754] Intl. Pat. Appl. Publ. No. WO 96/30516.
- 30 [755] Intl. Pat. Appl. Publ. No. WO 96/33739.
- [756] Intl. Pat. Appl. Publ. No. WO 97/24447.
- [757] Intl. Pat. Appl. Publ. No. WO 99/33488.
- [758] Aaroston and Todaro, *J. Cell. Physiol.*, 72:141-48, 1968.
- [759] Adelman *et al.*, *DNA*, 2:183, 1983.

- [760] Amin *et al.*, *Am. J. Pathol.*, 146:344-56, 1995.
- [761] Akaza *et al.*, "Expression of antitumor response. Role of attachment and viability of bacillus Calmette-Guerin to bladder cancer cells," *Cancer*, 72:558-63, 1993.
- 5 [762] American Type Culture Collection, Catalogue of Cell Lines and Hybridomas, 7th ed., 1992.
- [763] Avrameas, "Natural autoantibodies: Self-recognition and physiological autoimmunity," In: *Natural autoantibodies: Their Physiological Role and Regulatory Significance*, Shoenfeld and Isenberg (eds.), CRC Press, Boca Raton, Florida, pp. 10 1-14, 1993.
- [764] Azuma *et al.*, "Correlation Between Augmented Resistance to Influenza Virus Infection and Histological Changes in Lung of Mice Treated with Trehalose-6,6'-dimycolate," *Journal of Biological Response Modifiers*, 7:473-82, 1988.
- [765] Bajorin *et al.*, *Proc. Annu. Meet. Am. Soc. Clin. Oncol.*, 7:A967, 1988.
- 15 [766] Baker *et al.*, "Ability of Monophosphoryl Lipid A To Augment the Antibody Response of Young Mice," *Infection and Immunity*, 56:3064-66, 1988a.
- [767] Baker *et al.*, "Enrichment of Suppressor T Cells by Means of Binding to Monophosphoryl Lipid A," *Infection and Immunity*, 58:726-31, 1990.
- [768] Baker *et al.*, "Inactivation of Suppressor T-Cell Activity by Nontoxic Monophosphoryl Lipid A," *Infection and Immunity*, 56:1076-83, 1988b.
- 20 [769] Baker *et al.*, "Molecular structures that influence the immunomodulatory properties of the lipid A and inner core region oligosaccharides of bacterial lipopolysaccharides," *Infection Immunity*, 62:2257-69, 1994.
- [770] Baker *et al.*, "Structural Features That Influence the Ability of Lipid A and Its Analogs To Abolish Expression of Suppressor T Cell Activity," *Infection and Immunity*, 60:2694-701, 1992.
- 25 [771] Bakker *et al.*, "Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes," *J. Exp. Med.*, 179:1005, 1994.
- [772] Banchereau and Steinman, *Nature*, 392:245-51, 1998.
- 30 [773] Banerji *et al.*, "Membrane lipid composition modulates the binding specificity of a monoclonal antibody against liposomes," *Biochim. Biophys. Acta.*, 689:319-26, 1982.

- [774] Barnd *et al.*, "Specific tumor histocompatibility complex-restricted recognition of tumor-associated mucins by human cytotoxic T cells," *Proc. Natl. Acad. Sci. USA*, 86:7159, 1989.
- 5 [775] Barnoud *et al.*, *Am. J. Surg. Pathol.*, 24:830-36, 2000).
- [776] Bartlett and Zbar, *J. Natl. Cancer Inst.*, 48:1709, 1972.
- [777] Bast *et al.*, "BCG and Cancer," *N. Engl. J. Med.*, 290:1413-20, 1974.
- 10 [778] Bennett *et al.*, "Endogenous Production of Cytotoxic Factors in Serum of BCG-Primed Mice by Monophosphoryl Lipid A, a Detoxified Form of Endotoxin," *Journal of Biological Response Modifiers*, 7:65-76, 1988
- [779] Berkner, *Biotechniques*, 6:616-27, 1988.
- [780] Berra *et al.*, *Int. J. Cancer*, 36:363-66, 1985.
- [781] Berra *et al.*, *J. Neurochem.*, 40:777-82, 1983.
- [782] Bogoch, "Demonstration of serum precipitin to brain gangliosides," *Nature*, 183:392-93, 1960.
- 15 [783] Bouchon *et al.*, *Biochem. Internat.*, 10:531-38, 1985.
- [784] Bowen-Pope *et al.*, *Proc. Nat'l Acad. Sci. USA*, 81:2396-400, 1984.
- [785] Bowness *et al.*, "Clostridium perfringens enterotoxin is a superantigen reactive with human T cell receptors V beta 6.9 and V beta 22," *J. Exp. Med.*, 176:893-96, 1992.
- 20 [786] Brade *et al.*, "An Artificial Glycoconjugate Containing the Bisphosphorylated Glucosamine Disaccharide Backbone of Lipid A Binds Lipid A Monoclonal Antibodies," *Infection and Immunity*, 61:4514-17, 1993.
- [787] Brichard *et al.*, "The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas," *J. Exp. Med.*, 178:489, 1993.
- 25 [788] Brodin *et al.*, "Mouse monoclonal antibodies with specificity for the melanoma-associated ganglioside disialyllectosyl ceramide (GD3) also react with the structural analogue disialylparagloboside," *Biochim. Biophys. Acta.*, 837:349-53, 1985.
- [789] Brooks *et al.*, *Clin. Exp. Immunol.*, 39: 477, 1980.
- [790] Brown *et al.*, *J. Biol. Chem.*, 255:4980-83, 1980.
- [791] Burchell *et al.*, *J. Immunol.*, 131:508-13, 1983.
- 30 [792] Bystryn *et al.*, *Cancer*, 61:1065, 1988.

- [793] Cahan *et al.*, "Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2," *Proc. Natl. Acad. Sci. USA*, 79:7629-33, 1982.
- [794] Campbell *et al.*, "Intercellular adhesion molecule-1 expression by bladder cancer cells: functional effects," *J. Urol.*, 151:1385-90, 1994.
- 5 [795] Campbell, in *Monoclonal Antibody Technology, Laboratory Techniques in Biochemistry and Molecular Biology, Vol. 13*, Burden and Von Knippenberg (eds.), Amsterdam, Elseview, pp. 75-83, 1984.
- [796] Campbell *et al.*, *Int. J. Cancer*, 78:182-88, 1998.
- 10 [797] Carr and Morrison, "A two-step mechanism for the interaction of Re lipopolysaccharide with erythrocyte membranes," *Rev. Infect. Dis.* 6:497-508, 1984.
- [798] Carubia *et al.*, *Biochem. Biophys. Res. Commun.*, 120:500-04, 1984.
- [799] Chang *et al.*, *Crit. Rev. Oncol. Hematol.*, 22:213, 1996.
- 15 [800] Chase *et al.*, "Effect of Monophosphoryl Lipid A on Host Resistance to Bacterial Infection," *Infection and Immunity*, 53(3):711-12, 1986.
- [801] Chen *et al.*, "Activation of Macrophages From Aging Mice by Detoxified Lipid A," *Journal of Leukocyte Biology*, 49:416-22, 1991.
- [802] Chen *et al.*, *Cancer Res.*, 54:1065-70, 1994.
- 20 [803] Cheng *et al.*, "Bacillus Calmette-Gerin interacts with the carboxyl-terminal heparin bindings domain of fibronectin: implications for BCG-mediated antitumor activity," *J. Urol.*, 152:1275-80, 1994.
- [804] Cheresh and Klier, "Disialoganglioside GD3 distributes preferentially into substrate associated microprocesses on human melanoma cells during their attachment to fibronectin," *J. Cell. Biol.*, 102:1887-97, 1986.
- 25 [805] Cheresh *et al.*, "A monoclonal antibody recognizes an O-acetyl sialic acid in a human melanoma-associated ganglioside," *J. Biol. Chem.*, 259:7453-59, 1984.
- [806] Cheresh *et al.*, "Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytosis," *Proc. Natl. Acad. Sci. USA*, 82:5155-59, 1985.
- 30 [807] Cheresh *et al.*, "Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins," *J. Cell. Biol.*, 102:688-96, 1986.
- [808] Cheresh *et al.*, "Localization of gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells," *Proc. Natl. Acad. Sci. USA*, 81:5767-71, 1984.

- [809] Cheung *et al.*, "Detection of neuroblastoma cells in bone marrow using GD2 specific monoclonal antibodies," *J. Clin. Oncol.*, 4:363-69, 1986.
- [810] Chu and Sharom, "Gangliosides inhibit T-lymphocyte proliferation by preventing the interaction of interleukin-2 with its cell surface receptors," *Immunology*, 79:10-16, 1993.
- [811] Cohen, *Science*, 259:1691-92, 1993.
- [812] Colcher *et al.*, *Proc. Natl. Acad. Sci. USA*, 78:3199, 1987.
- [813] Coligan *et al.*, in *Current Protocols in Immunology*, Vol. 1, Wiley Interscience. Greene (ed.), 1998.
- [814] Coombes *et al.*, *Vaccine*, 14:1429-38, 1996.
- [815] Coulie *et al.*, "A new gene coding for a differentiation antigen recognized by autologous cytologic T lymphocytes on HLA-A2 melanomas," *J. Exp. Med.*, 180:35, 1994.
- [816] Deavin *et al.*, *Mol. Immunol.*, 33:145-55, 1996.
- [817] DeBruijn *et al.*, *Eur. J. Immunol.*, 21:2963-70, 1991.
- [818] Dippold *et al.*, "Immunohistochemical localization of ganglioside GD3 in human malignant melanoma, epithelial tumors and normal tissues," *Cancer Res.*, 45:3699-705, 1985.
- [819] Dippold *et al.*, "Inflammatory response at the tumor site after systemic application of monoclonal anti-GD3-ganglioside antibody to patients with malignant melanoma," *Am. Assoc. Cancer Res.*, 978:247, 1984.
- [820] Dippold *et al.*, *Proc. Natl. Acad. Sci. USA*, 77:6115, 1980.
- [821] Dresser and Phillips, in *Immunopotentiation*, CIBA Foundation Symposium 18, Elsevier, Amsterdam, p.3, 1973.
- [822] Dwivedi *et al.*, "Plasma lipid-bound sialic acid alterations in neoplastic diseases," *Experientia*, 46:91-94, 1990.
- [823] Elder, "Skin Cancer," *Cancer*, 75:245-56, 1995.
- [824] Elliott *et al.*, "The D-Galactosamine Loaded Mouse and Its Enhanced Sensitivity to Lipopolysaccharide and Monophosphoryl Lipid A: A Role for Superoxide," *J. Immunol.*, 10:69-74, 1991.
- [825] Euhus *et al.*, *Cancer Immunol Immunother.*, 29:247-54, 1989.
- [826] Fawwaz *et al.*, Statutory Invention Registration Patent No. H819, application no. 6-6-5,439, 1990.
- [827] Fischer, *Handb. Lipid Res.*, 6:123-234, 1990.

- [828] Fisher-Hoch *et al.*, *Proc. Nat'l Acad. Sci. USA*, 86:317-21, 1989.
- [829] Fitzgerald, "Syphilis vaccine: up-regulation of immunogenicity by cyclophosphamide, Ribi adjuvant, and indomethacin confers significant protection against challenge infection in rabbits," *Vaccine*, 9:265-72, 1991.
- 5 [830] Fleischmann, Park and Hassan, "Fibronectin expression on surgical specimens correlated with the response to intravesical bacillus Calmette-Guerin therapy," *J. Urol.*, 149:268-71, 1993.
- [831] Flexner *et al.*, *Ann. N.Y. Acad. Sci.*, 569:86-103, 1989.
- [832] Flexner *et al.*, *Vaccine*, 8:17-21, 1990.
- 10 [833] Foster *et al.*, *Cancer Res.*, 57:3325-30, 1997.
- [834] Fraizer *et al.*, *Blood*, 86:4704-06, 1995.
- [835] Fredman *et al.*, *Neurol. Res.*, 8:123-26, 1986.
- [836] Freimer *et al.*, "Gangliosides elicit a T-cell independent antibody response," *J. Autoimmun.*, 6:281-89, 1993.
- 15 [837] Freudenberg *et al.*, "ELISA for antibodies to Lipid A, Lipopolysaccharides and other hydrophobic antigens," *Infection*, 17:322-24, 1989.
- [838] Gaiger *et al.*, *Blood*, 96:1334, 2000
- [839] Garg and Subbarao, "Immune Responses of Systemic and Mucosal Lymphoid Organs to Pnu-Immune Vaccine as a Function of Age and the Efficacy of Monophosphoryl Lipid A as an Adjuvant," *Infection and Immunity*, 60:2329-36, 1992.
- 20 [840] Gaugler *et al.*, "Human gene MAGE-3 codes for an antigen recognized on a human melanoma by autologous cytolytic T lymphocytes," *J. Exp. Med.*, 179:921, 1994.
- [841] Gefter *et al.*, *Somatic Cell Genet.*, 3:231-36, 1977.
- 25 [842] Gennaro *et al.*, *Am. J. Ind. Med.*, 37:275-82, 2000.
- [843] Gillard *et al.*, "Antibodies against ganglioside GT₃ in the sera of patients with type I Diabetes mellitus," *J. Immunol.*, 142:3826-32, 1989.
- [844] Gillis, *Nature*, 268:154-56, 1977.
- [845] Glynn, McCoy and Fefer, *Cancer Res.*, 28:434-39, 1968.
- 30 [846] Goding, in *Monoclonal Antibodies: Principles and Practice*, 2d ed., Orlando, FL, Academic Press, pp. 60-61, 65-66, 71-74, 1986.
- [847] Goff *et al.*, *Eur. J. Biochem.*, 130:553-57, 1983.
- [848] Grabarek *et al.*, "Endotoxic Lipid A Interaction with Human Platelets," *The Journal of Biological Chemistry*, 265:8117-21, 1990.

- [849] Graus *et al.*, "Distribution of the ganglioside GD3 in the human nervous system detected by R24 mouse monoclonal antibody," *Brain Res.*, 324:190-94, 1984.
- [850] Guzman *et al.*, *Circulation*, 88:2838-48, 1993a.
- [851] Guzman *et al.*, *Cir. Res.*, 73:1202-07, 1993b.
- 5 [852] Hachida *et al.*, *Transplant Proc.*, 22:1663-70, 1990.
- [853] Hachida *et al.*, *Transplantation*, 56:479-82, 1993.
- [854] Harada *et al.*, *Mol. Urol.*, 3:357-364, 1999.
- [855] Hardings *et al.*, "Effects of pH and polysaccharides on peptide binding to class II major histocompatibility complex molecules," *Proc. Natl. Acad. Sci. USA*, 88:2740-44, 1991.
- 10 [856] Harel *et al.*, *Cancer Res.*, 50:6311, 1990.
- [857] Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988.
- [858] Hellling *et al.*, "Construction of Immunogenic GD₃-conjugate vaccines," *Ann. N. Y. Acad. Sci.*, 690:396-97, 1993.
- 15 [859] Hellstrom *et al.*, "Strong anti-tumor activities of IgG 3 antibodies to a human melanoma-associated ganglioside," *Proc. Natl. Acad. Sci. USA*, 82:1499-1502, 1985.
- [860] Hirabayashi *et al.*, "Syngeneic monoclonal antibody against melanoma antigen with interspecies cross-reactivity recognize GM₃, a prominent ganglioside of B16 melanoma," *Biol. Chem.*, 260:13328-33, 1985.
- 20 [861] Hirabayashi *et al.*, "Reactivity of mouse monoclonal antibody M2590 against B16 melanoma cells with chemically synthesized GM3 ganglioside," *Biochim. Biophys. Acta*, 875:126-28, 1986.
- [862] Hirabayashi *et al.*, *Jpn. J. Cancer Res.*, 78:614-20, 1987.
- 25 [863] Hoon *et al.*, "Gangliosides from melanoma immunomodulate response of T-cells to interleukin-2," *Cell Immunol.*, 4:1111-19, 1988.
- [864] Horibata and Harris, *Exp. Cell. Res.*, 60:61, 1970.
- [865] Horgan, "Total and lipid-bound sialic acid levels in sera from patients with Cancer," *Clin. Chim. Acta.*, 118:327-31, 1982.
- 30 [866] Houghten *et al.*, "Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: A phase I trial in patients with malignant melanoma," *Proc. Natl. Acad. Sci. USA*, 82:1242-46, 1985.
- [867] Houghton, "Cancer Antigens: Immune Recognition of Self and Altered Self," *J. Exp. Med.*, 180:1-4, 1994.

- [868] Hraba *et al.*, "The Influence of Monophosphoryl Lipid A (MPL™) on Erythrocyte Autoantibody Formation," *Immunobiol.*, 189:448-56, 1993.
- [869] Hunter *et al.*, *Vaccine*, 9:250: 1991.
- [870] Inoue *et al.*, *Blood*, 88:2267-78, 1996.
- 5 [871] Irie and Morton, "Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2," *Proc. Natl. Acad. Sci. USA*, 83:8694-98, 1986.
- [872] Irie and Ravindranath, "Gangliosides as targets for monoclonal antibody therapy of cancer," in *Therapeutic monoclonal antibodies*, Borrebaeck and Larrick (eds.), Stockton Press, New York, p. 75-94, 1990.
- 10 [873] Irie *et al.*, "Human antibody to OFA-I, a tumor antigen, produced *in vitro* by Epstein-Barr virus transformed human B-lymphoid cell lines," *Proc. Natl. Acad. Sci. USA*, 79:5666-70, 1982.
- [874] Irie *et al.*, "Melanoma gangliosides and human monoclonal antibody," in *Human Tumor Antigens and Specific Tumor Therapy*, Metzgar and Mitchell (eds.), Alan R. Liss, Inc., New York, pp. 115-126, 1989.
- 15 [875] Ishioka *et al.*, "MHC interaction and T cell recognition of carbohydrates and glycopeptides," *J. Immunol.*, 148:2446-51, 1992.
- [876] Jackson *et al.*, "Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy," *J. Clin. Pathol.*, 47:309-12, 1994.
- 20 [877] Johnson and Tomai, "A Study of the Cellular and Molecular Mediators of the Adjuvant Action of a Nontoxic Monophosphoryl Lipid A," *Adv. Exp. Med. Biol.*, 133:567-79, 1988.
- [878] Johnson *et al.*, "Characterization of a nontoxic monophosphoryl lipid A," *Rev. Infect. Dis.*, 9:512-16, 1987.
- 25 [879] Johnson *et al.*, "Structural Characterization of Monophosphoryl Lipid A Homologs Obtained from *Salmonella minnesota* Re595 Lipopolysaccharide," *J. Biol. Chem.*, 265:8108-16, 1990.
- [880] Johnston and Bystryn, "Effect of Cell Wall Skeleton and Monophosphoryl Lipid A Adjuvant on the Immunogenicity of a Murine B16 Melanoma Vaccine," *Journal of the National Cancer Institute*, 83:1240-45, 1991.
- 30 [881] Jones *et al.*, *J Natl Cancer Inst*, 66:249-54, 1981.
- [882] Kabat *et al.*, "Sequences of Proteins of Immunological Interest," 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD, pp 647-669, 1991.

- [883] Kass-Eisler *et al.*, *Proc. Nat'l Acad. Sci. USA*, 90:11498-502, 1993.
- [884] Katopodis *et al.*, "Lipid-associated sialic acid test for the detection of human cancer," *Cancer Res.*, 42:5270-75, 1982.
- [885] Kawaguchi *et al.*, "Characteristic mode of action of gangliosides in selective modulation of CD4 on human T lymphocytes," *Biochem. Biophys. Res. Commun.*, 158:1050-55, 1989.
- [886] Kawakami *et al.*, "Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor," *Proc. Natl. Acad. Sci. USA*, 91:3515, 1994.
- [887] Kawakami, Eliyahu, Sakaguchi, Robbins, Rivoltini, Yannelli, Appella and Rosenberg, "Identification of the immunodominant peptides of the Mart-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes," *J. Exp. Med.*, 180:347-52, 1994.
- [888] Kensil *et al.*, *J. Am. Vet. Med. Assoc.*, 199:1423, 1991.
- [889] Kloppel *et al.*, "Glycolipid-bound sialic acid in serum: Increased levels in mice and humans bearing mammary carcinomas," *Proc. Natl. Acad. Sci. USA*, 74:3011-13, 1977.
- [890] Kohler and Milstein, *Nature*, 256:495-97, 1975.
- [891] Kohler and Milstein, *Eur. J. Immunol.*, 6:511-19, 1976.
- [892] Kolls *et al.*, *Proc. Nat'l Acad. Sci. USA*, 91:215-19, 1994.
- [893] Koscielak *et al.*, "Glycolipid antigen and its antibody," *Immunochemistry*, 5:441-55, 1968.
- [894] Kovach *et al.*, "Lipid IV_A Inhibits Synthesis and Release of Tumor Necrosis Factor Induced by Lipopolysaccharide in Human Whole Blood *Ex Vivo*," *J. Exp. Med.*, 172:77-84, 1990.
- [895] Kwok and Higuchi, *Nature*, 339:237-38, 1989.
- [896] Kyogashima *et al.*, *Jpn. J. Cancer Res.*, 78:1229-32, 1987.
- [897] Ladisch *et al.*, "Shedding of GD2 ganglioside by human neuroblastoma," *Int. J. Cancer*, 39:73-76, 1987.
- [898] Lamm *et al.*, "A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder," *N. Engl. J. Med.*, 325:1205, 1991.
- [899] Lengle *et al.*, "Inhibition of the lectin-induced mitogenic response of thymocytes by glycolipids," *Cancer Res.*, 39:817-922, 1979.

- [900] Liepkalns *et al.*, *J. Neurochem.*, 36:1959-65, 1981.
- [901] Livingston *et al.*, "The Serologic Response to Meth A Sarcoma Vaccines After Cyclophosphamide Treatment is Additionally Increased by Various Adjuvants," *The Journal of Immunology*, 135(2):1505-09, 1985.
- 5 [902] Livingston *et al.*, "Approaches to augmenting immunogenicity of the ganglioside GM₂ in mice: purified GM₂ is superior to whole cells," *J. Immunol.*, 138:1524-29, 1987a.
- [903] Livingston *et al.*, "Vaccines containing purified GM₂ gangliosides elicit GM₂ antibodies in melanoma patients," *Proc. Natl. Acad. Sci. USA*, 84:2911-15, 1987b.
- 10 [904] Ljunggren *et al.*, *Nature*, 346:476-80, 1990.
- [905] Lozzio and Lozzio, *Blood*, 45:321-34, 1975.
- [906] Madonna and Vogel, "Induction of Early-Phase Endotoxin Tolerance in Athymic (Nude) Mice, B-Cell-Deficient (*xid*) Mice, and Splenectomized Mice," *Infection and Immunity*, 53:707-10, 1986.
- 15 [907] Mahvi *et al.*, *Immunology and cell Biology*, 75:456-60, 1997.
- [908] Maratea *et al.*, *Gene*, 40:39-46, 1985.
- [909] Masihi *et al.*, "Effects of Nontoxic Lipid A and Endotoxin on Resistance of Mice to *Toxoplasma gondii*," *Journal of Biological Response Modifiers*, 7:535-39, 1988
- 20 [910] Melling *et al.*, *J. Immunol.*, 117:1267-74, 1976.
- [911] Menssen *et al.*, *J. Cancer Res. Clin. Oncol.*, 126:226-32, 2000.
- [912] Merrifield, *J. Am. Chem. Soc.*, 85:2149-46, 1963.
- [913] Miller and Esselman, "Modulation of immune response by antigen reactive lymphocytes after cultivation with gangliosides," *J. Immunol.*, 115:839-43, 1975.
- 25 [914] Minden, "Shared Antigens Between Animal and Human Tumors and Microorganisms," in *BCG in Cancer Immunotherapy*, Lamoureux, Turcotte and Portelance (eds.); pp. 73-81, 1976.
- [915] Miotti *et al.*, *Cancer Res.*, 65:826, 1985.
- [916] Mitchell *et al.*, "Active specific Immunotherapy of melanoma with allogeneic cell lysates: Rationale, results and possible mechanisms of action," *Ann. N.Y. Acad. Sci.*, 690:153-66, 1993.
- 30 [917] Mitchell *et al.*, "Active specific immunotherapy of melanoma: Phase I trial of allogeneic lysates and a novel adjuvant," *Cancer Res.*, 48:5883-93, 1988.

- [918] Mitchell *et al.*, "Active-Specific Immunotherapy for Melanoma," *Journal of Clinical Oncology*, 8:856-59, 1990.
- [919] Miyake *et al.*, *Cancer Res.*, 48:6154-60, 1988.
- [920] Mooney *et al.*, "Bacterial superantigen signaling via HLA class II on human B lymphocytes," *Mol. Immunol.*, 31:675-81, 1994.
- [921] Morrison *et al.*, "Specific ganglioside binding to receptor sites on T lymphocytes that couple to ganglioside-induced decrease of CD4 expression," *Life Sci.*, 45:1219-24, 1989.
- [922] Morton and Ravindranath, in *Cancer Medicine*, 3rd ed., Holland *et al.* (eds.), Lea and Febiger, Philadelphia, p.967, 1993.
- [923] Morton *et al.*, "Polyvalent Melanoma Vaccine Improves Survival of Patients with Metastatic Melanoma," John Wayne Cancer Institute at Saint John's Hospital and Health Center, Santa Monica, California, reprinted from *Specific Immunotherapy of Cancer with Vaccines*, Volume 690 of the *Annals of the New York Academy of Sciences*, 1993.
- [924] Morton *et al.*, *Ann. Surg.*, 216:463, 1992.
- [925] Morton *et al.*, in *Biological Function of Gangliosides, Progress in Brain Research*, Vol. 101, pp 251-275, 1994.
- [926] Mosmann and Coffman, *Ann. Rev. Immunol.*, 7:145-73, 1989.
- [927] Munjal *et al.*, "Combined measurement and significance of lipid-bound sialic acid and carcinoembryonic antigen in detection of human cancer," *Diagn. Immunol.*, 2:36-43, 1984.
- [928] Murphy *et al.*, *Proc. Natl. Acad. Sci. USA*, 83:8258-62, 1986.
- [929] Myers *et al.*, "Monophosphoryl Lipid A Behaves as a T-Cell-Independent Type 1 Carrier for Hapten-Specific Antibody Responses in Mice," *Infection and Immunity*, 63:168-74, 1995.
- [930] Naiki *et al.*, "Properties of antisera to ganglioside GM₁ and Asialo GM₁," *J. Immunol.*, 113:84-93, 1974.
- [931] Nair *et al.*, *Nature Biotechnol.*, 16:364-69, 1998.
- [932] Natoli *et al.*, "A murine monoclonal antibody detecting the ganglioside GM2: Characterization of cell surface reactivity," *Cancer Res.*, 46:4116-20, 1986.
- [933] Nonomura *et al.*, *Hinyokika Kiyo*, 45:593-97, 1999.

- [934] Nudelman *et al.*, "Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody 4.2," *J. Biol. Chem.*, 257:12752-56, 1982.
- 5 [935] Odean *et al.*, "Involvement of Gamma Interferon in Antibody Enhancement by Adjuvants," *Infection and Immunity*, 58:427-32, 1990.
- [936] Oji *et al.*, *Jpn. J. Cancer Res.*, 90:194-204, 1999.
- [937] Old *et al.*, *Ann. N. Y. Acad. Sci.*, 101:80-106, 1962.
- [938] Pan *et al.*, *Leukemia*, 14:1634, 2000.
- [939] Parker *et al.*, *J. Immunol.*, 152:163, 1994.
- 10 [940] Pascal *et al.*, "Immunochemical studies on normal and Tay-Sachs' brain gangliosides," *Proc. Soc. Exp. Biol. Med.*, 121:739-43, 1966.
- [941] Patek, Collins and Cohn, "Transformed cell lines susceptible or resistant to *in vivo* surveillance against tumorigenesis," *Nature*, 276:510-11, 1978.
- [942] Patmasiriwat *et al.*, *Leukemia*, 13:891-900, 1999.
- 15 [943] Paul, *Fundamental Immunology*, 3rd ed., Raven Press, pp. 243-47, 1993.
- [944] Portoukalian *et al.*, "Humoral immune response in disease-free advanced melanoma patients after vaccination with melanoma-associated gangliosides," *Int. J. Cancer*, 49:893-99, 1991.
- [945] Portoukalian, "Alteration of gangliosides in plasma and red cells of human bearing melanoma tumors," *Biochem. Biophys. Res. Commun.*, 85:916-20, 1978.
- 20 [946] Portoukalian, "Immunoregulatory activity of gangliosides shed by melanoma tumors," in *Gangliosides and Cancer*, Oettgen (ed.), New York, VCH Publishers, pp. 207-16, 1989.
- [947] Powell and Newman (eds.), "Vaccine Design (the subunit and adjuvant approach)," Plenum Press, NY, 1995.
- 25 [948] Prokazova *et al.*, "Sialylated lactosylceramides. Possible inducers of non-specific immunosuppression and atherosclerotic lesions," *Eur. J. Biochem.*, 171:1-10, 1988.
- [949] Pukel *et al.*, "GD3, a prominent ganglioside of human melanoma: Detection and characterization of mouse monoclonal antibody," *J. Exp. Med.*, 155:1133-47, 1982.
- 30 [950] Qureshi *et al.*, "Purification and structural determination of nontoxic lipid A obtained from the Lipopolysaccharide of *Salmonella typhimurium*," *J. Biol. Chem.*, 257:11808-15, 1985.

- [951] Rabinovich *et al.*, "Vaccine Technologies: View to the Future," *Science*, 265:1401-02, 1994.
- [952] Raines and Ross, *J. Biol. Chem.*, 257:5154-60, 1982.
- [953] Rapport and Graf, "Immunochemical Reactions of Lipids," *Prog. Allergy*, 13:273-331, 1969.
- [954] Ravindranath and Irie, in *Malignant Melanoma: Biology, Diagnosis, and Therapy*, Nathanson (ed.), Kluwer Acad., Boston, p. 17, 1988.
- [955] Ravindranath and Morton, "Role of gangliosides in active immunotherapy with melanoma vaccine," *Int. Rev. Immunol.*, 7:303, 1991.
- [956] Ravindranath *et al.*, "Human melanoma antigen O-acetylated Ganglioside GD₃ is recognized by *Cancer antennarius* lectin," *J. Biol. Chem.*, 263:2079-86, 1988.
- [957] Ravindranath *et al.*, "An epitope common to gangliosides O-acetyl GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy," *Cancer Res.*, 49:3891-97, 1989.
- [958] Ravindranath *et al.*, "Ganglioside GM₃:GD₃ Ratio as an Index for the Management of Melanoma," *Cancer*, 67:3029-35, 1991.
- [959] Ravindranath *et al.*, "Efficacy of tumor cell vaccine after incorporating monophosphoryl lipid A (MPL) in tumor cell membranes containing tumor-associated ganglioside," *Experientia*, 50:648-653, 1994a.
- [960] Ravindranath *et al.*, "Attachment of Monophosphoryl Lipid A (MPL) to Cells and Liposomes Augments Antibody Response to membrane-bound Gangliosides," *Journal of Autoimmunity*, 7:803-16, 1994b.
- [961] Ravindranath *et al.*, "Factors affecting the fine specificity and sensitivity of serum antiganglioside antibodies in ELISA," *J. Immunol. Methods*, 169:257-72, 1994c.
- [962] Real *et al.*, "Class I (unique) tumor antigens of human melanoma. Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody," *J. Exp. Med.*, 160:1219, 1984.
- [963] Reeves *et al.*, *Cancer Res.*, 56:5672-77, 1996.
- [964] Reisfeld *et al.*, *Melanoma Antigens and Antibodies*, p. 317, 1982.
- [965] Ribi, "Beneficial modification of the endotoxin molecule," *J. Biol. Resp. Mod.*, 3:1-9, 1984.
- [966] Ribi *et al.*, "Lipid A and immunotherapy," *Rev. Infect. Dis.*, 6:567-72, 1984.

- [967] Ribi *et al.*, "Modulation of humoral and cell mediated immune responses by a structurally established nontoxic lipid A," in *Immunobiology and Immunopharmacology of Bacterial Endotoxins*, Szentivanji and Friedman (eds.), Plenum Press, New York, pp. 407-420, 1986.
- 5 [968] Rickman *et al.*, *Lancet* 337:998, 1991.
- [969] Rolland, *Crit. Rev. Therap. Drug Carrier Systems*, 15:143-98, 1998.
- [970] Rosenberg *et al.*, *Ann. Surg.*, 210:474, 1989.
- [971] Rosenberg *et al.*, *N. Engl. J. Med.*, 319:1676, 1988.
- [972] Rosenfeld *et al.*, *Science*, 252:431-34, 1991.
- 10 [973] Rothbard and Taylor, *EMBO J.*, 7:93-100, 1988.
- [974] Rott *et al.*, "Protection from experimental allergic encephalomyelitis by application of a bacterial superantigen," *Int. Immunol.*, 4:347-53, 1992.
- [975] Sato *et al.*, "Cytoplasmic membrane-associated protein (CAP) isolated from Streptococcus pyogenes: as a new bacterial superantigen," *Microbiol. Immunol.*, 38:139-47, 1994.
- 15 [976] Sato *et al.*, *Science*, 273:352, 1996.
- [977] Satoh *et al.*, *Pathol. Int.*, 50:458-71, 2000.
- [978] Schuster *et al.*, "Production of antibodies against phosphocholine, phosphatidylcholine, sphingomyelin, and lipid A by injection of liposomes containing lipid A," *J. Immunol.*, 122:900-05, 1979.
- 20 [979] Schwab *et al.*, "Superantigen can reactivate bacterial cell wall-induced arthritis," *J. Immunol.*, 150:4151-59, 1993.
- [980] Shafer and Spitznagel, "Sensitivity of *Salmonella typhimurium* to polymorphonuclear granulocyte extracts: Role of lipid A," *Rev. Infect. Dis.*, 6:577-81, 1984.
- 25 [981] Shepard *et al.*, *J. Clin. Immunol.*, 11:117-27, 1991.
- [982] Sherwin *et al.*, "The production of antisera to gangliosides from human nervous tissue," *Canad. J. Biochem.*, 42:1640-48, 1964.
- [983] Shimizu *et al.*, *Int. J. Gynecol. Pathol.*, 19:158-63, 2000.
- 30 [984] Shy *et al.*, "Antibodies to GM₁ and GD_{1b} in patients with motor neuron disease with plasma cell dyscrasia," *Ann. Neurol.*, 25:511-18, 1989.
- [985] Siddiqui *et al.*, *Cancer Res.*, 44:5262-65, 1984.
- [986] Sidell *et al.*, *Cancer Immunol Immunother.*, 7:151-55, 1979.
- [987] Sigma Cell Culture, Volume 9, Number 2, 1993.

- [988] Skeiky *et al.*, *Infection and Immun.*, 67:3998-4007, 1999.
- [989] Slavin and Strober, *Nature*, 272:624-26, 1977.
- [990] Spinsanti *et al.*, *Leuk. Lymphoma*, 38:611-19, 2000.
- [991] Stiess and Krüger, "Mammalian Cell Culture Media - Overview and Applications," *The Source* (Sigma Cell Culture Technical and Product News), 9:1-8, 1993.
- [992] Stoute *et al.* *New Engl. J. Med.*, 336:86-91, 1997.
- [993] Svennerholm *et al.*, "Tumor gangliosides as targets for active specific immunotherapy of melanoma in man," in *Biological Function of Gangliosides, Progress in Brain Research*, Vol. 101, 1994.
- [994] Tai *et al.*, "Ganglioside GM2 as a human tumor antigen (OFA-I-1)," *Proc. Natl. Acad. Sci.*, 80:5392-96, 1983.
- [995] Takada *et al.*, "Molecular and Structural Requirements of a Lipoteichoic Acid from *Enterococcus hirae* ATCC 9790 for Cytokine-Inducing, Antitumor, and Antigenic Activities," *Infection and Immunity*, 63:57-65, 1995.
- [996] Takahashi *et al.*, *J. Immunol.*, 140:3244, 1988.
- [997] Tamaki *et al.*, *Leukemia*, 13:393-99, 1999.
- [998] Tamauchi *et al.*, *Immunology*, 50:605, 1983.
- [999] Tanamoto, "Dissociation of Endotoxic Activities in a Chemically Synthesized Lipid A Precursor after Acetylation," *Infection and Immunity*, 63:690-92, 1995.
- [1000] Tanamoto, "Free Hydroxyl Groups Are Not Required for Endotoxic Activity of Lipid A," *Infection and Immunity*, 62:1705-09, 1994a.
- [1001] Tanamoto, *FEBS Lett.*, 351:325-29, 1994b.
- [1002] Tautu *et al.*, "Improved procedure for determination of serum lipid-associated sialic acid: Application for early diagnosis of colorectal cancer," *J. Natl. Cancer Inst.*, 80:1333-37, 1988.
- [1003] Thor *et al.*, *Cancer Res.*, 46:3118, 1986.
- [1004] Thurin *et al.*, "Proton NMR and fast-atom bombardment mass spectrometry analysis of the melanoma-associated ganglioside 9-O-acetyl GD3," *J. Biol. Chem.*, 260:14556-563, 1985.
- [1005] Timmerman and Levy, *Ann. Rev. Med.*, 50:507-29, 1999.
- [1006] Tomai and Johnson, "T Cell and Interferon- γ Involvement in the Adjuvant Action of a Detoxified Endotoxin," *Journal of Biological Response Modifiers*, 8:625-43, 1989.

- [1007] Tomai *et al.*, "The Adjuvant Properties of a Nontoxic Monophosphoryl Lipid A in Hyporesponsive and Aging Mice," *Journal of Biological Response Modifiers*, 6:99-107, 1987.
- [1008] Tsuchida *et al.*, *J. Dermatol.*, 11:129-38, 1984.
- 5 [1009] Tsuchida *et al.*, "Gangliosides of Human Melanoma: Altered Expression *in Vivo* and *in Vitro*," *Cancer Research*, 47:1278-81, 1987.
- [1010] Tsuchida *et al.*, "Gangliosides as tumor markers of human melanoma: biochemical and immunologic assays," in *New Horizons of Tumor Immunotherapy*, Torisu and Yoshida (eds.), pp. 315-325, 1989.
- 10 [1011] Tuting *et al.*, *J. Immunol.*, 160:1139-47, 1998.
- [1012] Ulmer *et al.*, *Science*, 259:1745-49, 1993.
- [1013] Vadhan-Raj *et al.*, *J. Clin. Oncol.*, 6:1636, 1988.
- [1014] van der Bruggen *et al.*, "A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma," *Science*, 264:716, 1991.
- 15 [1015] Verma *et al.*, "Adjuvant Effects of Liposomes Containing Lipid A: Enhancement of Liposomal Antigen Presentation and Recruitment of Macrophages," *Infection and Immunity*, 60:2438-44, 1992.
- [1016] Vijayasaradhi *et al.*, "The melanoma antigen gp75 is the human homologue of the mouse *b* (*brown*) locus gene product," *J. Exp. Med.*, 171:1375, 1990.
- 20 [1017] Von Bultzingslowen, *Pneumologie*, 53:266-75, 1999.
- [1018] Vosika *et al.*, *Cancer Immunol. Immunother.*, 18:107, 1984.
- [1019] Watson, Ralph, Sarkar and Cohn, "Leukemia viruses associated with mouse myeloma cells," *Proc. Natl. Acad. Sci. USA*, 66:344, 1970.
- [1020] Westrick *et al.*, *Biochim. Biophys. Acta*, 750:141-48, 1983a
- 25 [1021] Westrick *et al.*, *Cancer Res.*, 43:5890-94, 1983b
- [1022] Whisler and Yates, "Regulation of lymphocyte responses by human gangliosides. I. Characteristics of inhibitory effects and the induction of impaired activation," *J. Immunol.*, 125:2106-12, 1980.
- [1023] Wide *et al.*, in *Radioimmunoassay Methods*, Kirkham and Hunter (eds.), E. and S. Livingstone, Edinburgh, 1970.
- 30 [1024] Wilschut, "Preparation and properties of phospholipid vesicles," in *Methodologie des liposomes appliquee a la pharmacologie et a la biologies cellulaire*, Leserman and Barbet (eds.), INSERM, Paris, pp. 1-10, 1982.

- [1025] Yamaguchi *et al.*, "Cell-surface antigens of melanoma recognized by human monoclonal antibodies," *Proc. Natl. Acad. Sci. USA*, 84:2416-20, 1987.
- [1026] Yamamoto *et al.*, "In vitro Augmentation of Natural Killer Cell Activity and Production of Interferon- α/β and - γ with Deoxyribonucleic Acid Fraction from *Mycobacterium bovis* BCG," *Jpn. J. Cancer Res.*, 79:866-73, 1988.
- [1027] Yeh *et al.*, "A cell-surface antigen which is present in the ganglioside fraction and shared by human melanomas," *Int. J. Cancer*, 29:269-75, 1982.
- [1028] Yin *et al.*, "Effect of Various Adjuvants on the Antibody Response of Mice to Pneumococcal Polysaccharides," *J. Biol. Resp. Modifiers*, 8:190-205, 1989.
- [1029] Yokoyama *et al.*, "Immunochemical studies with gangliosides," *J. Immunol.*, 90:372-80, 1963.
- [1030] Zapata *et al.*, *Protein Eng.*, 8:1057-62, 1995.
- [1031] Zitvogel *et al.*, *Nat. Med.*, 4:594-600, 1998.
- [1032] All of the compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the composition, methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes. Accordingly, the exclusive rights sought to be patented are as described in the claims below:

WHAT IS CLAIMED IS:

1 1. An isolated polynucleotide as set forth in SEQ ID NOS: 1-3, 5, 7, 9,
2 11, 13-14, 16-17, 19-20, 22-25, 27-28, 30-31, 33-34, 36, 38-39, 41-42, 44, 46-47, 49, 51, 53,
3 55, 57, 59-60, 62, 64-65, 67-70, 72-73, 75, 77-81, 83, 85-86, 88-100, 102-103, 105-106, 108,
4 110-113, 115-116, 118, or 124 wherein said polypeptide encodes a polypeptide or an
5 immunogenic fragment thereof.

1 2. An expression vector comprising a polynucleotide of claim 1 operably
2 linked to an expression control sequence.

1 3. A host cell comprising an expression vector according to claim 2.

1 4. An immunoconjugate comprising an antibody that specifically binds to
2 a polypeptide or immunogenic fragment thereof encoded by a polynucleotide of claim 1.

1 5. The immunoconjugate of claim 4, wherein the antibody is linked to an
2 effector molecule.

1 6. The use, in the manufacture of a medicament, of an immunoconjugate
2 according to claim 4 as an active ingredient in a composition for treating cancer.

1 7. The method of claim 6, wherein the cancer is multiple myeloma cell.

1 8. The method of claim 6, wherein the cancer is chronic lymphocytic
2 leukemia.

1 9. An isolated polypeptide comprising an amino acid sequence as set
2 forth in SEQ ID NOS: 4, 6, 8, 10, 12, 15, 18, 21, 26, 29, 32, 35, 37, 40, 43, 45, 48, 50, 52, 54,
3 56, 58, 61, 63, 66, 71, 74, 76, 82, 84, 87, 101, 104, 107, 109, 114, 117, or 119-121.

1 10. An isolated antibody that specifically binds to a polypeptide of claim 9
2 or an immunogenic fragment thereof.

1 11. An immunoconjugate comprising an antibody as set forth in claim 10.

1 12. The immunoconjugate of claim 11, wherein the antibody is linked to
2 an effector molecule.

1 13. The immunoconjugate of claim 12, wherein the effector molecule is a
2 therapeutic moiety.

1 14. The use, in the manufacture of a medicament, of an immunoconjugate
2 according to claim 11 as an active ingredient in a composition for treating cancer.

1 15. The method of claim 14, wherein the cancer is multiple myeloma.

1 16. The method of claim 14, wherein the cancer is chronic lymphocytic
2 leukemia.

Outline of Microarray Chip Technology approach




FIG. 1

General protocol for *in-vitro* whole gene CD8 T cell priming





FIG. 2

General protocol for *in-vitro* whole gene CD4 T cell priming

**FIG. 3**

4/15

LEUKEMIA/LYMPHOMA CHIP #3: PROBES USED IN ANALYSIS

Cy3 Probe		Cy5 Probe	
Tissue	RNA#	RNA#	Tissue
Lymphoma, T cell	952	SPACT74	Kidney N
Lymphoma, B cell	955	SPACT81	Liver N
Lymphoma, B cell	953	SPACT78	Lung N
Lymphoma	916	SPACT42	Brain N
Lymphoma, Hodgkins	950	138598B	Skin N
Lymphoma, Hodgkins	950	SPACT49	Bone Marrow N
Lymphoma, B cell	CL151	888	PBMC resting
Lymphoma, T cell	904B	SPACT55	Stomach N
Lymphoma, Hodgkins see RNA 959	CL153	SPACT70	Thymus N
Lymphoma, B cell	CL152	SPACT75	Skeletal Muscle N
Lymphoma, B cell see RNA 958	CL155	SPACT73	Heart N
Lymphoma, B cell	944	243502B	Esophagus N
Lymphoma, B cell	958	1006	Colon N
Lymphoma, B cell	954	SPACT65	Small Intestine N
Lymphoma	960	779B	Trachea N
Lymphoma, T cell	957	S9327328	Bladder N
Lymphoma, B cell	914B		
Lymphoma, B cell	913		
Lymphoma, B cell	944B		
Lymphoma, B cell/failed	903		

GREEN: Tumor probes where gene expression would be desired.

RED: Normal essential tissue probes where gene expression is to be avoided.

BLACK: Normal tissue probes where gene expression is acceptable.

FIG. 4

Hematology Therapeutic Ab Candidates




FIG. 5

6/15

a. TMpred Report for Ly1484 Long

Date: 8/15/2001

RDFQSEVLLSAMELFHMTSGGDAAMFRDGKEPQPSAEAAAAPSLANISCF
 TQKLVEKLYSGMFSAADPRHILLFILEHIMVVTETASSORDIVLSTHYSSL
 NKVILLYCLSKPQOSLSECCLLLSILGFLOEEHDVVVFATYNSNISFLLCLM
 HCLLLNERSYPEFGLEPKPRMSTYHQVFLSPNEDVKEKREDLPSLSDV
 QHNIQKTVQTLWQQQLVAQRQQTLEDASFIDLSVKPGEREVKIEEVTPLWE
 ETMLKAQHYLASEKKSLASRSNVAAHSKVTLWSGSLSSAMKLMPGRQAK
 DPECKTEDFVSCIENCEYRRRGQELYASLYKDHVQRRKGCGNIKAANAWARIQ
 EQLFGELGLWSQGEETKPCSPWELDWREGPARMRKRIKRLSPLEALSSGR
 HKESQDKNDHISQTNNAENQDELTREAEGEPMDEVGVDCQLTFFPALHES
 LHSEDFLELCRERQVILQELLDKEKVTQKFSLVIVQGHILVSEGVLFLGHO
 HFYIGENFTLSPTCDVYCYTRHCLSNTSDPFLENLCSKDRSTDHYSCOGHS
 YADMRELROARFLLODIALEIFFHNGYSKFLVFYNNDRSKAFKSFCSFQP
 SLKGKATSEDTLNLRYPGSDRIMLQKWQKRDISNFYLMYLNTAAGRTC
 NDYMQYPVFPWVLADYTSETLNLANPKIFRDLSKPMGAQTKERKLKFQIR
 FKEVEKTEGDMTVQCHYYTHYSSAIIVASYLVRMPPFTQAFCALQCGSFED
 VADRMFHHSVKTWESASRENMSDVRLETPEFFYLPPEFLINCNGVEFGCMQ
 DCTVLDVOLPPWADGDPRKFISLHRKALESDFVSANLHHWIDLIFGYKO
 QGPAAVDAVNIEHPYFYGDRMDLSSITDPLIKSTILLGFVSNFGQVPKOLF
 TKPHIPARTAAKPLPGKDVTVPVSLPCHPOPFYSLQSLRPSQVTVKDMY
 LFSLCESESPKGATCHLVSTEKHTLAVERNKVLLPPLWNRTESWGDDFSC
 CLESYGGSDKVLMTFENLAACRCLCAVCPSPTHIVTSCTSTVVCVWELSM
 TKGRPRGLRLRQALYCHTOAVTCCLAASVIESLILVSGSQDCTCILWDLDHL
 THVTRLPAHREGTSATTISDVSGHTIVSCACAHLSLWNVNQPLASITTAW
 GPECAGTTCCCLMEGPAWDTISQJLITGSQDGMVRVWKTFEDVKMSVPGRPAG
 EEPLAQOPPSPRGHKWEKNIALSRELDVSTALTGKPSKTSPPAVTALAVSRN
 HIKLLVGDERGRTFCWSADG (SEQ ID NO: 10,847)

Black = Intracellular, Red = Transmembrane,

Blue = Extracellular

Ly1484 Long has 1269 amino acids and 5

Transmembrane Domains

Transmembrane Domain 1:	63 - 84	Score: 1.36675
Transmembrane Domain 2:	118 - 139	Score: 1.38695
Transmembrane Domain 3:	480 - 501	Score: 1.36185
Transmembrane Domain 4:	562 - 583	Score: 1.31785
Transmembrane Domain 5:	725 - 746	Score: 1.3521

FIG. 6

7/15

b. TMpred Report for Ly1484 (short)**Date: 8/20/2001**

MLQKWQKRDISNFEYLMYLNTAAGRTCNDYMQYPVFPWVLADYTSETLNL
ANPKIFRDL SKPMGAQTKERKLKFIQRFKEVEKTEGDMTVQCHYYTHYSS
AIIIVASYLVRMPPFTQAFCALQCCSEDVADRMFHVKSTWESASRENMSD
VRELLPPEFFYLPEELTNCNGVEECCMODCTVLCEDVOLPPWADGDPRKFIS
LHRKALESDFVSANLHHWQDLTFCYKQOCPAAVDAVNIEHPYFYCDRMDL
SSTIDPLTKSTILCFVSNFGQVPKQFLFKPHPARAAKPLPCKDVSTPV
SLPGHPQPEFFYSLQSLRPSQVTVKDMYLFSLCSESPKGATIHLVSTEKTI
LAVERNKVLLPPLWNR+FSWGDDFSCCLGSYGSDKVLMFENLAAWGRC
LCAVCPSPPTTIVTSGTSTVVGVWELSMFKGRPRGLRLRQALYGHTOAVTC
LAASVHFSLLVSCSQDCTCILWDLDHLLHVTRLPAHREGISATTISDVSC
TIVSCACAHLSLWNVNNGOPLASITTAWGPEGALTCCCLMECPAWDTISQII
ITCGQDEMVRWKTEDVKMSVPCRPAGEEPLAQPPSPRGHKWEKNLALS
ELDVSTALTEGPKSKTSPAVTALAVSRNHPKLLVGDERGRLEFCWSADG

(SEQ ID NO: 10,848)

Black = Intracellular, Red = Transmembrane,

Blue = Extracellular

Ly1484 has 646 amino acids and 1 Transmembrane Domains

Transmembrane Domain 1: 102 - 123 Score: 1.3521

FIG. 6 (cont.)

ANALYSIS RESULTS OF THE PROGRAM TSITES.

* * * * *

Mon, Aug 27, 2001 11:29:26 AM
These are the results of the analysis of the file--> LY1484~1.TXT
Beginning with residue: 1 and ending with residue: 1270
AMPHI Window size: 11

A-AMPHI mid points of blocks.
R-Residues matching the Rothbard/Taylor motif.
D-Residues matching the TAD motif.
G-Residues matching the IED motif.

EIGI 7

9/15

155 160 165 170 175 180 185 190 195 200 205 210 215 220 225
 HCLLLNERSYPEGFGLEPKPRMSTYHQVFLSPNEDVKEKREDLPSLSDVQHNTIQKTVQTLWQQQLVAQRQQTLED
AAAAA.AAAAAAA..... RRRR. R

230 235 240 245 250 255 260 265 270 275 280 285 290 295 300
 AFKIDLSVKPGEREVKIEEVTPWEETMLKAQHYLASEKKSLSRSNVAAHHSKVTLMSGSLSSAMKLMPGRQAK
 AAAA...AAAAAA. RRRRRRRRRRRRR. RRRRR. RRRRRR.

305 310 315 320 325 330 335 340 345 350 355 360 365 370 375
 DPECKTEDFVSCIENYRRGGQELYASLYKDHVQRRKCGNIKAANAWARIQEOLFGEGLWWSQGEETKPCSPWELD
 AAAA...AAAA. AAAA...AAAAAA. RRRR. RRRR. RRRR.

380 385 390 395 400 405 410 415 420 425 430 435 440 445 450
 WREGPARMRRIKRLSPLAEALSSGRHKESQDKNDHISQTNAENQDELTREAEGEDEVGVDCQLTFFPALHES
 AAAA...AAAAAA. RRRR. DDDDDD. dddd.

FIG. 7 (cont.)

10/15

FIG. 7 (cont.)

11/15

FIG. 7 (cont.)

12/15

FIG. 7 (cont.)

ANALYSIS RESULTS OF THE PROGRAM ITIES.

* * * * *

Mass Min 27 2001 10:31:51 AM

Mon, Aug 4, 2001 10:34:51 AM
These are the results of the analysis of the file--> LY1484~2.TXT
Beginning with residue: 1 and ending with residue: 647
AMPHI Window size: 11

A-AMPHI mid points of blocks.
R-Residues matching the Rothbard/Taylor motif.
D-Residues matching the IAD motif.
d-Residues matching the TID motif.

QID NO:	QID NO:	QID NO:	QID NO:
0,848) 5	MLQKWMOKRDISNFEYLINTAAGRITNDYMQYPVFPWVLADYTSETINLANEPKIFRDLSKPMGAOTKERKLKFI AAA.....	10 15 20 25 30 35 40 45 50 55 60 65 70 75 AAAAAAA.....	13/15
80	ORFKEVERKTKEGDMTVQCHYYTHYSSAITIVASYLIVRMPPEFTQAFCALLQGGSFEDVADRMFHSVKSTWESASRENMSD AAAAAAA.....	85 90 95 100 105 110 115 120 125 130 135 140 145 150 AAAAAA.....	
155	VRELTPEFFYLPEFLTNCGMVEFGCMQDGTVLGDVQLPPWADGDPRKFISLHERKALESDFVSAHLHWTDLIFGY AAA.....	160 170 175 180 185 190 195 200 205 210 215 220 225 AAA.....	

230 235 240 245 250 255 260 265 270 275 280 285 290 295 300
 KQQGPAAVDAVNIFHPYFYGDRMDLSSITDPLIKSTILGFVSNFGQVPKQLETKPHIPARTAAGKPLPGKDVSSTPV
 AAAA
 RRRR
 DDDDDD
 D D D D D D D D

 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375
 SLPGHPPQPFYFYSLLQSLRPSQVTVKDMYLFSLGSESPKGAIQHTVSTEKTTLAVERNKVLLPPPLMNRTFSWGFDFF
 AAAA
 RRRRRRRR RRRRRRRR RRRRRR RRRR RRRR
 DDDDDD
 D D D D D D D D

 380 385 390 395 400 405 410 415 420 425 430 435 440 445 450
 SCCLGSYGSDFKVLMTFENLAAWGRCLCAVCPSPTTIVTSGTSTWVCWELSMTKGRPRGLRLRQALYGHQTQAVTC
 AAAA
 RRRR
 DDDDDDDD DDDDDDDD DDDDDDD DDDDDDD DDDDDDD
 D D D D D D D D

 455 460 465 470 475 480 485 490 495 500 505 510 515 520 525
 LAASVTFSLLVSGSQDCTCILWLDHLTHVTRLPAHREGISAITISDVSGTIVSCAGAHLSLWNNGQPLASIT
 AAAA
 RRRRRR
 DDDDDD
 D D D D D D D D

FIG. 8 (cont.)

FIG. 8 (cont.)

INFORMAL SEQUENCE LISTING

<210> 1
<212> DNA
<213> *Homo sapiens*

<210> 2
<212> PRT
<213> *Homo sapiens*

<400> 2

2>Ly1728P, FOAP-12, full-length protein
MAGSPTCLTLIYILWQLTGSAAAGPVKELVGSVGGAVTFPLKSVKQVDSIVWTFNTTPLVTIQPEGGTI
IVTQRNRERVDFPDGGYSLKLSKLKKNDSGIYYVGIVYSSSLQQPSTQEYVLHVYEHLSKPVTMGLQSN
KNGTCVTNLTCMEEHGEEDVIYTWKALGQAANESHNGSILPISWRWGESDMTFICVARNPVSRNFSSPIL
ARKLCEGAADDPDSSMVLLCLLLVLPLLLSLFVLGLFLWFLKRERQEEYIEEKKRVDICRETPN1CPHSGE
NTEYDTIPHTNRTIILKEDPANTVYSTVEIPKKMENPHSLLTMPDTPRLFAYENVI

<210> 3
<212> DNA
<213> *Homo sapiens*

£400 > 3

3>Lv1732P, BCM, full-length cDNA

ttgttaagatattacttgtcccccaggctgttcttctgttagctcccttgaaaa
 gtgatcatgttcagatggctggcagtgcctccaaaatgaatatttgcacagtttt
 catgttcatacctgtcaactcgatgttcttctaataactcctctaaacatgtcag
 cgttattgtaatgcagaactgtgaccaattcgtgaaaggaaacgaatgcgattctggacc
 tggggactgactgttaataatttcttggcagttttcgtctaattttgtcaagg
 aagataagctgtgaaccattaaaggacgagttaaaacacaggatcaggtctctggc
 atggctaacattgacctggaaaagacgaggactgtgatgaaattatttccgagaggc
 ctgcgtacacggtaagaatgcacctgtgaagactgcataagagcaaccgaaggc
 gactctgaccattgtttcactccagctatggaggaaggcgaaccatttgcacc
 acgaaaacgaatgactattgcaagagcctgcagctgtttgactgtctacggagatagag
 aaatcaatttctgctaggttaatttaccatttcgactcgagcagtgcacattttaaaatct
 ttgtcagaatagatgttgcagatcttttaggtgactgtatttcagttgccga
 tacagttttgtcctctaactgtggaaactctttatgttagatatttctctaggtta
 ctggggagcttaatggtagaaacttccttggttatggattaaagtcttt

<210> 4
 <212> PRT
 <213> Homo sapiens

 <400> 4

4>Ly1732P, BCM, full-length protein
 MLQAGQCSQNEYFDSLLHACIPCQLRSSNTPPLTCQRYCNASVTNSVKGTNAILWTCLGLSLIISLAV
 FVLMFLLRKISSEPLKDEFKNTGSGLGMANIDLEKSRTGDEIILPRGLEYTVEECTCEDCIKSKPKVDS
 DHCFPPLPAMEEGATILVTTKTNDYCKSLPAALSAIEKSISAR

<210> 5
 <212> DNA
 <213> Homo sapiens

 <400> 5

5>Ly1888P, anti-Fas-induced apoptosis (TOSO), full-length cDNA
 ttgcactctagaaggacaatggacttctggcttggccacccatcttccgtatcgccccccctg
 aggatcctccccaaggtaaaggtagagggggagctggccggatcgttaccatcaagtggccacccatcttcc
 aaatgcattgtgaggatatatctgtccggggagatggctgtatcggaaacatgttgcgttatccac
 caccacactcatcaaggcagaatacaaggccggactctgttaccatcaaggcataccaccaagaatctgttc
 ctatggggatcacacagctgcacagaaaaggtagcagccggactctatgcctggagccggatcggacacag
 accggggaaagaccccaaggtaaaggactccctgaatgtccacagtgaaatacgcggccatcatggaaagacgc
 aatgcctgagactccaaatggtttcatctgccttatttgccttccagatgcctgcataatgccttcc
 aaattcgtaaaccagatgttaccacaccagctcaaaaggccggatgttcccttccagttaccactccctccccca
 ccacccaaatccccccggccctcgagtgccggatcttccatgcctgcataatgccttcc
 cctgcctccactacagcctcaaaatctcagctctggggggctgctcaagccccagacgccccagctac
 aaccaccacaccaggctgcacaggcagagactggactatggctcacagtctggggggaggccaaag
 gatttcacatctgtatccgaccatctggccctttctgttccatgcctggacttctggggctgttggaaaag
 ggccgttgaaggaggaaaggcccttcaggcggggccggactggccgttggatgcggccctggag
 agctcccgaggccccgggggtcgccgcggccactggccgttccaaaacaacatctcagccgttccggc
 gcgttgcggagccggacgtgcggaggcagggggaaaggccccgttccggccggagccgttcc
 cggccctgttgcggatgttgcataatctccctggccatgccttgcataatctgttgc
 agcccttaccaccaggccgtccgcctatgttgcggactgttgcggatgttgcataatctgttgc
 gacaactccccaggatcccccaacccaggctggactgttgcggatgttgcataatctgttgc
 ttccaataacctgttcatgttgcggatgttgcggatgttgcataatctgttgc
 tctatctgt

<210> 6
 <212> PRT
 <213> Homo sapiens

 <400> 6

6>Ly1888P, anti-Fas-induced apoptosis (TOSO), full-length protein
 MDFWLWPLYFLPVSGALRILPEVKVEGELGGSVTIKCPLEMVRIYLCREMAGSGTCGVVSTTNFIKA
 EYKGRVTLKQYPRKNLFLVEVTQLTESDGSVYACGAGMNTDRGKTQKVTLNVHSEYEPSWEEQPMETPK
 WFHLPYLFQMPAYASSSKFVTRVTPAQRGKVPPVHHSSPTTQITHRPRVRASSVAGDKPRTFLPSTTA
 SKISALEGLLKPKQTPSYNHTRLHRQRALDYGSQSGREGQGFHILIPТИLGLFLLALLGLVVRAVERRK
 ALSRRARRLAVRMRALESSQRPRGSPRPRSQNNIYSACPRARGADAAGTGEAPVPGPAPLPPAPLQVS
 ESPWLHAPSILKTSCEYVSLYHQPAAMMEDSDSDDYINVPA

<210> 7
<212> DNA
<213> *Homo sapiens*

<400> 7

<210> 8
<212> PRT
<213> *Homo sapiens*

<400> 8

8>Ly1452_His-tag-fusion, Old-SEQ-ID_10483, full-length protein
MQHHHHHHVQSSTVRQDSPVEPWEGISDHSGIIDGSPRLLNTDHPCQLDIRLMRHKA
VNPQDVQQQPQDLQSQVPAAGNSGTHFVTDAASPGSPSCLGDSLAEETLSEDDTSVG
SASP GSSEKSSSFSLSSTEVHMRPGYSHRVSLPTSPGILATSPY PETDSAFFEP
SHLT
SAADEGAVQVSRRTISSNSFSPEV FVL PVD VKE ENAHF YVADMI I SAME KMKCN
I LSQQQ
TESWSKEVSGLLGSDQPDSEMTFDTNIKQE SGSSTSSYSGYEGCAVLQVSPV
TETRTYHD
VKEICKCDVDEFVILELGDFNDITETCS
CSCSSSKSVTYEPDFNSAELLA
KELYRVFQK
WILSVVNSQLAGSLSAAGSIVVNEECVR
KDFESSMMNVQ
EIKFKSIRG
TEDWAPP
RQFQI
IFNIIHPPPLKRDLVVAAQNF
FCAGCGTPVEPKFVKRLRYCEYL
GKYFCDCC
HSYA
E
C
I
P
A
RILMWDFKKYVVSNFSKQLL
DSIWHQPIFNL
L SIGQSLYAK
AKE
LDRV
KEI
QEQLF
H
I
K
KL
LKT
CRF
ANS
AL
KE
FE
QV
PG
HL
TDE
LHF
SLED
LVR
I
KG
GL
A
PL
L
KD
I
K
L
A
S
H
V
A
G
C
E
L
C
Q
G
K
G
F
I
C
E
F
C
Q
N
T
V
I
F
P
Q
T
A
T
C
R
R
C
S
A
C
R
A
C
F
H
K
Q
C
F
Q
S
S
E
C
P
R
C
A
R
I
T
A
R
R
K
L
L
E
S
V
A
A
T

<210> 9
<212> DNA
<213> Homo sapiens

<400> 9

9>Ly1452P_LS_400351.4_Edited, splice-1, full-length cDNA
gggagccatagggtcaataactgcagtgtggggcttatggatgtggatgaagataagtggggaggttaca
gggacagcatcatgtcaggcctgagggcaagaatagtcctcagacccccagctggccatgtggtgagttcaggccca
aatcaagttagtaccacaatcgaaaactcttatctgtttgaatggattcacaccagccacaagccctggaaagatggtg
tcacaactacagtccaggatttcctgtggagccctggaaaggatcagcgatcactctggcatttgcattatgtatggttc
gcccagactcctgaacactgaccatcctccatggcaattagacatcaggctcatgaggcacaagctgtctggatataacc
cccaggatgtgcagcaacagcccaggacttgcacatctcagggtgcagcaggcaggaaacatggggaccattttgatgac
gtatgtgccttcctcaggcccttcacccatgtgcctggggactccctggcagagacaacatgtgtcaggataccac
agactccgttggcagcgttccccatgggtcagtagaaaagatgcagttctctgtcatttgcacatcaggatcaca
tggtcccccaggatcttcatgggtcagtagaaaagatgcagttctctgtcatttgcacatcaggatcaca
gacagtgttttttgcgcctccatgtacatctgtgtatgaaaggatttatgttgcacatcaggatcaca
ttcgaatccttcaccagaggatattgtgtcgttgcatttgcacatcaggatcaca
tgattatcagcaatggaaaaatgaagtgtaacatttgcacacagcagacagagactgggataaaaggatcag
gggttacttgggagtgatcagcgtactctaaatgactttgataccacataaagcaagactgtgggtcttctacttc
ttcatacagtggctatgaagggtgtgttacagtcagccactgtactgaaacacgtacttaccatgtgttgc
agatttgcacatgcgttgcatttttagatgttgcacatcaggatcaca
tcctgcagctcctctaagatgtcacttgcacatcaggacttgcacatcaggatcaca
gttccagaatgtgttgcacatgtcactgttgcacatcaggatcaca
atgaagatgtgttgcacatgttgcacatgttgcacatgttgcacatcaggatcaca
actgaagactgggttgcacatgttgcacatgttgcacatgttgcacatcaggatcaca
ccagaatttttctgtgcgcgtgttgcacatgttgcacatgttgcacatcaggatcaca
ggatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatcaggatcaca
aagtactacgtcacaatttgcacatgttgcacatgttgcacatgttgcacatcaggatcaca
ccaaagccgtatgcacatgttgcacatgttgcacatgttgcacatgttgcacatcaggatcaca
tgaagactgttaggttgcacatgttgcacatgttgcacatgttgcacatgttgcacatcaggatcaca
tttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatcaggatcaca
acatgtggctgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatcaggatcaca
ttcagacagcaacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgc
cggtgtgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgc
aaaagactgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgc
tatattaaaggaaaatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgc
gcacaggctgtatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgc
tttgtatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgc
gatgaatttactcaggatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgc
caaattgtttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgc
cacatttatttactcaggatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgc
tagcaggcgtgtggtccctgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgc
aacctgtatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgc
aggatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgc
tgattcttagtataacatataatcatgacatttgcacatgttgcacatgttgcacatgttgcacatgttgc
ttctaatagttcttatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgc
tgagaaaggggcctgtgggtccctgttgcacatgttgcacatgttgcacatgttgcacatgttgc
cattccctggatcatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgc
atgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgc
atgacttctgtcaatctctttcattcaggatgttgcacatgttgcacatgttgcacatgttgc
gtgttgcacatgttgcacatgttgcacatgttgcacatgttgcacatgttgc
cttc

<210> 10
<212> PRT
<213> *Homo sapiens*

<400> 10

10>Ly1452P_ls_400351.4_Edited, splice-1, full-length protein
MVSQSTVRQDSPVEPWEGISDHSGIIDGSPRLNTDHPPCQLDIRLMRHKA
VWINPQDVQQQPQDLQSQVPAAGNSGTHF
VTDAASPSPGPSPCLGDSLAAETLSEDTDSVGSASPHGSSEKSSFSLS
STEVHMVRPGYSHRVSPLTSPGILATSPYP
ETDSAFFEPSPHLSA
ADEGAVQVSRTI
SSNSFSPEVFVLPDV
KE
ENAHFYADMI
ISAME
KMCKN
ILSQQ
OTESWS
KE
VSGLLGS
DQPD
SEMT
FDTN
IQESGS
STSSYSG
YEGCA
LQVSP
TETR
YHDV
KE
ICK
CDV
DEF
V
I
LEL
GDF
FN
D
IT
ETC
SCSCSSSKV
TYEPDF
NSAELLA
KE
LAK
YRV
FQKC
WLSVV
NSQL
AGLS
SAAG
S
IV
NEEC
VRKD
FESS
MN
V
QE
IK
FK
SRI
RGTEDWAPP
RFQ
I
IFNI
HPP
KL
RDL
V
VAA
QN
FF
CAG
CG
CT
P
V
K
V
K
R
L
R
Y
C
E
Y
LG
KY
FC
DC
CH
CS
H
YA
E
SCI
P
A
R
I
L
MM
WD
FKK
YY
VS
NF
SK
QL
L
D
S
I
W
HQ
P
I
F
N
L
L
S
I
G
Q
S
LY
A
K
A
K
E
L
D
R
V
K
E
I
Q
E
Q
L
F
H
I
K
L
L
K
T
C
R
F
A
N
S
A
L
K
E
F
E
Q
V
P
G
H
L
D
E
L
H
L
F
S
L
E
D
L
V
R
I
K
K
G
L
L
A
P
L
K
D
I
L
K
A
S
L
A
H
V
A
G
C
E
L
C
O
Q
K
G
F
I
C
E
F
C
Q
N
T
T
V
I
F
P
F
Q
T
A
T
C
R
R
C
S
A
C
R
A
C
F
H
K
Q
C
F
Q
S
S
E
A
A
T

<210> 11

<212> DNA
 <213> Homo sapiens

<400> 11

11>Ly1452P, splice-2, FLJ21562, full-length cDNA
 cttctgtgttaccggagcgcggccacggAACGCTGCCGGAGCCCGCGGAGGGAGGACCCGACG
 CGCGCGTTACCCAGCAGCAGCTCCACCCTCGGGTTGGCTGGAAATAGCTCTCCAGACCCCCAGCTG
 GCGATGTGGTAGGTCAGGGCCAAATCAAGTAGTACCACTACAGTCAGGCAGGATTCTCCTGTGGAG
 GATTACACCAAGCCACAAGCCTGGAAAGATGGTGTACAACTACAGTCAGGCAGGATTCTCCTGTGGAG
 CCCTGGGAAGGGATCAGCAGTCACTCTGGCATTATTGATGGTTCGCCAGACTCCTGAACACTGACCATC
 CTCCTGCCAATTAGACATCAGGCTCATGAGGCACAAAGCTGTCTGGATTAAACCCAGGATGTGAGCA
 ACAGCCGCAAGGACTTGCAATCTCAGGTGCCAGCAGCAGGGAAACAGTGGGACCCATTGTGACAGATGCT
 GCCTCTCCCTCAGGCCCTCACCTCTGTGCCTCGGGACTCCCTGGCAGAGACAACGTTGTCTGAGGATA
 CCACAGACTCCTGGCAGCGCTTCCCCATGGCTCAGTAGAAAAGAGTAGCAGCTCTCTGTCTC
 AACAGAGGTACACATGGTCCCGCCAGGATACTCTCATCGGTGTCTGCCACAAGCCCTGGGATTTG
 GCCACCTCCCATACTCTGAGACTGACAGTCAGTGTCTTGTGAGCCTCCATCTGACATCTGCTGATG
 AAGGTGCTGTCAGTCAGTAGAAGAACCATTTCTGAATTCTCTCACCAGAGGTATTGTGCTGCC
 TGTGATGTAAGAAAAGGAAATGCCACTTTATGTTGAGATGATTATATCAGCAATGGAGAAAATG
 AAAGTGTAACTCTGAGTCACAGCAGACAGAGAGCTGGAGATAAGAAGTCAGTGGGTTACTTGGGAGTG
 ATCAGCCTGACTCTGAAATGACTTTGATACCAACATAAAGAACAGTCAGTGGGTTACTCTTCATA
 CAGTGGCTATGAAGGTTGTGCTGTACAGGTCAAGCCAGTGAACACAGTACTTACCATGATGTG
 AAAGAGATTGCAAATGCGATGTTGATGAATTGTTAGAGCTTGGAGATTAAATGATATCACAG
 AAACCTGTAGCTGTCTCGAGCTCCTCTAAGAGTCAGTCAGTATGAGCCAGACTTCAGTCAGAAGCT
 ATTGCGAAAGAGCTGTACCGCGTGTCCAGAAGTCAGTCAGTTAATTCTCAGCTGGCA
 GGTCCCTGAGTCAGCTGGCTCGATAGTCGTAATGAAGAGTGTCCGAAAGAGCTTGAATCCAGTA
 TGAATGTTAGGATCAGAGGACTGAAGACTGGCTCTCTAGATT
 TCAAATCATTTAATATTCATCCACCACTCAAGAGGGACCTTGTGGTGGCAGCCAGAAATTTCTGT
 GCCGGCTGTGAACTCCAGTAGAGCCTAAGTTGTGAAGCGCTCCGGTACTGCGAATACCTAGGGAGT
 ATTCTGTACTGCTGCCACTCATATGCAAGAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAG
 CAAGAAGTACTACGTCAAGCAATTCTCCAACAGCTGTCGACAGCATATGGCACCAGCCCATTCAAT
 TTGCTGAGCATCGGCCAAAGCCTGTATGCGAAAGCCAAGGGACTGGACAGAGTGAAGGAAATTCAAGGAGC
 AGCTCTCCATATCAAGAAGCTGTGAAGACCTGTTGCTAACAGTCAGTCAGTCAGGAAAGGGCTT
 ATTGTGAATTTCAGGAAATACGACTGTCATCTTCCATTTCAGACAGCAACATGAGTCAGATGTT
 CGTCAGGGCTTGTTCACAAACAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAGTCAG
 GAGGAGAAAACCTCTGGAAAGTGTGGCTCTGCAAGCAACATGATGCCCCCTGAGTCAGTGTGAAAGAGCTG
 TTCAACATGCTTATGATAACACCGATTGTGTTATTGTTGAGCATATTGGTATTGTTAGATATTGGTATTG
 TATATTAGGAAAAGATGGTCTATATTCTCTTATTGCAATATACTTAATGTTCAAAAGAATGAGCAGATT
 CTGTGTTAAAGCACAGGGCTGATAGTTGTGTTTACAATGTTCTGTTGCTGCTATTGGT
 TTAAAGAGGTTTATACTTGATTGAAATAGTTGTTACTGATGCTGAGCCAGTTGTATGT
 GTGTGATATATGTAACGTAACAGATGAAATTCTGTTCTCTAAAGCTTGTGTTGA
 TGAAGACTGGTGGCCTTCAGTGAACAAAAATGACCCCAA

<210> 12
 <212> PRT
 <213> Homo sapiens

<400> 12

12>Ly1452P, splice-form-2, FLJ21562, full-length protein
 MVSQSTVRQDSPVPEWEGISDHSGIIDGSPRLLNTDHPPCQLDIRLMRHKA
 WINPQDVQQQPQDLQSQVPAAGNSGTHFVTDAASPSGPSPSCLGD
 SLAETTLSED
 TTDVGSA
 PHGSSEKSSSFSL
 SSTEVMVRPGYSHRVSLPTSPGILATSPYPETDSAFFEP
 SHLTS
 AADEGA
 VQVS
 RRTISSNSFSPEVFVLP
 DVKE
 NAH
 FYVADMI
 ISAMEKM
 KCN
 ILSQQQTE
 WS
 KEV
 SG
 LLG
 SD
 QPD
 SEMT
 FDTNI
 KQESG
 SSTSSY
 SG
 YEGCAVL
 QVSPV
 TE
 TRY
 HDV
 KE
 CKCDV
 DEF
 VILE
 LGDFND
 IT
 ET
 CSC
 C
 SSS
 K
 SV
 YEP
 PDF
 NSAE
 LAKELY
 RVF
 QK
 CWI
 LS
 VV
 N
 SQL
 A
 G
 S
 IV
 V
 NE
 E
 C
 VR
 K
 DF
 E
 SS
 MN
 V
 Q
 E
 I
 K
 F
 K
 S
 R
 IR
 G
 T
 ED
 W
 APP
 PR
 FQ
 II
 F
 NI
 H
 PP
 L
 K
 RD
 LV
 V
 AA
 Q
 N
 FF
 C
 A
 G
 C
 G
 T
 P
 E
 P
 K
 F
 V
 K
 R
 L
 R
 Y
 C
 E
 Y
 L
 G
 K
 Y
 F
 C
 D
 C
 C
 H
 S
 Y
 A
 E
 S
 C
 I
 P
 A
 R
 I
 L
 M
 M
 W
 D
 F
 K
 K
 Y
 Y
 V
 S
 N
 F
 S
 K
 Q
 L
 D
 S
 I
 W
 Q
 P
 I
 F
 N
 L
 L
 S
 I
 G
 Q
 S
 L
 Y
 A
 K
 A
 E
 L
 D
 R
 V
 K
 E
 I
 Q
 E
 Q
 L
 F
 H
 I
 K
 K
 L
 L
 K
 T
 C
 R
 F
 A
 N
 S
 C
 V
 K
 E
 R
 A
 L
 F
 V
 N
 F
 A
 R
 I
 L
 R
 C
 V
 Y
 V
 W
 C
 V
 Y
 Y
 W

<210> 13
 <212> DNA
 <213> Homo sapiens

<400> 13

13>Ly1462P, Old-SEQ-ID_6411, partial cDNA
ctggttcacgtgtggagctagttaatacgtcctgccaagatggtaccaggacttgac
atgcttatcagatgtgtcaagatgctaaaaatggatttgttcaaaaagattccactt
qtaaaqtatccactgcaccctccacca

<210> 14
<212> DNA
<213> Homo sapiens

<400> 14

14>Ly1462P, Human Epstein-Barr virus complement receptor type II(cr2)_full-length
ccagagctggcggacgctcgccgggttcggaaacgcattccgcgcggggcttcggccgttgcattggcatggcg
ccggggccttcgggttttcttgctcgtcgaccggggcttcggatatttttgcatttcggat
tccgcctatcttaatggccgatttagttatttctaccatctgttgcatttgcataactaaagacaaagtggat
agttgttcaggatccgcattggagaaaaaagtctattatgcataactaaagacaaagtggat
gaacctggataaacctgtccataatgtgaatattcaataatattcttcggccctgagccat
accaggaggatacaaattagaggctcacaccacagacatggtattctgtgacattgcctgtaaa
accaacttccatgaacggaaacaagtctgttgcatttgcagcaataatatgtggggccgacacgac
taccaacctgtgtaaatgtttccctctcgagtgccagcacccatgcataatggacatcac
aagtggaaatgttggctccattgtccaggatgtctgtactacagctgtgaatctggattactgtt
gttggagaaaagatcattaaactgtttgtctcgggaaatggaggctgtgtccccccacatgtgaagagg
cacgctgtaaatcttaggacgatcccaatggggaaaggacccatgttgcatttgcgtgttgcatttgc
aactgcaaaacttttgcatttgcatttgcactgtcaaggccccacccatgttgcgtgttgcatttgc
ggcaggaggatgttggccatggggatgttgcatttgcactgtcaaggccccacccatgttgcgtgttgcatttgc
tcaatggaaagacatataaggcaactcactagcaaatgtctcatatgttgcatttgcactgttgc
cccggaccaggaggatgttgcacttgcatttgcatttgcactgttgcatttgcactgttgc
cagaagactgggacttgcatttgcatttgcatttgcactgttgcatttgcactgttgc
atcccaatgttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgc
atttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgc
gagccatctgcaccaggatgttgcatttgcatttgcatttgcatttgcatttgcatttgc
atagacacatggtccgcttgcatttgcatttgcatttgcatttgcatttgcatttgc
gggagaagaatccatcactgttgcatttgcatttgcatttgcatttgcatttgcatttgc
gcgtgtgaagctacaggaaacttgcatttgcatttgcatttgcatttgcatttgc
cttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgc
tatggagattgttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgc
gggatgttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgc
gatgttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgc
gatgttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgc
gatgttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgc
gatgttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgc
ttgtgaaaaaggctgcatttgcatttgcatttgcatttgcatttgcatttgcatttgc
tttgctctggatgtactgttagactacacttgcatttgcatttgcatttgcatttgc
actgtatgcatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgc
gatgttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgc
gatgttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgc
tttgacttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgc
gtaaaggatgttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgc
cttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgc
agtgcatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgc
ctaatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgc
gtatgttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgc
tgggtgccaggatgttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgc
acgggaaccatacttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgc
aggctacacttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgc
catttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgc
aatgttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgc
gagccatgttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgc
gttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgc
caaaccacatggatgttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgc
agtatatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgc
tggatgttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgc
gatcaatgttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgc
taaagatggggaggccatgttgcatttgcatttgcatttgcatttgcatttgcatttgc
ctgaaggccaggccatgttgcatttgcatttgcatttgcatttgcatttgcatttgc
aagagctgttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgc
ttataatgttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgcatttgc

gaagtatggtttatttgatagtagcttcctcgtggtaatcattcgttttacccttac
cttcgatttgagttctcacattactgtatataacttgcctccataatcaactcagtgttgcatt
tgcacaagtttttaattatggaatcaagatataacttgccttagagatttggtgtacaattcaggcttgc
gatgttttttagcagtggataagtttagttgtaaaatttacttaataatgtgtacatta
gtcattcaataaaattgttaattgtaaagaaaaacat

<210> 15
<212> PRT
213 Name: *canis*

<400> 15

15>Ly1462P, CR2/CD21/C3d/Epstein-Barr virus receptor, full-length
MGAAGLLGVFLALVAPGVLGISCSPPPILNGRISYSTPIAVGTVIRYSCSGTFRLIGEKSLLCITKDK
VDGTTWDKPKAPKCEYFNKYSSCPEPIVPGGYKIRGSTPYRHGDSVTFACTNFMSMNGNKSVWCQANNMWGP
TRLPTCVSVFPLECPALPMIHNCHHTSENVSIAPGLSVTYSCESGYLLVGEKIINCLSSGKWSAVPPTC
EEARCKSLGRFPNGKVKEPPILRUGVTANFCDEGYRLQGPPSSRCVIAGQGVAWTKMPVCEEIFCPSP
PILNGRHIGNSLANVSYSGSIVTYTCDPDPEGVNFILIGESTLRCVTDQSQTGTWSGPAPRCELSTS
CPHPQIILRGRMVSGQKDRTYNTDVIFACMFGFTLKGSQIIRCNAQGTWEPSAPVCCEKECQAPPN
KEDRHMVRFDPGTSIKYSCNPYGVLVGEESIQCTSEGWTTPVPCQKVAACEATGRQLLT
KPKHQFVRPDVNSSCGEGYKLSGSVYQECQGTIPWFMEIRLCKEITCFFPPVIIYNGAHTGSSLEDF
PYGTVTYYTCNPFG
ERGVEFSLIGESTIRCTSNDQERGTWSGPAPLCKLSSLAVQCSHVHIANGYKISGKEAPYF
YNGAHTGSSLEDFPYGTVTYYTCNPFG
YSGFTLKGSQIRKCADNTWDPEIPVCEKETCQHVRSQSLQEPAGSRVELVNTSCQDGYQLTG
HAYQMCQ
DAENGIWFKKIPLCKVHCHPPPVIVNGKHTGMMAENFLYGN
EVSYECDQGFYLLGEK
KLCRSDSKGHG
SWSGPSQCLRSPPVTRCPNPEVKHGYKL
NKNTHSAYSHNDI
VYVDCNPGFIMNGSRVIRCHTDNTWPGV
PTCMKKAFIGC
PPPPKTPNGNHTGGNIARFSPGMSILYSCDQGYLLVGEALLLCTHEGTWSQ
PAPHC
KEV
NCSSPADMDGIQKGLEPRKMYQYGA
VVTLECEDGYMLEG
SPQSQCSDHQWNPL
AVCRSRSLAPVLC
G
AAGLILLT
ELIVITLYV
ISK
H
R
E
R
N
Y
Y
T
D
T
S
Q
K
E
A
F
H
L
E
A
R
E
V
Y
S
V
D
P
Y
N
P
A
S

<210> 16
<212> DNA
<213> Homo sapiens

<400> 16

16>Ly1484P, Old-SEQ-ID_10493, partial cDNA
ctgggcaanaccaagtacagttccagcgtgctgcgtggccctccgagtggtgtgtgc
atccctttcatagaagtccatmkgsatggagagggttgggctgcaragctgwgattgc
cagaggcccttccttgagaactgtgggaaggaggccctggggtttctgttaggcag
agctcaggccccagtcacctctgccaccctcagcctggcactgttgtgccagagccctcg
ctgcctctcttcaccatctgcagacccaggcagaatattctcccccctctcatcacca
accaggagtttgggtgtggttctggacacggccagacggcagactcactgcggggctgttgc
ctgggctccctgtcaaaagcaatgtcaacgtccagctctgcactcaaggccagggttctc
tcccaactgtggcccttgggttggggctggaggttgcggccagggttgcggccgt
ccaggaacagacatctcacatctcagttccaaacccggaccatggcgttgcact
ccggtgatgtatgttgcgtgtgtccatgtggccctccatcaggcagcaacagggtt
atqgctcttcctggcccccaggctgtgtgtatgttgc

<210> 17
<212> DNA
<213> *Homo sapiens*

<400> 17

tccaaacacaacatccagaagacagtgcagactctctggcagcagctggcacaaggc
 agcagaccctggaggatgcctcaagatcgatctctgtgaaacctggagagaggaaag
 tgaagattgaagaggtcacaccgctctgggaggagacgtgccttcacggcggcaggatt
 acttagcatctgagaagaagtcaactggcaagtcgttcaaattgtgcacaccacagcaaag
 tcactttgtgagtgaaagccctgtccatcagccatgaagctgtatgcggccggcaggcca
 aggaccctgtgagtgcaagacagaggatttgtcatgtataagaactacagaagaagag
 gacaagagctatatgcacatcttataaaaagaccatgtcaaaaggcggaaaatgtggcaaca
 tcaaggcagccaacgcctggccaggatccaggcagctttttggggagctggcctgt
 ggagccaggggaaagaaaaccacggccctgttcccatgggaaactcgactggagagaaggac
 cagtcgaatgagggaaacgcataaacgcgtgtctcccttgaggccctgagctcaggaa
 ggcacaaggaaagccaagacaaaaatgtatcatatttcacaaacaatgtgaaaaccaag
 atgaactgacactgagggaggctgagggcgagccggacgaggtgggggtggactgcaccc
 agctgaccttctccacccggcttacacggaaagctgtcactcagaagacttcttggaaactgt
 gtcgggaaagacaagttatcccacaaagagcttcttgcataaaagaaaagggtacgcagaag
 ttccctgtgtgtcaggggccacctgtgtcagaagggttgcattttggccacc
 aacacttctacatctgcgagaacttcacactgtctccacgggtatgttactgtaccc
 gtcaactgttatccaaacatcagcgatcgttcatttcaactgtcagcaaaagacaggt
 ccactgaccattactcgtgccagtgcacagctacgctgacatgcggagactacggcagg
 ctgcgttccctctgcaggacatgcggctggagatcttccacaatggatattcaag
 ttcttgttttctacaacaatgtcgagtaaggcctttaaaagcttctgtctttcaac
 ccagcctgaagggaaagccacccctggaggacaccctcaatctaaggagataccccc
 ctgacaggatcatgtcagaagtgccagaaaaggagatcagcaattttgagtatctca
 tgtacctcaacaccgcggctgggagaacctgcaatgactacatgcagttccagggttcc
 cctgggtcctcgagactacacccctcagagacatgtgcaaaatccgaaagatttcc
 gggatcttcaaagcccatggggctcagaccaaggaaaggagactgtgaaattttatccaga
 ggtttaaagaagtgtgaaaaactgaaggagacatgactgtccagtgccactacaccc
 actacttcggccatcatcgtggcttctacctggcgttgcacgtggcagacagaatgttcc
 cttctgcgtctgcaggcggaaagcttcacgtggcagacagaatgttccacagtgta
 agagcacgtggagtcggctccagagagaacatgtgactgtcagtgccggagactgcccc
 agttcttctacactgtcgactgtcgactgtcgactgtcgactgtcgactgtcgatgc
 aggacgggactgtcgactgtcgactgtcgactgtcgactgtcgactgtcgactgtcg
 aattcatcagcctgcacagaaaggccctggaaagtgactttgtcagtgccaaaccc
 attggatagaccttattttgggtacaaggcagcaggggccacccgcactggatgttta
 atatcttcacccctacttctacggtgacagaatggacactcagcactgtcgactgtcc
 tcatcaaagcaccatcgtgggtttgtcgactgtcgactttggacaggctctgcctgg
 ttacccaaacccatcgtgggtttgtcgactgtcgactgtcgactgtcgactgtcg
 ccaccccccgtgagcgtcgactgtcgactgtcgactgtcgactgtcgactgtcg
 ggccttcgggttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgt
 aaggggccatggccacattgtctactgagaagaccattgtcgactgtcgactgtcg
 aagtgtcgactgtcgactgtcgactgtcgactgtcgactgtcgactgtcgactgtcg
 gctgttggggagctacggctccgacaaggctgtcgactgtcgactgtcgactgtcg
 gggggccgtgtgtcgccgtgtgcccattcccaacaacgattgtcacctctggacca
 gcactgtgggtgtgtgtggagactcagcatgacccaaaggccggccgggggttgcgc
 tccggcaggcctgtatggacacacacaggctgtcgactgtcgactgtcgactgtcg
 tcagcctccctgtgagcgtcccaggactgcacctgtatccgtggatctggaccacc
 tcacccacgtgacccgcctgcggccatcgggaaaggcatcgtccatcaccatcagt
 acgtctcaggcaccattgtctctgtcgccggagcacactgtccctgtggatgtcaatg
 gacagccccctggccaggcatcaccacgcctggggcccaaggagggccataacctgtcg
 gctgtatggggccaggcatgggacacaaggccatcatcgtccatcaccggagtcagac
 gcatggtccgggttggaaagactgaggatgtgaagatgtcgactgtcgactgtcg
 gagaggagccctggctcagccaaaggccacaaggccatgtgggagaagaacctgg
 ccttgcgtcgactgtcgactgtcgactgtcgactgtcgactgtcgactgtcgactgt
 ccgcgtgcgtcgactgtcgactgtcgactgtcgactgtcgactgtcgactgtcg
 gggggagaatattgtcgactgtcgactgtcgactgtcgactgtcgactgtcgactgt
 gcacaaacagtgcctggggactgtcgactgtcgactgtcgactgtcgactgtcg
 agaaaaccccccaggccctccctcccaacaggatctcaaggaaaggcccttggcaat
 tctgcagccccacccctctccatggccatggggacttctatgaaaaggatgagcac
 ctcggagggtcgactgtcgactgtcgactgtcgactgtcgactgtcgactgtcg
 attacacatgactcaccttataaggctattgtcgactgtcgactgtcgactgtcg
 cttactgtggaaattattgtattgtctttatattaaagcaactatgtttt

<210> 18

<212> PRT

<213> Homo sapiens

<400> 18

18>Ly1484P, KIAA1607, full-length protein

MNISSRDNAMPVFLRLNCAGHLSGLRTIGAVAVGQLGVRFHSSPAASSLDFIGGPAIILGLISLATDD
 HTMYAAVKVLHSVLTNSACDFLMQHICGYQIMAFLLRKKAISLNHRIFQLILSVAGTVELGFRSSAITN
 TGVFQHILCNFELWMNTADNLLELSFHLLEILOSPREGPRNAEAAHQALIPKLIFLFNEPSLIPSKIP
 TIIGILACQLRGHFSTQDLRIGLFVVYTLKPSSVNERQICMDGALDPSLPAGSQTSGKTIWLRNQLLEM
 LLSVISSPQLHLSSESKEEMFLKLGPWFLLLQGHLHASTVLAALKLLYFLASPSLRTFRDGLCAGS
 WVERSTEGVDIVMDNLKSQSPPLPEQSPCLLPGFRLVNDFLAHHVHIEPVYLVISTFFLQTPTELMGPK
 DSDLAMLQWLQRHHQEEVLQAGLCTEGALLLLEMLKATMSQPLAGSEDGAWAQTFPASVLQFLSLVHRT
 YPQDPAWRAPEFLQTLAIAAFPLGAQKGVAESTRNTSSPEAAAEGDSTVEGLQAPTKAHPARRKLREFT
 QLLRELLLGASSPKOWLPLEVLLLEASPDHATSQQKRDFQSEVLLSAMELFHMTSGGDAAMFRDGKEPQP
 SAEEAAAAPSLANISCFTQKLVEKLYSGMFSADPRHILLFILEHIMVVIETASSQRDTVLSTLYSSLNKVI
 LYCLSKPQQSLSECLGLLSILGFLQEHWDVVVFATYNSISFLLCLMHCLLLNERSYPEFGGLEPKPRMS
 TYHQVFLSPNEDVKEKREDLPSLSDVQHNQKTVQTLWQQLVAQRQQTLEDASFIDLSVKPGEREVKIEE
 VTPLWEETMLKAWQHYLASEKKSLASRSNVAHHSKVTLWSGSLSAMKLMGRQAKDPECKTEDFVSCIE
 NYRRRGQELYASLYKDHVQRKCGNIKAANAWARIQEQLFGEGLGLWSQGEETKPCSPWELDWREGPARMR
 KRIKRLSPLEALSSGRHESQDKNDHIISQTNNAEQNDETLREAEPEGDDEVGVDCQLTFFPALHESLHSE
 DFLELCRERQVILQELLDEKVTQKFLSIVVQGHLVSEGVLFFGHQHFYICENFTLSPTGDVYCTRHCLS
 NISDPFI FNLCSKDRSTDHYSCQCHSYADMRELQRARFLQDIALEIFFHNGYSKFLVFNNDRSKAFKS
 FCSPQPSLKGKATSEDTLNLRYPGSDRIMLQWKWKRDISNFEYLMYLNTAAGRTCDYMQYPVFPWVLA
 DYTSETLNLANPKIFRDLISKPMGAOTKERKLFIQRFKEVEKTEGDMTVQCHYYTHYSSAIIVASYLVRM
 PPFTQAFCALQGGSFVDADRMFHSVKSTWESARENMSDVRLETPEFFYLPEFLTNCNGVEFGCMQDGTV
 LGDVQLPPWADGDPRKFI SLRKALESDFVSANLHHWIDLIFGYKQQGPAADVNFHPFYGDRMDLS
 SITDPLIKSTILGFVSNFGQVPQLFTKPHPARTAAGKPLPGKDVTSPVSLPGHPQPFFYSLQSLRPSQV
 TVKDMYLFSLGSESPKGAIIGHIVSTEKTLAVERNKVLLPPLWNRTFSWGFDDFSCCLGSYGSDKS

<210> 19

<212> DNA

<213> Homo sapiens

<400> 19

19>Ly1486P, Old-SEQ-ID_5058, partial cDNA

ctggcccttcatgtcgtcacaggcataccggcggtggacccactgcttgggcccttgc
 gaagtagtagacttccgttggaaattgtatccactttcaggcacgtgttgcacacaaa
 gcccgtggacacacctgcacactccatccttagcttgcacccctcccgagtc
 caaatctgaagcttcgttccattctcggtcaattctggactgtaaagctgtc
 ttgaagccgttcaggtttcaggacagtcgttgcagatctgttcaatctgttgc
 agtcgaagtccctccatgttgcgttgcagatctgttgcgttgcactggat
 gtcaccgttgtggcttccaagtttttgcgttgcgttgcgttgcgttgcgttgc
 ttccag

<210> 20

<212> DNA

<213> Homo sapiens

<400> 20

20>Ly1486P, Fc fragment of IgE, low affinity II, receptor for (CD23A), full-length

ggcacgaggctgttaaacctctgtctgtacgggtccctgcaatcgctctggcgaccccaacacacta
 ggaggacagacacaggctccaaactccactaaccagagctgttgcggacttgc
 tcagggagtgtgtccatcatcgggagaatccaaggcaggaccatggaggacttgc
 gatcgaggagctcccaggaggcggtttgcaggcgtggactcagatgtctgttgc
 ggcgtctgtggctggctgtactctgtcttctgttgcactggacaccacagactaa
 agctggaaagagggctggccggaaactctcaagttccaagaacttggaaagccaccacgg
 gatggcgcaaaaatcccacttccacgcagatccacaggaaacttgcaggacttgc
 ttgaaatctcaggacttggagctgttgcgttgcacggcttcaaggacttgc
 cccaggaaatggaaacggaggaaacggaaacttgcgttgcggaaagacttgc
 aaggatggagggttgcagggttgcaggcggtttgttgcacacgttgc
 cggaaacttgcgttgcagggttgcagggttgcaggacttgcgttgc
 aaggcaggctgttgcagggttgcagggttgcaggacttgcgttgcagg
 ctccgttgcagggttgcagggttgcaggacttgcgttgcagggttgcagg
 tacagcaacttgcgttgcagggttgcagggttgcaggacttgcgttgc
 ccgttgcgttgcagggttgcagggttgcaggacttgcgttgcagg
 cagatccacaggccggaggaggacttgcgttgcagggttgcagg
 aaggcaggctgttgcagggttgcaggacttgcgttgcagggttgcagg
 acccccaacccacggctaaaaggcctttgttgcgttgcaggat
 gaggcaggacttgcaggatccacatccgttgcaggacttgcgttgc
 ctccaggatggagggttgcagggttgcaggacttgcgttgcagg

tgagagtacacccaacacgcacccctccagatgagagtacacccaacacgcacccctccagatgcagc
cccatctcctcagcacccaggaccctgagtatcccagtcaggtggtagtcctccgtccagcctgca
tcaataaaatggggcagtgatggcctccc

<210> 21
<212> PRT
<213> Homo sapiens

<400> 21

21>Ly1486P, Fc fragment of IgE, low affinity II, receptor for (CD23A)_full-length
MEEGQYSEIEELPERRRCRRGTQIVLLGLVTAAALWAGLLTLLLWHWDTTOSLKQLEERAARNVSQVSKN
LESHHGDQMKAQKSQSTQISQELEELRAEQQRRLKSQDLELSWNLNGLQADLSSFKSQUELNERNEASDLLER
LREEVTKLRMELQVSSGFVCNTCPEKWINFORKCYYFGKGTQWVHARYACDDMEGQLVSIHSPEEQDFL
TKHASHTGSWIGLRLNLDLKGEFIWVDGSHVDYSNWAPGEPTSRSQGEDCVMRGRWNDAFCDRKLGA
VCDRLATCTPPASEGSAESMGPDSPDPDGRLPTPSAPLHS

<210> 22
<212> DNA
<213> Homo sapiens

<400> 22

22>Ly1677P, novel, partial, cDNA
atcagcacgaatacattcacgtccaacaacacatcaactaccaacaccatcaccacgagcacattcatgccccacaacac
atcaccacccaacacacccatgtctacaacacatcaattaccacccaggcgccacqacat
tcacgtccatcaacacatcaaccaccaacaccatcagcacgacattccataacacatcaactaccaacacc
agcaccatgaacacacattcatgccccacaacacacgtaaacccctaactgtcaccacaaaacaccccttacagccagcagaacg
ccagtcaactacaccatcgccatcagcacattcgtggtagcaacacacccctcagctgacgccaatgtcaccacaaaacaccc
tggccagaagcagctcaaccaccaacaccgttattataaatacattttgaccatcaatgcttcaactgctgacaccatt
accataaatacatccatggccagcaataacttcaatccaacaccatgaccaggcagcacgtcagcggccatcaactgtcac
cacaacacccatcatatccaataacacttcaaccaccatcatcaccacaaacacccctcatagccaaacagtgcctcagccac
caaccccatcatgacaaacacccatggccagcagcacattcaaccaccaaaaaacccctcaaggtcagcaacaccc
tcaccgcacatattaacagaggtacccaccacccagcagcagcttatctccaccacccacaccc
accaaccacaccagccgttcatctactggcaccacgacaaaaaccactgtctggccaggtccaccagcgattactt
tcccaagcaccatccctaccaacagccctggtagtcatctactggcagaacccgcaccc
tggaaatttngatnattttttccactgtggaggctntggtaggagaccaatggattgcaagactaggtcccacaat
ccctcaaatatggtctttntcccccctccccccacc

<210> 23
<212> DNA
<213> Homo sapiens

<400> 23

23>Ly1682P, novel, partial cDNA
aggtafcggggacgttcaacgcacttacttggggagagaaaagaaaaggAACGGGAGCTGAG
agctgggagttggagttatgttggatggatggatattttccacttccatcttgc
acttccatcacaatcacagataatggatattttccacttccatcttgc
agatgttatggacatcttgcgttccatccatcttgc
ctttcacctatggagaacggaggctaaaggaggctaggtaggtgaccctc
agaggccccccactgttgcggccacttgc
tcttgcgttccatcttgc
ccagaataaaaaaaaaaaaaataaaaaaaaaatgaaaattgaaaggaaaaaaa

<210> 24
<212> DNA
<213> Homo sapiens

<400> 24

24>Ly1693P, Old-SEQ-ID_2611, partial cDNA
ccaccaacagtcaagggccaaggaaacctgttggctaaaagggtggtctatgttggcgtct
ggatccctgcctccctgtacttccgacttcatcttgcacgtcagtggcag
atgacagatatactgtgaccgcttccatcccaatgacttgcgggtgttgc
ttcagcacatcatggtggcttacccatgttgcctgttgcattgtcatttgc

ttatcatctccaagctgtcacactccaaggccaccagaagcgcaaggccctcaagacca
 cagtcatcctatcctggcttctgcctgttgctgcctactacattggatcagca
 tcgactcctatcctctggaaatcatcaagcaagggtgtgagtttggagaacactgtgc
 a

<210> 25

<212> DNA

<213> Homo sapiens

<400> 25

25>Ly1693P, CXCR4, full-length cDNA
 caattctgaatcctgcctttgcacttaatgttcataagtatccccatgtcactaaa
 aattcttccaaaataacattcacatgtccatattaatggaaatttcagatgtggatgaacccaaaa
 tctgtcaactattccactaacaatgggttatttaggtatgttcagacatattcactattta
 aaaaaaaaaatgttccacaaaataacattttgtggcataagttttatgtggatgttt
 ctgaagttcctgctgaatagaaaaatgtttccactgtggctgtcccagccacattttca
 tcagtgacaagcgagagacactgtgtttcaatccggagaccaaattatcttga
 aaaaaaaaaatggattttgcataattttgttagtccacaaaatagcatcttgcattttaa
 ttatctgttttttttagtagagatccaaaaagatctgaaaaggagtcttcagataaag
 gaaggagcttcttttgcgttacaatcaacaaatattattatgcaaaaccatttgc
 tccgagtttctcttt
 tagacatcgtcaggaggagttttaggttaggtgcagttacggccaggataaaaaca
 tactgattctgcccactaccaggcttgcggaaaagcaagtcatgaaaacgcgttgcatttt
 tagaccccttccatgttagataggatctaccgtgtctataaaaatataatgtggatcc
 ttaaagattcgaaaaaaaatgttttttttttttttttttttttttttttttttttttt
 ctttatcgttattataaaggatattataaaggatataatgtggatcc
 ggcctgtgagaagggcggtggagctccggaaacctttccagccaccacccttcaaac
 ctggagtt
 gcattatgtgtgtcttactcggtttctgagatccatctcccgccgggata
 tcatcttccctgtgtcagtgtggaaatgtcagatgtggatccatccatccatcc
 gggaggggtcccagacaaaaggggttaagtcatgtctgttagagaaaagggttccctgc
 cgaactaccccttggaaacactccaggtaaatgtttcttttgcataatggggatc
 gtgttagatgtggcgttgcggcaatcccttcctccgggaccatctccgggttaggggc
 tggtgtccgtgtcgacgcacgcgttgcgtcccgatctccggcagccggccaccc
 gcctgcggacgcaggatccctccggcccccacactcgctcccccggccgggatc
 cgccggggaggaaatgtggcggaggggaaaagactgtgtccggccactgc
 accggatctggatcgatccatccatccatccatccatccatccatccatccatcc
 ttaaacttccatccatccatccatccatccatccatccatccatccatccatcc
 cgatgtgggaccgaagacactgggtcaagccggcttggatccctccatccatcc
 catttcatctccgggttattgtgttttccatccatccatccatccatccatcc
 gctggatcccaacgcctagaacacgtgcgtggcacgcaggctcgccatccatcc
 gactaaatgcatctgtgtatggtaataccacacccatccatccatccatccatcc
 tctgtcaaggatctttagtgcgttacaaaatgtactggatccatccatccatcc
 taaagcatacttttaggataataaaggacttccatccatccatccatccatcc
 ttactgagcaatacatatcttacatctgtatcgatccatccatccatccatcc
 cttctgaaatgtatcttcaattatctgcacccatccatccatccatccatcc
 tatacgatccatccatccatccatccatccatccatccatccatccatccatcc
 tctgtcaaggatctttagtgcgttacaaaatgtactggatccatccatccatcc
 cctactgggtgggtactccatccatccatccatccatccatccatccatccatcc
 gtacgttccatccatccatccatccatccatccatccatccatccatccatcc
 acgcgttccatccatccatccatccatccatccatccatccatccatccatcc
 agggaaatgcctctggggggatggggggatggggggatggggggatgggggg
 gcagggtccctgggttccatccatccatccatccatccatccatccatccatcc
 cctccatccatccatccatccatccatccatccatccatccatccatccatcc
 gccgcgttccatccatccatccatccatccatccatccatccatccatccatcc
 gctgcggcagcaggatccatccatccatccatccatccatccatccatccatcc
 ctggagaaccacgcgttaccatccatccatccatccatccatccatccatcc
 tcaatgttccatccatccatccatccatccatccatccatccatccatccatcc
 ccaggacatccatccatccatccatccatccatccatccatccatccatccatcc
 atgcctatataatgtgcgggtgggtgggggggggggggggggggggggggg
 tcgaggagaaaacgactggaaagagcgttccatccatccatccatccatccatcc
 cggccgcgcggccggccggccggccggccggccggccggccggccggccggcc
 agagaaggcgtgcgcgtgcgtgcgtgcgtgcgtgcgtgcgtgcgtgcgtgc
 ggtgttccatccatccatccatccatccatccatccatccatccatccatcc
 tgatgttccatccatccatccatccatccatccatccatccatccatccatcc
 tcttgcacactgggtgcgtgtttgtttaacttcgggttaagccgcgtgcgt
 ccagcacagtaggcaggggggggggggggggggggggggggggggggggggg

ggatcgagtggtggcagcagctaggagttgatccgccccgcgcgttggtttgaggggg
aaaccccccgcgtccgaagcgccgtctcccccacggccgcagtggttcctgcagtt
cgagagttgggtcggtcagaggtcagcgagtggttgcaccccttgcacaccgcg
cagtcgcagccctgagattgcgtccgggataggagcgggtacggggtaggggg
ggcggttaagaccgcactggctccaggcttcaggatgtgtatgtttaaccgtcggtgg
tggggaaaccctttgaaacccttgcataggatgtttgttgcagcggcgcaatt
caaagacgctcgccggagcccaagtcgcctccagcacccctgtggacagagcctg
gcgtgcgcccagcggagccctgcagcgctgtgcgggggttgcgtgggttagtgc
ggcagccgcggccggccggctggacgaccggccccccgcgtgcccaccgcctggagg
cttccagctgcccacccgcgggttaactggatcagtggcgggtaatggaaacca
cccgaggagtgaggaaatgaaacttggggcgaggaccacgggtgcagaccccgatcc
tctccacccaggaaaatgcccgcctctaacgtccaaacgcgcacaatgtataaacacg
aggatggcaagagacccacacaccggaggagcgcggcttggggaggaggtggc
ttcatccatcgactccgcacaatatacccaagcaccacggcagggttgcgttttaaga
ccgattctccatccatcacaatgtgttgcgtccaaagcgcgcataatgttgcgt
gctggggaaaatataatgtttgcgttaggaaatgatgttgcgtcaacgcggcc
ccccccgtgtcccttctcccttcccttgcgtggggaaaaacttccataaaaaa
gttaatactgccccctccatcagcagcacccacccacccgcgtggagttggcc
tctttgtgttatccccctccatcagggatgttttttttttttttttttttttt
ggggcagaggatgttagccaagatgtacttggatccatcagcgtctcgtgc
ttctaaacaagaatttgtatattgttctaccaaagaaggatataatgtactatg
ggaaaagatggggaggaggtgttaggattctacattaattcttgcgtcccttagcc
ctacttcagaatttgcgttgcggatgttttttttttttttttttttttttt
atttttttactgggttaatgtgttgcgttgcatttttttttttttttttt
tttgcagatataacttcagatataactacaccggaggaaatggctcaggggactatgactc
catgaaggaacctgtttccgtgaagaaaatgcataatttcaataaaatccctgcccac
catctactccatcatcttttgcgttgcatttttttttttttttttttt
gggttaccagaagaaaactgagaagcatgcggacaagtacaggctgcacccgtc
cgacccctctttgtcatcaccgcgttccctctggcgttgcgtggcaactggta
cttgggaacttcctatgcaggcactgttgcatttgcacacgtcaaccttacagc
tgtcctcatcctggccttcatcagtcgttgcaccgcgttgcgttgc
cagttagggcaaggaagctgttttttttttttttttttttttttttttt
tgccctctgtactatccgcacttcatcttgcacgcgtcgttgc
atatatctgttgcgttgcgttgcgttgcgttgcgttgcgttgc
catcatgtttggccttacccatcgttgcgttgcgttgcgttgc
cttcaagctgtcacactccaaggggcaccagaagcgaaggccctca
cctcatctgttgcgttgcgttgcgttgcgttgcgttgc
cttcatctgttgcgttgcgttgcgttgcgttgcgttgc
gattttccatcaccggaggccctagtttgcgttgcgttgcgttgc
tttccctggagccaaatttttttttttttttttttttttttttt
gtccagcccaagatcctccaaaggaaagcgagggtggacattcat
gtctgatgttcaagtttactccagctacacacatgtaaaagact
ataaataacttttttaagttacacatttttgcgttgcgttgc
cagttttatgttttttttttttttttttttttttttttttt
tgacttatttatataaatttttttttttttttttttttttttt
gtctgatgttcaagtttactccagctacacacatgtaaaagact
ccagagcgttgcgttgcgttgcgttgcgttgcgttgc
aatcttcattccatccatccatccatccatccatccatccatcc
atggcacttataaccaaaagccaaatgttttttttttttttt
gtgggttgcatttcagcaccctacagtgcgttgcgttgc
tgttaaacttacttgcgttgcgttgcgttgcgttgc
acaaaagtaatacattatggatgcgttgcgttgcgttgc
tacttacccttacacaactctgtatatttttttttttttt
aagaggaaacggaggcacagaaagctaaatgttttttttttt
aaatctgtatttaaaccaggtaacatgtacttgcgttgc
aattcaaatgttgcgttgcgttgcgttgcgttgc
cagaggataagcatgttgcgttgcgttgcgttgcgttgc
catccacttgcgttgcgttgcgttgcgttgcgttgc
tatccctcgttgcgttgcgttgcgttgcgttgcgttgc
actttccatcatgttgcgttgcgttgcgttgcgttgc
cagcttgcgttgcgttgcgttgcgttgcgttgc
ctgttgcgttgcgttgcgttgcgttgcgttgc
aaaatactcccttgcgtatccatgttgcgttgcgttgc
gcaacacccatgttgcgttgcgttgcgttgcgttgc
gttagagtcagaaggaaaggtccactgttgcgttgcgttgc
atttggagacttatgttgcgttgcgttgcgttgc
ctcttgatgttgcgttgcgttgcgttgcgttgcgttgc

cctacacctcacattggAACACAAACAGGGTACACTCCAGGCATGCACTCAGATAATAAGTA
 ggtataattacgacaatatttggctacttttagtaattgttctggcacagaaaatcc
 attttggaggaaaaattgaatgccttatcttcgtaggcaaatcacattgttcaaggc
 aaattatagatcctgtgaagggaaataacttaattacttaaaatagaatccaatttggt
 gtacattttgtcgccgttatggatctgggttaattcaaaatgttattcatattctact
 tgaggacacaatttagatggatcacccttcatttaagcatagtttacatgcactctcaaggctt
 aaggctaattggatcacccttcatttaagcatagtttacatgcactctcaaggctt
 agtcttaaaggcacaaccattgagacagacttcacttgaaccctctataaaatattat
 tctccggagacaatagaagaaatcccttggaggcatgttttcttcatcttgg
 tgaaacaccttaccccagattccctcccttaccgtggagtccacaacaaaaggaaactga
 gccaaaacaaaattcccagtgtcaccagtcttaatggatatttcatttcccttgg
 aagatggaatagtttttccaaaagaaaaacaaggcctgctctccctgccccaaa
 agggtgccccccacccatcattctgtcccaaccctgcattgttagagcgtctccaa
 agcctccctgtgtcggttgcataatgtggggaaacccaggtctgtggccagcc
 cttgcatgaagtagctgattttcccttcattcccttgcataatggggcccttgaagt
 tcagtcatgttagattcagggttgcataatggggaaacccaggtctgtggccagcc
 ccaataacacgacatacatctgcataacttataaaatattgtatgcattgt
 ggaaagtggatgttttcttgcataagccttgcatttgcataatggggaaacccaggtctgt
 atctcccccactgcaggctccacggcccttgcataatggggaaacccaggtctgt
 gattctgggatactcttggggagataccctacaggcttattttataattgaactaa
 gtgttgtgactttcttgcataatggggaaacccaggtctgt
 agctgtcttattcccttgcataatggggaaacccaggtctgt

<210> 26

<212> PRT

<213> Homo sapiens

<400> 26

26>Ly1693P, full-length protein

MDVDEGQDMSQVSGKESPPVSDTPDEGDEPMPPEDLSTTSGAQQNSKSDRGMASNVKVE
 TQSDEENGRACEMNGECAEDLRMLDASGEKMNGSHRDQGSSALSGVGGIRLPNGKLKCD
 ICGIVCIGPNVLVMHKRSHTGERPFQCNQCSSLGVGGIRLPNGKLKCDICGIVCIGPN
 VLMVHKRSHTGERPFQCNQCSSLGVGGIRLPNGKLKCDICGIVCIGPN
 HLRTHSVGPKHKGCGRSYKQRSSLEEHKERCHNLYESMGLPGMYPVIKEETNHNEMAE
 DLCKIGAERSLVLDRLASNVAKRKSSMPQKFLGDKCLSDMPYDSANYEKEDMMTSHVMDQ
 AINNAINYLGAESLRPLVQTGGSSEVVPVISSMYQLHKPPSDGPPRNSHQAQDAVDNLL
 LLSKAKSVSSEREAPSNSCQDSTDTESNAAEQRSGLIYLTNHINPHARNGLALKEEQRA
 YEVLRRAASENSQDAFRVVSTSGEQLKVKCEHCRVLFLDHVMYTIHMGCHGCHGFRDPFE
 CNMCGYHSQDRYEFSSHITRGEHRYHLS

<210> 27

<212> DNA

<213> Homo sapiens

<400> 27

27>Ly1697P, novel, partial cDNA

ccagagagtaagaataggaggagaaaacatgtcgagatgtaggcgcccccagattgt
 gagcagcatagaaaataattttggctttcgttaattctcttagttttaggatacat
 ttttttaactttgttttagataatttttagatttacagaaggttgcaaaaagagta
 gagagagttcctgtacacccttacccagttctactgtctaacattttataatca
 tagtttcaacctgagaaatttagcatgggtacagtcattaaatggggccaggctta
 tttagatttccaccagggtttcgttaacatctttatctgtttcgttaattt

<210> 28

<212> DNA

<213> Homo sapiens

<400> 28

28>Ly1715P, lectin-like NK cell receptor (LLT1), full-length cDNA
 gaattccggccaaatgcgtacagtaacaatgtggagaaagacattacaccatctgt
 ccagggttgcattcaaaagagcattctattaaagctaccttaatttgcgttattttcttaatca
 tgggttgcataatcatagtgtgtggatgggtgtttcaagcgcaataagagacttgc
 gcatcgtatgtttcaagctgtcatgcccagaaaagctggattgggttcaagaaagtt
 tctgtatgcaccaagaactggacatcaagtgcagggtttgtactcacaagatgt
 ttgaaagcttccaggaaactgttgcataatggccatctgtatcactggattggctgag

cagagaacaaggccaaccatggaaatggataaattgtactgaatggacaagacagtccctatcctggga
gcaggagagtgtgcctatttgaatgacaaagggtgccagtagtgcgcaggcactacacagagaggaagtgg
tttgtccaaatcagatatacatgtctagatgttacagcaaagccccactaatctttagaagcatattg
gaactgataactccatTTaaaatgagcaaagaatttatttcttataccaacaggttatatgaaaatatgc
tcaatatcactaataactggggaaaatacaatcaaattcatagtaaaatattacctgtttcatgggtgc
aatattacctgttctcccactgctaattgacatacccgagaatgagtaattataaataaaaagagatttaa
ttqaaaaaaaa

<210> 29
<212> PRT
<213> *Homo sapiens*

<400> 29

29>Ly1715P, lectin-like NK cell receptor, full-length protein
MHDSNNVEKDITPSEL PANPGCLHSKEHS I KATLIWRLFFLIMFLTI I VCGMVAALSAIRANCHQE P SVC
LQAA CPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESFQELNFLRYKGPSDH WIGLSREQG
QPWKWINGTEWTFROFFPILGAGECAYLNDKGASSARHYTERKWICSKSDIHV

<210> 30
<212> DNA
<213> *Homo sapiens*

<400> 30

30>Ly1727P, Old-SEQ-ID_6042, partial cDNA
ccatggatggcttctgaccattggggccaggccaggccaggccaggcttagggcag
caaggaccaggccaaaggggcagggccttcgggttgcacatcccgcc
tgggtttgcattccagggtccagcaggatcttcagggtcgggaagaaggtt
ggggccaggcaccggcgattagggcacagcaatctggggaaacatgggttggaa
gtggagctcagcttcagaatctctggccttcggaaatgtccccacacacat
gtcatagaggaggatgcccagtggaccagacagtggccggagtgcattgtact
agagatccactctgggggtgtacacccttgccatcaaagtcaatgttagggtc
taaagcaggccaccagaacaaaatcaatgatgtcacatggcactggcgttaggtctat
caggatgntctcatcctgatgtcacatggcacaactncacggaaatggcagtgc
tggctgccactactttgg

<210> 31
<212> DNA
<213> *Homo sapiens*

<400> 31

ttttttttttttttttttgggtgaggggacccctactttgttatcccaagtgccttattctggtgagaa
gaaccttaattccataatttgggaaggaaatggaaagatggacaccacccggacaccaccaaataggatg
ggatggatggtttttggggatggctagggaaataaggctgtgtttcctgggcgtcccc
tccaattttcagattttgcacccctctcgagccggattgtccaattactaaaatgtaaataatca
cgtattgtggggaggggagttccaagtgtgccctcttttttcctgcctggattatttaaaaagccat
gtgtggaaacccactatttaataaaagtaatagaatcagaaaaaaaaaaaaaaaaaaaa

<210> 32
<212> PRT

188 22

32>Ly1727P, pim-2 proto-oncogene homolog pim-2h, full-length protein
MLTKPLQGPPAPPGTPTPPPGKDREAFEAEYRLGPLLGKGFGTVFAGHRLTDRLQVAIKVIPRNRVLG
WSPLSDSVCPEVALLWKVGAGGGHPGVIRLLDWFETQEGFMLVLERPLPAQDLFDYITEKGPLGEGPS
RCFFGVQVVAIQHCHSRGVVHRDIKDENILIDLRRGCAKLIDFGSGALLHDEPYTDFDGTRVSPPEWIS
RHQYHALPATVWSLGLLYDMVCGDIPFERDQEILEAELHFPAHVS PDCCALIRRCLAPKPSSRPSLEEI
IJDPRWMOTRAEDVTPQPIORRPCPFGLVATLSLAWPGLAPNGOKSHPMAMSQG

<210> 33
<212> DNA
<213> *Homo sapiens*

<400> 33

<210> 34
<212> DNA
<213> *Homo sapiens*

<400> 34

<210> 35
<212> DNA
<213> *Homo sapiens*

<400> 35

35>Ly1885P, CCP8, full-length protein
MSENSSSDSSCGWTVISHEGSDIEMLNSVTPTDSCPAPECSSLQEELQALQIEQGESSQNGTVMEE
TAYPALEETSSTIEAEEQKIPEDSIYIGTASDDSDIVTLEPPKLEEIGNQEVVIVVEAQSSEDFNMGSSS
SSQYTFCPETVFSSQPSDESSDETSNQPSAFRRRRAKKTVSASESEDRLVAEQTTEPSKELSKRQ
FSSGLNKCVILALVIAISMGFHFYGTIQIQRQQQLVRKIHEDELNDMDKYLSQLCQQEQESFIDYKSKE
NLARCWTLTEAEKMSFETQKTNLATENQYRLRSLEKEEKALSSLQEELNKLREQIIRILEDKGTTSTELVKE
NQKLKQHLEEEKQKHSFLSQRETLLEAKMLKRERLERLVTTLRGEQLQLSGSQLHGKDSNPVYTE
KKEIAILRERLTELERKLTFEQQRSDLWERLYVEAKDQNGKQGTGDKKKGGRRGSHRAKNSKETFLGSVK
ETFDAMKNSTKEFVRHHKEKIKQAKEAVKENLKKFSDSVKSTFRHKDTTKNI FDEKGKNRFGATKEAAE
KPRTVFSIDLHPQYKAPTEHNHSRPYYAKRKEEKPVHFKEFRKNTNSKKCSPGHDCRENSHSFRKACSGV
FDCAQQESMSLFNTVVIPIRMDEFROI IQRYMLKEELDTFCRWNELDQFINKFFLNGVFIHDQKLFTDFVN
DVKIIILGNMKEYEVNDNGVFEKLDEYIYRHFFGHTFSPPYGRPSVYIKPCHYSSL

<210> 36
<212> DNA
<213> *Homo sapiens*

<400> 36

36>Ly1905P_Old-SEQ-ID_546, partial cDNA
ccatggggatggctttctgaccattggggccaggccaggccaggccaggcttagggcag
caaggaccaggccaaaggggcaggcccttttgaggggtttaggggtacatctccggc
tggtgtttcatccagggtccaggatctttccagttaggggtcgaaaagggtt
ggggccaggcaccggcgatttagggcacagcaatctggggaaacatgggtttggaa
gtggagctcagttccagaatcttcgttcccttcataaggaaatgtccccacacacat
gtcatagaggaggatgcccagttagccagacagtggccggaggtgcatactgggtcg
agatccactctgggggtgtacacccttgcacatcaaagtcaagtgttagggtcata
taaaggcaggccaccagaaccaaataatcaatgatgtttggcacagccacggcgttaggtcat
caggatgntctatccatgtcacatggacaactncacggaaatggcagtgtctgg
tggctggccactacttttg

<210> 37
<212> PRT
<213> Homo sapiens

<400> 37

37>Ly1905P, Old-SEQ-ID_2169, partial protein
QVVAXIQHCHSRGVVHRDIKDENILIDLRRGCAKLIDFGSGALLHDEPYTDFDGTRVYSP
PEWISRHQYHALPATVWSLGIIXLYDM

<210> 38
<212> DNA
<213> Homo sapiens

<400> 38

38>Ly1905P_Old_SEQ-ID_5277 partial cDNA
aaataatccaggcaggagaagagaggaggcacacttggaaactccctccccacaatacg
tgattatttacatttttagtaattggacaatcccgctcaggaggagggttgcagaatctg
caaaagtggagggagcggccaggagaacaaacagcaagccttatttccctagccat
ccccaaaaaccatccatccatccatcttagtgtctgggtgtccgggtgtccatctc
cattccttcccaaatttatggaaagtaagggttttcaccagaataagagacacttgggata
acagagttagggtcccctcaccaaaaaaaaaaaaaaaangaagccttgggtaacaaca
ggcattacctcccccagaataaagaatcctgggtgaggcaggtaaagcagcttgaccca
atatgggacccttaggctagggaaagggtcccttactaaaataaaagctactgggtat
tggaaaggaaagcacccttgcctaagtaagagcatatgaactaagtggngtggngttagt
aggagngccaatgtgggtgacacatcatcagaataagagtcc

<210> 39
<212> DNA
<213> Homo sapiens

<400> 39

39>Ly1905P pim-2 oncogene_full-length cDNA
cgcgcgccgcgaatctcaacgcgtgcggccgtctgcgggcgtccggggccaccagttctctgccttccac
cctggcgccccccagccctggctcccccagctgcgcacccatgttgcacccgcgttgcggcttagcggg
ttcaagtgggctcaatctgcgcacccatgttgcacccgcgttgcacccgcgttgcggcttagcggg
ccgggaccccccacgcgcgcggcaggagaaggatcggaaagcgttgcaggccgatatcgactccggcc
cctctggtaagggggcttggcaccgtcttcgcaggacaccgcctcacagatcgactccagggtggcc
atcaaagtgttcccgaaatcggtgtgggtggccatgttgcacccgcgttgcacatgcggccactcg
aagtgcactgtatggaaagtgggtgcaggtgtggcaccctggcgtatccgcgtcttgactgggt
ttagacacaggagggttcatgtgtgcctcgacgcgccttgcggccaggatctttgactatatc
acagagaaggcccactgggtgaaggccaaagccgtctttggccaaagttagtggcagccatccagc
actgcattcccggtggagggtgtccatgtgacatcaaggatgagaacatctgtatagacactacgcgg
ctgtgcacactcattgtttgggtgtgcctgttgcacccatgtgacttgcactgtttatgg
acaagggtgtacagccccccagagtggatctcgacaccaggactcactccggccactgtctgg
cactggcatctctcatgtacatgtgtgtggacattttggagagggaccaggatctgg
agctgagctcacttcccgccatgtctcccgactgtgtgccttaatccgcgggtgcctggcccc
aaaccttcccgaccctactggaaagagatctgtgtggacccctggatgcaaacaccaggccgaggatg
tacccctcaaccctccaaaggaggcccttggcctggcttgcacccatgtgacttgcacttgc
cctggcctggccccaatggtcagaagagccatccatggcgttgcacaggatgatggacatttt
gacttggtttacaggtcattaccagtcatthaagtccagtattactaaggtaaggattgaggatcagg
ggtagaagacataaaaccaagtctgcccagttccctccaaatctacaaaaggagccttcctccagaac
ctgtgtccctgattctggagggggacttctgtttcttgcataaggatgttattttggtaag
ttgttcccatctgtgagccccggactcttattctgtatgtgtgcacccatgtgcacccactac
caccacacaacttagtcatatgtcttacttggcaagggtgtttccatattgggtcaagctgttac
ttatatttagtaaaggggacccttcccttagcctagggtcccatattgggtcaagctgttac
gcccaggatttttattctggggggaggtaatgcctgtgttaccccaaggcttcttttttt
tgggtggggggaccctactctgttatccaaagtgttcttattctgggtgagaagaaccttacttccataat
ttgggaaggaaatggaaagatggacaccacccggacaccaccaggacacttagggatggatggtttttgg
ggatgggctagggaaataaggctgtgtttttctctggattattaaaagccatgtgtggaaaccactat
ttgcaacctccctctgtgagccggatgtccaaattactaaaatgttaaaatcacgtattgtggggagg
agttccaagtgtgtccctctctttctgtccctggattattaaaagccatgtgtggaaaccactat
ttaataaaagtaatagaatcag

<210> 40

<212> PRT
<213> Homo sapiens

<400> 40

40>Ly1905P pim-2 oncogene full-length
MLTKPLQGPPAPPGTPTPPGGKDREAFEAEYRLGPLLKGFFGTVFAGHRLTDRLQVAIKVIPRNRLG
WSPLSDSVTCPELEVALLWKGAGGGHPGVIRLLDWFTQEGFMVLERPLPAQDLFDYITEKGPLGEGPS
RCFFGQVAAAIQHCHSRRGVVHRDIKDENILIDLRRGCAKLI DFGSGALLHDEPYTDFDGRTRVYSPPWEIS
RHQYHALPATVWSLGLLYDMVCGDIPPERDQEILEAEELHFPAHVSPDCALIRRCLAPKPSSRPSLEEI
LLDPWMQTTPAEDVPLNPSKGGPAPLAWSLLP

<210> 41
<212> DNA
<213> Homo sapiens

<400> 41

41>Ly663S_Old_SEQ-ID_2757 partial cDNA
ctggaactgcacntagtcctccagctctcccgccggctcctcggggntggtgcgtta
cttttggatggtttctctacnacntcccgaagcttccntccag

<210> 42
<212> DNA
<213> Homo sapiens

<400> 42

42>Ly663S CD37 antigen (CD37) full-length cDNA
gtctccccactgtcagcacctttctgtgtggtagtgaggcccttaccccacttaggtgaagatgtcag
cccaggagagctgcctcagcctcatcaagtacttccttcgtttcaaccttttcttcgtccctcg
cagcctgatcttcgtctccggatctggatcctcatcgacaagaccatctcgatctgtcccttgcggcttg
gccttcgtgcctctgcagatctggtccaaagtctggccatctcaggatcttaccatgggcattgc
tcctgggttgtgtggggccctcaaggagctccgtgccttcgtatgttggatgtgtgt
cctgtttgccacacagatcaccctggaaatcctatctccactcagcgggcccagctggagcgaagcttgc
cgggacgtcgtagagaaaaccatccaaaagtacggcaccaaccccgaggagaccgcggccgaggagact
gggactatgtcagttccagctgcgtctgcggctggcactaccgcaggactgggttccaagtc
cctgagaggttaacgggtcgaggccgcaccgcgtgcctctgtctacaacttgcggcaccac
tcacaaatccatagataagggtatcttcggccagatcagggcttgcggacac
gtcagacatcgtcgatctccctgcagagagccacatctaccgcgggctgcgc
gtggctgcacaaacattatccatagttggcatttgcctggcgtggcacttc
atgacgctctcgatattccctgtcagaaacctggaccacgttacaaccggctcgctc
cccgccctcccaaagtccgccccccccgtcacgtgcgtggcacttc
tttgttaatccccagttcgccctggagccctccgccttacattccctggg
cccctgtgtcaccttcccacgggacctgggcttgcacagcttc
cctac

<210> 43
<212> PRT
<213> Homo sapiens

<400> 43

43>Ly663S, CD37 antigen, full-length
MSAQESCLSLIKYFLFVNLFFFVLGSLIFCFGIWILIDKTSFVSFVGLAFVPLQIWSKVLAISGIFTMG
IALLGCVGALKELRCLLGLYFGMLLLFAQTQITLGILISTQRAQLERSLRDVVEKTIQKYGTNP
EWDYVQFQLRCCGWHYPQDWFQVLIIRGNNGSEAHRVPCSCYNLSATNDSTILDKVILPQLSRLGH
RHSADICAVPAESHIYREGCAQGLQKWLHNNLISIVGICLGVGLELGFMTLSIFLCRNL
DHVNRLARY
R

<210> 44
<212> DNA
<213> Homo sapiens

<400> 44

44>Ly664S, FLJ90810 fis, clone weakly similar to PROTEIN DISULFIDE ISOMERASE-
RELATED PROTEIN PRECURSOR, full-length

<210> 45
<212> PRT
<213> *Homo sapiens*

<400> 45

45>Ly664S, full-length
MPARPGRLPLLARPAALTALLLLLLGHGGGRWGARAQEAAAAAADGPPAADGEDGQDPHSKHLYTADM
FTHGIQSAAHFVMFFAPWCGHQCRLQPTWNLDGDKYNMSEDAKVXAKVDCTAHSVCSAQGVGYPTLKL
LFKPGQEAVKYQGPRDFQTLENWMLQTLNNEPVTPEPEVEPPSAPELKQGLYELASASNFEHLVAQGDHFI
KFFAPWCGHCKALAPTWEQLALGLEHSETVKGKVDCTQHYELCSGNQRGYPTLLWRDGKKVQDYGKQYK
RDLESLEYVESQLQRTETGATETVTPSEAPVLAEPADKGTVLALTENNFDTTAEGITF1KFYAPWC
GHCRTLAPTWEELESKKEFPGLAGVKIAEVDCTAERNICSKYSVRGYPTLLLFRGGKKVSEHSGGRDLDSL
HRFVLSOAKDEL

<210> 46
<212> DNA
<213> *Homo sapiens*

<400> 46

46>Ly667S, Old-SEQ-ID_9413, partial cDNA
ccagccagtgcacaaaaaaagagtgaatgtgccttaagaagaagagcaatgagacacag
tgtttcaacttcatccgtgcctggttcttacaatgtcacccatcttacacacctgcggc
acattccgccttcacccctqcttacattcattqaactcaagattcctacctgttgcccc

atctcgaggacaaggcatggagggaaaaggccaaagcccctttaccccgctcacaag
catacggtgttggatggatgcttattctgtactatgaacaacttcttggc
agttagccccatctgtatgcgcacactggatcccagctgtcccaagaccgacaacttc
ctccgttgtgtcatcatgacgccccctttgtggcagggatcccccttgacccaggctgtc
tacttcttctcgaggagacaggcagcgaggttgactttgagaggctccacacatcg
cggttgtgttagatgtctgcaagaatgacgtggcgaaaagctgctgcagaagaagtgg
accacacctt

<210> 47
<212> DNA
<213> *Homo sapiens*

<400> 47

<210> 48
<212> PRT
<213> *Homo sapiens*

<400> 48

48>Ly667S, Semaphorin B, full-length
 MALPALGLDPWSLLGLFLFQLLQLLPTTAGGGGQGPMPVRVYAGDERRALSFFHQKGLQDFDTLLS
 GDGNTLYVGAREAIALALDIQDPGVPRLNMPWPASDRKKSECAFKKSNETQCFNIRVLVSYNVTHLY
 TCGTFAFPACTFIELQDSYLLPISEDVKMEGKGQSPFDPAHKHTAVLVGMLYSGMTMNNFLGSEPILMR
 TLGSQPVLKTDNFLRWLHHDASFVAAPSTQVVYFFFETASEFDFFERLHTSRVARVCKNDVGGEKLLQ
 KKWTTFLKQQLSAPSRGSCPSTSSATRSCSPPILPQLPTSTQSSPPSGQVGGTRSSAVCAFSLLDIERV
 FKGKFKELNKETSRTWTTYRGPETNPRPGSCVGPGSSDKALTFMDHFLMDEQVVGTPLLVKSGVEYTRLA
 VETAQGLDGSHLVMYLGTGSLHAVVSGDSSAHLVEEIQLPDPPEPVRNLQLAPTQGAVFVGFSGGV
 WRVPRANCSVYESVDCVILARDPHCWDPERTCCLLSAPNLNSWKQDMERGNPEWACASGPMRSRLRPQ
 SRPQIKEVLAVPNSILELPCPHLSALASYYWSHGPAAVPEASSTVYNGSLLLIVQDGVGGLYQCWATEN
 GFSYPVISYWVDSQDQLALDPELAGIPREHVVKVPLTRVSGAALAAQQSYWPHFVTVTLFALVLSGAL
 IILVASPLRALRARGKVQGCETLRPGEKAPLSREQHLQSPKECRTSASDADNNCLGTEVA

<210> 49
 <212> DNA
 <213> Homo sapiens
 <400> 49

49>Ly677S, Old-SEQ-ID_465, partial cDNA
 accagcagtccgcggcacctacctccgcgtgcgccagccgggggggggggggggggggggggggggggggg
 acatggggggaggggcaccaagaaccgaatcatcacagccgaggggatcatcctcctgttct
 gcgccgggtggtgccctgggacgctgctgttnaggaaacgatggcaagaacganaactcn
 gg

<210> 50
 <212> PRT
 <213> Homo sapiens
 <400> 50

50>Ly677S, Old-SEQ-ID_1923, partial protein
 QQSCGTYLVRQPPPFPFLDMGE GTKNRIITAEGIILLFCAVVPGTLLLXRKRWQERXLX

<210> 51
 <212> DNA
 <213> Homo sapiens
 <400> 51

51>Ly677S, Old-SEQ-ID_5989, partial cDNA
 accagcagtccgcggcacctacctccgcgtgcgccagccgggggggggggggggggggggggggggggg
 acatggggggaggggcaccaagaaccgaatcatcacagccgaggggatcatcctcctgttct
 gcgccgggtggtgccctgggacgctgctgttnaggaaacgatggcaagaacganaactcn
 gg

<210> 52
 <212> PRT
 <213> Homo sapiens
 <400> 52

52>Ly677S, Old-SEQ-ID_1496, partial protein
 QQSCGTYLVRQPPPFPFLDMGE GTKNRIITAEGIILLFCAVVPGTLLLXRKRWQERXLX

<210> 53
 <212> DNA
 <213> Homo sapiens
 <400> 53

53>Ly677S, CD79A antigen (immunoglobulin-associated alpha), full-length
 tgctgcaactcaaactaaccacccactgggagaagatgcctgggggtccaggagtcctccaagctctgc
 ctgccaccatcttccctcttctgtctgtctgtctacactggccctgggtgcaggccctgtggat
 gcacaagggtcccagcatattgtatggtgagcctggggaaagacgcccacttccaatgcccgcacaatagc
 agcaacaacgccaacgtcacctggggcgcgtctccatggcaactacacgtggccccctgaggcttgg
 gcccggcggaggacccaaatggtagctgatcatccagaatgtgaacaagagccatggggcatatacgt

gtgcgggggtccaggagggcaacgagtcataccagcagtcctgcggcacctacccgcgtgcgccagccgcccccccaggcccttctggacatgggggagggcaccaagaaccgaatcatcacagccgaggggatcatccctctgtctgcgcgtgtgcctggacgtctgttcaggaaaacgtgcagaacgagaagctcggttggatgcggggatgaatatgaagatggaaaacctttatgaaggcctgaacctggacgactgtccatgtatgaggacatctccggggccctccaggcacctaccaggatgtgggcagccctaacataggagatgtccagctggagaagccgtgacaccctactccgtccaggctgccccccgcgtgtgcaccccgactccagtgctcagctacttccctggacattctcccttcagcccccttcgggggcttcctagtatcatatcccccaactgggggtggggtaacctctacttctccaggccaggcccttggactccccctgggggtgtccccacttttcccttaactgcccccacctctaaaccttaatccccacgccccgcgtgccttccaggctccccctccccagggtaatgagccctaattgcgtgcctctaggggagctgattgttagcagccctcgtagtgtcacccccctccctgatctgtcaggccacttagtgataataattcttcccaactgc

<210> 54
<212> PRT
<213> *Homo sapiens*

<400> 54

54>Ly677S, CD79A antigen, complete protein
MPGGPGVLQALPATIFLLFLLSAVYLGPGCQALWMHKVPASLMVSLGEDAHFQCPhNSSNNANVTWWRL
HGNYTWPPEFLGPGEDEPNTLIIQVNVKSHGGIYVCRVQEGNESYQQSCGTYLVRQPPrPFLDMGEGT
KNRIITAEGIILLFCAVVPGTLLLFRKRWQNEKLGLDAGEYEDEDENLYEGLNLDDCSMYEDIISRGLQGTY
QDVGSNLNIGDVQLEKP

<210> 55
<212> DNA
<213> *Homo sapiens*

<400> 55

55>Ly1891P, orphan G-protein coupled receptor (GPRC5D), full-length
atgtacaaggactgcacgactggagactatttctctgtgacgcgcggggccatggggca
tcattctggagtccctggccatacttggcatcggtcacaattctgtactcttagcattctttct
catgcgaaagatccaagactgcagccagtggaatgtcccccaccagtccttcctctgagtgct
ctggggcttcggactcgctttgccttcatcatcgagctcaatcaacaactgccccgtacgctact
ttctcttggggttctttgtctctgtttctatgccttagctatgcctcaatctgtgaagct
ggttcggggtgtgtctccctctcctggacacaattctgtgatgttgcagtctgttgc
atcattattgccactgagtatgtgactctcatcatgaccagaggatgttatgtttgt
gccagctcaatgtggactttgttactccctgttatgttcttctgtgcgtccctcacatttctgt
ctccaaagccacccctctgtggccctgtgagaacttggaaagcagcatggaggc
cttctccatcatcatctgggtgtgttatctccatgtcttgcacccgc
agccccagtggacgacccggcgtctgcattgtctgttgc
catgcctctgtgagctctgcatttctacagatgttagacaggagtgcccttacaagg
ccgcacagcctaccaacacagcttcaagtggagaaccaggagctctcc
gagctgaggaggatgttagcattaacttcatatgttactccattc
aagatgtttcatcccacaggctaaactaagccccccagcaagatgc
caggaggatataa

<210> 56
<212> PRT
<213> *Homo sapiens*

<400> 56

56>Ly1891P, orphan G-protein coupled receptor (GPRC5D), full-length
MYKDCIESTGDYFLLCDAEGPGIILESLAILGIVVTILLLAFLFLMRKIQDCSQWNVLPTQLLFLLSV
LGLFGLAFAFIELNQQTAPVRYFLFGVLFALCFSCLLAHASNLVKLVRGCVFSWTTILCIAIGCSLLQ
IIIATEYVTLIMTRGMMFVNMTPCQLNVDFVLLVYVFLMALTFVSKATFCGPCENWKQHGRLIFITV
LFSIIIWVWISMLLRGNPQFORQPQWDDPPVVCIALVTNAWFLLLYIVPELCILYRSCRQECPLQGNAC
PVTAYOHSFOVENOELSRRARDSDGAEEEDVALTSYGTPIQPQTVDPTQECEFIPQAKLSPQQDAGGV

<210> 57
<212> DNA
<213> Homo sapiens

S7>CD138, syndecan 1 (SDC1), full-length cDNA
ggcacggggaaqqqccctatqqqtttattataaaggcgagctcggcgggagaggtgcgggcccgaatccgag

ccgagcgcggaggaaatccggcagtagagagccgactccagccggccggaccctgcagccctcgccctgggac
agccggcgcgctggcaggcgccccaaagagagacatcgagcagccgaaccgcgaagccggccgcagccgcg
acccgcgcagccctgcgcctcccgccgcggctccggcagcatgaggcgccggcgtctggctctgg
tgtgcgcgtggcgtgagccgcagccgcggctccgcggcaatttgtggctactaatttgcggccctgaaga
tcaagatggctctgggatgactctgacaacttctccgcgtcagggtcagggtctttgaagatatacc
ttgtcacagcagaccctccacttggaggacacgcagctctgcggctattccacgcgtccccaag
ccaccggcctggaggctacagtcgcctccacctccaccgcggctggagaggggcccaaggaggaga
ggctgttagtcgcgcagaagtggaggcctgcaccgcggcggaggcaggaggcccaccccccacccagg
gagaccacacagctccgcggaccactatcaggcctcaacgaccacagcaccacgcggcccgagg
cctcccccacccacaggacatgcagcgcgcaccatgagacactcaaccctgcaggaccaggccaagg
tgacacttcacactcccccacacagaggatggaggctcttgcaccaggagggctgtgaggatggaggc
tccagtcagctcccgacgcaggactctgggagcaggacttcaccccttgaacactcgaaaaaaa
cggtctgttagtggccgtggaggctgaccgcggaaaccagtccccagttggatcaggggacccgggg
acaggggcctctggacaggaaagagggtctgggggtcattgcgttaggcctcgtnnnnnnnnnnnnn
gctgtgtgcctggggtttcatgtctgtaccgcataagaagaaggacgaaggcagactactccctggagg
agccgaaacaagccaaacggcggggcctaccagaagccaccaaacaggaggaaattctatgcctgacgcgg
gagccatgcgccccctccgcggccactacttagggccccacttgccttcttgcataagaactgcgg
ctggccctccctgcaccaggccaccctcccgatccctccaggccctctgtgtctgcaccagg
ctgggggtgtgtctggggactccactctgtctgtacttgcctggagacttgcacttcgggttctccaaact
ctgcataaggacccctccaccacaggccgcacccgcatacgaccatctgcacttcgggttctccaaact
aaggcactctcccgaggctccagctctggagggggaggggatccgcactgtttggacctaattgcct
tgtgtctggaaagatcctgcgggtggggcttgggctcacacacctgtactactgttaggaccaagg
atcttgggggggtggccgctgagtggcggggacaggagttccacttttgcgtgggggggggtctaatct
gatatcgacttgcatttgcacatgtttccctctgtttcttgcatacgccaggatcccttgcattt
gaggtaagttaaagttaaagttgttgcgtatccccccatcttgcctccctaatctatgttgcgggg
tcagggttaagaagacttt
ggcttagttgtgttgccttgcgttgcgtcatgtgtcaacagggtatggactatctgtctgg
tggcccccgttctgggtctttgcggcaggctggccagttccaggctggcgccgtggggccgccttca
agcagtcgtgcctgtgtccatgcgcctaggccatgcgtggccgtggccgtccacgtttggagaaggc
cgtgtgagaagttaaagttgttgcgtatccccccatcttgcctccctaatctatgttgcgggg
gagatcccttcgtcaggaccacgcggccgtctggcgtggccgtctccaggggcttgccttgc
tgacgggggtgtttggcaggagctgcgttgcgtggccgtccatccaaggccagggttctccgg
tggcccccacccctggccctggctggaaatcaggaatattttccaaagttgtatgttgc
gcaaaactctacttaatccaatgggttttccctgtacagtagatttccaaatgtataaaaactttaata
taaaatgt

<210> 58
<212> PRT
<213> *Homo sapiens*

<400> 58

58>CD138, syndecan 1 (SDC1), full-length protein
MRRAALWLWLCALALSQPALPQIVATNLPEDQDGSGDDSDNFSGSGAGALQDITLSQQTPSTWKDTQL
LTAIPTSPEPTGLEATAASTSTLPGEGPKGEAVVLPVEPGLTAREQEATPRPRETTQLPTTHQASTT
TATTAQEPAHSHPHRDMQPQGHETSTPAGPSQADLHTPHTEDGGPSATERAAEDGASSQLPAAEGSGEQD
FTFETSGENTAVVAVEPDRRNQS PVDQGATGASQGLLDRKEVLGGVIAVGLVGLIFAVCLVGFMLYRMKK
KDEGSYSLEEPKOANGGAYQKPTKQEEFYA

<210> 59
<212> DNA
<213> *Homo sapiens*

<400> 59

59>CD22, Old-SEQ-ID_4021, partial cDNA
ctggggctgaggatggagtccaagactgagaatggatggAACGAAatacacacccatgtc
tctgaagggcctttcacctcatatccagtcgtccctccagaaattcaagagtcccaggaa
gtcactctgacacctgtgtatccatgtatgggtatccgatccaattgcagtgg
ctccctagaggggttccaatgaggcaggctgtgtcacctcgacccttgcaccatcaag
tctgtcttcaccccgagcgcagtcagttcccccacagtggagtcacccatggaaagatt
qtqacacctgcacgttcaggatgcagatggaaagtcccttcacatgacacacggcggcag

<210> 60
<212> DNA
<213> *Homo sapiens*

<400> 60

60>CD22, full-length cDNA
ccatccccatagtgagggaaagacacgcggaaacaggcttcacccagacacgacaccatgcacccatcgatctccctcg
ccccctggctcctgtcctggtttagataacttggttctgtactcaagtaaatgggttttgagcac
cctgaaaccctctacgcctggagggggcctgcgtctggatccctgcacctacagagccctagatgtg
acctggaaagcttcatcctgttccacaatccctgagttataacaagaacacccctgcgaagttgtatgggacaaag
actctatgaaagcacaaggatggaaagggttcctctgagcagaaaagggtgcattccctggagatgg
aataagaactgcacactgtatccacccggcgtcaccctcaatgcacagtggcgtcgtggggctgaggatgg
agtccaaagactgagaaatggatggaaacgaaatccctcaatgtctgttgcacccatcat
ccagctcccccagaaattcaagactccaggaaagtactctgcacctgttgcataatttcctgttat
ggtagtccatgttccatgttgcagttccatgggggttccatgtaggcaggctgtgtcacccgcacct
ccttgaccatcaagtctgttccatccggagcgtcaagttctcccccacagtggagtcaccatgg
gattgtgacctgcagttcagatgcagatggaaaggttcttccaatgacacccgtgcagctgaacgt
aaggcacaccccgaaagttggagatcaaggtaactcccaatgtgcacccatgtgagggagggggactctgt
ccatgacccgtcgaggtcagcagcagcaacccggagttacacgcggatccctgcctcaaggatgggaccc
gctgaagaaggcagaatacattcagctaaacccctgcgcgaagttgaccaaggaccaggatgggaaagttactgc
tgtcagggttccatgtacgtggcccccggaaagggtcggaaaggatgttcttgcacagtgcagttatgg
aacccctccacgggttccatgttgcacccatccggctgtggagggaaagtcacgtcgatgttcttgc
actggccatcccttccaaacaaattacacgtgttccatggaaaggaaaggatggggaggcaggagg
gagaaagtccacatcccaaaggatccctccctggcacgtggacttattccctgtgttgcagaaaacattc
ttggtagtggacagaggggcccccggagctgatgtccatgttccatgttccatgttgcacccat
gatccaaacccatccatgtccgattcggaaaggagacacaggatgttccatgttgcacccatgttgc
ccctgttccatgttgcacccatgttgcacccatgttgcacccatgttgcacccatgttgc
tccaaacgttggctggacaacacaaaccatccctgcgcacgttgcacccatgttgcacccatgttgc
ccctgttccatgttgcacccatgttgcacccatgttgcacccatgttgcacccatgttgc
atttactctggaaactcggtcagcccttcaatgttgcacccatgttgcacccatgttgc
tctggagaaaaatggcaggcttggggaaaggaaaggccatgttgcacccatgttgc
tgctggagttacagctgtgggtgaacaactccataggacacagcgtccaaaggccctggacacttgg
gtgtgtatgcacccaggaggctgcgtgttccatgtggcccccggaccatgttgcacccatgttgc
caaccctgcacccatgttgcacccatgttgcacccatgttgcacccatgttgcacccatgttgc
aaggctcccccaccacacggccagaaggctgatgttgcacccatgttgcacccatgttgc
tgccaggggaccacaggatgttgcacccatgttgcacccatgttgcacccatgttgc
agaccatccgcaggcgatgttgcacccatgttgcacccatgttgcacccatgttgc
gctcaaggtcccgccacgttgcacccatgttgcacccatgttgcacccatgttgc
agcttccatgttgcacccatgttgcacccatgttgcacccatgttgc
acaatccatgttgcacccatgttgcacccatgttgcacccatgttgc
tggagatgcacccatgttgcacccatgttgcacccatgttgcacccatgttgc
ttgcacccatgttgcacccatgttgcacccatgttgcacccatgttgc
acttgcacccatgttgcacccatgttgcacccatgttgcacccatgttgc
caaacattgcacccatgttgcacccatgttgcacccatgttgc
tccccagacaccgcacatggctccctgcgtgcacccatgttgc
acacacacacttgcacccatgttgcacccatgttgcacccatgttgc
acccatgttgcacccatgttgcacccatgttgcacccatgttgc
tgacatgcacccatgttgcacccatgttgcacccatgttgc
tctgttgcacccatgttgcacccatgttgcacccatgttgc
gaatattatggccatgttgcacccatgttgcacccatgttgc
cgttgcacccatgttgcacccatgttgcacccatgttgc
gactctggggactccgggtttgagatggacacactgttgc
aataaaaaatggctcagatgccacttcaaaaaaaaaaaaa

<210> 61
<212> PRT
<213> *Homo sapiens*

<400> 61

61>CD22, full-length protein
MHLLGPWLLLLVLEYLAFLSDSSKWVFEHPETLYAWE~~GACVWI~~PC~~TYRALDG~~DLESFILFHNP~~EYNKNTSK~~
FDGTRLYESTKD~~GKV~~P~~SEQ~~KRVQFLGDKNKN~~CTL~~S~~I~~H~~PVHLND~~SGQLGLR~~MESKTE~~W~~ERI~~H~~LNVS~~ERP
FPPHIQLPPEI~~QES~~QEV~~T~~LTC~~LN~~F~~SCY~~GYPIQLQWLLEG~~VPMR~~QAAV~~T~~STSLT~~I~~K~~S~~V~~F~~TRSELKFSPQW
SHHGKIVTCQLQDADGKFLSND~~T~~QLNV~~KH~~TPKLEI~~KV~~TPSDAIVREGDSV~~TM~~TC~~EV~~SSSN~~P~~E~~Y~~TTV~~SWL~~
KDG~~T~~SLKKQ~~N~~TF~~N~~LR~~E~~V~~T~~KDQS~~G~~KYCC~~Q~~VSNDVG~~P~~GR~~SE~~E~~V~~F~~L~~QV~~Y~~A~~P~~EST~~V~~Q~~I~~LH~~S~~PAVE~~G~~SQ~~V~~E
FLCMSL~~AN~~PL~~P~~LT~~N~~TY~~W~~HN~~G~~KEM~~Q~~GR~~T~~E~~E~~KV~~H~~IP~~K~~1L~~P~~W~~HAG~~T~~Y~~SC~~V~~A~~E~~NI~~L~~G~~T~~Q~~R~~G~~P~~G~~D~~V~~Y~~Q~~V~~PK~~K~~
KV~~T~~TV~~I~~Q~~N~~P~~M~~IRE~~G~~D~~T~~V~~T~~L~~C~~SY~~N~~PS~~N~~PS~~V~~TRY~~E~~W~~K~~PHGA~~E~~EP~~S~~LG~~V~~K~~I~~Q~~N~~W~~D~~NT~~T~~I~~A~~C~~A~~R~~C~~NS~~W~~
CSWASPVAL~~N~~Q~~Y~~A~~P~~RD~~V~~R~~V~~K~~I~~K~~P~~L~~S~~E~~I~~H~~G~~NS~~V~~SL~~C~~D~~F~~SS~~H~~P~~K~~E~~V~~Q~~F~~W~~E~~K~~N~~G~~R~~L~~G~~K~~E~~SQL~~N~~F~~D~~
IS~~P~~E~~D~~AG~~S~~Y~~C~~W~~V~~NN~~S~~I~~G~~Q~~T~~A~~S~~K~~A~~T~~L~~V~~E~~LYA~~P~~R~~R~~L~~R~~S~~M~~S~~P~~G~~D~~Q~~V~~ME~~G~~K~~S~~A~~L~~T~~C~~E~~S~~D~~A~~N~~P~~P~~V~~S~~H~~Y~~T~~WF
DWNNQSLPHHSQKLRL~~E~~P~~V~~K~~Q~~H~~S~~G~~A~~WC~~Q~~GT~~N~~SV~~G~~K~~R~~S~~P~~L~~T~~LV~~Y~~Y~~S~~P~~E~~T~~I~~G~~R~~R~~V~~A~~V~~GL~~G~~S~~C~~L~~A~~I~~L~~
I~~A~~I~~C~~G~~L~~K~~L~~O~~R~~R~~W~~K~~R~~T~~Q~~S~~O~~Q~~G~~LO~~E~~N~~S~~SG~~Q~~FF~~V~~R~~N~~K~~V~~R~~R~~A~~P~~L~~S~~E~~G~~PH~~S~~LG~~C~~YN~~P~~M~~M~~E~~D~~GI~~S~~Y~~T~~TL~~R~~PE~~M~~

NIPRTGDAESSEMQRPPRTCDDTVTYSALHKRQVGDYENVIPDFPEDEGIHYSELIQFGVGERPQAQENV
DYVILKH

<210> 62
<212> DNA
<213> Homo sapiens

<400> 62

62>CD79beta, old-SEQ-ID_504, partial cDNA
ctgggggtccggaaagggttggccatgagccaggcagtcgcgaagcagtcaactgag
gccaggagctgcaccaggcatggcgacactggctctactcctggctgggtct
cacctacagaccacttcacttcccgtccgcagcgtactatgtcctcataggtggctg
tctggtaatgtccaggccctcgtagtgtatcttcctccatgccagcctgtcat
cctgtccagcagcaggaagataggcacatgtgaagaggatgtcagcagcgtctgga
tcatgtatgataccatcctcagcgtttccctctgtttcag

<210> 63
<212> PRT
<213> Homo sapiens

<400> 63

63>CD79beta, old-SEQ-ID_1747, partial protein
LKQRNTLKDGIIMIQTLIILFIIVPIFLLLDKDDSKAGMEEEDHTYEGLIDQTATYEDI
VTLRTGEVKWSVGEHPGQE

<210> 64
<212> DNA
<213> Homo sapiens

<400> 64

64>CD79beta, Old-SEQ-ID_5238, partial cDNA
ctgggggtccggaaagggttggccatgagccaggcagtcgcgaagcagtcaactgag
gccaggagctgcaccaggcatggcgacactggctctactcctggctgggtct
cacctacagaccacttcacttcccgtccgcagcgtactatgtcctcataggtggctg
tctggtaatgtccaggccctcgtagtgtatcttcctccatgccagcctgtcat
cctgtccagcagcaggaagataggcacatgtgaagaggatgtcagcagcgtctgga
tcatgtatgataccatcctcagcgtttccctctgtttcag

<210> 65
<212> DNA
<213> Homo sapiens

<400> 65

65>CD79beta, full-length cDNA
ccacgcgtccgcacgcgtccgcagagcggtagccatggccaggctggcgttgttcctgtgcccagcc
actggatggggcggtgtctgctcagctgagccatgaccaggcagatcgaggaccggta
ccggaatccccaaaggtagtgcttgcgcgatctggcagagccacgtttcatagccaggaaacggggc
ttcacggtaaaatgcactgtcatatgaacagcgcctccggcaatgtgagctggcttggaaaggaga
tgacgagaatccccagcagctgaaagctggaaaaggccgcattggaaagagtcccagaacgaatctctgc
caccctcaccatccaaggcatccgttggaggacaatggcatctacttctgcgcagcagaatgtcaacaac
acctcgaggcttaccaggcgccacagagctgcgagtcatggattcagcacccctggcacagctga
aggcaggaaacacgctgaaaggatggatcatcatgtatccagacgcgtgtatcatcttcatcatgt
gcctatcttctgtctggacaaggatgacgcgcaaggctggcatggaggaaagatcacacctacgaggcc
ctggacattgaccagacagccacatgaggacatgtgacgcgtgcggacaggaaatgtgaagtggctg
taggtgagcaccaggccaggatgtgagggccaggatggccatgcgttggcggcagggctccctggcctca
gtgactgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
tggcccccaggatgtgcattttgtctccagccccctggcccccaggatgttgcgttgcgttgcgttgcgtt
ggacaacaggcagcaacttggaggagttctctggggatggacggggccaggccttctgggggtctat
gaggtgatccgtccccacacatggatggggaggcagagactggccatggccaaatggactcgga
gcccaggcccccaggcagatggggccatggacccaactggcccccagaagagccacaggaac
atcatcttctccgcaccactcccaccccccaggccctggccctccagtgccctccccctggaaata
aacgggtgttcctgagaaaaaaaaaaaaaaaaaaa

<210> 66

<212> PRT
<213> *Homo sapiens*

<400> 66

66>CD79beta, full-length protein

MARLALSPPVSHWMALLLSAEPVPAARSEDYRNPKGSACSRIWQSPrFIARKRGFTVKMHCYMNSA
SGNVSWLKQEMDENPQQQLKLEKGRMEESQNESLATLTIQGIRFEDNGIYFCQQKCNNTSEVYQCGTEL
RVMGFSTLAQLKQRNLTLDGIIMIQTLLIILFIIVPIFLLLDKDDSKAGMEEDHTYEGLIDQQTATYEDI
VTLRTGEVKWSVGEGHPGQE

<210> 67

<212> DNA

<213> Homo sapiens

<400> 67

67>Ly1450P, Old-SEQ-ID_6695, partial cDNA

aaaattgtatcacaacnaggggaaaacaaaataaaattagggggcaaagggttaggagtatgg
ggggaggggagagcaaacctatcgaaatatcttagaattttgctcagaaatcaactgctg
cctctcaagtgttgcattgtccctgcctaaaccaagaaggctaaacaaagccccctctgt
ttgaattcttaaggttaagaaatttcctaagctaaagaaaacactatttgctctaaaccaatgt
tagtgtggactcatttacaaataggcatgcctcacacacacagtcacaaaggcaagacactg
gctttgaatttaggctcatgtatgttgcatttatatatgtacctgattttttaggcccc
aggatgtggaccagagttaatgtcatgactcttcaagatgtatgtaaaagttgtccctta
aaaatctagagatgtatgtttatataatt

<210> 68

<212> DNA

<213> Homo sapiens

<400> 68

68>Lv1450P, partial cDNA

<210> 69

<212> DNA

<213> Homo sapiens

<400> 69

69>Ly1451P, Old-SEQ-ID_3507, partial cDNA
 cctaaggccgctaaggggctgcctcgctgtccatcagttaacctcggtttccctgagcagag
 taattgggtgagattgttcatggaggcattgtggctcttagtcctggaaacctacagtt
 ggtccaattcattatgccaagggtcgtctaggaggttcttgcataatgttgc
 cccgagagaagttaggtcccccttagatagaacgagtttcagaggtatggcagcag

<210> 70

<212> DNA

<213> Homo sapiens

<400> 70

70>Ly1451P, partial cDNA
 gcccgtccgcgtccaggagacagggtccatcaggaaatggaaacatggaaaggaaagag
 gggggccagctccctgagtcgttccaccagctgtctaaatacctctgagaaactc
 tggttctatctaaggggacctacttctctcggaatctcaataacttggacaagaacctc
 ctagacggacccttggcataatgaattggaccaactgttaggttccaggactagagac
 agcaatgcctccatgaacaatctcaccaattactctgtcaggaaacgaggttaactgt
 ggacacggcaggcagcccttaggcggcttaggcctccctgtggagcatccctgaggcg
 gactccggccagcccgagtgtatgcgtccaaagagactccgggttagggaaattgccccg
 gtggaatgcctcaccagagcagcgttagcagtccctgtggaggattaacacagtggct
 gaacaccggaaaggaactggacttgagttccggacatctggaaactttagactggagc
 tgtacatggatgggagcagcttccacccctgtcaaaagtgtactctgtgaagaagac
 gcccgtcccgactcacaacccggaaaggtgactggccacgcacgtgaagcatggagaaa
 ctcatcgccggactaattttctttaaaatttttagatctgcacatgttcaactgt
 cttccctcgactgagaactgtttccatatacatcaagtgcactgtggtaggacaaaag
 attgttacatttcttatttttaagggttacattttggggacccctttcttctgtt
 agctattaccccttcttgcacctagaaaaaggaccagtccatattgtattttaaaac
 tggatcatggaaagctttaattggatcaataacacgcataatgttggattttcttgg
 gctacatacccttggatagat

71>Ly1451P, partial protein

MDSRGSPGGGLGLPCGASLRRTPASPDSAIQRALPGRKLPWNASPEQRVAVPCGGLTQWLNTGKEIALGVRTSETCRLG
 AVHGWEQLHQLPLQSDSEEDDKPCSSHTRKLTPRTAEA

72>Ly1454P, Old-SEQ-ID_3577, partial cDNA

aaaaaggttatttcagcatttggcacctaaaaggaaacttcatctgttttacacagg
 ccagaagcaaaagacaagattgtatgttttttttttttttttttttttttttttttt
 tgataaaaaatatttttaagccgtgaaagtttatggatattctgggttaagcctgtt
 aagaataccacaaatagcttggagatcgtgtatttttttttttttttttttttttt
 gtgggattgtggatt
 actccagtaagtacttcgcacaacgtacatgtgttttttttttttttttttttttt
 taggtgtcccttggcagaataactggcatccacacgaaaaatagggttccataggat
 acagcattt
 ctgcatt

73>Ly1454P, FLJ40597, full-length cDNA

attgttatcaactcttgcataatgtatcaatgtccaaagaattggatataatttttacacaatat
 ttt
 cccaacaaggccaggatt
 tcacagcatatgaaatgaaaatcggtgcatttttttttttttttttttttttttttttt
 ggttagatgttattgttatt
 gaagggtgttatt
 ttacaccagggttatt
 ggtcaccagggttatt
 gggaaatggccggaaaaaaaacccatcatttttttttttttttttttttttttttttt
 aacatt
 cgacagcatgaaaaaaaaagacacttctgtcatcaacttgcatttttttttttttttt
 aattt
 cagaatataataccataaaggacaagtttttttttttttttttttttttttttttttt
 gatacagaatgttt
 aagaataatggatggatggatggatggatggatggatggatggatggatggatggat
 ttt
 ttatctgttt
 ctt

74>Ly1454P, FLJ40597, full-length protein
MLQRIGLILFLHNIVVVSNCFYFQAFLDEFTNWSRINPNKARI PMAGDTQGVGTVSKPCFTAYEMKIGAI
TFQVATGDIATEQVDIVVNSTARTFNRKSGVSRAILEGAGQAVESECAVLAAOPHRDFI ITPGGCLKCKI
IIHVPGGKDVRKTVTSVLECECERQKYTSVSLPAIGTGAGKNPITVADNI IDAIVDFSSQHSTPSLTKTVK
VVIFQPPELLNIFYDMSMKKRDLASLNLFQSTSMTCNL PEHWTDMMNHQLFCMVQELEPGQSEYNTIKDKFT
RTCSYYAIEKIERIQNAFLWQSYQVKKRQMDIKNDHKNERLLFHGTDADSVPYVNQHGFnRSCAGKNAV
SYGKGTYFADVASYSAKDTYSKPDNSGRKHMYVVRLTGVFTKGRAGLVTPPPKNPHNPTDLDFTSNTNN
RSPKLFFVFFDNOAYPEYLITFTA

75>Ly1485P, Old-SEQ-ID_2789, partial cDNA
cgaggctgagctccctggttctcttagacactgtccctctctgaaatgcaggccg
tgccttaatgggctttggattctgtctccagaccccttcatactgaaggcct
caggagaacagagaaaaaccagcgtctccaaactggccgttcaggactggggc
cttacccccactgtaaatgcactttacagcgtcgactatgc
tccttcagatagtggatgggtctctcgatcattctgtataactaacatttgccatgtt
aagtgtttccacatcatgttacacttcaactactccctggtgtgatatacggttata
gccccatttcacaattaagaattgggctaaaaggattaaagagtttttagaggaga
aacaqcttccttacaaqaggatccaa

76>Ly1485P, Old-SEQ-ID_2417, partial protein
RSHLTLLYCSAVKSASFTGGKGQSLRRASLETGWFFLCSPESPDSDEKGGLETECQKPIK
GTALHEREGAGILEKNORSS

taatatttgcattttccactggactcttccccgggctcttctggccagct
cctttgtatcccgcggcccggtcctcgccctcacccctcagccggggccccctg
ctgtcgaaagcggtcgaccggcagagggtgtatctggactctgggttctcagcccg
gggacagcgaaccggagggcagatcatccatcagaaaagagccggactgcccagcccc
cgccccctgccccctgcctttccggagcgcgcgcgcacccgtacggccgcttgc
ccccatcttgagccggccccaagctctggaccgtgtgccccatcaaggaagagc
caaggacccaaggagaaggctcaggagcggcggtgtggatgtccccctggctcagggccc
gcccgcactcccttcagtcttcctcttagggaccaggtagcatcagtgccttgat
ctcggcccttgcgtgcctgtccctgccccacctaagaaccataactgatctgggttccacgg
ctcccaagagctggaaaccctttagctactaagaaccataactgatctgggttccacgg
gacctgtgtgccttgcctgtccctgccccacccatctcagggtggggccaccccttccctcca
ctatgggctggccagtcggcaccgtgcggccacagggtccatggaa
tcgttctgtctttaaaatcagaaggaaagacatcattacccctttaggtcgaagaaaatgttt
tagtacacagaataacttattgtcttatccaaacagccataaaaatataactttaata
ttcttattgtatagaaaaaggaggtcatgaaggcagaaaatgcctggggccacgaacatccc
agtgtggccctggacggacatcatgtctggcaacacagctaaaatgcgggtgaagacca
gatttctgcacatggcggtacgggatgtcccttagagagcttcaagtggatttttgc
tttttattttctcttaataaaaatgtatgtttacattgtcagagaaaaaaaaaaaa
aaaaaaaa

78>Ly1500P, Old-SEQ-ID_5226, partial cDNA
aaagcgaattcatactataacagcagaaaacaaaacttcagattcagaatttgttattgg
caaaaatttattcttattatacctgcattatgggtatattactattaaaacagaatacc
atagagtaattgcattttgaaaattctntcatttacaatgcacttcaccaatggaaaac
agntaattccatttgaaaattaaaagaaaacagcacagagaaggtaatgcgggttag
caaagtatgggtctgcgtggggcaactaacctcaacagatttcttcctccatcgat
aataaccatgaaaatacacaattttacttagcacatttgttttaagtagctggttcat
tttgcattttccacatttcagatgttcaggatattgttacatcatgtttcagaaaac
cttgcatt
tctatatctcaaattaatatacatttcataacacctaccccttgnattaagacttgcaattt
tatcaatctattat

80>Ly1500P, splice-1 FLJ20706, full-length protein
MIYEEDAEWALYLTEVFLHVVKREAILLYRLENFSFRHLELLNLTSYCKLILSNSLRLDTPKKCQF
LEKILHSPKS VVTLLCGVKSSDQLYELLNISQSRWEISTEQEPEDYIVSIQSIIFKDSEDYFEVNIPTDL
RAKHSGEI SERKEIEELSEASRNTPA LAVVLPTEIPCENPGEIFIILRDEVIGDTVEFTSSNRKIRTR
PALWNKKVWC MKALEFPAGSVHVNVYCDGIVKATT KIKYPTAKAKECLFRMADSGESLCQNSIEELDGV
LTSIFKHEIPYYEFQSLQTEICSQNKYTHFKELPTLLHCAAKFGLKLNIAHLIQLCSGATWASKMNMEGS
DPAHIAERHGKHKEKKI FEDFSI QEIDINNEQENDYEEIDIASFSTYIPSTQNP A FHESRKTYQGSADGA
EANEMEGEKQNGSGMETKHSPELVGESS EDQYDDLYVFI P GADPENN S QEP LMS RPPPLPPR PVANA
FQLERPHFTLPGTMVEQ MERSQNWGHPGV RQETGDEPKGEKEKKEEEKEQEEEEDPYTFAEIDDSEYDM
I LANLSIKKKTGSRSFI INRPPAPTPRPTSI PPK ETT PYI A QVFQ QKTARR QSD DDKF RGLPKK QDRAR
IESPAFSTLRGCLTDQEE L I LIQEKVKN GKM SDE A LEK FKH WQM GKSG LEMI Q QEK L RQL RDCI I GKR
PEEENVYKLTIVHPPGGKETA H NENKF YVNHF S NKL PARP QV EKE FGF CKKD H

cattttgttttaagttagctggtcatttctgaatttcacattcagagttccagtcattattgtt
 acatcatgtttcagaaacacctgttatttagtgtctattgcataaccctgaaaacatttattt
 gaaaactttctatatctcaaattaatatacatttcataacccatcacccgttattaaagacttgcaattt
 atcaatctattatttcttagaaacaattactagtttagaaatagaaagcaatgttatcgcatataattt
 tcatgtacaaatgccacaaataattgaatgtttaaagctaaaaa

82>Ly1500P, splice-2, DKFZp667N1611, full-length protein
 GRENRGESLAGRVQVALGGQQCAGPSASTATMLPAAPGKGGLGSPDPAPCGPAPPNTKDIIMIYEEDAEE
 WALYLTEVFLHVVKREAILLYRLENFSFRHLELLNLTSYKCKLLILSNSLRLTPKKCQFLEKILHSPK
 SVTLLCGVKSSDQLYELLNISQRWEISTEQEPEDYISVIQSIIIFKDSEDYFEVNIPDLRAKHSGEIS
 ERKEIEELSEASRNNTIPLAVLPTEIPCENPGEIFIILRDEVIGDTVEVEFTSSNKIRTRPALWNKKVW
 CMKALEFPAGSVHNVYCDGIVKATTIKIYYYPTAKAKECLFRMADSGESLCQNSIEELDGVLTSIFKHEI
 PYEFQSLQTEICSQNKYTHFKELPTLLCAAKFGLKNLAIHLLQCSGATWASKMKNMEGSDPAHIAERH
 GHKELKKIFEDFSIQEIDINNEQENDYEDIASFSTYIPSTONPAFHESRKTYGQSADGAEANEEMELEG
 KQNQSGMETKHSPLEVGSSESSEDQYDLDLYVFIPGADPENNSEQPLMSSRPLLPPRPVANAFQLERPHFT
 LPGTMVEGQMRERSQNWGHPGVRQETGDEPKGEKEKEEEEKEQEEEDPYFAIEDSEYDMILANLSIKK
 KTGSRSFIINRPPAPTPTPRTSIPPKEETTPYIAQVFQQKTARRQSDDDKFRGLPKQDRARIESPAFSTL
 RGCLTDGQEEILLQEKVKNGKMSDEALEKFHKWQMKGKSGLEMIQQEKLQLRDCIIGKRPEENVYNK
 LTIVHHPGGKETAHNENKFYNVHFSNKLPARPQVEKEFGFCCKDH

83>Ly1500P, splice-3, FLJ34204 fis, full-length cDNA
 attttggtttcttcaagaattaacaaccactactcttgaattcttttagttaacacaggcatca
 ctacttccaattgtatctcaggatgtggatcctcatacacatttgaacaaaatccttgcggcag
 gaattcatatttgcataatgttgaagatgggttctgaagttagatcagaagtagagcttcaatgaccccc
 agaagcactgagtgaccaagtgcatacctgcacaggccatgtgtccatcgcttcagagcagctgggg
 atttgcttgcgtcccagagctatggtgcaaaaggcgggggtcgctaggggccactcaggaaagagaaccc
 agaaacatggcatgtgcacaaaaggtagtgcgttccatccagcttctgtgttgcgttgcgttgcgtt
 atgtcaactgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 aatgggctgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 ggagaatttcttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 tcaaatagcctgttagagacctaactccaaagaaaatgtcgttgcgttgcgttgcgttgcgttgcgtt
 aaagtgttagttacttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 aacgcagatgggagatctcaactgaacaggaaaccttgcgttgcgttgcgttgcgttgcgttgcgtt
 aaagattctgaagactactttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 gtgagagaaaggaaatttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 cactgaaattccatgtgaggatcctggatcataatttgcgttgcgttgcgttgcgttgcgttgcgtt
 gtagaggttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 ggtgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 agtacaacaaaaatttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 ggagaggttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 taccatatttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 acttccaaacttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 tcaggagcaacctggcatcttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 atggtcacaagaactcaagaaaatcttcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 agaaaatgatttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 catcatgaaagcaggaagacatacggcagactgtcagatggagactggcaatgttgcgttgcgttgcgtt
 gaaaacagaatggatcggcatggagacccacacggccacttgcgttgcgttgcgttgcgttgcgtt
 ccagtatgtatgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 agcagcagaccccttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 ctttaccaggacaatggggaaatggggaaatggggaaatggggaaatggggaaatggggaaatggggaa
 agaaaacaggagatgaacccaaaggagaaaaagagaagaaaagagggggaaatggggaaatggggaa
 gacccatatactttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 aaaaaactggggatcggatcggatcggatcggatcggatcggatcggatcggatcggatcggatcgg
 tccaaataggaaactacgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 gatgacaagtccgtggcttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 tcaggggctgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 gtctatggatgactctggatggatggatggatggatggatggatggatggatggatggatggatgg
 caggagaaaattacgacaactacgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 aactcaccatgtgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 cttcagcaataagcttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 taaaagaagtttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 ttggatttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 ttgttatttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 catagagaatttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 ccattttgaaaattaaaagaaaacagcacagagaagttaaatgcgttgcgttgcgttgcgtt
 tgagggactaacctcaacagatttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 cacatttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt
 ttacatcatgtttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgttgcgtt

ttgaaaactttctataatctcaaattatacattttcataacccacccgttgcattaaagacttgcaatt
ttatcaatctattatttcttagaaacaatttactagcttagaatagaagcaatgttacgtcatataat
tttcatgtacaaatgccacaaataattgaatgtttaaagctatgtctgagttttaagtaaattata
agaattaqccaataaaattgctctcgccctttggctaagatc

87>Ly1516P, Similar to CD47 antigen, splice_form-1, full-length protein
MWPLVAALLLGSACCGSAQLLFNKTKEVFTFCNDTVIPCFVTNMEAQNNTTEVYVKWKFGRDIFYTFDG
ALNKSTVPTDFSSAKIEVSQLLKGDAALKMDKSDAVSHTGNYTCEVTELTRGETIIELKYRVRVSWFSPN
ENILIVIFPIFAILLFWGQFGIKTLKYRSGGMDEKTIALLVAGLVITVIVGAILFVPGEYSLKNATGL
GLIVTSTGILILLHYYVSTAIGLTSFVIAILVIQVIAYILAVVGLSLCIAACIPMHGPLLISGLSILAL
AQQLGLVYMKFVASNQKTIQPPRNN

88>Ly1516P, cDNA DKFZp313F0317, splice_form-2, partial cDNA
ggagatatttcttgtcaatttaaggagaggtaaatttggtatcaatagaaaaaatgttctgaaaaat
ttaaaccctggaaatgtatttgcgttgaggcgtcataatggccatggggagagaacaatcaagaagca
ttgcaagtatgctcatatggaatgctaaggctgtgtttaaaaatatatatatggctgtcaatgtc
ttaggctcatggtagcagcagaaatcgtaataattcttcgtcacatgggttatccatattggagaga
attaactcaggtaaattactgtacactgtttgggttataatatttagagggatcacaactgtactga
tgtcccttgaagtaccattcttcataaaatctttttttcagaatggccagccaactgtgcacatccc
ttggatcggagattagaactagaaagtattcttcacattatttaggaaagaaaaggagttacttggcg
gttagcaatattctattttgtttgttttagagacagggtctattatgttgcacaggctggcc
tcgagctcctgggctcaagcaatgtcccacctcagctcccaactgtgcacatgtgcac
ctcacccatggcagttttattctgataaaatcatttatgagctcaaaaatgtactctaaaacccatct
ctgaactccatattaccatcagaaatttagatagtgttttagtctttttttagatagaacatagat
ataaggatcgggttattgtcaagtcaagggttgcatacatgtactatcctgtatgttcccaaataaagctct
gtatttatgtttagtttattggggaggctgtcaatgttagtgcattccaaaccatttaccctgttctac
tttaaaaagagggtggcttcttggatacaaggaccaactcactcccccaagggttccacagtaag
ggaggccatattaaagcccccattggcactaacagaaactggactctatgagctcagatacataactgg
gcctcacaggggtggacagtatgttagtcttaggaatttggaggatccattccatataaagaactgaagc
atcggttgccttcagcagcaagagaatgttagtgcattccaaaccatttaccctgttctac
ctttgattctttgcatttagccagctagtcacccttgcattatgcccactgttttttccatattcat
gccttcacagacaacttttccatcacaacttttgcatttttgcatttgcatttagatccagggttgcac
actttcccttccatcacaacttttgcatttttgcatttttgcatttgcatttagatccagggttgcac
actttgcatttagtgcatttttgcatttttgcatttttgcatttgcatttagatccagggttgcac
atggcttcccttgcatttagtgcatttttgcatttttgcatttttgcatttgcatttagatccagggttgcac
gcattgggttaataatagtaaggacacagagcatttttgcatttttgcatttttgcatttgcatttagatccagg
aaatccatgtgtcatccaggccaggcccaggtccagcggatggccctctgttgcatttagatcccttgc
qctqagtggttcatggcatgttgcatttttgcatttttgcatttttgcatttgcatttagatcccttgcatttgc

90>Ly1678P, Old-SEQ-ID_8607, partial cDNA
ccatatcatgtacaaaaaggtagttcttcgttgc
atgacttcacactttttcgtagttctctgttatgtatggcgtgagtgtgtct
tgggtaccgtgtactactgtgtgcctagattccatgcactctcggtgttgaat
aaatattggagaccggagggtAACAGGTTGGCTGTGATTACAGCTAGTAATCGCTGT
TCTTGTCCGCCCTCCCTGACACCCCAAGTTCCCGAGGTGGAAAAGCCTGGATCTCA
GCTCTTGCCCCATATCCCTCTGTAAATTGTACCTAAAGAGTGTGATTATCTTAATTCA
AGAGTCATAAAGACTCATCACATTATCATTGATCATCAGCAAAGGGTAAAGTCCTAGCAC
CAATTGCTTCACATACCAAGCATGTTCCATTCCAATTAGAATTAGCCACATAATAAAAT
CTTAGAATCTTCCTTGAGAAAGAGCTGCCTGAGATGTAGTTGNTATATGGNTCCCCCAC
CQACCATTTC

tacagcttagtcttcagtcgccttctggcgagttacatgcacaggattgtaaatgaaaaatgcagtcataattccagt
ctgcctctatgatgatgttaattattgtctttagctgtgaacaagggtatcaccactggaggaatagatgtatcccttt
gtacacatggaaatgcttctgttagtgatagaacaaataatgcAACGAAACTCTGTCAaaaaaaaaaaaaaaaaaaaa
aaaaaaaa

92>Ly1678P, splice_form_1b (longer), partial cDNA
ccatatcatgtacccaaaagttgtctgaagttcttcttagctggtaaagttaggagttgcattgcacttcacacttttttg
cgtagttcttctgttatgtatggcgtgagtgtgtctggtagccgtgtactactgtgtgcattccatgc
actctcggtgtttgaagtaaatattggagaccggaggtaacagggtggcgttgcattacagcttagataatcgctgtg
tcttgtccgccccccctccgtacaccccaagttcccaggatgtggaaagcctggatctcagtccttgcggccatataccct
tctgtatattgtacctaagaggtgtgattatcctaattcaagagtcactaaactcatcacattatcattgcatacagc
aaaggtaaagtccatgcaccaattgtccatcacaccaggatgtttccatattcaatttagaatttagccacataataaaat
cttagaaatcttcttgagaaagagctgcctgagatgtatgtttgtatatggtccccaccgaccatttgtgtctttt
tcttgtttgtttgtttgtactgcactgtgagttttgtatgtgccttcttgcacaaacaaacgcgagatgaactgg
cttagttagacaaatcgtatgcgcaggatgtatcctcccttgcattccagaataatgaatggtcaactttttaaaa
tctagatctctcattcattcaatgtatttacttaagatgaaccaaatttagacttatttaagatgtacagg
catcagaaaaaaagaagcacataatgtttggcgcattgcactcactgtgaacatgtgttaaccacatattaatgcaa
tattgttccaatacttctaatacagttttataatgttgcgttgcatttttttttttttttttttttttttttttttttttt
tacagcttagtcttcagctgccttctggcagtt
ctgcctctatgtatgttt
gtacacattt
tccacactggcgtaaagagaaggcccccaggcagcaggacatgtgccttagacttttcccaatgttgcatttttttttt
agaagagatggccctcaggacagctgcataaccatcttggacacatgtgggtgttttttttttttttttttttttt
gcacaacgtacattcccatatcacaacagtgtggacgtggaaatttcaagtcccaactgttttttttttttttttttt
gcaaaacaaagagatacatttccaggatctccactgcacatgttttttttttttttttttttttttttttttttttt
atttcaactaccccttgcatt
attnaacccttttgcattccctggaaacagggtgcctggattgccttcttcttcc

94>Ly1680P, partial cDNA

95>Ly1686P, partial cDNA

cctaataatgacattttcaaaagcttattataaaggAACAGTaaactcgcaattttggcataaagttagaaaaaa
cagatcaatgaaggcagaagagagactccaggaaacagaactgcacatttatgttttgtgaatgccagggattcagcttag
gtctgattgctcaccacacagaaagccaatctactgagacaacaagtactgccaggaagaaaggcttatgtctgtatg
ccagccaggatatggggagacaagtctaaaatctgtctgttaaccaataaaagttaggagttatgttaggagttgtctcaac
aggcagttaggttagttgaatcagggttctggcaccttgcgtgttaggatgcagcgatctggaaatcttcagcttctgatac

tatctgggagg

97>Ly1706P, FLJ21578, partial cDNA
tctaaaagctgcggattcctcgagcaactgttggccttggtagatgcccctctggagagatccccagg
ggtgcacgcattggcccttggaaaggccctggctaggacagggaccagagccagtccaggagaggaca
gagccaatggactgggttactgtAACAGCCCTGCTGGCAGAGGGACCAGGGACCGTCCTCCAGGGA
GCCCATGTCAGTCGGGCCAGAGGTGCCCCCTGAACCTGAAGGCCAATGAGACCCAAGAGCAGGCCAAGT
GGGTTGTAGACCCCTGAGGAGCTGGGCCCTGGTCCCAGGCAGCGCTGGCCCTGCTGCTGGGTCTG
GCCATGGTCGCCATTGGCCTGTCGCCCAATGGTGCACCGCAAAAGCGGGGACCCAGACCTTGGAGGCT
CAGTTGGAAGCAGCGCATCCGGCTGGGAGCCTGTGGGAGCGTAAGGGCAAGAGATACTGGGGCT
CTGAGCAGAGCTGGGAAAGGGTGGACCAAGGGGGACAAGCCAGAGGAGTGGAGGAAGGTTAACCCCT
AAGGGGGCTGGGTGACACTGGCTTAGTAATGGGTGATATTGTCATCACAGATTGTTGATT
TACTGTTTTAATCATATTACGATATTATTTCTCATTTCTGAGTTCTGGCGCCACTAAATT
TCACCAAGGGTCACTGCCTCAATCACCTAGTCAGTCCTCTGGTAGGGAAGGAACAGAGGAGCAGGGACAG
GACATCCACAGGGGGTGGTGGCAGTCCTCCACAGGGTGGCCAGGCTGTTCTCCCCCTCCTCCTC
TGCCCATGTCCTCTGCCAGTGAGGGCAGGGGCCACTCCCTGGAGAAGGCAGCAAGGGCTGGTTGG
TCTCCCCAAGGCTGTCGTTAACCAACTGTCACATAAATACTTACTGGGCCAGGCTCAAGGACACAGG
GAGGGTGGGATGAACCGAGGGGAGCTGTCAGTCATTGGAACAGGCCACGGCCATGTTGCGCAATG
AAGGGAGAGGGCATTCCTCTGGATGATGCCAGGCTGGTCACAGATCAGGGGACTGGCTGTG
ATGGGTGCCAAAAGACAGAGCAGTCAGGGAGAGGAGAGGAGAGGATGGGGAGCTGGGGAGCTCTGG
GTGACTGGGAAGGGAGGGCAAGAACAGCATAGGGTCCGTGACCATTCGGCAGTCAGGACGAGTCCTGG
ATGGATTAGGTTAGATTGATTACAGAGTCAGATTGTTGGAAAAATCAGCACCGGATTGGAGGC
TGTGCGACGCCATTAGAGGGAGGGAGGGGGTGGATGGCCAAGTCAGGGTAGGTGGGGATCTGG
GAGGAAGCGTGCCTGGGATGGGGAGGACACTCAGATTGAGGACCCAGGGGCCAGTTCTATGA
AATGGGAGCATGAGGTTGAAGTGAGGGCTGAGCAGAGGGAGCAGACACGCTGGGGACTGTCTATGGG
ATTGAAAATGTATAACCATTAGCAACAGGCGCGAGTCAAAACCCAAGGTGTTATCTAAACTCTGG
CAATTCTCTCTAGGAATTATCCTAAGGGTGGTGGGGAAATAATCAAAGCTGAAACCAATCTTA
TAACAAGGGTGGTAGGTAGCATTCTAGTGTGGAGAAAATCCAATATCTACCA
AAGGGTGTAAAAACACAATTGATTGGGGACTGTTGTTGAAACAGTCCTGATCTG
TTGCTCAGGCTGGAGTACAGTGGCGTGGCCACAGCTCACTGCAAGCCTCAACCTCCAGGGCTCAAAGATC
CTCCAGCCTCAGGCCCTGAGTAGTTAGGACTACAGTCAGGCCACTACACCTGGCTAATTGTTGATTAG
GATTATCATTAGTTAGAGACAGAGCCTGCTATATTGTCAGGGCTGTCTCAAATTCTAAGCTCAAGC
AATCTTCTGCTCAGTTCCACGTCGGTAATTACAGGCGTGGAGCCACTGCACCTGACCCAACTGTGT
TTTAAAGTATATGTCAGTTCAAAACCTGTCAGAAAATAGAAAATGTCATGGTGTCTGGCT
GGCTGATGGGATTCACCTAATTAAATGTCAGGCTTATAATTCTGGTTGTGAAGTGTTCACAAAAA
AGAGACATTCTCTAATATAATTAAACAGTAATGTACTCATGTCATTACTCTTTGTAA
QAQTATATTACAAATGTAATGACTTTGTACATTACTCTTTCTTGCCAAAAA

98>Ly1712P, partial cDNA
ccacaaaataaggcttaattcaaaaattatgtaaattaatgtaatataatattacatgccactaaaaagaataaggta
gctgtatattcctggatggaaaaaacatattaatatgttataaactattaggttggtgcaaaactaattgtggtttt
gccattgaaatggcattgaaataaaagtgtaaagaaaatctataccagatgttagtaacagtggttggctggaggttg
gattacagggqagcattgattctatgttngtatttctatantgtttgaatgttttagaatgaatctgtntt

99>Ly1729P, Old-SEQ-ID_6586, partial cDNA

101>Lyl1729P, hematopoietic cell-specific Lyn substrate 1 (HCLS1), full-length protein
MWKSVVGHDSVSVETQGDDWDTDPDFVNIDISEKEQRWGAKTIEGSSGRTEHINIQLRNKVSEEHDVLRK
KEMESGPKASHGYGGRFGVERDRMDKSAVGHEYVAEVEKHSSQTDAAKGFGGKGYGVVERDRADKSAVGFDY
KGEVEKHTSQKDYSRGFGGRYGVKEKDKWDKAALGYDYKGTEKEHESQRDYAKGFGGQYGIQKDRVDKSAV
GFNEMEAPTTAYKKTTPIEAASSGARGLKAKFESMAEKRKREEEEKAQQVARRQERKAVTKRSPEAPQ
PVIAMEEPAVPAPLPPKISSEAWPPVGTTPSSESEPVTSREHPVPLLPPIRQTLPEDNEEPPALPPRTLE
GLQVEEEPVYEAEPEPEPEPEPEPENDYEDVEMDRHEQEDEPEGDYEEVLEPEDSSFSSALAGSSCPA
GAGAGAVALGISAVALYDVOGEGSDELSFDPPDVITDIEMVDEGWWRGRCHGFGLFPANYVKLLE

102>Ly1848P, partial cDNA
ctgacagacatctggcttcagttcctcagtcaccactactttgtaccaaattcactgtttggctctaaaatctaatttt
gagtttaqcaaggatg

103>Ly1859P, old-SEQ-ID_640, partial cDNA
ccagagtgcaggatacatcattggaccaagggtctttcaatttctggtcaatccct
cgacaaacccccccggatgacgtcctcatagatgcctcagtggtcagagccctggctgc
ccacggcaaggacatccccctcgaactcaggcagtccttttgcagccctggctcgagg
ggctcagcacaaaaggtaaaaagatgcagagaccccagcctcgatgaacctcctctgc
ccaaccggctgtccgatttgaatttcttcagcacgcggccctgactctctccagccct
qqqcaqccctggtcacagttgaggggccgtcgtcagacaactggtcagccag

104>Ly1859P, old-SEQ-ID_2452, partial protein
LADQCLTTALNCDQAAQRLERVGRVLKKFKSDSGLAQR FIRGWGLCIFLPFVLSQLEP
GCKKELPEEEGDVIAVGSOALTTEGIYEDVIRGCLLORIDOELKKTGANDVSCTL

105>Ly1859P, Old-SEQ-ID_3313, partial cDNA
ctgcaagacagcagagaanctgccaatatccaggtagcagatgactttgctggcaagcag
aggaaagnccgtaaaagcttgcgtcccagccaggaaacttgacaccaagntaagatttggaa
gcttaggaacacaaccaaaaggctcacagcaagcggagaaaaaaaaaccccaaaatctgtaaa
cctgtatcacaaaqcqttcatatccttcagatataaagagttattagatatcaataagaa

aaatgc
aaacactc
ctgaaaagtagaaaaaaagctatgaacaggcaattcactgaaattaa
aaaaaaaaaa

tgcagtgagtggattgcaccactgcactccagcctgggtatgggagtgagaccctgtctcaaaaaac
aaaatccaaatatgtgatttagccattacatgttttagtttttttaatttcagtgaattgcc
tgttcatagtttttctactttcaggagtgttgcattttcttattgatactaataactttata
tctgaaggatatgaacgcttgtgatacaggttacagatttgggtttttcccgcttgctgagc
cttttggtttggtttctagctccaaatcttaacttgggtcaagtttccgggtggagacaagctt
accgacttctctgttgcacagaaagtcatgtcaactggatattggcagcttctgtctgtcttgc
gtgttccggagtgggttccacaggattccctgttgcagtttgcagaggactttcaca
ctccctggagacggtttcccccattctgttgcagtttgcagtttgcagaggactttcaca
gaccccttccaccaatttcccaaccccacccatccaaaatcacatttgcataacatattgcacttc

107>Ly1859P, FLJ00140, full-length protein
QAVVVGKGRGAPGDDSSMGGRPSSPLDKQQRQHRLRGQVDTLLRNFLPCYRGQLAASVLRQISRELGQPQE
TGSQLLRSKKLPRVREHRGPLTQLRGHPPRWPQPIFCVLRGDRLEWFSHKEEYENGHCLGSTALTGYTL
LTSQREYLRLDALCPESLGDHTQEEPDSLEVPSFPLFLQHPFRRLHLCFAATREAQHAWRLALQGGI
RLQGTVLQRSQAPAARAFLDAVRLYRQHQHGFDDVTLSDAEVLTAVLMREQPALRAQTLPGLRGAG
RARAWAWTELLDAVHAAVLAGASAGLCAFQPEKDELLASLEKTI
RTPDVLQRLRQARAVGRLRTDIDRGL
ESCLRRREVDPQLPRVVTLLRTVEASLEAVRTLLAQGMDRLLSHRLRQSPSGTRLRRREVYSFGEMPWDLAL
MQTCYREAERSRGRGLQAAQFGFLGMQSLVFGAQDQLAQMLADAVATFLQLADQCLTTALNCQAAQRL
ERVRGRVLLKKFKSDSGLAQRFFIRGWGLCIFLPFVLSQLEPGCKKTESRSVAQAVVQWCIDLSSLRPPPPR
FKRSSHLGLPSSWDYRHPL

108>Ly1866P, Similar to hypothetical protein PRO1722, full-length cDNA
ctagaatgctaattgcaacttaggcctatggttctagaaacggcagctgtggccctttgccttcc
cctgttcttggcctcacatctccaggctgagctgcggcttggcttcgtgcctctgtcccagagat
ggtcccaggagccatcttagggcaggtagactgaggctctgtggaaacaggagccacctgctagga
gacccttcctgaggaagtccctacctctcccttggatgtaaaaatggtccagcagagacaagctcc
cgtggaaaacagacaggagcatggggcagctgtcatggctgtggccggcactttcctcagagtttctg
ccttgcgtgtccaggagccatcttgcaccaaggacttggtaggcagaggcagccccactgtaaagaag
ggtcagattaaaacaaaaactgccaaaagcatccccctgtggcactggcatcattctct
gcttcctgggaggaatttttccatgttattgaagggatggttcattaaggactccccctcaga
gctcaactcagaccccaaggacagaggtactgggtcttggactgttactgttactccttttcccaggat
actgaaggggtgcacagagagaggtcttcatggcagaccggcctcacagctaaatgggagaggactca
tgttacctctgcagggcttgggtcttgggggtcttgcaggggttgcagcgttcccccaaggactgtatc
atccccatgtccctcagctcagtgcttctcccccccccccccccccccccccccccccccc
gaaccaaggctatgacttctggagagagggctcaggggttgcagggctgcacactccacccctcagg
gagcttaggtttctcagaggctcagctggacagacttttagaaaagtttagcattaaagctgttta
aaatatgaagttgttttgcagggcttgcagctgactgactgtctgaagttgagacgaggaa
ttatccatgtggggcccaatgtatctaattggggacaattgtgcctcatatgtctcaa
attccctggcccccaagtttagccccctccaggagtggtcaggggtcacagctgccccactctataag
cagggctaattgttaccccttgcagaaatgtttttggctccatccccaaatactcacaagggtttatc
agacgcccgtctaaagtccagcatgtcagggaccctgttaggatctcggttgcggtagtggggctgc
tctgagggtctccactggctgcatttagccatgtgccttgcagactcaggggtttactccccatt
ccttggctctggagcttccccaaagaatatacatcagagaaaaggaaaggggcctgcaggaccattt
ggaatgatgtttaatactgaaatgttgcactgttgcacactgttgcctccatatggctgttgc
gggagctgccttcaggctgttgccttcgtgtcagcagctgccttgcgttgccttgcactgtcccttca
cacccctgcctggccaaggggctagacactccaggctaaagcctcagattcagtgccaggacacaagctcatg
cccccttgccttcaggactgacacttgcagcccccacttgccttgcactgttgcaggacacatttgatgg
tatt
gtgcagtgccctgatctcgctcaactgcaccccttcgcctccagggttcaagcgatttttttttttt
tccagagtagctggactatagacatgcacccaccacgccccgtaatttgtattttttttttttttttt
gttttgcctatgttagtgcaggctggcttgcacttgcacccatgttgcaggacacatggatgg
tatt
gtgttgcaggatgcaggcgcacgcaggccaccaggccaggctgtgttgcaggatggatgg
ttaaaacgagggtaaagagaaaagccagtgtttctgaggtaataattctgcctcaggaaacttcc
cccaccacgccccccctaaaaaatcactcggttgcctccaggacttctaaagcttgggctccaggaaa
tcatccacttagatgtggagattcagagatttttttttttttttttttttttttttttttttttt
aagggtttagaatagaccagagggtgtccctttccacagataatggatcggctgttgccttgc
ggaaagaggggagggtgtcaagctgtaaaaactggctttaggttgcactgttgccttgc
tgcgttgccttgcgttgcactgttgcaggatggatggatggatggatggatggatggatgg
ttgttgcgttgcgttgcactgttgcaggatggatggatggatggatggatggatggatgg
atgttgcgttgcaggatggatggatggatggatggatggatggatggatggatggatgg
ggccaggctgcgtggctctgggtgagctgaagaacccctgcctgtggacttttgc
cgagagaacatgttgcctccaggacttgcgggttgccttgcggccctgggttgccttgc
gttttatgagcaccatgttgcactgttgcaggatggatggatggatggatggatgg
ggggaaac

109>Ly1866P, Similar to hypothetical protein PRO1722, full-length protein
MESRSVAQAGVQWPDLGSLQPLPPRFKRFFCLSLQSSWDYRHAPPRPANFVFLVETGFCHVSQAGLELLT
SSDPPPPRPPKVLR

110>Ly1867P, Old-SEQ-ID_3570, partial cDNA
aaaccttaagaaccacataataactatataatgtctttctgtacaatctcaagaaacact
ttcattcattaaaacatcatgaaaatccttaaatgtgttaaatggaaaaatggaaacca
tgaacaaaaagctatacatatgttaggtgcataatattatctcctcgagtggagaaatct
ttctaaggatagaaaacaatggtagaaaaagagaagatagatttgctggatataacaata
aaaaatttctgcggaaaaatggaaaaattcaatttagaaaaattcaataataaacaaaatt
aatatagacaaagggtgttacacagggtgttcctcagagaagataaaatcatgattattaa
cataaaaagaaaatgttcaatgttctagaagacaaataattacaacactaaacaaaattgt
atatttggtagattggcataaattataataatccaaacatttgagttangtggaatataaat
tggtaaaaatattctggaaagacaatttgg

111>Ly1868P, partial cDNA
agaagtgattatgggattaaaagaatacataattacagtgtttgggattgggctttttttttaatagaaaagcag
aaacttcataaataatagctgtgttagataccagataacaatattgttccctgaagatatgcacctactagaacta
ctcacatataatgtccaataattgtctacttaataggatggtaaaatagctgataataaagtcaagacttc
tgtacattgtgatttgcacaaattcattgttttatccacttaaaggaaacatgtgtgtggggagggggtggggactggg
cacaacataatctgaaggagatcaaacatctgttaaggacaggatcccagtgtatgataatatatctgaaaacacaaggcat
ttttatttttatcccaattaacttgaggtaactctaattatgtgaagcactcgattgcactatgaccccttgagttgatggg
caqcttqttccctctcaattttgttttttaatatgcaaa

112>Ly1886P, Old-SEQ-ID_6454
aaaaaaaaagacaattttagcaggacgaccctctccaaatctgggttagcatggtttagcctgtg
cagtaacaacgttaggcttgaggatgggtncaaatgaaaatgattctgattcgaaaacgtt
ttgactttggactgtanaagctttcttgcacccgtgttgtggagggaaaggaaaagaagc
ctt

113>Ly669S, intercellular adhesion molecule 3 (ICAM3), complete cDNA
cagctctgtcagaatggccaccatggtaccatccgtgttgccaggcccagggctgctggactctgcgg
tctgtgtctgtcgtaccccaagggtgtccaggggcaggagtccctttcgccggggagccccagaacctgt
gctctgtgtggagggtccctgttgtgaactgcagtaactgattgtcccagctctgagaaaatcgccctg
gagacgtccctatcaaaggagctggtggcagtgcatggctggcagccctcaatctcagcaacgtga
ctggcaacagtcggatcctctgtcgtactgcataacaggctccctcaatcac
cgtgtacgggtcccccggagcgtgtggagctggcaccctgccttggcggccgggtggccagaacttc
accctgcgtgccaagtggagggtgggtgcggccggaccgcgtcagcgtgggtgtctgtctgtggagg
aggagctgagccggcagcccgactggaggagccaggccggaggactggcactgtgtctggccagcagaga
cgaccacccggagccctttctcatggcgcacagaactggacatgcagcccccaggggctggactgttcgt
aacacccctcagcccccccccgcacgcgtccgaacctttgtctgtcccgtagcccccccgccctgtggcccccc
gttcttggagggtggaaacgtcgtggccggactgcaccctagacgggtttccagcgtcagaggc
ccaggctacctggcgtggggaccagatgctgaatgcacagtcataaccacggggacacgcctaacc
gccacaggccacaggccacggcgccgcggatcaggagggtgcccggagatcgtctgcaacgtgaccctag
ggggcgagagacgggaggcccccggagaacttgcggcttttagttctcttaggaccatgtgaacctcag
cgagcccccccgcccatgggggtccacagtgcacgttagttgcacgggtgggtcgaggtccaggtaac
ctggacggagttccggccgcggccccgggcagccagctcaactcagtaaatgttacccggaggtgacg
acggacgcagcttcttctgcagtgccactctcgagggtggacggcgagttcttgcacaggaaacagtagcgt
ccagctgcgagtcctgtatggtccaaaattgaccgagccacatgcggccactgtggccggggatgtggaaagat
aaaacgcagacacgtccgtcgcagtgccaaaggccggggacccctgcgtcaacgttgcgggtttgaaggaaag
gttccaggccggggagggtggccgggtggggatccctgttgcgtcaacgttgcgggtttgaaggaaag
ccaagcgtccagctcaccaggaaatacaccctgtgtggatggacatttggaggtggagctccca
tttgcggccgttctgtggccgggttactgcaccctggcgtggactatgcactggcttaatgtacg
tcttcaggaggcacaacggagcggcagttaccatgttagggaggagagcacctatctggccctcagtc
tatgcagccgcacagaagcaatggggaaagaacccgtccagagctgagtgacgcgtggatccggatcaaag
ttggccgggggttgctgtggccctcagattccgcaccaataaagccctaaactccctaaaaaaaaaaaaaa

114>Ly669S, intercellular adhesion molecule 3, complete protein
MATMVPSDLWPRACWTLLVCCLTPGVQGQEFLRVEPQNPNVLSAGGSLFVNCTDCPSSEKIALETSLS
KELVASGMGWAANLNSVTGNSRILCSCVNGSQITGSSNITVYGLPERVELAPLPPWQPVGQNFTRLRCQ
VEGGSPRTSLTVVLLRWEELSRQPAVEPAEVATVLASRDDHGAPFCSRTELDMQPQGLGLFVNTSAP
RQLRTFVLPVTPPRLAPRFLEVETSWPVDCTLDGLFPASEAQVYLALGDQMLNATVMNHGDTLTATATA
TARADQEGAREIVCNVTLLGGERAREARENLTUVFSFLGPIVNLSEPTAHEGSTVTVSCMAGARQVTLGDGV
AAAPGQPAQQLNATESDDGRSFFCSATLEVDEGDFLHRNSSVQLRVLYGPKDIDRATCPQHLWKDKTRHV
LQCQARGNNPYPELRLCKEGSSREVPVGIPFPVNVTNGTYOCQASSSRGKYTLVVVMDIEAGSSHFPVVF
VAVI-LTI-GVTVTIVLA MYVFRHORSGSYHREESTYLPPLTSMQPTTEAMGEEPSRAE

115>Ly672S, Old-SEQ-ID_3042, partial cDNA
cctgtatcccgaatttcagttggacttacagcgaatctgagagaaaaaccgaggaga
cgatactcaggccatcaagtacttgtcatacctgctgtaccctctgtgtcggggggtgc
tgtctatcacccatcaaatataaaqagactqgtactcctqgttaatcaacagct

cgtcaacggggctatgcctttggttcccttcatgtgcggccagctcttgcact
caagttgaagtcatggcacatctgcacctggaagg

116>Ly672S, cisplatin resistance related protein CRR9p, full-length cDNA
cagctccctcaccagcttgggtggcggttcgtggctacgtggcacaacctgctgggtcatgtac
ggcatcgctcaccccccgtgtccggcgcgcacactgcacccctacctggcgccggccca
agctgcagctgagcggtgtacaccacgacgagggtcccacctgggtgtgagaacaacatcgacactggctt
aatgtgaaagactttgtatgtggagtccaaatttgaaggacagtaatgtttctgtaccaaaaacg
agaaaacaatgggacgctgtatgcctacatttccatcacgtgggtctgtccgtggcacgcacggga
agcagggtcacctggtcagtcctgtgaccacctacatgggtccccaaagccagaaaaatcaacactgtcac
cggggaggtctgatacacacagcagatcgaggcggagaagaagccgacgagtgtccctggatgagccagtgtcc
caactggcaccgcggctggcgtaacgtgatggcgacaactttgtttcgacgggtctccctgcctg
ccgatgtcatcggtacatgaagatgtccacgtggggaaaaccgtgcattacatgcaccatctgttat
cgaccagctcagcaaccgcgtgaaggacacccgtatggtcataaaccgtccaccaccgagctgcccctcacc
gtgttctacgacaaggctctactggggcgggtcgcttggatccacatgcaggacgcgtgtactccc
tgcagcagttcggttttcagagaaaagatgtgtatgggtgaaaggattttttagataccaactata
cttcctggcgctgacccctttgtcgacgttccatctttgtattttcgccctttaaaaatgac
atcagtttctggaaagaagaagagacatgtccaccaaggcagtgctctggcgctgtttca
gcaccgtggcatcttcgttctgtggacgacgacgacgacgcgtgtgggtggccgggtgt
tggagccgcattgagctgtggaaagtgaagaaggcattgaagatgactatttttggagaggcgtatg
cccgaaatttcagttggcacttacagcgaatctgagaggaaaaccgaggagtacgataactcaggccatga
agtacttgtcatacccgtgttccctctgtgtcggggtgtctattactcctgtatccaaata
taagagctggactccgttaatcaacagctcgtcaacgggtctatgccttggttcccttcatg
ctgccccagctttgtgaactacaagttgaagtcagtgacatctgcctggacggccttcacca
aggcttcacacccattgtatgcgttgccttcatcatcaccatgcggccacgttcacccggctgc
ctgttccgggacgacgtgggtttctgtgttccatctgttccatgcgtggctttatctgtggataaaacgc
agagtgaacgagtttggggagttccgtacgaggagaaggccacgcggcccccacacggactgaaaggccgc
ccgggctccggccaccaactgtcaattgttcaatgagtttggaaagcatttggaggaatttc
tagacatgtttttgtgttgcggccaaatcccttcgcacatttcagacatctcccaagttccatca
cgtcagatgtttggagctgttagcgttacatgcgttccatgcgtggatccatgttccatgttcc
gtgtgtccgggtcacccctgttagctgtggctccggcacacgcagtgccgggttccatgttccac
gcgggcaagggtggagccctcacaggcaaggggtgttggatttccatgttccatgttcc
ctcccttatgtgaattcaaacacgtatggaaatttccatgttccatgttccatgttcc
cttttggttt

117>Ly672S, cisplatin resistance related protein CRR9p, full-length protein
MWSGRSSFTSLVGVFVVYVWHTCWMYGVYTRPCSGDANCIQPYLARRPKLQLSVYTTTRSHLGAE
IDLVLNVEDFDVESKFERTVNVSVPKKTRNNGTLYAYIFLHHAGVLPWHDGKQVHLVSPLT
INLLTGESDTQQIEAEEKKPTSALEDEPVSHWRPRLALNVMDNFVFDGSSLPADVHRYMKM
PILFIDQLSNRVKDLMVINRSTTELPLTVSYDKVSLGRLRFWIHMQDAVYSLQOFGFSE
DTNLYFLALTFFVAAFHLLFDLFLAKKNDSFWKKKKSMIGMSTKAVLWRCFSTVV
VPAGVGAAIELWKVKKALKMTIFWRGLMPFQFGFTYSESERKTEEYD
LNKIKWSWLSLINSFVN
SHRLACFRDDVVFLVLYQRWLYPVDKRRVNEFGESYE
KTRAPHTD

118>Ly675S, KIAA0906 gene, partial cDNA
cttcccgccccagccaaggctgcgtttacgtgtcgacattcaggagctgtacatccgtgtgggtac
aagggtggagattgggaagacagtgaaggcatacgtcccggtctggacttgacaaagaagcccttccttg
ccaaatacttcccttatggacctgaagctccgagcagcctcccgatcattacattggcccttg
tgaaggcccttgacaactacaccatcacattcctcatccgcgggtgtggccatccggccagaccagtctaact
gcaagtgtgaccaataaagctggacagagaatcaactcagccccacaacagattgaagtcttcccccgt
tcaggctgtatgcccaggaaagggtgacactgttatacgggccacgtacgggtcacccggggcc
ccagccctcagttccaaacatcctttccatcagaaatggagagcgttgcgtgtggccggggcc
gtacaggggccctgcctatcggtttccatcagaaatggagagcgttgcgtgtggccggggcc
aggtggtcatcatcttcaggacactctgtgttgcagggtggagggtctgtctgtcaaggccgtgaggatccgcgc
ccccatcatgcggatgaggacgggcaccaggatgccatctatgtcaccggcatcacaaccaccagaac
cctttctccatttggaaatggccgtccaggcgttgcacacttccactgtgttgcaccaagcgggacgtccgg
acctccggaggcgccaccacggcgatccgactcccgtaactacaactttggcatgaacgtgt
cgccgggtaaaaggccggaccgggtcgagggtgttcaaggctgtggacccacatcgccggcagctg
tatggccatggccagagaactctcgatggatggatccaagtcagggtttgagaagctgcagctgtcaacc
ctgaaatagaagcagaacaaatattaatgtcgcccaactcatatataaagctgcagacaaacagggtatgg
tgcagccctctgttagctaccggcgtctggatggaccggaaaagggttccagggtgttgcatgttgcatgaaaa
ggctttcttagcatcagggtctatgtatcgggacatccaccatcgaagtgttgcacaaagggccctttgggg
ccaaacccaaaccatcatgtgtgtgttcaaggatcccttgcgttgcagggtttccatgagccctgt
cctgcacaccggcggccatcggggggccatggccgtgccttggaaatggccgtgacccactgtccac
ttccacgacaactctggagatgttccatgtccacagggtgttgcacttgcacaaacagagac
acttgtcagatcggtggcccccaccaacaacaccctgcgtgtccgcacagtcaacgtggcccttgac
actgtccgtgtgtggacgcagacccggccctcggacttcgtccatgcctgttgcacaggcc

atccccccagagctgtctggggccatggggacgtgtctgtctggccactgttctgaccagcc
tggaggccttcaggAACCTGGAGCTCCTCAGCCAACAGCATCTCCACATGACCCCCAAGACGGGTGT
ggctgtggccggggcggtggatccgtacggttactatgaggtcgctggcacctgaggacataag
gagggtgtggtcagcgtccctcagaggatcatggccgtcacctccacccatccagacaagcttccagg
aggctacagcctccaaagtgttgcgggtggagacagaagcttaacctgagaggcgagtgcacccc
caccaggaggaaagtcatccaggcctgcacccagagacccctcatcagctgcaggccatgtcaaggccg
gcccgtcttgattttccatctaagatgttgtaccctggagccacagttgacactgtctcggccagg
acttctgtcaatcacaatgcacaggctgacggacaacgcggaaacgcacctgagcatgaagaagacgc
tctgtgtgtcagtgccttcctccaggcacttccacagacggcgggtggggccggagggtgccttc
agcccagggtcttcggccgaccaggctgaaatctttgagcaaccactacaccagttccgagatcaagg
tctttgggtttccggagggtctggagaacttgaggtgaaatccgggtccccggcgtgtgcattcgc
aaaggagaagtctttgggtggcccgacttcatcacatacaggctggcgtctggaccggcggctggc
agccaaggccctgtccactaccctgaccccttcacagccgggtgaccaaccaaggcattgcctatccag
tgacagttgttttgtatggatgcgggtggggccggctttatggagccagcttccagcacttct
ggattccattaccaggcatgttccacgccttcggccctgtggctggacagcggtcatgtatcatagcc
taccacactgtctgacgccccggatctgtgtgcctgcagccctcagcctcgaggccctgac
acagccccactatccgtgcctcatccccacatctccaaatgcattgccttcgtcgcggaaaggccag
ccctccctcagggtgtggagcccgactatgcctccactaggccgcgtgaaggttcccgaggatgg
tctcaggccgaggcctgtgcaccccccacatggacatccctgtcattcacactggaaacaaggcccccc
agatgagtgcggccggcccgaggccacttcactgccttcacacagactgttagttccgctgtc
ccattagctcatttatgttaggagttaaatgtgtttttttccatgttacaaaagcttaagac
ttttggctattccctttgtatgggttgcattgggttctggacatgtgttttttt
ctagccctgtaaaatcttccttcataagactttgagcatttttttttttttttttttttttttt
gggtatgttactgttagtggctcaggaaaggattgtccaggacttttaggggggttttttttttt
ttccccctgtaaaacttactttggcccttagtctgggtgcttaggactttgtgaggacatgggacat
gagtgtccctgtatctgcgcactgcgcacagggaaaggccctcaggaaccagcacctggagggcaggatgc
caagccctgggtgagcgagaggctggagaacacaggagctcaccaggccgtgtgcacccatgggcca
ctgtgaacagacttcaggcctgtgttttttttttataagccgttgagacatctgtatggacttggctttagg
ccctgctggacatccacgtgtatcccttcactccatcaggacaccaggactgtcccttagaaaaatg
tcctttagatggcaggcaggactcatatttctgtgtgtttggaaaggccgtgtgcctgcctcag
cacaagacccagggtcatttgcctccctgtttctgtgcactccaggacccatcagcatctgagccac
ccgcctgcagggtgagggccacttcatggcaggcttcatggcactccaggacccatcagcatctgagccac
ggccggcccttagagccggcctggggcaatgtatggggggggccacccaggccgtgtgcctccatccagaa
gggacttcccccaggggctggggggaggagacccctgtggaaaaggctcttttcttccacgtcctgat
ttagattttctcagatcaggccccctgtgtccaggccaggctggccacccatcagggagatccagagac
tcattgccttcatggccatccatgcgtggacgcgtgtgtggagactccaggatgcgggatccgcacaagtc
ccttcagtccttcagggctggccatgtgtgtttttctaaagactggggaaaaggaaaggaaatttgtgcctt
gcataattacttgagcttaaactgacaacccatggatgttaataggagccttctacttggttatttaataaa
gttctatgtgatTTT

119>Ly675S, KIAA0906 protein, partial protein
FPAPAKAVVYVSDIQELYIRVVDKVEIGKTVKAYVRVLSDLHKKPFLAKYFPFMDLKLRAASPIITLVAD
EALDNYTITFLIRGVAIGQTSLTASVTNKAGQRINSAQQIEVFPPFRMPRKVTLLIGATMQVTSEGGP
QPQSNILFSISNESVALVSAAGLVQGLAINGTVSGLVQAVDAETGKVIISQDLVQVEVLLRAVRIR
PIMMRMRTGTQMPIYVTGIFTNHQNPFSFGNAVPGLTFHWSTKRDVLDRGRHHEASIRLPQYNFAMNV
GRVKGRTGLRVVVKAVIDPTSGQLYGLARELSDEIQVQVFEKLQLLMNPEIQAELQILMSPNSYIKLQTNRDG
AASLSYRVLVDGPEKPVVHVDEKGFLASGSIGTSTIEVIAQEPCGANQTIIVAVKVSPSYLRVSMSPV
LHTQNKEALVAVPLGLMTFTVHFHDNSGDFVHAHSVLFATNRDDFVQIGKGPNTNCVVRTVSVGLT
LLRWVDAEHPGLSDFMPLPVLQAISSPELSCAMVGDVLCLATVLTSLEGLSGTWSSANSILHIDPKTGV
AVARAVGSVTVYEVAGHLRTYKEVVVSVPQRIMARLHPIQTSFQEATASKVIVAVGDRSSNLRGECTP
TQREVIQALHPLTEPLISCQSQFKPAVFDFPSQDVFTVEPQFDTALGQYFCSITMHRLTDKQRKHLSMKKTA
LVVSASLSSSHFSTEQVGAEVFPSPGLFADQAEILLSNHYTSSEI RVFGAPEVLENLEVKSGBPAVLAF
KEKSFGWPSFITYVGVDPAAGSQGPLSTLTFSVPVNQAIAPTVAFMDRRGPGPYGASLFQHFL
DSYQVMFTLFALLAGTAVMIIAYHTVCTPRDLAVPAALT PRA SPGHSPHYFAASSPTSPNALPPARKAS
PPSGLWPSPAYASH

```
<210> 121  
<211> 1270  
<212> PRT  
<213> Homo sapiens
```

Cys Phe Thr Gln Lys Leu Val Glu Lys Leu Tyr Ser Gly Met Phe Ser
 50 55 60
 Ala Asp Pro Arg His Ile Leu Leu Phe Ile Leu Glu His Ile Met Val
 65 70 75 80
 Val Ile Glu Thr Ala Ser Ser Gln Arg Asp Thr Val Leu Ser Thr Leu
 85 90 95
 Tyr Ser Ser Leu Asn Lys Val Ile Leu Tyr Cys Leu Ser Lys Pro Gln
 100 105 110
 Gln Ser Leu Ser Glu Cys Leu Gly Leu Leu Ser Ile Leu Gly Phe Leu
 115 120 125
 Gln Glu His Trp Asp Val Val Phe Ala Thr Tyr Asn Ser Asn Ile Ser
 130 135 140
 Phe Leu Leu Cys Leu Met His Cys Leu Leu Leu Asn Glu Arg Ser
 145 150 155 160
 Tyr Pro Glu Gly Phe Gly Leu Glu Pro Lys Pro Arg Met Ser Thr Tyr
 165 170 175
 His Gln Val Phe Leu Ser Pro Asn Glu Asp Val Lys Glu Lys Arg Glu
 180 185 190
 Asp Leu Pro Ser Leu Ser Asp Val Gln His Asn Ile Gln Lys Thr Val
 195 200 205
 Gln Thr Leu Trp Gln Gln Leu Val Ala Gln Arg Gln Gln Thr Leu Glu
 210 215 220
 Asp Ala Phe Lys Ile Asp Leu Ser Val Lys Pro Gly Glu Arg Glu Val
 225 230 235 240
 Lys Ile Glu Glu Val Thr Pro Leu Trp Glu Glu Thr Met Leu Lys Ala
 245 250 255
 Trp Gln His Tyr Leu Ala Ser Glu Lys Lys Ser Leu Ala Ser Arg Ser
 260 265 270
 Asn Val Ala His His Ser Lys Val Thr Leu Trp Ser Gly Ser Leu Ser
 275 280 285
 Ser Ala Met Lys Leu Met Pro Gly Arg Gln Ala Lys Asp Pro Glu Cys
 290 295 300
 Lys Thr Glu Asp Phe Val Ser Cys Ile Glu Asn Tyr Arg Arg Arg Gly
 305 310 315 320
 Gln Glu Leu Tyr Ala Ser Leu Tyr Lys Asp His Val Gln Arg Arg Lys
 325 330 335
 Cys Gly Asn Ile Lys Ala Ala Asn Ala Trp Ala Arg Ile Gln Glu Gln
 340 345 350
 Leu Phe Gly Glu Leu Gly Leu Trp Ser Gln Gly Glu Glu Thr Lys Pro
 355 360 365
 Cys Ser Pro Trp Glu Leu Asp Trp Arg Glu Gly Pro Ala Arg Met Arg
 370 375 380
 Lys Arg Ile Lys Arg Leu Ser Pro Leu Glu Ala Leu Ser Ser Gly Arg
 385 390 395 400
 His Lys Glu Ser Gln Asp Lys Asn Asp His Ile Ser Gln Thr Asn Ala
 405 410 415
 Glu Asn Gln Asp Glu Leu Thr Leu Arg Glu Ala Glu Gly Glu Pro Asp
 420 425 430
 Glu Val Gly Val Asp Cys Thr Gln Leu Thr Phe Phe Pro Ala Leu His
 435 440 445
 Glu Ser Leu His Ser Glu Asp Phe Leu Glu Leu Cys Arg Glu Arg Gln
 450 455 460
 Val Ile Leu Gln Glu Leu Leu Asp Lys Glu Lys Val Thr Gln Lys Phe
 465 470 475 480
 Ser Leu Val Ile Val Gln Gly His Leu Val Ser Glu Gly Val Leu Leu
 485 490 495
 Phe Gly His Gln His Phe Tyr Ile Cys Glu Asn Phe Thr Leu Ser Pro
 500 505 510
 Thr Gly Asp Val Tyr Cys Thr Arg His Cys Leu Ser Asn Ile Ser Asp
 515 520 525
 Pro Phe Ile Phe Asn Leu Cys Ser Lys Asp Arg Ser Thr Asp His Tyr
 530 535 540
 Ser Cys Gln Cys His Ser Tyr Ala Asp Met Arg Glu Leu Arg Gln Ala
 545 550 555 560
 Arg Phe Leu Leu Gln Asp Ile Ala Leu Glu Ile Phe Phe His Asn Gly
 565 570 575
 Tyr Ser Lys Phe Leu Val Phe Tyr Asn Asn Asp Arg Ser Lys Ala Phe
 580 585 590

Lys Ser Phe Cys Ser Phe Gln Pro Ser Leu Lys Gly Lys Ala Thr Ser.
 595 600 605
 Glu Asp Thr Leu Asn Leu Arg Arg Tyr Pro Gly Ser Asp Arg Ile Met
 610 615 620
 Leu Gln Lys Trp Gln Lys Arg Asp Ile Ser Asn Phe Glu Tyr Leu Met
 625 630 635 640
 Tyr Leu Asn Thr Ala Ala Gly Arg Thr Cys Asn Asp Tyr Met Gln Tyr
 645 650 655
 Pro Val Phe Pro Trp Val Leu Ala Asp Tyr Thr Ser Glu Thr Leu Asn
 660 665 670
 Leu Ala Asn Pro Lys Ile Phe Arg Asp Leu Ser Lys Pro Met Gly Ala
 675 680 685
 Gln Thr Lys Glu Arg Lys Leu Lys Phe Ile Gln Arg Phe Lys Glu Val
 690 695 700
 Glu Lys Thr Glu Gly Asp Met Thr Val Gln Cys His Tyr Tyr Thr His
 705 710 715 720
 Tyr Ser Ser Ala Ile Ile Val Ala Ser Tyr Leu Val Arg Met Pro Pro
 725 730 735
 Phe Thr Gln Ala Phe Cys Ala Leu Gln Gly Gly Ser Phe Asp Val Ala
 740 745 750
 Asp Arg Met Phe His Ser Val Lys Ser Thr Trp Glu Ser Ala Ser Arg
 755 760 765
 Glu Asn Met Ser Asp Val Arg Glu Leu Thr Pro Glu Phe Phe Tyr Leu
 770 775 780
 Pro Glu Phe Leu Thr Asn Cys Asn Gly Val Glu Phe Gly Cys Met Gln
 785 790 795 800
 Asp Gly Thr Val Leu Gly Asp Val Gln Leu Pro Pro Trp Ala Asp Gly
 805 810 815
 Asp Pro Arg Lys Phe Ile Ser Leu His Arg Lys Ala Leu Glu Ser Asp
 820 825 830
 Phe Val Ser Ala Asn Leu His His Trp Ile Asp Leu Ile Phe Gly Tyr
 835 840 845
 Lys Gln Gln Gly Pro Ala Ala Val Asp Ala Val Asn Ile Phe His Pro
 850 855 860
 Tyr Phe Tyr Gly Asp Arg Met Asp Leu Ser Ser Ile Thr Asp Pro Leu
 865 870 875 880
 Ile Lys Ser Thr Ile Leu Gly Phe Val Ser Asn Phe Gly Gln Val Pro
 885 890 895
 Lys Gln Leu Phe Thr Lys Pro His Pro Ala Arg Thr Ala Ala Gly Lys
 900 905 910
 Pro Leu Pro Gly Lys Asp Val Ser Thr Pro Val Ser Leu Pro Gly His
 915 920 925
 Pro Gln Pro Phe Phe Tyr Ser Leu Gln Ser Leu Arg Pro Ser Gln Val
 930 935 940
 Thr Val Lys Asp Met Tyr Leu Phe Ser Leu Gly Ser Glu Ser Pro Lys
 945 950 955 960
 Gly Ala Ile Gly His Ile Val Ser Thr Glu Lys Thr Ile Leu Ala Val
 965 970 975
 Glu Arg Asn Lys Val Leu Leu Pro Pro Leu Trp Asn Arg Thr Phe Ser
 980 985 990
 Trp Gly Phe Asp Asp Phe Ser Cys Cys Leu Gly Ser Tyr Gly Ser Asp
 995 1000 1005
 Lys Val Leu Met Thr Phe Glu Asn Leu Ala Ala Trp Gly Arg Cys Leu
 1010 1015 1020
 Cys Ala Val Cys Pro Ser Pro Thr Thr Ile Val Thr Ser Gly Thr Ser
 1025 1030 1035 1040
 Thr Val Val Cys Val Trp Glu Leu Ser Met Thr Lys Gly Arg Pro Arg
 1045 1050 1055
 Gly Leu Arg Leu Arg Gln Ala Leu Tyr Gly His Thr Gln Ala Val Thr
 1060 1065 1070
 Cys Leu Ala Ala Ser Val Thr Phe Ser Leu Leu Val Ser Gly Ser Gln
 1075 1080 1085
 Asp Cys Thr Cys Ile Leu Trp Asp Leu Asp His Leu Thr His Val Thr
 1090 1095 1100
 Arg Leu Pro Ala His Arg Glu Gly Ile Ser Ala Ile Thr Ile Ser Asp
 1105 1110 1115 1120
 Val Ser Gly Thr Ile Val Ser Cys Ala Gly Ala His Leu Ser Leu Trp
 1125 1130 1135

Asn Val Asn Gly Gln Pro Leu Ala Ser Ile Thr Thr Ala Trp Gly Pro
 1140 1145 1150
 Glu Gly Ala Ile Thr Cys Cys Cys Leu Met Glu Gly Pro Ala Trp Asp
 1155 1160 1165
 Thr Ser Gln Ile Ile Ile Thr Gly Ser Gln Asp Gly Met Val Arg Val
 1170 1175 1180
 Trp Lys Thr Glu Asp Val Lys Met Ser Val Pro Gly Arg Pro Ala Gly
 1185 1190 1195 1200

Glu Glu Pro Leu Ala Gln Pro Pro Ser Pro Arg Gly His Lys Trp Glu
 1205 1210 1215
 Lys Asn Leu Ala Leu Ser Arg Glu Leu Asp Val Ser Ile Ala Leu Thr
 1220 1225 1230
 Gly Lys Pro Ser Lys Thr Ser Pro Ala Val Thr Ala Leu Ala Val Ser
 1235 1240 1245
 Arg Asn His Thr Lys Leu Leu Val Gly Asp Glu Arg Gly Arg Ile Phe
 1250 1255 1260
 Cys Trp Ser Ala Asp Gly
 1265 1270

<210> 121
 <211> 647
 <212> PRT
 <213> Homo sapiens

<400> 121
 Met Leu Gln Lys Trp Gln Lys Arg Asp Ile Ser Asn Phe Glu Tyr Leu
 1 5 10 15
 Met Tyr Leu Asn Thr Ala Ala Gly Arg Thr Cys Asn Asp Tyr Met Gln
 20 25 30
 Tyr Pro Val Phe Pro Trp Val Leu Ala Asp Tyr Thr Ser Glu Thr Leu
 35 40 45
 Asn Leu Ala Asn Pro Lys Ile Phe Arg Asp Leu Ser Lys Pro Met Gly
 50 55 60
 Ala Gln Thr Lys Glu Arg Lys Leu Lys Phe Ile Gln Arg Phe Lys Glu
 65 70 75 80
 Val Glu Lys Thr Glu Gly Asp Met Thr Val Gln Cys His Tyr Tyr Thr
 85 90 95
 His Tyr Ser Ser Ala Ile Ile Val Ala Ser Tyr Leu Val Arg Met Pro
 100 105 110
 Pro Phe Thr Gln Ala Phe Cys Ala Leu Gln Gly Gly Ser Phe Asp Val
 115 120 125
 Ala Asp Arg Met Phe His Ser Val Lys Ser Thr Trp Glu Ser Ala Ser
 130 135 140
 Arg Glu Asn Met Ser Asp Val Arg Glu Leu Thr Pro Glu Phe Phe Tyr
 145 150 155 160
 Leu Pro Glu Phe Leu Thr Asn Cys Asn Gly Val Glu Phe Gly Cys Met
 165 170 175
 Gln Asp Gly Thr Val Leu Gly Asp Val Gln Leu Pro Pro Trp Ala Asp
 180 185 190
 Gly Asp Pro Arg Lys Phe Ile Ser Leu His Arg Lys Ala Leu Glu Ser
 195 200 205
 Asp Phe Val Ser Ala Asn Leu His His Trp Ile Asp Leu Ile Phe Gly
 210 215 220
 Tyr Lys Gln Gln Gly Pro Ala Ala Val Asp Ala Val Asn Ile Phe His
 225 230 235 240
 Pro Tyr Phe Tyr Gly Asp Arg Met Asp Leu Ser Ser Ile Thr Asp Pro
 245 250 255
 Leu Ile Lys Ser Thr Ile Leu Gly Phe Val Ser Asn Phe Gly Gln Val
 260 265 270
 Pro Lys Gln Leu Phe Thr Lys Pro His Pro Ala Arg Thr Ala Ala Gly
 275 280 285
 Lys Pro Leu Pro Gly Lys Asp Val Ser Thr Pro Val Ser Leu Pro Gly
 290 295 300
 His Pro Gln Pro Phe Phe Tyr Ser Leu Gln Ser Leu Arg Pro Ser Gln
 305 310 315 320
 Val Thr Val Lys Asp Met Tyr Leu Phe Ser Leu Gly Ser Glu Ser Pro
 325 330 335

Lys Gly Ala Ile Gly His Ile Val Ser Thr Glu Lys Thr Ile Leu Ala
 340 345 350
 Val Glu Arg Asn Lys Val Leu Leu Pro Pro Leu Trp Asn Arg Thr Phe
 355 360 365
 Ser Trp Gly Phe Asp Asp Phe Ser Cys Cys Leu Gly Ser Tyr Gly Ser
 370 375 380
 Asp Lys Val Leu Met Thr Phe Glu Asn Leu Ala Ala Trp Gly Arg Cys
 385 390 395 400
 Leu Cys Ala Val Cys Pro Ser Pro Thr Thr Ile Val Thr Ser Gly Thr
 405 410 415
 Ser Thr Val Val Cys Val Trp Glu Leu Ser Met Thr Lys Gly Arg Pro
 420 425 430
 Arg Gly Leu Arg Leu Arg Gln Ala Leu Tyr Gly His Thr Gln Ala Val
 435 440 445
 Thr Cys Leu Ala Ala Ser Val Thr Phe Ser Leu Leu Val Ser Gly Ser
 450 455 460
 Gln Asp Cys Thr Cys Ile Leu Trp Asp Leu Asp His Leu Thr His Val
 465 470 475 480
 Thr Arg Leu Pro Ala His Arg Glu Gly Ile Ser Ala Ile Thr Ile Ser
 485 490 495
 Asp Val Ser Gly Thr Ile Val Ser Cys Ala Gly Ala His Leu Ser Leu
 500 505 510
 Trp Asn Val Asn Gly Gln Pro Leu Ala Ser Ile Thr Thr Ala Trp Gly
 515 520 525
 Pro Glu Gly Ala Ile Thr Cys Cys Cys Leu Met Glu Gly Pro Ala Trp
 530 535 540
 Asp Thr Ser Gln Ile Ile Ile Thr Gly Ser Gln Asp Gly Met Val Arg
 545 550 555 560
 Val Trp Lys Thr Glu Asp Val Lys Met Ser Val Pro Gly Arg Pro Ala
 565 570 575
 Gly Glu Glu Pro Leu Ala Gln Pro Pro Ser Pro Arg Gly His Lys Trp
 580 585 590
 Glu Lys Asn Leu Ala Leu Ser Arg Glu Leu Asp Val Ser Ile Ala Leu
 595 600 605
 Thr Gly Lys Pro Ser Lys Thr Ser Pro Ala Val Thr Ala Leu Ala Val
 610 615 620
 Ser Arg Asn His Thr Lys Leu Leu Val Gly Asp Glu Arg Gly Arg Ile
 625 630 635 640
 Phe Cys Trp Ser Ala Asp Gly
 645

<210> 122
 <211> 32
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PDM-797 PCR primer for His-Ly1452P

<400> 122
 gtgtcacaat ctacagtcag gcaggattct cc

32

<210> 123
 <211> 35
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PDM-799 PCR primer for His-Ly1452P

<400> 123
 gttatgtac ggccgcattat catgttgctg cagag

35

<210> 124
 <211> 980
 <212> DNA
 <223> Incyte LifeSeq database template #LS_1076101.8,

human endogenous retroviral sequence (HERV)

<400> 124

gcccgtgccg	ctccaggaga	caggttccca	tgcaggaatg	aaagacatgg	aaggaaagag	60
ggggggccagc	tccctgagtc	ctgtgtccac	cagctgctgc	taaataacctc	tgagaaactc	120
tgcttctatc	taaggggacc	tacttctctc	gggaatctca	atacttggaa	caagaacctc	180
ctagacggac	cctttggcat	aatgaattgg	accaactgta	ggttccagga	ctagagagcc	240
agcaatgcct	ccatgaacaa	tctcacccaa	ttactctgt	cagggaaacga	ggttaactgtat	300
ggacagccga	ggcagccccct	taggcggctt	aggcctcccc	tgtggagcat	ccctgaggcg	360
gactccggcc	agccccagtg	atgcgatcca	aagagcactc	ccgggttagga	aattgccccg	420
gttggaatgcc	tcaccagagc	agcgtgttagc	agttccctgt	ggaggattaa	cacagtggct	480
gaacaccggg	aaggaactgg	cacttggagt	ccggacatct	gaaacttgta	gactgggagc	540
tgtacatggg	tgggagcagc	ttcaccaacc	cctgcaaaagt	gactctgaag	aagacgacaa	600
gccctgctcc	agtccacaccc	ggaagctgac	tggtccacgc	acagctgaag	catgagggaaa	660
ctcatcgccg	gactaatttt	ccttaaaatt	tagacttgca	cagtaaggac	ttcaactgac	720
cttcctcaga	ctgagaactg	tttccagtat	atacatcaag	tcactgaggt	aggacaaaag	780
attgctacat	tcctattatt	ttaagggtac	attttgggg	acccctctt	cttctgttct	840
agcttattacc	tttcttgtgt	cacctagaaa	aggaccagtc	cttaatttgta	ttttaaaaac	900
tgtgatcatg	ggaagcttta	aattggttca	ataacacgca	tcaagtttgt	tatccctgg	960
gctacatacc	ttggatagat					980

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.